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Abstract 
Receptors for the neuropeptides VIP and P ACAP belong to a novel 
sub-family of G protein-coupled receptors, the secretin/ calcitonin/ 
parathyroid hormone receptor family. The rat VIP2 receptor was recently 
cloned in this laboratory and the present project was carried out to 
characterise the signalling mechanisms used by this receptor and define the 
role of crucial receptor domains. 
These studies have primarily involved the transient expression of 
receptors in host cells. The results demonstrated for the first time that both 
the VIP1 and VIP2 receptors can stimulate phospholipase C (PLC) in addition 
to adenylate cyclase (AC) and that this stimulation occurs by a pertussis 
toxin(PTx)-sensitive mechanism. Correspondingly, GTP,.S modulation of 
ligand-binding to the VIP2 receptor in COS 7 cell membranes was shown to 
be partially PTx-sensitive, suggesting an interaction of the receptor with a 
PTx-sensitive G protein. An epitope-tagged human VIP2 receptor was 
expressed in COS 7 cells and imrnunoprecipitated with its associated G 
proteins for Western-blotting studies. Immunoreactivity for Gaq, Ga5 and a 
member of the G<Xif o/ t/ z family, other than Gan or G<Xi2, appeared to be 
associated with the receptor. The use of specific calcium channel blockers 
identified a role for receptor-mediated calcium influx in VIP2 receptor-
mediated PLC stimulation. 
The P ACAP and VIP2 receptors contain many common structural 
features but have their own distinct pharmacological profiles. The function 
of specific domains of the VIP2 receptor was investigated by creating 
P ACAP /VIP2 receptor chimaerics and C-terminal truncations of the Vll'2 
receptor. These constructs allowed identification of the primary region of 
the receptor responsible for ligand-binding and the probable site of 
interaction with a PTx-sensitive G protein and also assessment of any 
contribution of the C-terminus to AC and PLC stimulation. 
A number of further studies were carried out on native receptors. The 
signalling pathways activated by the endogenous Vll'2 receptor in the Gfl3 
rat pituitary tumour cell line were investigated. Consistent with previous 
evidence that a Vll' receptor in other cells can stimulate nitric oxide 
production, VIP2 receptor-mediated stimulation of nitric oxide synthase, 
PLC and AC was demonstrated in GHJ cells. As a result of reports 
describing the effects of VIP and P ACAP on cerebral blood flow the Reverse 
Transcriptase-Polymerase Chain Reaction technique was used to determine 
the type of VIP receptor present in rat cerebral microvessels. 
Some of the results presented in this Thesis have been published as follows: 
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1.1 The secretin/calcitonin/parathyroid hormone/parathyroid 
hormone-related peptide family of G protein-coupled receptors 
The vasoactive intestinal peptide(VIP)l (Ishihara et al., 1991), VIP2 (Lutz et 
a!., 1993) and pituitary adenylate cyclase-activating polypeptide(PACAP) 
(Morrow et al., 1993) receptors belong to the secretin / calcitonin/ parathyroid 
hormone(PTH)/parathyroid hormone-related peptide (PTHrP) family of G protein-
coupled receptors (GPCRs) which also includes the secretin receptor (Ishihara et al., 
1991), the calcitonin receptor (Lin et al., 1991), the PTH/PTHrP receptor (Juppner 
et a l. , 1991), the GLP-I receptor (Thorens, 1992), the GHRH receptor (Mayo, 1992), 
the glucagon receptor (Jelinek et al., 1993). These receptors are distinct from the 
rhodopsin and metabotropic glutamate receptor families of GPCRs and are 
identified as a family as a result of their sequence homology (Segre & Goldring, 
1993). 
Receptors of the secretin/calcitonin/ PTH/ PTHrP receptor family have a 
high degree of sequence homology with each other and less than 12% homology with 
the members of other G protein-linked receptor families (Attwood et al., 1991; 
Probst et al., 1992). All are glycoproteins ranging from 423 to 593 amino acids in 
length and have an N-terminal hydrophobic signal sequence, a large N-terrninal 
domain, highly conserved N-terrninal cysteine residues and N-linked glycosylation 
sites in extracellular domain(EC)l and EC2. The putative TMS, TM6 and TM7 
regions and theN-terminal portion of the C-terminal tail regions are also highly 
conserved in the family (Segre & Goldring, 1993). 
All GPCRs have common structural features such as the seven hydrophobic 
domains which are believed to constitute transmembrane-spanning regions, an 
extracellular amino(N)-terminus and intracellular carboxyl(C)-terminus (see Figure 
1.1), and the ability to activate heterotrimeric G proteins by stimulating the rate of 
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change of GDP for GTP on the a-subunit of the G protein (for review see Baldwin, 
1994). 
Heterotrimeric G proteins 
The extraceUular portion of a GPCR such as the VIP2 receptor recognises 
specific molecules which on binding cause a conformational change in the 
intracellular portion of the receptor. Specific heterotrirneric G proteins will then 
interact with cytoplasmic domains of the receptor and the release of GDP from the 
Ga subunit will result. GTP is abundant in the cell and will replace the GDP in the 
binding cleft of the Ga subunit causing a change in the "switch" regions of the Ga 
subunit and thereby weakening the affinity of Ga and G~y for each other and 
releasing them to act on their respective effectors. The advantage of such a 
mechanism is in the regulation of the response: the activation of multiple G proteins 
by an activated receptor means that the response is amplified, a further 
amplification step may occur at the level of the effector enzyme or ion channel; the 
short half life of many second messengers means that the duration of the signal can 
be closely regulated; mechanisms such as phosphorylation can be used to modulate 
the activity of receptors, G proteins and effectors; the ability of the receptor to be 
activated by a limited number of agonists and to only interact with specific G 
proteins provides a high degree of specificity to the response. 
There are currently 23 distinct Ga subunits known of size range, 39-52 kDa. 
The C terminus of the Ga subunit interacts with the receptor (as suggested by the 
ability of PTx to uncouple G protein receptor-interactions by ADP-ribosylation of a 
cysteine four residues from the C-terminus) and the first 21 N-terminal amino acids 
are invoLved in interacting with the l3r subunits. Ga subunits which contain the 
\1GXXXS consensus myristoylation signal are N-terminally myristoylated (Gat, Gai, 
Gao, Gagust and Gaz). All Ga subunits appear to be palmitoylated at a cysteine 
3 
residue near theN-terminus, disrupting myristoylation or palmitoylation prevents 
both the correct localisation of the Ga. subunit and inhibits it's activity. 
Palmitoylation appears to be a reversible phenomenon which can be used a 
regulatory mechanism (for review see Bimbaumer & Bimbaumer, 1995). 
There are six different G~ subunits and twelve different Gy subunits known, 
giving seventy two potential dirners. However it is known that certain combinations 
do not occur e.g. G~2 with Gn. Denaturing conditions are required to dissociate the 
G~y dimer. The ~subunit consists of anN-terminal helix of approximately twenty 
amino acids and a WD repeat region believed to be a ring of small antiparallel ~ 
strands which form a propeller structure (each blade of which consists of four 
twisted ~ strands). The WD repeat motif is thought to be important for protein-
protein interactions. The size range for the G~ subunits is 35-39 kDa. The Gy 
subunit N terminus forms a coiled-coil with theN terminal non-WD repeat region of 
the ~ subunit (the rest of the Gy subunit stretches out across the surface of the ~ 
subunit). The Gy subunit C terminus contains a CAAX motif which directs the 
prenylation of the subunit. Gyl is famesylated whereas the others are 
geranylgeranylated. The cysteine in the CA.AX box is the attachment point for these 
moieties (via a stable thioester bond). The most well-defined function of 
prenylation is to facilitate membrane association. The geranylgeranyl group is more 
hydrophobic than the famesyl group causing a more tightly membrane-associated 
complex. The N-terminal three amino acids are also clea\·ed off and the remaining 
isoprenylated N-terminal cysteine is carboxymethylated. The size range for Gy 
subunits is 6-8 kDa (for review see Clapham & Neer, 1997). 
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Regulation of G protein function 
Phosphorylation of Gaz and Ga12 has been shown to inhibit it's ability to 
interact with Gpy subunits thereby extending it's time in the active state (Fields & 
Casey, 1995; Kozasa & Gilman, 1996). 
Regulation of adenylate cyclase by G proteins 
All eight characterised isoforrns of adenylate cyclase are directly activated 
by Gas. Gpy subunits were also found to stimulate ACII and ACIV but not ACV or 
ACYL Gai inhibited ACI, ACV and ACYl but not ACII. Gaz inhibited ACI and 
ACY. Gao inhibited ACI but not ACII, ACV and ACVI. Gpy subunits were found 
to inhibit ACV and ACVI. The concentration of py subunits required to activate AC 
is higher than that which results from Gs activation, the activation of G1 or G0 
results in much higher levels of py subunits and therefore allows a degree of 
differentiation between the sources. The activation of ACII and ACIY by py 
subunits is dependent on coincident activation by Gas. Gan, Gai2, Gai3 and Gaz 
were all found to be effective inhibitors of ACV and ACYL Gai and G<Xo were 
found to be moderately effective inhibitors of ACI, the Ca2+ -CaM-stimulated 
isoforrn (for review see Sunahara, Dessauer & Gilman, 1996). 
A number of AC isoforrns contain consensus sequences for phosphorylation 
by PKA and PKC; ACII and ACV are phosphorylated in vivo in response to 
phorbol myristate acetate causing an activation that is synergistic with the effect of 
forskolin or Gag (Kawabe et al., 1994; Jacobowitz & Iyengar, 1994). The action of 
PKA appears to be inhibitory on ACV and ACVI (Premont et al., 1992). 
5 
Regulation of phospholipase C/3 by G proteins 
The o: subunits of the Gq/ 11 and G14-16 subfamily have been demonstrated 
to stimulate the P isoforms of PLC but not the 8 or y isoforms (see Singer et al., 
1997). However PTx-sensitive G proteins have also been reported to stimulate 
PLCP isoforms, primarily through the action of Gpy subunits independently of the 
Go: subunits (Smrcka & Stemweis, 1993; Boyer et al., 1992; Park et al., 1993). The 
concentration of py subunits required to stimulate PLC is generally found to be two 
orders of magnitude greater than for Go:q (Exton, 1997). The potency of Gpy 
stimulation of purified PLCP isoforms is: PLC P3>P2>P 1 (Smrcka & Sternweis, 
1993; Park et al., 1993), PLCP4 is insensitive to Gpy stimulation (Jiang et al., 1994). 
The order of potency of Gq stimulation of PLCP isoforms is: PLC P1;:;:P3>P4>P2 (Lee 
& Rhee, 1995). It appears that the P1 isoform appears to be primarily Go:q 
stimulated, PLCP2 is primarily py-stimulated and the PLCP3 isoform is responsive 
to both Go: and Gpy subunits. Most cells contain members of both the Gq/11 and 
Gifo families of G proteins; the latter constituting 1-2% of the protein in bovine 
brain (Stemweis & Robishaw, 1984). 
Activation of adenylate cyclase and phospholipase C by G 
protein-coupled receptors 
All members of the secretin /calcitonin/parathyroid 
hormone(PTH)/ parathyroid hormone-related peptide (PTHrP) family of GPCRs 
are known to couple to adenylate cyclase stimulation by activation of the 
stimulatory G protein, G5. A number of these receptors have also been shown to be 
capable of stimulating an increase in intracellular calcium concentrations and 
phosphatidyl inositol(Pl) hydrolysis. In transfection studies the PTH/PTHrP 
(Abou-Samra et al., 1992), calcitonin (Chabre et al., 1992; Force et al., 1992) and 
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GLP-1 (Wheeler et al., 1993) receptors were shown to couple to PLC stimulation as 
well as to adenylate cyclase stimulation. Studies in native cells suggest that VIP 
receptors (Malhotra et al., 1988), GHRH receptors (Login et al., 1986) and secretin 
receptors (Trimble et al., 1987) are also capable of mediating PLC stimulation. 
GPCRs which do not belong to the secretin/calcitonin/PTH/ PTHrP 
receptor family, such as the dopamine Dl receptor (Liu et al., 1997), TSH receptor 
(Van Sande et al., 1990), LH recep tor (Gudermann et al., 1992), vasopressin V2 
receptor and P-adrenergic receptors (Zhu et a l., 1994) have also been shown to have 
this dual signalling capability. 
In the majority of cases cAMP stimulation occurs at lower agonist 
concentrations and requires a lower receptor density than PLC stimulation (Zhu et 
al., 1994; Van Sande et al., 1995). Adenylate cyclase stimulation is therefore 
preswned to occur by a more 'tightly-coupled' mechanism than PI hydrolysis i.e. 
receptor activation of G5 occurs by a more efficient mechanism. [t has often been 
observed that there are more binding sites available for agonist than are required for 
maximal stimulation of cAMP production, that a 'receptor reserve' exists. This 
reserve was not normally found when PI hydrolysis stimulated by the same 
receptors was studied (Zhu et al., 1994; Van Sande et al., 1995). 
1.2 Agonists of the secretin/calcitonin/PTH/PTHrP family of 
G protein-coupled receptors 
GPCRs are responsive to a very wide range of agonists, for example photons 
(in the case of the rhodopsin receptors), opioids, thrombin, ca techolamines, cAMP, 
prostaglandins, large glycopeptide hormones, such as luteinising hormone(LH) and 
follicle stimulating hormone(FSH), and small peptide hormones such as vasopressin 
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and oxytocin (for reviews see O'Dowd et al., 1989; Dohlman et a l., 1991; Reed, 
1992)). Many of the agonists for this family of receptors are peptides with related 
amino add sequences and structural similarities (see Figures 1.2 & 1.3). Secretin 
(Kopin et al., 1990), VIP (Said, 1986), GLP-1, glucagon (Bell, 1986), PHI (Ta temoto 
& Mutt, 1981), PHM (Itoh et al., 1983), PACAP (Miyata et al., 1989), Growth 
hormone-releasing factor (GRF / GHRF /GHRH: Rivier et al., 1982), gastric inhjbitory 
peptide and helodermin (Vandermeers et al., 1984) are all small peptides belonging 
to the same family (see Fig. 1.3). PTH is however much larger at 84 amino acids in 
length, PTHrP has a high degree of homology with PTH at theN-terminus (eight out 
of thirteen amino acids being identical) but its remaining sequence is entirely 
dissimilar (Kronenberg et al., 1993; Martinet al., 1991). The first thirty-four amino 
adds of PTH have been found to be suificient for full activity with residues 15-34 
being particularly important for receptor binding affinity (Nussbaum et al., 1980). 
The N-terminal residues are crucial for the stimulation of adenylate cyclase activity 
(Goltzman et al., 1994; Horiuchi et al., 1983) and it has been demonstrated for 
various members of the VIP peptide family (Haffer et al.. 1991; Gallwitz et al., 
1990) that theN-terminus cannot be truncated without affecting the potency of the 
peptide and its affinity for its receptor. 
A brief description of each relevant peptide is given below: 
Vasoactive intestinal polypeptide (VIP) is a 28 amino acid peptide which was 
originally isolated from porcine small intestine by Said & \1utt (1970). The isolated 
peptide was found to have a structure similar to that of secretin and glucagon (Said 
& Mutt, 1972). Chromatographically different VTP-like immunoreactivity was 
isolated from intestinal mucosa (Dimaline & Dockray, 19/8; Gafvelin et al., 1988) 
and subsequently Oirnaline & Vowles (1988) observed alternative processing of 
prepro-VIP in different areas of the GI tract. 
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Peptide histidine isoleucine (PHI) was also isolated from porcine gut by Tatemoto 
& Mutt (1981). It has a structure very similar to that of VIP and is now known to 
be a product of the same precursor polypeptide as VIP (ltoh et al., 1983). VIP and 
PHI have been identified as coexisting in the intramural neurones of the small 
intestine (Ekblad et al., 1984). 
Peptide histidine methionine (PHM) is a variant of PHI which occurs in humans 
(Itch et al., 1983). 
Pituitary adenylate cyclase-activating polypeptide(PACAP)-38 is a 38 amino acid 
peptide first isolated from ovine hypothalamus and found to stimulate adenylate 
cyclase activity in cultured rat anterior pituitary cells (Miya ta et al, 1989). 
PACAP-27 is the C-terminally truncated form of the PACAP-38 also isolated from 
ovine hypothalamus and with similar activity (Miyata et al, 1990). 
Helodermin is a 35 amino acid homologue of VIP which was isolated from the 
venom of the lizard Heloderma suspechmz (Gila monster). Non-amidated forms 
occur and are known as helospectins. Helodermin-like immunoreactivity has been 
identified in a range of mammalian tissues (Robberecht et al. , 1985). 
Glucagon (29 amino acids) is synthesised in the a cells of pancreatic islets and in 
non-human mammalian gastric mucosa. This peptide is secreted in response to 
falling glucose levels and increases the blood glucose concentration. It stimulates 
glycogenolysis and gluconeogenesis in the liver, increased lipolysis in adipose tissue 
and increased insulin secretion (Unger & Orci, 1981; Premont & Iyengar, 1987). 
Glucagon, glucagon-like peptide(GLP)-1 and GLP-2 are derived from the same 
precusor peptide (Bell et al., 1986). 
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Glucagon-like peptide(GLP)-1 (37 amino acids) potentiates the effect of glucose 
on insulin secretion (Creutzfeldt & Ebert, 1985) and stimulates insulin gene 
transcription (Drucker et al., 1987). Infusion of GLP-1 modulates post-prandial 
insulin secretion and glucose disposal in non insulin-dependent diabetes 
mellitus(Nathan et al., 1992). 
Parathyroid hormone (PTH; 84 amino acids) primarily acts on the kidney and bone 
and is the major hormone responsible for regulation of extracellular levels of calcium 
and phosphorous (for review see; Rosenblatt et al., 1989). 
Parathyroid hormone-related peptide (PTHrP) can bind to the same receptors as 
PTH due to its N-terminal homology but is a larger molecule (Mangin et al., 1989) 
and fills an as yet undefined role. PTHrP is associated with hypercalcaemia of 
malignancy and was originally identified in tumours from cancer patients with 
elevated blood calcium levels (Mangin et al., 1988). 
Calcitonin (32 amino acids) increases renal calcium clearance and inhibits 
osteoclast-mediated bone resorption causing a lowering of serum caldwn levels. 
Calcitonin is a natriuretic agent modulating both nociception and food intake 
(Azria, 1989; Kopin et al., 1990). 
Secretin (27 amino acids) stimula tes the exocrine cells of the pancreas to secrete 
potassium, bicarbonate and various enzymes (Bayliss & Starling, 1982). 
Maxadilan is a 61 amino acid peptide from sand flies which has high affinity for 
the PACAP receptor without having significant affinity for the VIP receptors ( Moro 
& Lerner, 1997). 
A number of synthetic peptides selective for VIP2 receptors have now been 
developed: 
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Ro 25-1392 [Ac-GiuB,ocH3,TyrlO,Lysl2,Niel7, Ala 19,Asp25,Leu26,Lys27,28_ 
vasoactive intestinal polypeptide(cyclo 21-25)] is a cyclic peptide analogue of VIP 
which is selective for the VIP2 receptor over the VIP1 receptor (Xia et al., 1997). 
Ro 25-1553 is also a cyclic analogue of VIP which contains a lactam ring (O'Donnell 
et al., 1994) and has also been demonstrated to be highly selective for the VIP2 
receptor over the VIP1 receptor (Gourlet et al., 1997). 
[LyslS,Arg16,Leu27]VIP(l-7)GRF(8-27)-NHz is a VIP /GRF hybrid peptide which is 
believed to be selective for VIP1 receptors and does not activate GRF receptors 
(Gourlet et al., 1997). 
Studies with VIP and secretin 
A large proportion of the research into the structure and function of this 
family of peptides has been carried out on the VIP and secretin peptides. A brief 
review of this work is therefore given here. O'Donnell et al. (1991) replaced residues 
24-28 of VIP (which includes residues in the putative helical domain) with Ala 
residues and found that potency was barely affected, Gourlet et al. (1996) replaced 
secretin 20-27 with the corresponding sequence of PACAP and found no significant 
change in affinity. O'Donnell et al. (1991) however found that the whole secretin 
sequence and VIP (1-27) was required for optimal activity. TheN-terminus 
however could not be truncated without seriously affecting the affinity and activity 
of the peptides. Deletion of the N-terminal His residue causes a marked reduction 
in the affinity of VIP and secretin peptides for their receptors (Couvineau et al. 
(1984); Vilardaga et al. (1994)). Deletion of the first four residues in either sequence 
markedly reduces the peptides affinity and activity whereas further truncation of 
VIP or secretin removes their ability to stimulate AC. Musso et al. (1988) first 
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suggested that the peptides form a C-terminal a-helicoidal structure with segregated 
hydrophilic and hydrophobic domains as shown in figure 1.2. Holtmann et al. 
(1995) and Vilardaga et al. (1995) have shown that the receptors N-terminus 
discriminates between peptides. Gourlet et al. (1996) have carried out studies using 
C-terminally truncated secretin and VIP peptides and examining their ability to 
bind to VIP /secretin receptor chirnaerics with swapped N-terrnini. These studies 
have identified the C-terrninus of the peptides as being the region which determines 
their binding selectivity profile and which interacts with the receptors N-terrninus. 
A study using chimaeric peptides on the same N-terminal swap chirnaeric receptors 
has produced evidence that residues 9-15 of secretin have a major role in interacting 
with the receptors N-terrninus. The authors identify residues Asp8, Tyrl3 and 
Lysl5 as lowering the affinity of PACAP-27 for the secretin receptor whereas 
residues nu-S, Glu9, LeulO, GJulS, Gly16 and certain residues in the 17-20 region 
(Ala, Arg, Leu, Gln) lower the affinity of secretin for the VIP1 receptor (Gourlet et 
al. , 1996). Their data suggests that Ser9, TyrlO, LysiS, Glnl6 and residues in region 
17-20 of PACAP-27 are important for PACAP-27 binding to the VIP1 receptor and 
that Tyrl3 and residues 1-7 are not. The evidence for the role of Ile5 is inconclusive 
and it is probable that Serll, Argl2 and Argl4 are not required for PACAP-27 
binding. These data are broadly supportive of the idea that the N-terminus of the 
peptide is important for activation rather than binding. A degree of identity 
between the C-termini of secretin and PACAP-27 makes it difficult to draw any 
conclusions about their roles from these data. 
Both secretin and VIP bind to the rat secretin receptor with high affinity 
whereas secretin binds with very low affinity to the rat VIP1 receptor (Holtmann et 
al., 1995). High affinity VIP binding did not correspond to high activity levels at 
the secretin receptor, this was not true of secretin itself. The authors suggest that 
the VIP binding site may be physiologically irrelevant. Chimaeric receptors were 
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created in which theN-termini and EC1 regions of the receptors were swapped. 
The secretin N-terrninus and EC1 loop proved sufficient to confer secretin receptor-
like binding and activity on the VIP1 receptor whereas the secretin N-terrninus on 
the VIP1 receptor body created a receptor which had high affinity fo r neither VIP 
nor secretin. The VIP receptor N-terrninus was enough to give the secretin receptor 
the ability to cause cAMP generation in response to VIP binding and to decrease the 
potency of secretin. The addition of the VIP1 receptor EC1 region further decreased 
the potency of secretin. The authors therefore found that the N-terminus of the 
VIP1 receptor is sufficient for VIP activity, the N-terrninus and the EC1 region of the 
secretin receptor are sufficient for secretin activity and VIP binding and the secretin 
N-terminus binds neither VIP nor secretin welL Holtmann et al. (1996a) further 
investigated the necessary sequences and identified the first ten residues of the 
secretin receptor N-terminus as being necessary for secretin recognition. A 
construct containing the secretin N-terminus with the N-terrninal half of the secretin 
ECl region displayed high affinity secretin binding but poor responsiveness 
suggesting that binding and activation domains were separate. Two basic residues 
in the secretin ECl region were identified (His189 and Lysl90) which assisted in 
binding secretin, there are indications that AsplS in secretin is involved in binding 
this motif. A four residue sequence in the N-terminal portion of EC2 (Phe257, 
Leu258, Asn260 and Tru261) was able to substitute for the ECl but EC3 was not 
found to be involved in ligand binding. 
Holtmann et aL (1996b) found that the rat secretin receptor was capable of 
high-affinity binding of VIP and that the human receptor was not. There is only one 
acidic residue which is not conserved between the :\-termini of these receptors and 
when trus was mutated by SDM (Asp98Asn) the high affinity binding at the rat 
receptor was lost. Although binding affinity was high for VIP at the rat receptor the 
ability to stimulate cAMP was very poor. The authors suggest that the Asp98 
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residue interacts with the LyslS of VIP (which was previously demonstrated as 
being important). The equivalent region of the rat VIP2 receptor contains two 
aspartate residues, the sequence is not conserved. Vilardaga et al. (1996) identified 
Lys 173 in the secretin receptor as being important for the recognition of pep tides 
with an Asp3 residue such as secretin, VIP and PACAP. This study involved using 
rat secretin / glucagon receptor chirnaerics and peptide analogues which 
demonstrated that the ability of the receptor to discriminate between ligands that 
have an Asp at position three or another residue, rested in the EC1 region and could 
be removed by mutation of Lys173. EC2 appears to have a role to play in binding 
ligand but not in discriminating between ligands. 
1.3 Antagonists of VIP and P ACAP receptors 
Although no satisfactory antagonists have been found for these 
receptors a number of antagonists are available which appear to be selective 
under certain conditions, a brief description of these is given below: 
Neurotensin(l-6)VIP(7-28)-NH2 is a VIP / neurotensin hybrid peptide which 
displaces 90% of 125{-VIP binding in glial cell cultures and reduced YIP-stimulated 
cAMP production. It also attenuated sexual behaviours stimulated by VIP (Gozes 
et al., 1989). In this hybrid the first 6 residues of VIP (HSDAVF) were replaced 
with the equivalent region of neurotensin. 
VIP(l0-28) is an antagonist of the human VIP1 receptor activity in HT29 cells 
(Turner e t al., 1986). It does not cause the down-regulation of VIP receptors in 
HT29 cells which is observed after treatment with VIP or PHI (Turner et al., 1986) 
but blocks VIP-evoked AC stimulation in rat pancreatic acini (Dehaye et al., 1986). 
Cox & Cuthbert (1989) observed that VIP(l0-28) caused a smaU reduction in 
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electrogenic anion secretion from rat jejunum preparations but did not have any 
intrinsic agonist activity nor did it behave as a competitive antagonist of VIP in 
these preparations. Antagonistic properties have however been observed in some 
systems (Brenneman & Eiden, 1986). 
[AcTyr1D-Ph e2]GRF-(1-29)NH2 was observed to be a competitive antagonist of 
VIP in rat pancreatic plasma membranes (Waelbroeck et al., 1985) this was not the 
case in rat jejunum (Cox & Cuthbert., 1989). 
AcTyrlhGRF-(1-40)-0H was found by Laburthe et al. (1986) to be a competitive 
antagonist of VIP in rat but not human intestine. Cox & Cuthbert (1989) observed 
some inhibition of VIP stimulated activity but not competitive antagonism in rat 
jejunum. 
[4Cl-D-Phe6,Leu17]VIP was ineffective in rat jejunum as a VIP antagonist (Cox & 
Cuthbert, 1989). ln T84 colonic epithelia however VIP-stimulated sec (short circuit 
current) was inhibited and in exocrine pancreas YIP-stimulated amylase release was 
inhibited by this compound (Pandol et al., 1986). 
[Ac-Hisl, D-Phe2, LyslS, Arg16]VIP (3-7)GRF(8-27)-NH2 is a selective antagonist 
for the rat and human VIP1 receptors (Gourlet et al. , 1997a). 
P ACAP(6-38) is a potent antagonist of P ACAP receptors but has affinity for the 
VIP2 receptor without being active at the VIP1 receptor (Dickinson et al., 1997). 
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1.4 Physiological Roles 
Since first being identified, VIP and its receptors have been implicated as 
being central to a wide range of physiological processes. ln the interests of clarity a 
brief description of each distinct major area is given below: 
Neurotransmission - YIP is recognised as a neurotransmitter and 
neuromodulator (for a review see; Rostene, 1984). In autonomic ganglia VIP is 
found in neurons containing ACh (Hokfelt et al., 1980) and the signal induced by 
ACh is modulated by VIP (Lundberg et al., 1982; Kawatani et al., 1985). There is 
evidence that VIP is the neurotransmitter of the non-adrenergic non-cholinergic 
i.n.hibitory nervous system (Cameron et al., 1983). 
Effects 0 11 growth of neural tissue- VIP has both trophic and mitogenic effects 
on embryonic neural tissues (Brenneman et al., 1985; Brenneman & Eiden, 1986) but 
inhibits growth in certain tumours (Aile et al., 1985) and is also considered to be a 
part of a new group of neurotrophic factors since it stimulates differentiation and 
survival of several types of neuronal cells (Pincus et al., 1990; Pence & Shorter, 
1990; Watanabe et al., 1990; Deutsch & Sun, 1992; Okwnura et al., 1994). VIP also 
regulates ceU death and differentiation of retinal ganglion cells and sympathetic 
neuroblasts (Kaiser & Lipton, 1990; Pincus et aL, 1990). 
Electrolyte secretion- VIP is found in myenteric and submucous neurones of the 
rat intestinal wall (Dimaline et al., 1984; Ekblad et al., 1984:) and has long been 
associated with electrogenic anion secretion / intestinal ion & fluid secretion 
(Barbezat & Grossman, 1971; Schwartz et al., 1974; Racusen & Binder, 1977; 
Amiranoff et al., 1978; Binder et al., 1980). 
Endocrine ftmction- Immunoreactive PACAP and VIP are found in neurons 
projecting to the median eminence of the rat hypothalamus (Koves et al., 1991) and 
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the hypophysial portal blood in rat has been found to conta in high levels of both 
peptides (Rostene, 1984; Dow et aL, 1994). VIP has been identified as a 
physiological regulator of prolactin release from lactotrophs (Rostene, 1984). 
i) Regulation of insulin secretion- The VIP2 receptor is expressed in pancreatic 
islets and insulin-secreting cell lines (Inagaki et aL, 1994). P ACAP-like 
immunoreactivity is present in the nerve fibres innervating pancreatic islets (Fridolf 
et a.l., 1992). Kulkarni et al. (1995) demonstrated VIP and PACAP-38 stimulation 
of insulin and islet amyloid polypeptide (lAP) secretion from HIT-T15 cells. 
Bertrand et aL (1996) showed VIP2 receptor mediated stimulation of insulin 
secretion from rat pancreas and VIP1 receptor mediated stimulation of glucagon 
secretion . VIP and PACAP are thought to be potentiators not initiators of glucose-
induced insulin release. 
U) Circadian rhythms- The expression of VIP and arginine vasopressin(AVP) 
mRNA in the suprachiasmatic nucleus(SCN) is modulated by photoperiod (Duncan 
et al., 1995). Photoperiod information is communicated to the pineal gland from 
the retina via a multisynaptic pathway which involves a number of hypothalamic 
nuclei including the SCN (for review see Rusak & Bina, 1990). VIP- and AVP-
containing neurons project to the pineal gland from the SCN (fbata et al., 1989; 
Kalsbeek et al., 1992; Watts & Swanson, 1990) which is thought to be the circadian 
pacemaker (Meijer & Reitveld, 1989). VIP production is a central part of the 
mechanism which, by modulating melatonin secretion from the pineal, has profound 
effects on fertility in many mammals (McArthur et al., 1997; Duncan et al., 1995). 
VIP stimulates serotonin N-acetyl transferase activity (Klein & Berg, 1970; Klein & 
Weller, 1970; Klein & Weller, 1973; Yuwiler, 1987) and melatonin synthesis and 
release from the pineal gland (Spessert, 1993; Simmoneau.x et al., 1993). 
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Smooth muscle relaxation -VIP receptors in dispersed gastric smooth muscle 
cells stimulate a constitutive Ca2+ /calmodulin dependent NOS which causes the 
activation of guanylate cyclase and smooth muscle relaxation as a result of cGMP-
dependent protein kinase activity (Murthy et al., 1993). VIP release from myenteric 
neurons is partly responsible for relaxation of gastric (Grider & Rivier, 1990; Gu et 
al., 1992), intestinal (Grider & Makhlouf, 1986) and sphincteric smooth muscle 
(Goyal et al., 1995). VIP stimulates the relaxation of visceral and vascular smooth 
muscle (Li & Rand, 1990; Gaw et al., 1991; Grider et al., 1992). 
i) Vasculature- Radioimmunoassay and immunohistochemical methods have shown 
VIP innervation of cerebral blood vessels (Larsson et al., 1976; Edvinsson et al., 
1981). In rat, PACAP and VIP have similar potency for decreasing systemic arterial 
pressure (Nandha et al., 1991; Absood et al., 1992) and relaxing tail or mesenteric 
arteries (Absood et al., 1992; Huang et al., 1993). VIP caused vasodilation of 
isolated cerebral artery or vein through direct application and increased cerebral 
blood flow when applied intra-arterially to baboons (Edvinsson et al., 1981). 
Anzai et al. (1995) observed similar concentration-dependent relaxations in canine 
basilar arteries and rat intracerebral arterioles on addition of PACAP-27, P ACAP-
38 and VIP. The VIP1 receptor is involved in the relaxation of blood vessels in the 
rat pancreas (Bertrand et al., 1996). 
ii) Erectile function- VIP has been suggested as being the neurotransmitter that 
mediates penile erections and which can also stimulate sexual behaviours (Gozes et 
al., 1989). YIP is present in nerve fibres innervating the cavernous smooth muscle 
and blood vessels and is elevated during erection. Injection of exogenous VIP 
causes erection in man (Ottesen et al., 1984; Dixon et al ., 1984) and VIP levels have 
been shown to be decreased in impotent men (Gu et al., 1984). 
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iii) Airway smooth muscle- Ollerenshaw et al. (1989) postulated that the absence 
of VIP in the lung is responsible fo r the development of asthma since 
imunohistochemical methods failed to detect VIP in samples from asthmatic 
patients. Human lung contains high levels of VIP (Polak & Bloom, 1982) and VIP 
immunoreactive neurons (Carstairs & Barnes, 1986). VIP1 and VIP2 receptor 
mRNA was found in the bronchi and the vascular epithelium of the lung (Usdin et 
al., 1994). O'Donnell et al. (1994a;1994b) found that the VIP analogue, 
Ro 25-1553, was a more potent bronchodilator than isoproterenol or sa lbutamol 
and was effective in relaxing airway smooth muscle and reducing inflammation in 
guinea p ig lung in vitro and in vivo. 
Cerebral energy metabolism- VIP stimulates glycogenolysis in the cerebral 
cortex (Magistretti et al., 1981). Stimulation of VIP receptors on astroglia has also 
been shown to increase glycogenolysis and to change the cells morphology from flat 
to predominantly process-bearing cells (Magistretti, 1993). 
Immune System - VIP has potent immunoregulatory properties in both 
experimental animals and humans (Ottaway, 1991). VIP affects murine monocyte 
chemotaxis (Bondesson et al., 1991), inhibits the proliferRtive response of murine 
lymphocytes to mitogens (Ottaway & Greenberg, 1984; Stanisz et al., 1986; 
Ottaway, 1987; Boudard & Bastide, 1991) and modulates the production of 
immunoglobulins (Stanisz et al., 1986) and IL-2 (Ottaway, 1987) in response to 
Concanavilin A stimulation (an agglutinating and mitogenic protein). Matthew et 
al. (1992) have shown that VIP stimulates the release of IL-5 from activated T cells 
in murine schistosomiasis. 
In human lymphocyte cultures VIP can modulate the production of 
immunoglobulins in response to mitogen stimulation (Drew & Shearman, 1985), T 
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cell proliferative responses (Nordlind & Mutt, 1986) and the expression of natural 
killer ce ll activity (Drew & Shearman, 1985; Rola-Piesczynski et at., 1985). 
The VIP2 receptor has been demonstrated to have a role in IL-6 production 
and haematopoiesis in rat bone-marrow derived stromal cells (Cai et at., 1997). 
VIP and P ACAP are secretagogues for IL-6 in anterior pituitary cells as are 
cytokines (Spangelo et al., 1991; Matsumoto et at., 1993). VIP-immunoreactive 
nerve fibres and lymphoid cells have been shown in both primary and secondary 
lymphoid organs (Felten et at., 1985; Ottaway et al., 1987; Fink & Weihe, 1988; 
Gomariz et al., 1990, Gomariz et at., 1992) and the existence of VIP receptors has 
been documented on various types of immune cells (Guerrero et al., 1981; Danek et 
al., 1983; Beed et al., 1983; Ottaway & Greenberg, 1984; Calvo et al., 1986; Finch et 
al., 1989; O'Dorisio et al., 1989; Ottaway et al., 1990). 
1.5 Receptor Distribution 
1.5.1 VIP receptors 
VIPt and VIP2 receptors appear to be distributed in what is generally a 
mutually exclusive fashion in the brain. The VIPt receptor is found exclusively in 
the cerebral cortex and hippocampus whereas the VIP2 receptor is found in a 
number of areas of the diencephalon and brains tern (see Table 1.1, Figures 1.4 & 
1.5). These receptors are also largely distributed in a complementary fashion in 
other tissues (see Table 1.1 & 1.2). The VIP2 receptor is found in stomach and 
duodenal muscle and cells in the pancreatic islets (whereas the VIPt receptor is only 
found in associated cells). In the spleen, testes and ovary only VIP2 receptor is 
found at significant levels (in the parenchymal cells). In the kidney, VIPt and VIP2 
receptors are present in different parts of the nephron. In the thymus and adrenal, 
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the cortex and medulla contain both receptors but in varying amounts. Uterus and 
blood vessels appear to contain both receptors but they are quite possibly present 
in different cell types (Usdin et al., 1994). Wei & Mojsov (1996) failed to detect 
any VIP1 receptor mRNA in human pancreas by RNase protection assay but did 
find VIP2 receptor mRNA in human skeletal muscle (see Table 1.3). Adamou et al. 
(1995) also found two VIP2 receptor transcipts to be present in human skeletal 
muscle, there are currently no other published examples of VIP or PACAP receptors 
being detected in skeletal muscle. The difficulty in making a muscle preparation 
which is free of blood vessels must be considered with respect to these data. 
Human adipocytes express VIP1, VIP2 and PACAP receptors (Wei & Mojsov, 
1996) and rat bone marrow-derived stromal cells strongly express VIP2 receptor 
mRNA, rat bone marrow tissue expresses VIP and PACAP mRNA (Cai et al., 
1997). Cultured cells which express VIP or PACAP receptors are listed in 
Table 1.4. 
Fahrenkrug (1993) suggested that VIP in the brain was involved in regulating 
coupling between energy metabolism, blood flow and neuronal activity. The 
association of the VIP1 receptor with the cortex, hippocampus and amygdala 
indicate that its effects may be primarily on behaviours and higher cortical 
functions. The presence of VIP2 receptor mRNA in the brain stem motor nuclei and 
thalamus suggests that it may be involved in sensory information processing. VIP2 
receptor mRNA is present at relatively high level in the anterior pituitary and the 
hypothalamus where VIP1 receptor mRNA is either absent or present at very low 
levels (Usdin et al., 1994). It is therefore not surprising that the VIP2 receptor has 
been found to be important for the regulation of secretion from the pituitary 
(Rostene, 1984). VIP2 receptor mRNA has been found to be abundant in the 
suprachiasmatic nucleus and VIP1 receptor mRNA in the pineal gland (Usdin et al., 
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1994). VIP has been found to play a central role in the regulation of circadian 
rhythms (Duncan et al., 1995). 
1.5.2 PACAP receptors 
A high density of PACAP receptors was detected in rat brain and spinal 
cord (Gottschall et al., 1990; Lam et al., 1990; Cauvin et al., 1991; Gourlet et al., 
1991), bovine brain (Ohtaki et al., 1990), rat anterior pituitary (Gottschall et al., 
1990), cultured rat astrocytes (Tatsuno et al., 1991; Nilsson, 1994), the AR4-2J 
pancreatic acinar cell line (Buscail et al., 1990; Gourlet et al., 1991), retina (Nilsson, 
1994), a rat phaeochromocytoma cell line, PC12 and a human neuroblastoma cell 
line, NB-OK (Cauvin et al., 1990). A monocytic leukaemia cell line, THP-1, also 
expresses PACAP receptor (Chedeville et al., 1993) as do human adipocytes (Wei 
& Mojsov, 1996). 
PACAP receptor binding sites were identified in the hypothalamus, 
brainstem, cerebellum, cerebral cortex and basal ganglia of both rat and human 
(Lam et al., 1990; Suda et al., 1991). Masuo et al. {1991) used autoradiography to 
demonstrate a high density of P ACAP receptor binding sites in rat anterior 
pituitary, hippocampus and superior colliculus, moderate to high labelling in the 
periaqueductal gray matter, substantia nigra pars compacta and habenula and 
moderate labelling in the hypothalamus, ventral tegmental area, rnammilary body 
and medial geniculate nucleus. A high density of binding sites was also identified in 
the spinal trigeminal nucleus in the brainstem, lamina I-III and X in the spinal cord 
and the intermediolateral column of the thoracic cord. Legradi et al. (1994) found 
that in all other areas of the spinal cord the white matter was unlabelled and the 
grey matter moderately labelled. 
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The results of Morrow et al. (1993) and Spengler et a l. (1993) are tabulated 
in Table 1.5. This additionally demonstrates the presence of type I PACAP 
receptor mRNA in rat testes, adrenal gland, olfactory bulb and occipita l cortex. 
Spengler et al. (1993) identified a number of splice variants of the PACAP receptor 
as described in Section 1.6.3. Spengler et al. (1993) found the PACAP receptor 
without insert (see Figure 1.5) to be dominant in all tissues tested except in 
olfactory bulb, which had low 'hip' isoform levels and high 'hop' levels, and in testes 
and adrenal gland which were predominantly 'hop'. The hippocampus had low 
'hip' isoform levels. The distribution of PACAP and VIP receptors is distinct but 
overlapping. The PACAP receptor is expressed predominantly in the brain and 
very little in peripheral tissue and is present at higher levels in the brain than the 
VIP receptors (Ishihara et al., 1992). This was demonstrated by Masuo et al. (1992) 
who compared [125I]P ACAP-27 and [125I]VIP binding sites in rat brain sections, 
these authors found that [125J]PACAP-27 binding sites appeared to be more 
numerous than [125J]VIP binding sites in all tissues tested, the difference being 
particularly striking in the substantia nigra and areas of the cerebral cortex, where 
the levels of [125J]VIP binding were low. The VIP receptors are expressed at higher 
levels in various peripheral tissues. 
1.6 Isolation and Cloning of the Receptors 
Paul & Said (1987) solubilised VIP receptors from guinea pig lung using the 
zwitterionic detergent CHAPS. They used high performance gel filtration to 
separate the functional solubilised receptors and found that they had two active 
fractions. One fraction had a Stokes radius of 5.9±0.1 nm and an ICso for 
homologous displacement of 125I-VIP binding of 240 pM. The other fraction had a 
Stokes radius of 2.3±0.1 nm and an ICso for homologous displacement of 125£-VIP 
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binding of 1.2 )..lM. The authors found that a large proportion of the high affinity 
binding complex could be dissociated into a low affinity binding form by treatment 
with a higher CHAPS concentration and that the non-hydrolysable GTP analogue 
guanyl-5'-yl-i.midophosphate (Gpp(NH)p) had a similar effect. This indicated that 
the high affinity binding fraction was a G protein-complexed receptor (larger size, 
higher affinity for ligand) and the lower affinity binding fraction contained a 
receptor without associated G protein. It is interesting that PHI and GRF were 
respectively 88- and 23-fold less potent than VIP at disp lacing l25I-VIP binding 
from the high affinity receptor complex whereas PHI was 31-fold less potent than 
VIP a t displacing binding from the low affinity receptor and GRF was 23-fold more 
potent, suggesting that the high and low affinity states of the receptor have different 
ligand binding preferences. Couvineau et al. (1990) used affinity chromatography 
to purify a VIP receptor (53 kD) from porcine liver. Sreedharan et al. (1991) 
believed that they had cloned a human VIP receptor from the pre-8 lymphoblastic 
cell line Nalm 6 and the colon carcinoma cell line HT-29. They cloned the rat 
homologue of this receptor to confirm their results but it was found that when the 
eDNA was expressed in COS cells there was no specific binding of 125I-VIP. 
1.6.1 VIP1 receptor 
i) Rat 
Ishihara and coworkers cloned the rat secretin receptor (Ishihara et al., 1991) 
and then went on to clone the rat VIP1 receptor from a rat lung eDNA library 
(Ishihara et al., 1992). The authors used rat secretin receptor eDNA for cross-
hybridisation and isolated the rat receptor eDNA. The sequence contains an open-
reading frame of 459 amino acids with a N-terminal signal sequence of 30 amino 
acids The mature receptor is therefore 429 amino acids long with a mass of 49 kD 
which agrees reasonably well with the mass of 53 kD determined by Couvineau et 
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al. (1990) in porcine liver, when glycosylation is considered. The receptor contains 
seven putative transmembrane-spanning domains as determined by a 
hydrophobicity plot (Kyte & Doolittle, 1982). There is 48% homology at the amino 
acid level with the rat secretin receptor (Ishihara et al., 1991), 33% with the porcine 
calcitonin receptor (Lin et al., 1991) and 39% with the opposum receptor for PTH 
and PTHRP (Juppner et al., 1991). 
The eDNA was expressed in mouse COP cells and membranes were 
prepared for ligand binding studies. A Scatchard analysis of 1251-VIP binding 
revealed two distinct binding sites with dissociation constants of 173 pM and 21 
ru\11 at concentrations of 4.1 and 53 pmol/mg protein respectively, similar to those 
obtained in rat lung membrane fractions (Leroux et al., 1984). Displacement of 125y_ 
VIP binding gave ICsos of: 1.0 nM for PACAP-38; 2.5 ru\11 for PACAP-27; 3.0 nM 
for VIP; 6.0 nM for helodermin and PHM. Secretin was approximately 100-fold 
less potent than VIP and glucagon at 2.5 11M had no effect on VIP binding. These 
results are very similar to those from rat lung. The eDNA was expressed in 
COSGs1 cells which overexpress the a subunit of the rat G5 protein (Ishihara et al., 
1991). Stimulation of cAMP production was comparable to that obtained with the 
secretin receptor. ECsos were: 0.28 nM for PACAP-38; 0.42 nM for PACAP-27; 
0.57 nM for VIP. Helodennin and PHM had ECsos around 1 nM, the ECso for 
secretin was around 9 nM whereas glucagon hardly caused any stimulation. 
ii) Human 
In 1993 Sreedharan et al. succeeded in cloning the human VIP1 receptor from 
a human colon carcinoma cell-line (HT29). A PCR-derived secretin receptor probe 
was used to screen the HT29 eDNA library. A clone was selected which encoded a 
457 amino acid protein with a putative molecular mass of 52 kD. Northern blot 
analysis using a clone containing the partial VIP1 receptor sequence revealed 2.8 kb 
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transcripts in human lung, HT29 cells and Raji B-lymphoblasts with weaker 
expression in the human brain, heart, kidney, liver and placenta. At the nucleotide 
level the sequence had 85% identity with the rat VIP1 receptor and 56% with the rat 
secretin receptor. At the amino acid level the homology was 84%,44% and 35% 
with the rat VIPt, secretin and GLP-1 receptors respectively. The protein is missing 
the Gin 134 and lle290 which are present in the rat receptor . There are eight cysteine 
residues in the N-terminus and four conserved potential N-glycosylation sites 
(Asn58, Asn69, AsnlOO and Asn290). The clone was expressed in COS 7 cells and 
12Sf-VIPbinding was observed to occur with a Kd of0.8 ru\1 as determined by 
Scatchard analysis. The construct was then expressed in HEK-293 cells where 
cAMP production was measured with and without G5a cotransfection. In the 
absence of additional G5a, 10 !!M VIP caused a 3-fold stimulation of intracellular 
cAMP levels and a 14-fold stimulation in it's presence. ECsos were not determined 
but it appears that VIP, PACAP-38 and PHM were of similar potency (around 1 
ru\1) with secretin approximately an order of magnitude less potent. 
Couvineau et al. (1994) isolated two cON A clones from a human jejunal 
epithelial cell eDNA library which were divergent only in their N-termini. The clone 
hlVR8 encodes a 460 amino acid protein the sequence of which is 81% homologous 
with the rat lung VIP1 receptor (Ishihara et al., 1992). Hydrophobicity analysis 
predicts the typical seven transmembrane-spanning regions. There is a 30 amino 
acid N-terminal signal sequence (cleavage between Ala30 and Ala31) indicating a 
mature protein 430 amino acids in length. The protein has a predicted mass of 49 
kD after cleavage of the signal sequence; affinity cross-linking studies give a mass of 
67kD probably as a result of glycosylation. The sequence has four potential N-
glycosylation sites; Asn58, Asn69 and AsnlOO in theN-terminus and Asn293 in EC2. 
The sequence contains one cysteine each in EC1 and EC2 (Cys208 and Cys288), a 
potential PKA phosphorylation site on Ser451 in the C-terminal tail and a site for 
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PKC at Ser250 in IC2. When expressed in COS 7 cells h!VR8 facilitated specific 
12SJ-VIP binding at a single site with a dissociation constant of 0.6 nM and a Bmax 
of 211 fmol / mg membrane protein. The rank order of potency for VIP and its 
related peptides was: VIP = PACAP-27 > PACAP-38 > heloderrnin > hGRF = 
PHM > secretin. hiVR8 has 48% sequence identity with the rat VIPz receptor (Lutz 
et al., 1993); rat PACAP receptor, 54% (Pisegna & Wank, 1993); human GRF 
receptor, 42% (Gaylinn et al., 1993); rat liver glucagon receptor, 39% (Jelinek et al., 
1993); opossum kidney PTH receptor, 37% (Juppner et al., 1991); rat pancreatic 
GLP I receptor, 37% (Thorens, 1992); porcine kidney calcitonin receptor, 29% (Lin 
et a!., 1991). 
The other clone hiVRS, as mentioned on the previous page, was identical in 
sequence to hiVR8 except for its N-terrninal 67 amino acids This clone was 495 
amino acids in length. When expressed in COS 7 cells this clone caused no specific 
binding of 125f-VIP or 1251-PACAP-27. Couvineau et al. suggest that the two forms 
of the protein may result from alternative splicing of the same mRNA transcript and 
that proteolytic maturation may produce a functional receptor. There have been no 
further developments to date regarding this hypothesis. 
1.6.2 VIP2 receptor 
i) Rat 
The rat VIPz receptor (see Figure 1.1) was cloned by Lutz et al. (1993) from 
a rat olfactory bulb and pituitary eDNA library. OUgonucletide primers 
corresponding to conserved regions of TMIII and TMVII of the secretin, calcitonin 
and PTH receptors were used to amplify fragments from rat pituitary which were 
subdoned and sequenced. One fragment contained a 500 bp insert which 
represented a new member of this family. This fragment was used as a hybridising 
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probe for Northern blot analysis of rat tissue. This revealed a 3.5 kb transcript in 
pituitary and other brain regions with the strongest band appearing in the olfactory 
bulb sample. A rat olfactory bulb eDNA library was therefore screened with probes 
for the novel sequence and three clones were isolated, one of these clones contained 
the complete open reading frame giving a protein of 437 amino acids and a 
predicted molecular mass of 49,519. The protein contains a predicted hydrophobic 
22 amino acid signal sequence with a cleavage point between Pro22 and Glu23. The 
hydrophobicity plot predicts the expected seven transmembrane spanning domains. 
The eight cysteine residues conserved in the rat VIP1, secretin, GHRH and PACAP 
receptors and human VIP1 are also conserved in this receptor. There are putative 
N-glycosylation sites at Asn57, Asn87 and Asn91 in theN-terminus. There is 50% 
sequence identity at the amino acid level with the rat VIP1 and PACAP receptors 
with the highest homology occurring in the transmembrane regions. TheN- and C-
terrnini are highly divergent in sequence. 
The construct was expressed in COS 7 cells in order to assess the receptor's 
ability to stimulate cAMP production. P ACAP-38, P ACAP-27, helodermin and 
VIP were of similar potency (ECsos of 0.18 nM, 0.43 ru\11, 0.25 nM and 0.17 nM 
respectively), PHI was less potent (2.14 nM) and CRF, CGRP, secretin and glucagon 
had negligible effect. From a single dose it was assessed that rGHRH was less 
potent than PHI. The rank order of potency being; VIP - P-27 - P-38 - heloderrnin 
> PHI>> rGHRH. 
In situ hybridisation of VIP2 receptor mRNA in rat brain revealed its 
presence predominantly in the suprachlasmatic nucleus and paraventricular nucleus 
of the hypothalamus (with lower levels in the supraoptic nucleus), the mediodorsal 
and ventral thalamus, the CAl and CA3 subfields of the hippocampus and in the 
dentate gyrus. The mRNA was present in all layers in the olfactory bulb except the 
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external plexiform layer. Low levels were observed in the pituitary. No labelling 
was observed in the cerebral cortex or cerebellum. 
ii) Human 
Adamou et al. (1995) cloned the human VIP2 receptor from a human 
placental eDNA library. They used degenerate oligonucleotide primers based on 
conserved regions in the first intracellulaT loop and seventh transmembrane regions 
of the secretin, PTH and glucagon receptors to amplify a fragment encoding the 
human VIP2 receptor. The open-reading frame encodes a 438 amino acid protein 
with a predicted molecular weight of 49.5 kD. The sequence contains a predicted 
signal sequence of 20 amino adds with a cleavage point between Ser20 and Jle21. In 
addition to the hydrophobic signal peptide, the sequence contains another seven 
hydrophobic regions which are putative transmembrane spanning regions. Cleavage 
of the signal peptide would give a predicted molecular weight of 46.5 kD. There are 
3 potential N-glycosylation sites in the N-terrninus; Asn58, Asn88 and Asn92. The 
human and rat receptors are 85% identical at the amino acid sequence level and 
82% identical at the level of nucleotide sequence. The human VIP2 receptor is 52% 
homologous to the human PACAP receptor (Ogi et al., 1993); 49% with the human 
VIP1 receptor (Sreedharan et al., 1993); 48% with the rat secretin receptor (Juppner 
at al., 1991); 41% with the human GHRH receptor (Mayo, 1992); 49% with the 
human PTH and glucagon receptors (Schneider et al., 1993; MacNeil et al., 1994). 
Scatchard analysis of 1251-VIP binding showed a single high affinity binding site 
(Kd, 63.6 pM; Bmax, 34.7 fmol / mg protein) when the eDNA was transiently 
expressed in COS 7 cells. VIP and PACAP-38 displaced 1251-VIP binding with 
IC5os of 0.93 ru\11 and 6.2 nM respectively. Secretin was very poor at displacing 
1251-VIP binding. 
29 
1.6.3 PACAP Receptors 
i) Rat 
Morrow et al. (1993) cloned the PACAP receptor from a rat olfactory bulb 
eDNA library using degenerate oligonucleotide primers for the conserved regions in 
TM3 and TM7 of the calcitonin, secretin and PTH receptors. The receptor was 
cloned in two splice variant forms, with and without an 84 bp exon (28 amino 
acids: see Figure 1.10). The firs t 19 N-terrninal amino acids of this receptor were 
predicted to be a signal sequence with a cleavage site between Ala19 and Met20. 
The mature receptor without the 28 amino acid insert in IC3 was therefore 448 
amino acids long. Potential N-glycosylation sites were identified at positions 47, 
59 and 116 on the N-terrninus, position 299 in EC2 and position 342 in IC3. It is 
worth noting that potential phosphorylation sites were found at Ser365 and Thr375 
in the 28 amino acid insert portion of IC3. They observed that the eDNA when 
expressed transiently in COS 7 cells was functionally coupled to adenylate cyclase 
stimulation with the following potency of ligands: P ACAP-38 = PACAP-27 > VIP 
> PHI. Hashimoto et al. (1993), Hosoya et al. (1993), Pisegna & Wank (1993), 
Spengler et al. (1993) and Svoboda et al. (1993) also went on to done this receptor 
and a number of splice variants from rat tissue. Spengler et al. (1993) isolated five 
splice variants of the PACAP receptor from a new-born rat colliculi eDNA librar y. 
They used the transcriptional induction of a cAMP-responsive luciferase gene as a 
novel expression cloning strategy to identify receptors positively coupled to 
adenylate cyclase. The DNA and reporter construct were cotransfected into LLC 
PKl cells which do not have endogenous receptors responsive to PACAP or VIP. 
Two cDNAs were cloned which had identical sequences except for the presence or 
absence of an 84 bp (28 amino acids) cassette in the C-terminal portion of the third 
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intracellular loop. The authors used primers for the 3' and 5' untranslated regions of 
the isolated cON As to isolate an additional 3 clones from a rat genomic library. 
The clones were divergent only in the presence or absence of two 84 bp cassettes in 
the C-terminal portion of the third intracellular loop (see figure 1.9). The authors 
found that the exon-intron boundaries were in excellent agreement with the 
consensus exon-intron junction sequences and also identified two contiguous splice 
acceptor sites used to generate the hop 1 and hop2 (which contains a serine residue 
missing from hop 1) variants of the P ACAP receptor. The presence of introns in the 
P ACAP receptor gene is of particular interest since many G protein-coupled 
receptor genes lack introns. There are however a number of examples now of 
secretin family receptors genes containing introns (Mayo, 1992). The first 19 amino 
acid residues in the N-terminus are believed to encode a signal sequence (Hosaya et 
al., 1993). The signalling characteristics of the P ACAP receptor splice variants will 
be discussed later. 
U) Human 
The human PACAP receptor was cloned by Ogi et al. (1993) and consists of 
525 amino acids with a predicted 77 residue N-terminal signal sequence. The length 
of the mature receptor is therefore 448 amino acids, the same length as the rat 
receptor without an insert. There is 92.5% homology at the level of amino acid 
sequence between. the rat and human isoforms of this receptor. The gene for the 
human receptor has been localised to chromosome 7 by using human-mouse somatic 
cell hybrids. Human genomic DNA and the hybrid cells containing chromosome 7 
both produced bands after Southern blot analysis using the PACAP receptor DNA 
as a probe (Ogi et al., 1993). 
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iti) Bovine 
Ohta.ki et al. (1993) used a synthetic oligonucleotide probe based on the 
sequence of the N-terminus of the purified bovine P ACAP receptor to clone two 
splice variants of the PACAP receptor from a bovine brain eDNA library. One 
clone had an open reading frame of 513 amino acids with the first 37 N-terminal 
residues being a signal sequence (based on the sequence of the purified receptor). 
This means that the clone is the same length as the hopl-containing rat and human 
PACAP receptors. There were four potential N-glycosylation sites in the 
extracellular loops and another in the putative EC3. The other clone was shorter by 
28 amino acids and corresponds to the short P ACAP receptor which has no insert. 
1.7 Nomenclature 
The lntemational Union of Pharmacology (fUPHAR) Committee on Receptor 
Nomenclature have proposed an alternative nomenclature for the VIP1, VIP2 and 
P AC.AP receptors, it is suggested that they be known as the Vl' AC 1, VP AC2 and 
PAC 1 receptors respectively (Hannar et al., 1998). 
1.8 Aims of this Study 
Despite the cloning of the VIP1 and VIP2 receptors from a number of 
different species, the signalling characteristics of the VIP receptors has not been 
extensively characterised. The rat VIP2 receptor was cloned by Dr. Eve Lutz in this 
laboratory and this study was initiated with two main aims: 
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i) to characterise the ability of the rat VIP2 receptor to activate intracellular 
signalling cascades in a heterologous expression system (transient transfection of 
COS 7 cells) and in cells expressing endogenous VIP2 receptors (the GH3 rat 
anterior pituitary cell line). 
ii) to investigate the function of specific receptor domains through the use of 
chimaeric PACAP /VIP2 receptors and C-terminally truncated VIP2 receptors. 
Constructs were created by Dr. Eve Lutz in this laboratory and exploited the 
homology between the VIP2 and P ACAP receptors to allow an investigation of the 
role of receptor domains in determining the VIP2 and P ACAP receptors signalling 
and ligand binding characteristics. 
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Fig. 1.1 Identity between the rat VIP2 wt receptor and PACAP receptor sequence. 
The red residues are those conserved between the V1P2 wt and PACAP receptors. The blue bar indicates the site of cleavage of the signal sequence. 
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Secondary structure 
The first two lines below the ·sequence are an estimate of secondary 
structure. The second line of prediction represents a subset with a higher 
expected average accuracy(> 82%). 
E represents a probable extended strand of the sequence 
H represents a probable helix 
L or a space in the first line, represents a probable looping portion of 
the sequence 
represents a residue for which no confident prediction can be made 
Solvent Accessibility 
The third and fourth lines are estimates of the solvent accessibility of the 
individual residues. The fourth line is a subset with an average expected 
correlation > 0.69. 
b represents a 'buried' residue 
e represents an 'exposed' residue 
represents a residue for which no confident prediction can be made 
A system of neural networks perform the prediction task from multiple 
sequence alignment input. Secondary structure is determined by the 
PHDsec programme and solvent accessibility by the PHDacc programme 
on the PHD server at EMBL-Heidelberg. A full description of the 
methods used can be found in Rost & Sander, 1993; Rost et al., 1994; Rost 
& Sander, 1994. 
Fig. 1.3 





















The table shows the amino acid sequences of the VIP family peptides. o, ovine; h, human; r, rat; p, porcine;, ra, rabbit; go, 
goat; do, dog; b, bovine; gp, guinea pig; hs, Heloderma suspectum (Gila monster); a, -NH2. Certain residues are coloured red 
to emphasise the conservation of sequence between peptides. 
Table 1.1 
Distribution of VIP1 and VIP2 receptor mRNA in the rat: 
as assessed by in situ hybridisation 
i) VIP1 receptor distribution 
Cerebral cortex 
Layers ill and V 
Several amygdaloid nuclei 
Hippocampus 
Olfactory bulb 
External plexiform layer 
Thalamus 






Midbrain, pontine or medullary neurons 
No labelling 
010roid plexus 
Some cells of pia mater 
Stomach & Duodenum 
No labelling 
Spleen 
Light labelling of certain cells 
Kidney 
High epithelium of proximal and distal tubules with renal cortex and 
some juxtaglomerular cells 
Thymus 
Mostly in cortical areas 
Adrenal 





Walls of blood vessels with both thick and thin muscular layers 
Vascular epithelium and large and moderately sized bronchii 
epithelium 
Cells within connective tissue septa 
Ovary 
No labelling 
Table 1.1 (cont.) 
Uterus 
Intense labelling of smooth muscle cells 
Pituitary 
Little or no labelling 
ii) VIP2 receptor distribution 
Thalamus 






Internal granular layer 
Cerebral cortex 
Layer VI 
Medial geniculate body 
Heavy labelling 





Bed nucleus of stria temtinalis 
Diagonal band of Broca 
Hypothalamus 
Medial preoptic areas 
Lateral preoptic areas 
Organon vasculosum laminae terminalis 
Suprachiasmatic nucleus 
ventral subdivision (heavy labelling) 
peri ventricular portion 
Magnocellular hypothalamic nuclei 
Para ventricular nucleus 
Supraoptic nucleus 
:Midbrain 
Accessory magnocellular nucleus 
Arcuate nucleus 
Posterior hypothalamic nucleus (heavy labelling) 
Mamillary nucleus (heavy labelling) 
Superior colliculi (heavy labelling) 
Solitary tract 
Reticular formation neurons 
Table 1.1 (cont.) 
Brains tern 
Motor neurons inc. facial and hypoglossal neurons 
Choroid plexus 
Stomach 





Primarily in areas of thin epithelium including thin segments of the 
loops of Henle and collecting tubules in the renal medulla 
Thymus 
Cortex and medulla 
Adrenal 






Blood vessels with both thick and thin muscular layers and cells 
within islets 
Light labelling 
Small and terminal bronchioles, vascular epithelium 
Ducts in epididymus (heavy labelling) and spermatocytes within 
epithelium. Probably not Leydig cells, presence in Sertoli cells is 
unknown. 
Granulosa cells in developing follicles 
Uterus 
Intense labelling of smooth muscle cells 
Pituitary 
Anterior lobe (many cells) 
Intermediate lobe (a few cells) 
(after Usdin et al., 1994) 
Table 1.2 





















- - no mRNA for receptor detected 
+- mRNA for receptor present 
++-large amount of mRNA for receptor present 
1By RT-PCR- Hashimoto et al., 1993 
2By RT-PCR - Hosoya et al., 1993 
3By RT-PCR - Inagaki et al., 1994 
4By RT-PCR - Cai et al., 1997 
5By Northern hybridisation - Ishihara et al., 1992 
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Table 1.3 
Distribution of VIP1 and VIP2 and PACAP receptor mRNA in 











- - no mRNA for receptor detected 





+I - - low levels of mRNA for receptor present 
























Cell lines expressing VIP or P ACAP receptors 
a mouse insulin-secreting 13 cell line which has high levels of 
VIP2 receptor m.RNA (Inagaki et al., 1994) 
a hamster insulin-secreting 13 cell line which has moderate VIP2 
receptor m.RNA levels (Inagaki et al., 1994) 
a rat insulin-secreting 13 cell line which has moderate VIP2 
mRNA levels (Inagaki et al., 1994) 
a human adenocarcinoma (intestinal epithelium) cell line 
which expresses the VIP1 receptor (Turner et al., 1988; 
Sreedharan et al., 1993) 
a human lymphoblast cell line which expresses the VIP2 
receptor (Svoboda et al., 1994) 
a rat neuroblastoma cell line which expresses the P ACAP 
receptor (Cauvin et al., 1990) 
a rat phaeochromocytoma cell line which expresses the P ACAP 
receptor (Watanabe et al., 1990) 
rat pancreatic acinar cell line which expresses the P ACAP 
receptor (Buscail et al., 1990) 
a rat monocytic leukaemia cell line which expresses the P ACAP 
receptor (ChedeviUe et al., 1993) 
a rat anterior pituitary tumour cell line which expresses the 
VIP2 receptor (E.M. Lutz; personal communication) 
a rat anterior pituitary tumour cell line which expresses the 
VIP2 receptor (Rawlings et al., 1995) 
Table 1.5 
Distribution of PACAP Receptor mRNA in rat: 
as assessed by Northern Blot, Reverse Transcriptase-mediated 
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+(NB)l / +(PCR)2/ +(I5)2 
+(PCR)2/ +(15)2 
+(PCR)2 
- - no mRNA for receptor detected 
+- mRNA for receptor present 
++-large amount of mRNA for receptor present 
NB - by Northern blot 
PCR- by Reverse Transcriptase- Polymerase Chain Reaction 
IS- by in situ hybridisation 
(1 Morrow et al., 1993; 2 Spengler e t al., 1993) 
Fig. 1.4 Areas of the rat brain which express high levels of VIP2 receptor 
Cortex 






Figure 1.5 The rat PACAP receptor with HOP-1 cassette 
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HOP-I CASSETTE 
The rat PACAP receptor amino acid sequence is shown. The sequence of the HOP-1 cassette insertion as found in the PACAPtong wt receptor is 
identified in the box. The Y -shaped structures indicate the position of putative N-linked glycosylation sites. 
Chapter 2 
Materials & Methods 
2.1 Materials 
The standard laboratory chemicals were of Analar grade and the majority 
were obtained from BDH Chemicals Ltd., Poole, UK. Tissue cu lture reagents were 
obtained from GIBCO BRL, Life Technologies, Paisley, UK. Foetal Calf Serum was 
obtained from Harlan Sera-Lab, Crawley Down, UK. Tissue culture plastics were 
obtained from Costar UK Ltd. DEAE-dextran was from Promega, Southampton, 
UK. Ch loroquine phosphate, ampicillin (0[-]-o:-aminobenzylpenicillin), DMSO 
(dimethylsulfoxide), 1,1,2-trichlorotrifluoroethane, tri-n-octylamine, 3-isobutyll-
methylxanthine (IBMX), Dowex anion exchange resin (1x8, 200-400 mesh, H+ 
form), Dowex cation exchange resin (50X8, 100-200 mesh, Na+ form), Tween-20, 
Guanosine 5'-0-(2-thiodiphosphate) (GTP.yS), PDBu, ionomycin, pertussis toxin, 
mastoparan, cholera toxin, forskolin, thapsigargin, methoxyverapamil, nifedipine, 
AEBSF (4-(2-Aminoethyl)benzenesulionyl Fluoride, aprotinin, leupeptin, pepstatin, 
Na3 V04, NaF, bacitracin and soybean trypsin inhibitor were obtained from Sigma-
Aldrich Co. Ltd., Poole, UK. H-89 dihydrochloride, KT-5823, KT-5720, 
staurosporine, Pertussis toxin B oligomer, SK&F 96365 and peptide agonists were 
obtained from Calbiochem-Novabiochem (UK) Ltd. Coomassie Protein Assay 
Reagent was pbtained from Pierce, Chester, UK. The radioligands 
myo-[2-3H]inositol, L-[2,3-3H]arginine and 125[-PACAP-27 were from NEN-
DuPont (UK) Ltd., Stevenage, UK. 125[-heloderrnin was synthesised by John Bennie 
(MRC Brain Metabolism Unit, University of Edinburgh, Scotland, UK). COB-
Wistar rats were obtained from Charles River UK Ltd. The COS 7 cells were a gift 
from Janet Allen (Glasgow University, Scotland, UK). 
Primary anti-sera and control peptides for Go:5, Go: q/ 11 and GCJ.ijo / t/ z were 
obtained from Santa Cruz Biotechnology Inc., Santa Cruz, Ca., USA. Anti-serum 
for Go:tl-2 and control peptide were obtained from Calbiochem-Novabiochem (UK) 
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Ltd. PhastSystem materials were obtained from Pharmacia, UK. lmmobi lon 
transfer membranes were obtained from Millipore, UK. Enhanced 
ChemiLuminescence (ECL) solutions were obtained from Amersham Ltd, UK. 
Rabbit anti -cAMP antiserwn (Rl87) was a generous gift from Dr. I. Gow, Dept. of 
Physiology, University of Edinburgh. Non-immune rabbit serwn and ail secondary 
anti-sera were from the Scottish Antibody Production Unit (SAPU), Carluke, 
Lanarkshire, UK. 
The Strategene RT PCR kit and Taq polymerase were obtained from 
Strategene Ltd., Cambridge, UK. RNAzol B Isolation of RNA kit was obtained 
from Biogenesis Ltd., Poole, UK. RNaseZAP solution was from Ambion Inc., 
Austin, Texas, USA. The QIAGEN Plasmid Maxi Kit was obtained from QIAGEN 
Ltd., Crawley, West Sussex, UK. 
2.2 Methods 
2.2.1 Cell Culture 
All cell lines were grown in a humidified atmosphere of 95% air/5% carbon 
dioxide at 37°C. The medium was normally changed every 3 to 4 days (every day 
for GH3 cells). The cells were harvested by either trypsin digestion or a brief 
incubation with Hank's Buffered Saline Solution (HBSS) without calcium, 
magnesium or phenol red, containing 0.1% w / v EDT A. The cell medium was 
removed and 0.25% v / v trypsin solution in GIBCO solution A (0.4 g/ 1 KCl, 2.2 g/ 1 
NaHC03, 6.8 g/ 1 NaCl, 1.0 g/ 1 glucose, 0.005 g / 1 Phenol Red) was applied (1 ml 
per 80 cm2 flask or 2 mls per 175 cm2 flask) to the cell layer and then aspira ted off 
after approx. 15 seconds. After a further 20 minutes the cells were washed off the 
flas k's surface with medium and pelleted by centrifugation a t 200 g fo r 5 minutes. 
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The cells were then resuspended in medium and distributed into new flasks (usually 
at a ratio of 1:3 or 1:4) or seeded into 12- or 24-well plates for assay. Alternatively 
the HBSS/EDTA soJution was applied (1 ml per 80 cm2 flask or 2 mls per 175 cm2 
flask) for 10 minutes before the cells were washed off as described above. 
For storage purposes 0.5 ml volumes of cells at 106 ce lls/ml in medium or 
Foetal Calf Serum containing 7% dimethylsulfoxide (OMSO) were aliquoted into 
cryostat tubes and placed at -7ooc overnight in a polystyrene box. The tubes were 
then placed into Liquid nitrogen. To recover the cells from the liquid nitrogen the 
tubes were allowed to thaw at room temperature and then warmed in a 37oc 
waterbath for several minutes. A small volume of medium was added to the tube 
and the cells were removed and resuspended in approx. 8 mls of appropriate 
medium. The cells were pelleted by centrifugation at 200 g fo r 5 minutes before 
being resuspended in medium and transferred into a 25 cm2 flask. The next day the 
medium was aspirated off and fresh medium added to remove traces of DMSO. 
The cells were then grown as normal. 
i) COS 7 cells 
This monkey kidney fibroblast cell line was a gilt from janet Allen (Glasgow 
University, Scotland, UK). These cells were maintained in Dulbecco's Modified 
Eagle Medium (with 580 mg/1 L-Glutamine, 4500 mg/l D-Glucose, without Sodium 
Pyruvate) supplemented with 10% Newborn Calf Serum v /v and 100 units/ml 
Penicillin and 100 )lg/ml Streptomycin and were passaged every 5 to 7 days when 
close to 100% confluency. These cells were used for transient transfection and 
assays of their native receptor activity. 
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ii) GH3 cells 
This rat anterior pituitary tumour cell line was maintained in Dulbecco's 
Modified Eagle Medium (with 580 mg/ 1 L-Glutamine, 4500 mg/ 1 D-Glucose and 
110 mg/ 1 Sodium Pyruvate) supplemented with 10% Foetal Calf serum v / v and 
100 units / ml Penicillin and 100 ~g/ml Streptomycin. The cells were passaged every 
4 to 5 days when 50-70% confluent. The medium was changed every day. 
2.2.2 Preparation of eDNA 
i) Transformation of competent cells 
Approx. 100 ng of eDNA was added to a 50 111 aliquot of MC1061/P3 
competent ceUs (a strain of Escherichia coli) which was mixed gently and left on ice 
for 30 minutes. The cells were kept at 420C for 45 seconds and placed back on ice 
for 10 minutes. The cells were added to 1 ml of Luria Bertani (LB)-broth (10 g/ 1 
tryptone, 5 g/ l yeast extract, 5 g/ 1 NaCl) and placed on the rotator (New 
Brunswick Scientific, Edison, N.L USA) in the 370C incubator (Gallenkamp Plus 
lncunbator; Gallenkamp, Loughborough, UK) for 1 hour. 100 f.l.l of this suspension 
was spread onto LB-agar plates (LB-broth + 1% bactoagar) supplemented with 
ampicillin at 12.5 f.l.g/ml (Sigma) and tetracycline at 7.5f.l.g/ml (Gibco) to select for 
plasmid-containing cells. The plates were left in the 37oc incubator overnight. A 
distinct colony was then picked from the plate and used to inoculate a 2 ml volume 
of LB-broth containing ampicillin and tetracycline. The culture was incubated 
overnight at 370C on the rotator. The 2 ml culture was then used to inoculate a 500 
rnl volume of L-broth containing ampicillin and tetracycline in a conical flask which 
was left on the Gallenkamp orbital incubator (Gallenkamp) overnight at 370C. 
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ii) Plasmid purification 
Plasmid purification was carried out using the QIAGEN Plasmid Maxi Kit 
(QIAGEN Ltd., Crawley, West Sussex, UK) according to the manufacturers 
instructions. The bacterial cells were harvested by centrifugation at 6000 x g for 15 
minutes at 4°C (Sorvali GSA rotor). The supernatant was poured away and the 
pellet resuspended in 10 ml of Buffer P1 (resuspension buffer: 50 mM Tris Cl, pH 
8.0,; 10 mM EDTA) containing 100 ).lg /ml RNase A solution. 10 ml of Buffer P2 
(Lysis buffer: 200 mM NaOH, 1% sodium dodecyl sulphate) was added and the 
solution mixed gently by inversion and left to incubate at room temperature for 5 
minutes. The lysis reaction causes the production of a viscous solution. 10 ml of 
chilled Buffer P3 (Neutralisation buffer: 3.0 M potassium acetate, pH 5.5) was 
added, the solution was inunediately mixed by inversion and incubated on ice for 
20 minutes. A viscous precipitate of genomic D1 A, protein, cell debris and SDS is 
visible at this point. The solution was mixed again and loaded into polypropylene 
tubes for centrifugation in the Sorvall SS-34 rotor at 20,000 g for 30 minutes at 4oc. 
The supernatant containing the plasmid DNA was rapidly removed and 
recentrifuged for 15 minutes at 20,000 g to remove particulate matter and prevent 
clogging of the filters. A QIAGEN-tip 500 was equilibrated by the application of 10 
ml of QBT buffer (Equilibration buffer: 750 mM NaCl, 50 mM MOPS (3-[N-
Morpholino] propanesulfonic acid), pH 7.0, 15% isopropanol, 0.15% Triton X-100). 
The supernatant was applied to the column and washed with 2 x 30 ml of Buffer 
QC (Wash buffer: 1.0 M NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol). The 
DNA was eluted with 15 ml of Buffer QF (Elution buffer: 1.25 M NaCl, 50 rru\11 Tris 
HCl, pH 8.5, 15% isopropanol) and collected. The DNA was precipitated by the 
addition of 10.5 ml of isopropanol at room temperature, the solution was mixed 
and centrifuged at 15,000 g for 30 minutes at 4°C (Sorvall SS-34 rotor). The outside 
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of the tube was marked beforehand to identify the position of the pellet which can 
be difficult to see. The peUet was washed with 5 ml of room temperature 70% 
ethanol v / v and centrifuged at 15,000 g for 10 minutes. The last step was repeated 
and then the pellet was air-dried for 10 minutes before being dissolved in TE buffer 
(10 mM Tris HCl, pH 8.0, 1 mM EDT A) pH 8.0. 
2.2.3 Transfection by the DEAE dextran method 
COS 7 cells were trypsinised, or treated with EDT A as described earlier, 
and plated out into 80 cm2 flasks at approx. 50% confluency for transfection the 
following day. The cells growth medium was replaced with prewarrned OptiMem 
twice (10 minutes between washes) before the transfecting medium was added to 
the cells. The eDNA for transfection was suspended in OptiMem (typically at 10 
)l.g/ml) and DEAE dextran at 0.4 mg/ml (DEAE dextran stock was at 10 mg/ ml in 
PBS and filter-sterilised), 2 mls of this solution was added to each flask and gently 
distributed over the cell layer. After 30 minutes incubation 3 mls of OptiMem 
containing 0.4 mg/ml DEAE dextran and 1671..!..M chloroquine phosphate (Sigma) 
(10 mM stock made up in PBS and filter-sterilised) was added to the solution and 
the flasks left to incubate for a further 3 hours. After this time the transfecting 
medium was aspirated off and replaced with PBS and 10% DMSO in Optil'vfem for 
2 minutes. This medium was then aspirated off and replaced with the growth 
medium for transfected COS 7 cells (DMEM supplememented with 2% UltroSer G 
v /v (Gibco), 100 units/ml Penicillin and 100 !!g/ml Streptomycin). 24 hours later 
the cells were trypsinised or treated with EDT A and seeded into 24- or 12-well 
plates for assay (two 80 cm2 flasks per plate). For binding studies the medium in 
the flasks was changed and the cells were not trypsinised or EDT A treated. The 
cells were assayed after a further 40 hours. 
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2.2.4 Assay for [3H]inositol phosphate production 
Cells in 12-well tissue culture plates (maintained at 37°( in a 5% C02/ 9S% 
02 environment) were labelled with 0.5 or 1 IJ.(i / ml of myo-[2-3H]inositol (NEN 
DuPont) for 16-18 hours in Earle's Balanced Salt Solution with 10 mM glucose, 10 
mM HEPES, pH 7.4 (NaOH). The cells were then washed twice in Earle's Balanced 
Salt Solution with 10 mM glucose, 10 m.t\1 HEPES, 0.2% Bovine Serum Albumin 
(Fraction V; Sigma), pH 7.4 (NaOH) and preincubated fo r 10 minutes with 10 mM 
LiCl before agonist stimulation. Reactions were stopped by aspiration of medium 
and addition of 700 1-1.1 of ice-cold 1.34 M trichloroacetic acid. The wells were 
scraped and the solution transferred into a l.S ml eppendorf tube for centrifugation 
to pellet the precipitated protein (5 minutes, 12,000 g, JO(), a SOO 1-1.1 sample of the 
supernatant was then added to SO Ill of 0.1 M ethylenediaminetetraacetic acid 
(EDT A) and SOO 1-1.1 of a 1:1 mixture of 1,1,2-trichlorotrifluoroethane and tri-n-
octylamine. The sample was vortexed and centrifuged (5 minutes, 12,000 g, 40C) 
and a 300 1-1.1 volume of the aqueous phase was added to 200 1-1.1 of 1 M NaHC03 
containing universal indicator. The sample was applied to a 1 rnl column of Dowex 
anion exchange resin (1x8 resin, formate form, 200-400 mesh; Bio-Rad) and a 
stepwise gradient of ammonium formate was used to elute the [3H]inositol 
phosphates, a method previously described by Berridge et al. (1983). 
The sample in the column was washed with: 
1) 1S mls of UHP water 
2) S rnls of SO mM ammonium formate 
3) 10 mls of 1 M ammonium formate / 0.1 M formic acid. This fraction contains 
the [3H] inositol phosphates and was collected in a Zinsser scintillation vial 
(Zinsser Analytic GmbH) 
4) S mls of 2M ammonium formate / 0.1 M formic acid 
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5) 15 mls of UHP water 
500 J .. d al iquots were distributed into Pony vials (two from each collected 
fraction) and 4 mls of Emulsifier-Safe LSC cocktail for aqueous samples (Packard) 
was added to each Pony vial. The samples then shaken briefly and left overnight 
before being counted (4 minute count per sample, each sample counted twice) on the 
Beckman LS 5801 Series analyzer (Beckman). 
2.2.5 Radioimmunoassay for cAMP production 
Cells were washed in MEM-BSA(0.25%) and pre-incubated with 0.5 mM 
3-isobutyll-methylxanthine (IBMX) for 15 minutes before agonis t stimulation. The 
stimulation period was terminated by either, aspiration of the medium and addition 
of a 500 Jll volume of ice-cold 0.1 N HCI (for intracellular cAMP measurement) or 
the addition of an equal volume of ice-cold 0.2 N HCl to the medium (for total 
cAMP measurement). The plates were then frozen at -700C. After thawing, the 
cells were homogenised by trituration. Duplicate 50 Ill aliquots were taken from 
each well and assayed for cAMP content by radioimmunoassay. 
All solutions were made up in 50 rnM sodium acetate buffer (pH 6.0), 0.1% 
BSA (fraction V), 0.1% sodium azide and the assays carried out in polypropylene 
microrack tubes (1.2 ml, Alpha Labs). RIB7 cAMP antiserum at a final 
concentration of 1:166,000 was used as a primary antibody, 125J-cAMP at approx. 
167 KBq per tube was added and the tubes were mixed by Vibrax and left a t 4°C 
overnight. Donkey anti-rabbit IgG (at a titre of 1:400) was used as a secondary 
antibody and non-immune rabbit serum was also added at a titre of 1:40 for a final 
assay volume of 275 j..tl. The tubes were mixed and incubated at 4°C for 3 hours. 
700 Ill of ice-cold PEG-8000 (8.7%) in 0.1 M sodium phosphate buffer (pH 7.7) was 
then added to each tube in order to aid the precipitation of the 125[-
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cAMP /antibody complex and the tubes were spun at 1,500 g for 25 minutes at -1-oc. 
The supernatant was then aspirated off and the gamma radiation remaining in the 
pellet, and thereby the cAMP content, was determined using the Cobra Autogamma 
counter (Packard) and the associated software. The specific binding was typically 
40% of the total applied counts and the non-specific binding typically comprised 
less than 10% of the specific binding. The assay included a cAMP standard curve 
running from 1 to 512 ru\1 cAMP. The cAMP concentration of the unknowns were 
determined by interpolation of the % Bound counts and the log of the cAMP 
concentration: 
% Bound counts= unknown- non-specific binding x 100 
total binding- non-specific binding 
2.2.6 Assay for [3H]citrulline production 
Cells in 12-well tissue culture plates (maintained at 37°C in a 5% C02/95% 
02 environment). The normal growth medium was replaced with Earle's Balanced 
Salt Solution with 10 mM glucose, 10 mM HEPES, pH 7.-l (NaOH) for 16-18 hours. 
3 ~Ci/ml of L-[2,3-3H]arginine (NEN DuPont) was added to the medium for 30-60 
mmutes. The medium containing label was then aspirated off and replaced with 
fresh medium. Agonist was then added for a 10 minute incubation period. 
Reactions were stopped by aspiration of the medium and addition of 700 ~ of ice-
cold 1.34 M trichloroacetic acid. The wells were scraped and the solution 
transferred into a 1.5 ml eppendorf tube for centrifugation to pellet the precipitated 
protein (5 minutes, 12,000 g, 40C), a 500 ~1 sample of the supernatant was then 
added to 50 ~1 of 0.1 M ethylenediaminetetraacetic acid (EDT A) and 500 J.Ll of a 
1:1 mixture of 1,1,2-trichlorotrifluoroethane and tri-n-octylamine. The sample was 
vortexed and centrifuged (5 minutes, 12,000 g, 40C) and a 300 ~l volume of the 
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aqueous phase was added to 1.75 mls of 20 mM HEPES pH 6.0 with 1 mM 
dtrulline. 
The sample was then applied to a 1 ml Dowex cation exchange resin column 
(SOX8, 100-200 mesh, Na form; Sigma). The column was prepared by washing with 
4 mls 2 M Na Acetate, 0.1 M NaOH. The sample was applied to the column and 
the 'run-through' was collected in a Zinsser scintillation vial, a further fraction was 
eluted with 4 mls of UHP H20 and also collected in a Zinsser scintillation vial. The 
column was then washed with 8 mls 20 mM Na HEPES pH 6.0. Duplicate 500 ).11 
aliquots were taken from each of the collected fractions. and transferred into Pony 
vials 4 mls of Emulsifier-Safe LSC cocktail for aqueous samples (Packard) was 
added to each. The samples then shaken briefly and left overnight before being 
counted (4 minute count per sample, each sample counted twice) on the Beckman 
LS 5801 Series analyzer (Beckman). 
2.2.7 Ligand-binding studies 
i) Preparation of membranes 
A confluent flask of cells (80 cm2) was placed on ice and the medium 
discarded. The cell layer was gently washed with 10 rnls of ice-cold EBSS. 1 ml of 
Buffer A (50 mM Tris HCl pH 7.4, 1 mM EGT A (ethyleneglycol-bis(b-aminoethyl 
ether)-N,N,N',N'-tetraacetic acid), 1 mM AEBSF (4-(2-Arninoethyl)benzenesulfonyl 
Fluoride, 2 )lg/ml aprotinin, 4 )lg/rnlleupeptin, 2 ).l.g/ml pepstatin, 1 mM Na3V04, 
1 rn1'v1 NaF, 50 )lg.ml soybean trypsin inhibitor) was added to the cell layer and the 
cells scraped and transferred into a clean tube on ice. Another 1 ml volume of 
Buffer A was added to the flask and the process repeated. The cells were then 
homogenised using the Ystral cell homogeniser (Scientific Industries International, 
Loughborough, UK) at setting 3 for 30 seconds. A sample of homogenate was taken 
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for protein determination. The homogenate was aliquoted into 1.5 ml eppendorf 
tubes and centrifuged at 1,000 g for 5 minutes at -!OC. The supernatant was 
transferred into fresh tubes leaving the pellet of intact cells, nuclei etc. behind. The 
supernatant was centrifuged at 12,000 g for 30 minutes at -!OC. The pellet formed 
contained the membranes, the supernatant was discarded. A 1 ml syringe with a 
20c1l /2 40/9 Yale Microlance needle was used to resuspend the pellet from 1 flask 
in 1.0 ml Buffer A, a sample of this was taken for protein determination. The 
suspension was then recentrifuged as previously and the membranes resuspended in 
1-2 ml of assay buffer (SO mM Tris HCt pH 7.4, bacitracin 0.5 mg/mt AEBSF 2 
J..l.g / ml, BSA 1 %). 
il) Homologous and heterologous displacement of ligand from membranes 
The assay was normally carried out at 370C in a shaking water bath. The 
assay volume was SOO J..l.l in a screw-top eppendorf tube. 300 J..!.l of assay buffer, SO 
~of lOX peptide (normally helodermin, VIP or PACAP-27) and SO J..l.l of 1251-
heloderrnin or 1251-P ACAP-27 was added to each tube. ...\ high dose of displacing 
peptide (e.g. 10 J..!.M) was used to determine non-specific binding The reaction was 
started by the rapid addition of 100 ~ of membrane suspension using an 
Eppendorf repeater pipette. The samples were stimulated for 10-1S minutes. The 
reactions were stopped by centrifugation at 12,000 g for 30 minutes at 4oc. The 
supernatant was then aspirated off, 500 ~ of assay buffer was added to each tube 
and the samples were recentrifuged as above but for 15 minutes. The supernatant 
from the samples was then aspirated off again and the bottom of the eppendorf 
tube (which contained the pellet) was dipped into a disposable tube for the 
counter. The gamma radiation remaining in the pellet and therefore the amount of 
membrane-associated iodinated ligand in the samples, was determined using the 
Cobra Autogamma counter (Packard) and the associated software. 
45 
iii) Homologous displacement of ligand from whole cells at ooc. 
Transfected cells in 12-well plates were washed twice and incubated for 60 
minutes on ice in Medium 199 containing 0.2% BSA and [l25I]PACAP-27 or 
[125I]VIP in the absence or presence of increasing concentrations of unlabelled 
PACAP-27 or VIP. A high dose of displacing peptide (e.g. 10 ~M) was used to 
determine non-specific binding. Unbound radioactivity was removed by washing 
cells three times with EBSS containing 0.1% BSA. Bound radioactivity was 
removed by an acid wash procedure, a 5 minute incubation with 0.2 M acetic 
acid/0.5 M NaCl, and the gamma radiation measured using the Cobra Autogamma 
counter and the associated software. 
iv) Homologous displacement of ligand from whole cells at 370(. 
Transfected cells in 12 -well plates were washed twice and incubated at 
37°C in a waterbath for 10 mins in Medium 199 containing 0.2% BSA, 30 11g/ ml 
bacitracin and 1 J.lg/ ml aprotinin with [125J]VIP or [125I]PACAP-27 in the absence 
or presence of increasing concentrations of tmlabelled VIP or P ACAP-27. A high 
dose of displacing peptide (e.g. 10 J.1M) was used to determine non-specific binding. 
Unbound radioactivity was removed by washing cells three times with Earles 
Balanced Salt solution (EBSS) containing 0.1% BSA. Bound radioactivity was 
removed by acid wash (0.2M glacial acetic acid/0.5 M NaCl) for 5 mins on ice. The 
amount of internalised radioactivity was also determined by solubilising the cell 
layer by treatment with 0.5 M NaOH overnight. Gamma radiation in the samples 
was measured by the Cobra Autogamma counter and the associated software. 
v) GTPyS modulation of ligand-binding 
This procedure is identical to the membrane ligand binding protocol above 
except that the effects of increasing concentrations of GTP·tS (Guanosine 5'-0-(2-
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thiodiphosphate): Sigma) on the binding of an iodinated ligand (125 t-he1odermin) 
are investigated as opposed to the effects of increasing concentrations of unlabelled 
peptide. lOX GTP"(S replaced the lOX peptide in the assay. A high dose of 
helodermin was used to determine non-specific binding. 
2.2.8 Protein Assay 
Protein concentration was determined using the Coomassie Protein Assay 
Reagent (Pierce, Chester, UK). A standard curve was constructed using a 2 mg/ml 
albumin standard solution (Pierce, USA) covering the range from 75 to 1500 !lg/rnl. 
Duplicate 10 Ill volumes of sample were added to the wells in a 96-well microtiter 
plate, 300 JJ.l of Coomassie reagent was then added to each well and the sarnpies 
left for 30 to 45 minutes. The absorbance at 595 nm in each well was then 
determin.ed using the Microplate Biokinetics Reader EL 312e (BIO TEK Instn.unents, 
Vermont, USA) running the KC Jr. application software. 
2.2.9 Animals 
COB-Wistar rats obtained from Charles River UK Ltd., or bred in this 
department from rats originally obtained from this source, were maintained at a 
constant temperature of 220C under controlled lighting, whid1 was on from 0500 to 
1900 hours each day. The rats had free access to tap water ?.nd food pellets. The 
rats were killed by cervical dislocation and the brains were rapidly dissected out 
and the appropriate tissue removed for homogenisation. 
2.2.10 Cerebral Microvessel Preparation 
The brain was removed from 4 to 8 male COB-v\.istar rats. The cortex was 
rapidly separated from the other brain tissue and placed into phosphate-buffered 
saline (PBS) pH 7.4. Ice-cold solutions are used at ail times through this procedure. 
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The tissue was weighed and then homogenised with 20 mls PBS pH 7.4 (per 4 rats) 
in a p.t.f.e./glass homogeniser (30 ml capacity, 25 mm bore; Philip Harris) 12 
passes by hand then 30 seconds at slow speed on the variable speed stirrer (Griffin 
& George, UK). The homogenate was distributed into 2 centrifuge tubes and the 
volumes made up to 12 mls PBS pH 7.4 per tube. The homogenate was spun in the 
Sorvall RC-3B refrigerated centrifuge (DuPont, UK): 420 g, 4oe, 10 minutes. The 
supernatant was aspirated off leaving a large pellet. 9 mls of PBS pH 7.4/ 15% 
dextran (580K) w /v was added to the pellet which was resuspended by vortexing. 
The solution was spun again in the Sorva ll centri fuge: 950 g, 40C, 20 minutes. The 
suspension now had a large floa ting layer of pink mnteria l, this was aspirated off 
leaving a pale dispersed pellet in the bottom of the centrifuge tube. 3 mls of PBS 
pH 7.4 was added to the tube which was then vortexed. The suspension was 
poured over a 100 J.lil1 mesh-opening net filter, 25 rrun diameter in a 2 piece glass 
filter holder (Millipore, UK). The holder and filter were pretreated with RNaseZAP 
(Ambion, Inc., USA) and washed with UHP H20 and 24 mls of PBS pH 7.4 before 
the suspension was added. The suspension on the filter was washed with 36 mls 
PBS pH 7.4 the filter with the trapped microvessels was then removed and placed 
in the -700( freezer. Examination of the filter at X200 magnification confirmed the 
presence of blood vessels on the mesh. 
2.2.11 RNA extraction 
RNA extraction was carried out using the RNAzol B Isolation of RNA kit 
(Biogenesis Ltd., Poole, UK) which functions by promoting the interaction of RNA 
with guanidinium and water ions and inhibiting the hydrophilic interactions of 
DNA and proteins thereby significantly purifying the sample through a simple 
phase separation step. 
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The microvessel/filter preparation was homogenised in an RNaseZAP-
treated, UHP H20 rinsed, p.t.f.e. / glass homogeniser (Millipore, UK) containing 1 
ml RNAzol B. 100 111 of chloroform was added to the sample in an RNase-free 
eppendorf and the solution was shaken vigorously for 15 seconds by hand. The 
sample was then centrifuged at 12,000 g for 15 minutes at 4oc. The aqueous upper 
phase is equivalent to 50% of the Rt'\JAzol volume plus a volume of the tissue used 
for homogenisation. 800 )..ll of the upper phase was transferred to a fresh tube and 
an equal volume of isopropanol was added to it. The sample was stored at 4oc 
overnight before being centrifuged at 12,000 g for 15 minutes at 4oc. After this s tep 
the pellet was obvious as a smear up the side of the eppendorf tube. A drawn 
pipette was used to aspirate off the supernatant and 1 ml of 80% ethanol was 
added, the tube was shaken vigorously to dislodge the pellet and the sample was 
centrifuged at 12,000 g for 5 minutes at 4°C. A drawn pipette was used to aspirate 
off the supernatant and the tube was left open on it's side on the bench for 10 
minutes, inside an open plastic bag, to allow the ethanol to evaporate from the 
pellet. The pellet was then solubilised in 100 Ill of tissue culture water (Gibco, UK), 
10 Ill SM NaCl (Ambion Inc., USA)and then reprecipitated by the addition of 200 
)..ll of ethanol. The solution was left at -20°C for 1 hour. The sample was then 
centrifuged at 12,000 g for 20 minutes at 40C. The supernatant was aspirated off 
using a drawn pipette and the pellet was washed once more in 1 ml of 80% ethanol 
and the sample centrifuged at 12,000 g fo r 5 minutes at JOC. The pellet was 
allowed to dry on the bench as previously for 10 minutes and then placed in -7QOC 
freezer. 
2.2.12 Reverse Transcriptase-Mediated Polymerase Chain Reaction 
Fragments from the total RNA extracted from tissue were amplified using 
the Stratagene RT-PCR kit according to the manufacturers instructions. 
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i) 1st Strand Reaction 
5- 10 ~g of total RNA in DEPC-treated water in a final volume of 38 111 was 
used, 300 ng of random primers was added in 3 J..Ll and the solution mixed gently. 
All reactions were carried out in GeneAmp ).5 ml thin-walled reaction tubes 
(Perkin-Elmer). The mixture was then incubated at 650C for 5 minutes in the 
Omn-E Thermal Cycler (Hybaid Ltd., Middlesex, UK)) before being cooled to room 
temperature over 15 minutes to allow annealing of the primers to the RNA. 5 J..Ll of 
lOX first strand buffer was then added to each tube, 40 U of RNase Block 
Ribonuclease Inhibitor in lJ..Ll, 2111 of 100 mM dNTPs (final cone. 1 mM each dNTP) 
and 1 J..Ll of Moloney murine leukaemia virus reverse transcriptase (MMLV -RT) (50 
U). The mixture was incubated at 37°C for 1 hour and 9QOC for 5 minutes. The 
completed reactions were then placed on ice. 
ii) Polymerase Chain Reaction 
1-5 J..Ll of 1st strand reaction (made up to 5 J..Ll using DEPC-treated water) 
was transferred into a fresh tube and 88 J..Ll of a "master mix" was added. The 
"master mix" consisted of 10 111 of lOX Taq DNA polymerase buffer, 0.8 111 100 mM 
dNTPs and 77.2 111 of DEPC-treated water for a final volume of 88 111 per tube. 15 
pM of each primer in 1111 is added to each tube (total of 211-1 primers per tube). 
Mineral oil was then added to the tube to prevent evaporation. The tubes were 
place in the thermal cycler and heated to 95°C for 5 minutes, 6QO( for 5 minutes 
and noc for 3 minutes. The samples were kept at a holding temperature of noc 
for addition of the Taq DNA polymerase (Stratagene, Cambridge, UK) which was 
added as a 5 Il-l volume of 0.4 U I 111. The PCR cycling was normally carried out for 
35 cycles of 1 minute at 94°C, 1 minute at 60°C and 1 minute at noc. The samples 
were then kept at 72°( for 30 minutes before being returned to room temperature. 
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iii) Agarose gel electrophoresis of DNA 
A 100 ml 0.7% (w / v) agarose gel (Sigma, UK) containing 0.1 J..Lg/ ml ethidium 
bromide (Sigma, UK) was made up in 1X Tris-Acetate-EDTA buffer (4.84 g Tris 
base; 1.142 ml glacial acetic acid; 2 ml 0.5 M EDTA per litre: lOX from Sigma, UK). 
The 110 mm x 140 mm gel was run on the BRL H5 horizontal submerged gel 
electrophoresis system (BRL, MD., USA) using the LKB 2197 power supply 
(Bromma). The gel was submerged in 800 ml of 1X TAE buffer, 10 J..Ll of eDNA was 
added to 41ll of loading buffer (0.25% w /v bromophenol blue, 0.25% w /v xylene 
cyanol, 1 mM EDT A, 30% glycerol) for addition to the gel. The gel was run fo r 
approx. 1 hour 45 minutes at 100 volts, 60-80 milliamps. Boehringer Mannheim 
molecular weight markers VI and VII were used (Boehringer Mannheim GmbH, 
Mannheim, Germany) at 3 J..Ll per lane. 
The DNA bands were visualised using the Chroma to-vue transilluminator 
model TM-15 (UVP Inc., Ca. , USA). The gels were photographed using a Polaroid 
Cu-5 camera and Polaroid 667 film (Sigma). 
2.2.13 Immunoprecipitation 
3 mls of Buffer B (20 mM HEPES, 1 mM AEBSF, 2 J..Lg/ml aprotinin, 4 
J..L.g/mlleupeptin, 2J..Lg/ml pepstatin, 1 ml\1 sodium orthovanadate, 1 mM sodium 
flouride, SO J..L.g/ml soybean tryspin inhibitor). was added to the cell layer of a 75cm2 
flask and the cell layer scraped and transferred into a dean tube on ice. The cells 
were then homogenised using the Ystral cell homogeniser at setting 3 for 30 seconds. 
The homogenate was centrifuged at 12,000 g for 30 minutes. The pellet was 
resuspended in Buffer 8 and recentrifuged at 12,000 g for 30 minutes. The pellet 
was then solubilised in 0.7 ml of Buffer B with 5 mM CHAPS, 0.1 % chelate and1 M 
sodium chloride and left 'rolling' at 4°C for 30 minutes. The salt concentration was 
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then reduced by the addition of an equal volume of Buffer B with 5 mM CHAPS 
and 0.1% chelate. 15111 of Protein G-sepharose suspension (1:100: Sigma) was 
added to the tube which was left 'rolling' at 4°C for 15 minutes. The solution was 
centrifuged at 12,000 g for 30 minutes. The supernatant was removed and primary 
antibody (1:100, 'mHA' anti-HA; Boehringer-Mannheim) was added. The tube was 
left 'rolling' overnight at 4°C. 25 j.Ll of Protein G-sepharose suspension (1:100: 
Sigma) was added to the tube and left 'rolling' at 40C for 4 hours. The suspension 
was centrifuged at 12,000 g for 15 minutes. The supernatant was removed and the 
pellet was resuspended in 'Novamok' (20 mM HEPES, 5 mM CHAPS, 0.1% 
chelate) and centrifuged at 12,000 g for 15 minutes. The supernatant was 
discarded and the pellet resuspended in 2X Laemmli Buffer (2% SDS, 50 mM Tris, 
5% MeOH). The sample was boiled for 5 minutes before undergoing SDS -PAGE 
Electrophoresis. 
2.2.14 Western Blotting 
Heat thawed samples for 5 minutes under hot water tap (approx. SOOC) 
and centrifuge for 2 minutes at room temperature in Eppendorf centrifuge to 
remove particulate material. 
i) SDS -PAGE Electrophoresis 
The 7.5% homogeneous polyacrylamide gel pre-cast onto a rigid polyester 
film (PhastGel Homogeneous 7.5, Pharmacia) was removed from its wrapping and 
carefully placed onto 80 J1l of UHP H20 on the gel bed of the PhastSystem 
Separation and Control unit (Pharmacia Biotech AB, Uppsala, Sweden) in such a 
manner as to exclude air bubbles. The gels have a 13 mm stacking zone and 32 mm 
separation zone (dimensions; 43 x SOx 0.45 mm). The PhastGel SDS buffer strips 
were then positioned in the buffer strip holder. The samples were loaded (4 Jll) 
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onto the sample strip holder in a humidified chamber and the holder was 
positioned in the apparatus. The separation program was then started to run for 
60 Vh (approx. 30 mins). 
ii) Electroblotting 
Immobilon transfer membranes (polyvinyldifluoride, 10 ern x 10 em, 0.45 11M 
pore size; Millipore) were cut to size (5 em x 5 ern) and marked for identification 
and orientation. The filters were immersed in methanol and then rinsed in UHP 
H20 briefly 5 times. The fil ters were then shaken for 2 x 5 minutes in UHP H20 
and in blot buffer (25 mM Tris, 192 rnM glycine, 20% methanol, pH 8.3) for 3 x 5 
minutes using the rotary shaker. 
After the gel had nm it was removed from its backing using Pharmacias 
clamp and wire apparatus. The immobilon was placed over the separation zone of 
the gel and the gel was removed from its backing whilst remaining in contact with 
the irnmobilon. 3 pieces of PhastTransfer filter paper (50 rnm x 50 mrn) were 
soaked in blot buffer and placed on the anode of the PhastSystem Development 
Unit, 6 more drops of blot buffer were applied to the filters and the imrnobilon 
placed on top of them. Another 3 filters were then soaked and placed on top of 
the immobilon/ gel. The cathode was then placed on top of the filters and pressed 
into place gently. The blot was run for 45 minutes. 
ill) Immunostaining 
The blot was given 5 quick rinses in UHP H20 before being given 4 x -l 
minute washes on the shaker. The blot was then stained for 5 minutes in 0.1% 
coomassie blue-R250, 50% methanol before being given 2 or more 1 minute washes 
in destain (SO% methanol, 10% acetic acid) until the protein bands were clearly 
visible against a clear or pale background. Several 1 minute washes in UHP H20 
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were then carried out to stop the destaining process and remove residual methanol. 
The blot was then marked and the lanes cut up as appropriate. The blot was 
washed two or more times for 2 minutes in methanol until the bands were no longer 
visible. A further 3 x 4 minute washes in methanol were carried out before the blot 
was given 5 x 5 minute washes in UHP H20 to remove residual methanol. 
The blot was incubated overnight at 4°C in either 5% BSA (w /v)/PBS or 5% 
dried milk. The blot was given 2 quick rinses and 5 x 5 minute washes in PBS/0.1% 
Polyoxyethytenesorbitan monolaurate (Tween-20;Sigma). The blot was incubated 
overnight with the primary antibody in 0.25% BSA/PBS/ 0.05% Tween-20: 
1) GCL il-2 (Calbiochem, Nottingham, UK)- anti-GCL il and GCL i2 ( C terminat 
345-354 and 346-355) rabbit polyclonal IgG. Supplied in 100 mM potassium 
phosphate, 140 mM NaCt pH 7.5. Original titer 1:8,000. IgG added as 2 ~l/mt 
control peptide as 20 ).11/ml. 
2) GCL q/11 (Santa Cruz) - anti-GCL q/ 11 (GCLq 341 -349, mouse) rabbit 
polyclonal IgG. 100 ).lg of IgG in 1 ml PBS/0.1% sodium azide /0.2% gelatin. 
Control peptide 100 ).lg in 0.5 ml PBS containing 0.1% sodium azide/100 ).lg BSA. 
lgG added as 5 ~1/ml, control peptide as 25 ~1/ml. 
3) GCL i/o/t/z (Santa Cruz)- anti-GCL i/o/t/z (GCL z C terminus, 325-344, rat) 
rabbit polyclonal IgG. 100 ~g of IgG in 1 ml PBS/0.1% sodium azide/0.2% gelatin. 
Control peptide100 ~gin 0.5 ml PBS containing 0.1% sodium azide/100 ).lg BSA. 
IgG added as 5 ).ll/ml, control peptide as 25 ~1/ ml. 
An appropriate blocking peptide was mixed with the primary antibody for 
use as a control. 
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The blot was given 2 quick rinses and 5 x 5 minute washes in 0.25% 
BSA/PBS/0.1% Tween-20 (Sigma) and incubated for 1 hour with horseradish 
peroxidase (HRP)-Iabelled anti-rabbit IgG (Scottish Antibody Production Unit) at a 
1:5000 dilution in 0.25% BSA/PBS/0.05% Tween-20. The blot was then rinsed as 
previously. 
In the darkroom the blot was incubated for 1 minute in 2.5 ml of a 1:1 
mixture of Enhanced ChemiLuminescence (ECL) 1:ECL2 solutions (Arnersharn). 
Excess liquid was removed from the blot by touching the edge with a mediwipe 
tissue. The blot was then sealed in clingfilrn and exposed against ECL film in an 
X-ray cassette for between 30 seconds and 5 minutes. The film was developed by 
incubation for 4 minutes in Phenisol developer, rinsing in water, and a 1 minute 
incubation in Hyparn fixer followed by a minimum of 2 minutes in running water. 
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Chapter 3 
Signalling characteristics of the 
wild -type VIP2 receptor 
3.1 Introduction 
In order to study the expression and signaiUng characteristics of the cloned 
rat VIP2 receptor in contrast with PACAPshort and PACAPiong receptors, a 
heterologous expression system was used. The receptors were mainly transiently 
expressed in a Green Monkey kidney fibroblast cell line, COS 7 cells. The primary 
objective of this study was to investigate VIP2 receptor-mediated signalling. 
However, the signalling characteristics of the closely related PACAP receptors 
provide a useful comparison for VIP2 receptor-mediated signalling and because of 
the high degree of sequence homology between the receptors, the comparison could 
provide indications of the motifs and domains important for any differential 
aspects of their signalling behaviour. This approach was also exploited in the 
creation of the chirnaeric receptors used in the experiments described in Chapter 4. 
The rat VIP2 receptor was cloned by Lutz et al. (1993) from a rat olfactory 
bulb eDNA library. When expressed in COS 7 cells this receptor was found to be 
coupled to cAMP production. The order of potency of ligands for cAMP 
production mediated by this receptor was VIP-PACAP-38-PACAP-27-
heloderrnin>PHI-rGHRH. Two isoforms of the rat PAC-\P receptor were cloned 
from a rat olfactory bulb eDNA library by Morrow et al. (1993), one isoform 
contained an extra 84 bp segment in the putative intracellular loop 3(IC3), this 
receptor was designated PACAPJong in this study, the other isoform being 
PACAPshort· When transiently expressed in COS 7 cells these receptors were also 
found to be coupled to cAi\II.P production. The order of potency of ligands for this 
stimulation was PACAP-38-PACAP-27>VIP>PHI. All known members of the 
secretin/ calcitonin/ PTH/ PTHrP receptor family are coupled to cAMP production 
(Segre & Goldring, 1993). The rat PACAP receptors were additionally shown to be 
capable of stimulating PI hydrolysis and the mobilisation of intracellular Ca2+ in 
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tissue (Gottschall et al., 1991; Deutsch & Sun., 1992; Tatsuno et Cll., 1992). Spengler 
eta L (1993) identified further splice variants of the rat P ACAP receptor cmd 
demonstrated the ability of the PACAP receptor to stimulate PLC when expressed 
in LLC PK1 cells. 
Although there were indications that the agonist-activation of VIP receptors 
was capable of stimulating PI hydrolysis and Ca2+ -release from intracellular stores 
and activating PKC (Audigier et al., 1986; Malhotra et al., 1988; Weill et al., 1989; 
Russell et al., 1990; Fatatis et al., 1994) there was no direct evidence of PLC 
stimulation by VIP1 or VIP2 receptors. 
The VIP receptor in rat lung was found to be coupled to both G5 (Kermode et 
al., 1992) and Gi3 (Diehl et al., 1996), as determined by cross-linking studies, 
whereas Murthy & Makhlouf (1994) reported the coupling of a VIP receptor in 
dispersed gastric smooth muscle cells to Gil/2· 
VIP receptors have been implicated in, amongst other things, the control of 
cerebral energy metabolism and cerebral blood flow, neuronal survival (Gozes et al., 
1989; Arimura, 1992), insulin release from the pancreas (Yada et al., 1994; Straub et 
al., 1996), melatonin synthesis and release from the pineal (Spessert, 1993; 
Simrnoneaux et al., 1993), catecholamine synthesis and release from the adrenal 
medulla (Wakade et al., 1991; Watanabe et al., 1995), smooth muscle relaxation, 
stimulation of electrolyte secretion and vasodilation in the peripheral nervous 
system (Gozes & Brenneman, 1989; Christophe, 1993). Despite the obvious 
physiological importance of YIP-evoked and VIP receptor-mediated signalling 
events, the specific signalling mechanisms utilised by the VIP receptors were poorly 
understood. 
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3.2 Specific Methodology 
Expression of receptors- COS 7 cells were transiently transfected with eDNA 
encoding the rat VIP1, VIP2, P ACAP short and P ACAPtong receptors and the C-
terminally haemagluttinin(HA)-tagged human VIP2 receptor as described in sections 
2.2.1, 2.2.2 and 2.2.3. A C-terrninally myc-tagged human VIP2 receptor was 
created by Dr. Eve Lutz in this laboratory, Dr. T. MacDonald exchanged the myc 
tag for an HA tag and that construct was used here. 
Ligand-binding- Ligand binding on whole cells at 0°C for 60 minutes using 
iodinated ligand was carried out to determine the expression level of the receptors 
(see section 2.2.7). GTPyS modulation of ligand-binding was investigated using 
iodinated ligand on membrane preparations from transfected COS 7 cells (see 
section 2.2.7). 
Protein assay - Coomassie protein assay reagent was used to determine the protein 
level in samples (see section 2.2.8). 
Second messenger assays - Intracellular cAMP production over a 10 minute 
stimulation period was measured in whole cells by radioimmunoassay as described 
in Section 2.2.5. 
[3H]inositol phosphate production was used as a measure of PLC activity. The 
cells were stimulated for 60 minutes with agonist before separation of [3H]inositol 
phosphates by anion exchange chromatography as described in Section 2.2.4. 
Immunoprecipitation- Immunoprecipitation of the HA-tagged human VIP2 receptor 
expressed in COS 7 cells was accomplished with the use of a specific antibody to 
the haemagluttinin sequence expressed at the C-terrninal end of the receptor (see 
section 2.2.13). 
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Western blotti ng- Western blotting fo r specific G protein isoforms associated with 
the immunoprecipitated human VIP2 receptor was carried out after using the Phast-
system after SDS-PAGE of the immunoprecipitate, as described in section 2.2.14. 
Data ?!nalysis- Curve fitting was performed by the non-linear curve-fitting 
programme, P-fit (Elsevier Biosoft, Cambridge). 
3.3 Results 
3.3.1 Ligand-binding studies to monitor expression levels of the rat VIPz, 
PACAPshort and PACAPtong receptors and their affinities for PACAP-27 
Homologous displacement of [12Sr]PACAP-27 from whole COS 7 cells (see 
'Materials & Methods' section 2.2.7) was used to give an estimate of the receptor 
binding capacity of the system (Bmax) and the affinities of the receptors for 
PACAP-27 (ICso) (see Figure 3.1), using the method of Swillens (Swillens, 1992). 
Binding was performed on whole cells at ooc for 60 minutes (see Figure 3.1). 
PACAP-27 was used as opposed to P ACAP-38 because it was the only PACAP 
and VIP2 receptor agonist commerdally available as a radioligand. The 
PACAPiong receptor had a Bmax value of 520±52 fmol / 105 COS 7 cells (see Table 
3.1) and an ICso of 31±3 nM. The PACAPshort receptor displayed a Brnax of 
494±37 fmol/105 cells and an ICso of 30±1 ru\11.. The VIP2 receptor had a Bmax of 
59±5 fmol/105 cells and an ICso value of 19±1 nM. 
The expression levels of the P ACAP receptors were therefore very similar as 
was their affinity for P ACAP-27. The VIP2 receptor was however expressed a t a 
lower level than the PACAP receptors (approximately 11% of the PACAP receptor 
value) and had a slightly higher affinity for PACAP-27. 
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3.3.2 Agonis t-evoked cAMP production med iated by the rat VIP21 
PACAPshort and PACAP!ong receptors 
Concentration-response curves for VIP- and PACAP-38-evoked cAMP 
production were constructed for the VIP2, PACAPshort and PACAPJong receptors. 
Figure 3.2 shows a typical concentration-response curve for YIP-evoked cAMP 
production mediated by the VIP2 receptor transiently expressed in COS 7 cells. 
The ECsos for PACAP-38 evoked cAMP production were similar for the VIP2, 
PACAPshort and PACAP!ong receptors (in the range 0.5-0.9 nM: see Table 3.1). 
Whereas VIP and P ACAP-38 had similar potencies and maxima for cAMP 
production mediated by the VIP2 receptor (0.3±0.1 ru\lf and 7.8±0.5-fold of basal 
control for PACAP-38 and 0.9±0.1 ru\.1 and 8.2±0.1-fold of basal control for VIP). 
VIP was very much less potent than PACAP-38 at stimulating cAMP production 
mediated by the PACAPshort and PACAP!ong receptors (ECso values of 28.6±0.2 
and 38.6±3.8 nM respectively) and the maxima were also reduced (from 22.4±1.1 to 
12.1±0.5-fold of basal control for PACAPtong and 19.8±1.4 to 15.7±0.2-fold of 
basal control for the PACAPshort receptors). 
3.3.3 Agonist-evoked [3H]inositol phosphate production mediated by the 
rat VIP2, PACAPshort and PACAPtong receptors 
Concentration-response curves for VIP- and PACAP-38-evoked VIP2 
receptor-mediated [3H]IP production (see Figure 3.3) were therefore carried out. 
These curves showed clear agonist-evoked concentration-dependent increases in 
[3H]IP production mediated by this receptor when transiently expressed in COS 7 
cells (see Table 3.1). The VIP2 receptor displayed an EC,;o for YIP-evoked [3H]IP 
production of 45.0±6.6 ru\.1 and a maximum stimulation of 2.4±0.1 fold of basal 
control; fo r PACAP-38 the ECso was 36.9±8.1 ru\11 and the maximum stimulation 
3.0±0.3 fold of basal control. Concentration-response curves for VIP- (see Table 
61 
3.1) and PACAP-38-evoked PACAPshort and PACAPtong recepto r-mediated 
[3H]IP p roduction were also ca rried out (see Fig. 3.4). The ECsos fo r PACAP-38-
evoked [3H]IP production were 10.6±0.6 nM and 17.6±0.6 nM, respectively and the 
maximum stimulation values were 9.8±0.7 and 11.1±0.3 fold of basal control 
respectively for the PACAP:;hort and PACAPtong receptors. No YIP-evoked 
[3H]IP production mediated by the PACAPshort and PACAPtong receptors was 
detected at concentrations up to 3 J..LM. 
This represents the firs t direct evidence of VIP2 receptor -mediated 
stimula tion of [3H]IP production. PACAP-38 was approximately 2.5 times more 
potent in eliciting [3H]IP production at the PACAP receptor than at the VIP2 
receptor. The PACAP receptor also mediated a higher fold stimulation of [3H]IP 
production than the VIP2 receptor. VIP and PACAP-38 were equipotent for 
[3H]IP production mediated by the VIP2 receptor whereas VIP was ineffective at the 
PACAP receptor. 
3.3.4 Time-courses for agonist-evoked cAMP and [3H]inositol phosphate 
production at the VIP2.r PACAPshortand PACAPtong receptors 
In order to determine whether the VIP2 or P ACAP receptor-mediated 
stimulation of [3H]IP production or cAMP production 'Vvas subject to 
desensitisation, the accumulation of [3H]IP was measured fo r up to 80 minutes and 
cAMP for up to 120 minutes. The 111M YIP-evoked accumulation of [3H]IP 
mediated by the VIP2 receptor was linear over the measured time-period; there was 
no evidence of desensitisation of this response (see Figure 3.5), although the dose of 
agonist used may affect this response (it is also the case that earlier time points 
would be advantageous in these time courses since an early peak of IP production 
might be expected and this would not be detected with a first time point at 10 
minutes). The 300 nM PACAP-38-evoked response mediated by the receptor (see 
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Figure 3.6) was also linear over the measured time-period and showed no evidence 
of desensitisation. The maximum responses mediated by the VIP2 and PACAP1ong 
receptors were 2.01±0.05 and 7.31±1.04 fold of basal control. The 100 nM 
PACAP-38-evoked stimulation of cAMP production mediated by both the VIP2 
and PACAP receptors was clearly subject to desensitisation (see Figure 3.7). 
Responses mediated by the VIP2 and PACAP receptors involved the rapid 
accumulation of intracellular cAMP until a plateau phase was reached after 
approximately 15 minutes. At their respective 15 minute time points the VIP2 
receptor had caused a 13.7±0.4 fold of basal control increase in intracellular cAMP, 
the PACAPshort receptor mediated a 27.1±0.9 fold of basal control increase and 
the PACAP!ong receptor a 25.2±0.5 fold of basal control increase. 
Thus it appears that under the present conditions the VIP2 and PACAP 
receptor-mediated [3H]IP responses are not subject to desensitisation whereas the 
cAMP responses mediated by these receptors are subject to a relatively rapid 
desensitisation process. 
3.3.5 Pertussis toxin-sensitivity of responses mediated by the VIP and 
P ACAP receptors 
The effect of PTx pretreatment on VIP and P ACAP receptor-mediated 
responses was assessed. VIP (3 l..lM) caused an increase in [3H]IP formation to 
2.55±0.16 -fold of basal control for the VIP1 receptor and 1.99±0.05 -fold of basal 
control for the VIP2 receptor at a concentration of 3 j..lM (see Figure 3.8(a)). [3H]IP 
production mediated by the VIP1 and VIP2 receptors was partially inhibited by PTx 
pretreatment. Treatment of cells with PTx at 100 ng/ ml for 16 hours prior to 
stimulation reduced the VIP-stimulated response by 46±9% for the VIP1 receptor 
and 38±10% for the VIP2 receptor. A PTx treatment of :wo ng/ml had no effect on 
basal [3H]IP production (100±2% of control). Treatment of ceils with the 
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pharmacologicall y inactive PTx 8 subunit (Tamura et at., 1983: nt n concentration 
of 200 ng/ ml for 16 hours) had no significant effect on the VIP stimulated [3H]IP 
production; the VIP1 receptor maintained 100±3% of its VIP stimulated activity 
and the VIP2 receptor 99±7%. A maximal effect of PTx was observed at 100 
ng/ ml, 200 ng/ ml did not cause any greater an inhibition of activity. It might 
however be advantageous to directly measure PTx activity by incubating 
membranes with [adenylate-32P]NAD and measuring ADP ribosylation of 
membrane proteins by SDS-polyacrylamide gel electrophoresis and 
autoradiography (Burns et al., 1987). 
In order to determine whether a pathway activated by the G protein G5 
could be responsible for either the PTX-sensitive or -insensitive components of PLC 
activation the cells were preincubated with cholera toxin (CTx) for 16 hours prior to 
stimulation (a protocol reported to down-regulate Gs: Eason & Liggett, 1994). A 
direct measurement of G5 levels by Western blotting could provide a means of 
determining the effectiveness of the CTx pretreatment. A 16 hour preincubation 
with CTx at a concentration of 20 J.lg/ml caused no increase in basal [3H]IP 
formation (100±3% of the basal value which was 9,348±303 dpm/assay. n=6) and 
had no effect on VIP -evoked PLC responses. Figure 3.8(b) shows that in cells 
pretreated with 20 J.tg/ml CTx for 16 hours the VIP-evoked PLC response mediated 
by the VIP1 receptor was 105±6% of control and for the VIP2 receptor, 95±6%. 
Treatment of COS 7 cells expressing the VIP2 receptor with 10 J!M forskolin (the 
adenylate cyclase-stimulating diterpene: Seamon et al., 1981) also caused no 
increase in [3H]IP production (102±3% of basal control, n=4) indicating that the 
VIP2 receptor-mediated PLC stimulation is not dependent on cAMP production (a 
20 minute stimulation with 10 J!M forskolin increased cAMP levels from 1.11±0.02 
to 127.7±16.2 pmol / rnl; n=6). It is however possible that simultaneous VIP 
occupancy of the receptor may alter the response to forskolin. 
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Figure 3.8(c) also shows the fYrx-insensitivity of PLC activ ity stimula ted 
through the PACAPshort and PACAPtong receptors. 100 ru\tt PACAP-38 
stimulated a 7.71±0.55 -fold of basal control response fo r the "short" form of the 
receptor; after treatment with 200 ng/ ml PTx this was 7.81±0.20 -fold of basal 
control. The "long" form of the receptor mediated a 10.59±0.82 -fold of basal 
control response to 100 nM PACAP-38; after PTx treatment the response was 
11.00±0.27 -fold of basal control. PTx treatment alone (200 ng/ ml fo r 16 hours 
prior to stimulation) had no effect on basal activity (91±9% of basal control). 
Agonist-evoked [3H]IP production mediated by the VIP1 and VIP2 
receptors occurs by a mechanism that is partially inhibited by treatment with 
pertussis toxin, indicating the involvement of a member of the Gi/o/ z family of G 
proteins. This is not true of the PACAP receptor-mediated response which is more 
likely to occur by the classical GqJ n-mediated pathway. VIP receptor-mediated 
[3H]IP production is not dependent on and does not appear to be modulated by 
cAMP. 
PLD activation mediated by the VIP and P ACAP receptors 
Experiments performed by O.A. McCulloch in this lab demonstrated that 
both the VIP1 and VIP2 receptors showed concentration-dependent activation of 
PLD (100 nM-1 f..!M). The 1 ~YIP-elicited response was 1.93±0.13 -fold of basal 
control for [3H]phosphatidylbutanol production through the VIPt receptor and 
1.62±0.24 -fold of basal control for the VIP2 receptor. After PTx pretreatment the 
responses were 97±4% and 109±6% of the controls respectively for the VIPt and 
VIP2 receptors (MacKenzie et al., 1998). 
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GTPyS modulation of ligand binding to the VIP2 receptor 
A functional interaction between the VIP2 receptor and a PTx-sensitive G 
protein can also be demonstrated by the effect of PTx-pretreatment on the GTPyS 
modulation of ligand binding (see Section 2.2.7). The affinity of the receptor for 
ligand is reduced by increasing the levels of active-state G proteins with increasing 
concentrations of the non-hydrolysable GTP analogue, GTPyS (DeLean et aL, 1980). 
The GTPyS modulation of [125J]helodermin binding to the VIP2 receptor was 
observed for untreated and for PTx-pretreated membranes prepared from COS 7 
cells transiently expressing the VIP2 receptor (see Figure 3.9). The maximum 
specific binding of [125I]helodermin was 13,344±252 cpm/assay. The resultant 
concentration effect curve for GTPyS on this specific binding showed a clear 
reduction in binding which was maximal at approximately 100 ru'vt GTPyS (retaining 
70.8±2.2% of the maximwn specific binding of [125I]helodermin). PTx-pretreatment 
reduces the dissociation by 45±6% at 3(..LM GTPyS. Binding to membranes treated 
with PTx inactivated by glutaraldehyde-treatment (Bums et al., 1987) was identical 
to that from untreated membranes at 3f..lM GTPyS (71.1±1.7% of the maximum 
specific binding of [125I]helodermin). 
This evidence indicates that there was a direct interaction between the VIP2 
receptor and PTx-sensitive G proteins and that these may constitute a significant 
percentage of the G proteins that associate with this receptor. 
In order to confirm that the inhibitory effect of Ptx is not the result of an 
indirect effect on the VIP2 receptor, the non-specific G protein activator AlCl3/ NaF 
was used to stimulate [3H]IP production and the effect of Ptx-pretreatment on this 
stimulation was observed. Treatment of the cells for 30 minutes with 10 11M AlCl3 
and 50 mM Naf produced a 6.4±0.4 fold of basal control stimulation of [3H]IP 
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production (a typical basal value being 8,431±170 dpm/assay). Pretreatment of 
the cells fo r 16 hours with 100 ng/ml PTx reduced this stimulation to 5.4±0.2 fold 
of basal control (81.8±4.3% of the untreated value). This inhibition was 
statistically significant (Wilcoxon two-sample signed rank test, P<0.05). This 
indicates that Ptx-sensitive G proteins in general are capable of stimulating [3H]IP 
production in COS 7 cells. 
The tetradecapeptide, mastoparan , is a compound which has been reported 
to activate PTx-sensitive G proteins through binding to the N-terminus of the G 
protein ex subunit (Higashijima et al., 1988; Higashijima & Ross, 1991; Weingarten et 
al., 1991). This compound was therefore used to assess whether the activation of 
PTx-sensitive G proteins alone was sufficient to stimulate [3H]IP production in 
these cells. A clear, though modest, concentration-dependent stimulation of [3H]IP 
production was observed in these cells on treatment with mastoparan (see Figure 
3.10). The maximum response, stimulated by 15 J.LM mastoparan, was 1.34±0.08 
fold of basal control. The mastoparan-stirnulated response was inhibited an 
average of 45.8±10.8% by pretreatment of the cells for 16 hours with 100 ng/ml 
PTx. This inhibition is statistically significant as assessed by the Wilcoxon matched 
pairs signed rank test (p<0.05). Higashijima et al. (1988) also found that PTx-
pretreatment was only partially effective in blocking mastoparan-mediated effects. 
These data suggest that it is possible that the stimulation of [3H]IP production in 
COS 7 cells could result from the activation of PTx-sensitive G proteins alone. 
3.3.6 The role of Ca2+ entry in VIP2 receptor-mediated [3H]inositol 
phosphate production 
There are increasing numbers of reports of G proteins modulating Ca2+ 
channel activity (Hamilton et al., 1991; Zhu & Ikeda, 1994). These reports most 
often implicate PTx-sensitive G proteins (Hescheler et al., 1987; Hescheler et al., 
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1988; Harris-Warrick, 1988, Ewald eta!., 1989; Sweeney & Dolphin, 1992; Kleuss 
eta!., 1991; Dolphin et al., 1991; Dolphin, A.C., 1995). Murthy & Makhlouf (1994) 
reported the VIP receptor-mediated stimulation of a Ca2+ channel through a PTx-
sensitive G protein in dispersed gastric smooth muscle cells. In order to determine 
whether Ca2+ entry had a role to play in agonist-evoked VIP2 receptor-mediated 
[3H] IP production, the effect of a number of Ca2+ channel blockers on this response 
was assessed. 
The calcium ionophore, ionomycin, was used to investigate whether Ca2+ 
influx alone was sufficient to stimulate [3H]IP production in COS 7 cells. A 20 
minute application of 10 ~M ionomycin stimulated a 7.9±0.5 fold of basal control 
response (n=4). The basal value was 4,273±343 dpm/ assay. 
ATP powerfully stimulates PLC activity in COS 7 cells (Kosugi eta!., 1992). 
This response is likely to be mediated by a native purinoreceptor. The P2Y I-P2Y 4 
and P2Y 6 subtypes of metabotropic purinoreceptor have all been shown to couple 
to PLC stimulation (for review see North & Barnard, 1997). ATP-evoked [3H]IP 
production was therefore used as a control for the effects of Ca2+ channel blockers 
on VIP2 receptor-mediated [3H]IP production. A concentration-response curve for 
ATP-evoked [3H]IP production was performed (see Figure 3.11). The ECso value 
for ATP-stirnulated [3H]IP production was 28.2±0.5 ~M and the maximum 
response 32.9±0.1 fold of basal control. The response stimulated by 50 ~M ATP 
was not PTx-sensitive (16 hours pretreatment with 200 ng/ml PTx). The [3H]IP 
production levels with or without PTx-pretreatment were 11.7±0.2 and 11.2±0.3 
-fold of basal control respectively. 
Co2+ is a commonly used blocker of divalent cation channels (Hiriart et al., 
1988; Rorsman et al., 1986; Plant, 1988). Concentration-response curves for Co2+ 
on both ATP-evoked and PACAP-38-evoked [3H]IP production in COS 7 cells 
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expressing the VIP2 receptor were carried out (see Figure 3.12(a)). The VIP2 
receptor-mediated response was clearly inhibited in a concentration-dependent 
manner by Co2+ (to 22±9% of the control response at 0.3 mM Co2+) whereas the 
A TP-evoked response was unaffected by Co2+ treatment (94±4% of the control 
response at 0.3 mM Co2+). 
Methoxyveraparnil, the phenylalkylamine blocker of L-type Ca2+ channels 
(dihydropyridine-sensitive (DHP) Ca2+ channels), was used by Murthy & Makhlouf 
(1994) to block the YIP-receptor activated Ca2+ channel in gastric smooth muscle 
cells. Concentration response curves for methoxyveraparnil were carried out on 
both A TP-evoked and PACAP-38-evoked [3H]IP production in COS 7 cells 
expressing the VIP2 receptor (see Figure 3.12(b)). No significant inhibition of [3H]IP 
production mediated by either receptor was observed at concentrations of 
methoxyverapamil up to 100 J.l.M (101±15 and 82±4% of the control response for 
the PACAP-38- and ATP-evoked responses respectively). Nifedipine is a 1,4-
DHP compound which is a selective and effective blocker of DHP-sensitive Ca2+ 
channels (Nowycky et al., 1985; Fox et al., 1987). Concentrations of up to 10 J.l.M 
nifedipine had no inhibitory effect on PACAP-38-evoked [3H]IP production 
mediated by the VIP2 receptor expressed in COS 7 cells (120±13% of the control 
response after treatment with 10 J.1M nifedipine, n=6). SK&F 96365 is a compound 
described by Merritt et al. (1990) which inhibits both calcium-release activated 
calcium influx (CRACi) and DHP-sensitive Ca2+ channels. Concentration response 
curves to investigate SK&F 96365 effects on both ATP-evoked and PACAP-38-
evoked [3H]IP production in COS 7 cells expressing the VIP2 receptor were carried 
out (see Figure 3.12(c)). This compound was observed to have a marked 
concentration-dependent inhibitory effect on PACAP-38-evoked [3H]IP production 
(the response in the presence of 100 J.1M SK&F 96365 being 16±8% of the control 
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response). The A TP-evoked response however was only s lightly reduced (83±3'X, 
of the control response) by treatment of the cells with 100 J.l.M SK&F 96365. 
The experiments with Ca2+ channel blockers demonstrated that [3H]IP 
production mediated by the VIP2 receptor is at least partially dependent on Ca2-r 
channel activity. The ineffectiveness of both methoxyverapamil and nifedipine 
strongly suggests that the Ca2+ channel activity is not attributable to a DHP-
sensitive (L-type) Ca2+ channel. The inhibitory effect of SK&F 96365 on VIP2 
receptor-mediated [3H]IP production indicates that the Ca2+ channel may be of a 
type activated by Ca2+ release from intracellular stores. 
ln experiments on dorsal root ganglion neurons it was found that GTP 
analogues potentiated the effect of receptor agonists to inhibit Ca2+ currents in a 
PTx-insensitive manner. However an L-type current remained which was resistant 
to this inhibition. Scott & Dolphin (1987) therefore examined the effects of the 
L-type calcium channel antagonists methoxyverapamil (0600), nifedipine and 
diltiazem on GTPyS modulated Ca2+ currents. Surprisingly, all three compounds 
produced a marked PTx-sensitive potentiation of the Ca2+ current in the presence 
of GTP'y$. The effects of nifedipine, methoxyverapamil and SK&F 96365 were 
examined on [3H]IP production in COS 7 cells stimulated by the non-specific G 
protein activator AlC13/NaF (see Table 3.2). Interestingly, a clear and significant 
potentiation of AlCl3/NaF s timulated [3H]IP production was observed for all 
three compounds. Treatment with 10 J..LM nifedipine increased the A1Cl3/NaF-
stimulated response to 141.9±4.3% of the control response stimula ted by 10 J.l.M 
AlCl3 and 50 rru\11 NaF {10.5±0.5 fold of basal control), 30 ).l.M methoxyverapamil 
increased the response to 132±5% and SK&F 96365 increased the response to 
130±6% of the control response. 
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All three Ca2+ channel blockers had similar effects on AICI3/NaF 
stimulated [3H]IP production despite SK&F 96365 being the only one to 
significantly block PACAP-38-evoked [3H]IP production mediated by the VIP2 
receptor. These data are consistent with the idea that nifedipine, 
methoxyverapamil and SK&F 96365 can effectively modulate G protein-regulated 
L-type Ca2+ channel activity and thus potentially influence PLC activity in these 
cells, but this, as outlined above, is not the mechanism by which the VIP2 receptor 
mediates PLC activation. 
Thapsigargin is a well-established inhibitor of intracellular Ca2+ store Ca2+ 
pumps (sarcoplasmic and endoplasmic Ca2+-ATPase(SERCA) inhibitor: Thastrup 
et al., 1990). By inhibiting refilling of Ca2+ stores thapsigargin stimulates calcium-
release activated calcium influx (CRACi)· Concentration-response curves were 
constructed for thapsigargin-evoked [3H]IP production in the presence and absence 
of PACAP-38 (see Figure 3.13). The cells were treated with thapsigargin and / or 
P ACAP-38. Thapsigargin alone caused a concentration-dependent increase in 
[3H]IP levels (reaching 30±5% of the control response at a concentration of 3 !1M). 
Thapsigargin caused a significant potentiation of PACAP-38-evoked [3H]IP 
production at a concentration of 3 ).Ll\1 (an increase of 71±20% over the control 
response: the responses stimulated by 3 J..LM thapsigargin, 1 J..LM P ACAP-38 and 
1 J..LM PACAP-38 in the presence of 3 J..LM thapsgargin were; 1.28±0.03-, 2.75±0.03-
and 3.56±0.15-fold of basal control respectively). These data demonstrate that a 
modest stimulation of [3H]IP production may result from Ca2+ influx caused by the 
emptying of intracellular stores in COS 7 cells and that this mechanism causes a 
slight potentiation of the VlP2 receptor-mediated stimulation of [3H]IP production. 
The VIP2 receptor-mediated stimulation of [3H]IP production was partially 
PTx-sensitive. It is possible that the VIP2 receptor may stimulate PLC by a number 
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of different mechanisms, for example, by the interaction of a G protein with a Ca2+ 
channel to stimulate Ca2+ influx and by the simultaneous activation of PLC by a G 
protein. ln order to determine whether the Ptx-sensitive component of the VIP2 
receptor-mediated stimulation of [3H]IP production could be associated with the 
activation of Ca2+ channels, the effect of increasing concentrations of Co2+ on the 
PACAP-38-evoked stimulation of [3H] IP production in PTx-treated and untreated 
cells was examined (see Figure 3.14). In these experiments Ptx-treatment reduced 
the PACAP-38-evoked response to 70±12% of the control response, while the 
p resence of 0.01 or 0.03 mM Co2+ did not reduce this further (va lues of 70±1 and 
74±6% of the control response respectively). Co2+ however, caused a clear 
concentration-dependent reduction in PACAP-38-evoked [3H]IP production in the 
absence of Pix-treatment. These data indicate that the PTx-sensitive component of 
the VIP2 receptor-mediated stimulation of [3H]IP production was more sensitive to 
Co2+ treatment than the Pix-insensitive component suggesting that the activation 
of PTx-sensitive G proteins by the VIP2 receptor may well be associated with the 
stimulation of Ca2+ channels. 
3.3.7 The involvement of pertussis toxin-sens itive G proteins in agonist-
evoked cAMP production mediated by the rat VIP2 receptor 
The stimulation of PLC by PTx-sensitive G proteins is known to occur 
predominantly as a result of PLC activation by ~y subunits (Lee & Rhee, 1995; 
Exton, J.H., 1996). There are very few instances of Ct. subunits from PTx-sensitive G 
proteins being implicated in the agonist-evoked stimulation of PLC (Exton, J.H., 
1996). PTX-sensitive G proteins are most commonly associated with the inhibition 
of AC activity (Taussig et al., 1993; Taussig et al., 1994). It is therefore possible 
that the Pix-sensitive G proteins activated by the VIP2 receptor not only stimulate 
PLC activity, through the action of their ~y subunits, but also cause the inhibition of 
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adenyla te cyclase as a result of their CJ. subunit activity. The effect of PTx-
pretreatment on VIP-evoked cAMP production mediated by the VIP2 receptor 
transiently expressed in COS 7 cells was therefore examined (see Figure 3.15). The 
treatment of ceUs with 200 ng/ ml PTX for 16 hours before stimulation with VIP 
(0.01 ru\ll - 100 nM) had no detectable effect on cAMP production (117.2±3.6 and 
117.4±3.9 pmol/ml cAMP at a concentration of 100 nM VIP with and without PTx-
treatment respectively). The inhibitory effect of Gi/o activation on AC activity 
depends on the AC isoform involved (Taussig et al., 1993; Taussig et al., 1994). 
The effect can be quite small and may be difficult to identify over the simultaneous 
stimulatory effect of G5. In order to observe the effect of the inhibitory G proteins 
in such cases it is necessary to remove the influence of the stimula tory G proteins. 
This can be accomplished by pretreating the cells with 20 ~g/ml cholera toxin 
(CTx) for 16 hours before stimulation with receptor agonist, a protocol known to 
down-regulate G5 (Eason & Liggett, 1994), and stimulating AC with 10 11M forskoli..'1 
at the time of adding agonist. This results in a maximally stimulated adenylate 
cyclase system with reduced G5 levels in which an inhibitory effect on cAMP 
production should be easily identified. A concentration-response curve for 
PACAP-38-mediated cAMP production was performed on CTx and forskolin-
treated cells (see Figure 3.16). Basal c.A.MP production was 1.11±0.02 pmol/mL 
10 ).l.M Forskolin applied to CTx-treated cells stimulated the production of 
438.±28 pmol/ml cAMP. PACAP-38 a t concentrations up to 3 ~M caused no 
apparent inhibition of cAMP production but stimulated an increase in cAMP 
production (596±43 pmol/ml at 1 ~M PACAP-38). It is possible that down 
regulation of G5 by CTx pre treatment has made this the limiting factor in the VIP2 
receptor-mediated stimulation of aden~.rlate cyclase and has 'right-shifted' the 
concentration-response curve for PACAP-38-evoked cAMP p roduction to the 
extent that it fa lls within the same range as the concentration-response curve for 
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PACAP-38-evoked [3H]IP production. Alternatively, the VlP2 receptor may be 
mediating the stimulation of AC by a mechanism other than G5 activation at high 
agonist concentrations. 
The PTx-sensitive G protein activator mastoparan, at a concentration of 
8J..1.M, caused a clear inhibition of CTx- (20 !lg/ml for 16 hours) and forskolin- (10 
!lM for 10 minutes) stimulated cAMP production in COS 7 cells (from 630±26 to 
388±55 pmol/ml; an inhibition of 38±10% of the CTx/forskolin-stimulated 
response: see Figure 3.17). PTx-pretreatment (100 ng/ml for 16 hours) reversed the 
inhibition, returning the cAMP levels to 682±29 pmol/ml. PTx-pretreatment had 
no effect on basal cAMP production but almost doubled the CTx-stimulated level 
(from 119±9 to 202±24 pmol/ml). CTx and forskolin have a synergistic effect on 
cAMP production; together producing 630±26 pmol/ml cAMP (forskolin alone 
stimulated the production of 199±21 pmol / ml cAMP). Ptx-treatment increased the 
CTx/forskolin stimulated level of cAMP production from 630±26 to 680±2-1 
pmol/ml. This slight increase is not significant but is probably equivalent to the 
increase observed after PTx-treatment of CTx-treated cells. These data 
demonstrate that the activation of adenylate cyclases in COS 7 cells by CTx and 
forskolin is subject to inhibition by treatment with mastoparan, the presumed 
Gifo/z activator. This inhibition is completely reversed by PTx-treatment suggesting 
that it is mediated by PTX-sensitive G proteins. In conclusion, under the present 
conditions, an inhibition of AC by Ptx-sensitive G proteins activated by the VIP2 
receptor could not be demonstrated. 
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3.3.8 The effect of various kinase inhibitors on [3H]inositol phosphate 
production mediated by the VIP2 and related receptors transiently 
expressed in COS 7 cells 
In order to deterrnme whether agonist-evoked VIP2 receptor-mediated 
stimulation of [3H]IP production in COS 7 cells was modulated by protein kinases 
a number of protein kinase inhibitors were tested on this response. Certain of the 
inhibitors were also tested on related receptors (see Table 3.3). 
Treatment of cells with the PKC inhibitor GF 109203X (Toullec et al., 1991), 
at a concentration of 10 ~M, caused the VIP1 and VIP2 receptor-mediated YIP-
evoked responses to increase slightly but not in a statistically significant manner 
(117±9 and 122±6% of their control responses, which were; 2.84±0.19 and 
2.03±0.04 fold of basal control respectively). The VIP1 and VIP2 receptor-mediated 
VIP -evoked responses were also unaffected by treatment of the cells with 30 J.LM 
H-89, an isoquinolinesulfonamide inhibitor of cAMP-dependent protein kinase 
(PKA) (Chijawa et al., 1990). The values after treatment were 100±8 and 108±16% 
of the control responses for the VIP1 and VIP2 receptors respectively. The treatment 
of cells with the non-specific protein kinase inhibitor, staurosporine (Tamaoki et al., 
1986), at a concentration of 1J.LM, increased VIP}, VIP2 and PACAProng receptor-
mediated agonist-evoked [3H]IP production to 175±51, 257±42 and 173±19% of 
their respective control responses (7.74±0.63 fold of basal control was the control 
response for the P ACAPiong receptor-mediated P ACAP-38 -evoked activity). The 
AlC}J/NaF stimulated response was similarly increased to 162±1% of the control 
response, which was 13.4±0.3 fold of basal control. This indicates that 
staurosporine is likely to be active at a point downstream of the receptor e.g. at a G 
protein or PLC itself. Treatment of cells with the tyrosine kinase inhibitor, genistein 
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(Akiyama & Ogawara, 1991), at a concentration of 100 !lM had no effect on VIP2 
receptor or PACAPtong receptor-mediated [3H]IP production (83±11 and 103±4<Yo 
of their control responses respectively after treatment). 
These data indicate that there are no apparent tonic effects of GF 109203X-
sensitive PKC isoforms, H 89-sensitive PKA isoforms or genistein-sensitive tyrosine 
kinases on VIP2 receptor-mediated stimulation of [3H]IP production in COS 7 cells. 
The PACAPtong receptor-mediated stimulation of [3H]IP production is similarly 
unaffected by genistein-sensitive tyrosine kinases and the VIP1 receptor-mediated 
stimulation of [3H]IP production is unaffected by GF 109203X-sensitive PKC 
isoforms and H 89-sensitive PKA isoforms. The agonist-evoked [3H]IP production 
mediated by all three receptors was potentiated by staurosporine treatment of the 
cells but this was also true of the response stimulated by the non-specific G protein 
activator AlCl3/NaF indicating that the effect of staurosporine or its target 
kinase(s) is downstream of the receptor at a G protein or possibly PLC itself. 
3.3.10 Preliminary experiments on immunoprecipitation and 
immunoblotting for VIP2 receptor-associated G proteins 
In order to identify the G proteins associated with the VIP2 receptor which 
were involved in PLC stimulation, a human VIP2 receptor construct with a 
haernagluttinin(HA) tag sequence attached to its C-terminus was used. The human 
VIP2 receptor sequence varies from the rat receptor sequence in a limited number of 
residues (see Table 4 . .3). As a means of confirming that there were no major 
differences in the signalling characteristics of the tagged human and the rat isoforms 
of the receptor, the HA-tagged human receptor was expressed in COS 7 cells and a 
concentration-response curve for PACAP-38-evoked [3H]IP production was carried 
out (see Figure 3.18). The human receptor mediated a 1.73±0.10 fold of basal 
control response with an ECso value of 66.7±9.7 nM. The stimulation of [3H]IP 
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production was PTx-sensitive, being inhibited to 63±11'!/o of the 111M PACAP-38-
evoked response (1.58±0.12 fold of basal control) by 16 hours pretreatment with 
100 ng/ ml PTx. The HA-tagged human VIP2 receptor, when expressed in HEK293 
ceUs, behaves identically to the untagged human VIP2 receptor with respect to YIP-
evoked cAMP production (ECso values of 1.4±0.2 and 1. ?±0.2 n.NI respectively: 
Diane Oinnis; personal communication). The HA-tagged human VIP2 receptor-
mediated signalling appears to be very similar to that of the rat VIP2 receptor. It is 
therefore likely that the two receptors will interact with equivalent G proteins when 
expressed in the same cell line. 
The HA-tagged human VIP2 receptor was expressed in COS 7 cells and the 
receptor was irnmunoprecipitated from a solubilised membrane preparation of the 
cells using an antibody specific for the HA tag (see section 2.2.13). The conditions 
for receptor solubilisation and specific immunopredpitation under conditions 
retaining associated proteins have been extensively characterised by other workers 
in the lab. Western blots of the immunoprecipitate were immunostained with 
antibodies for Gaq, Gail/.2 and Gai /o/t/z· To confirm the specificity of staining, 
antisera were preincubated (15 minutes, 200C) with a specific peptide antigen. 
In these experiments the presence of Gaq was clearly detected in the 
immunoprecipitate (see Figure 3.19(c)) as was a member of the Gaijo/t/z· family 
(see Figure 3.19(b)). The specific bands identified by their anti-sera were 
approximately 42 and 47 kDa in size respectively and were blocked by 
preincubation with the appropriate peptide antigen. The antiserum for Gail-2 
produced no bands which were convincingly blocked by the appropriate peptide 
antigen (see Figure 3.19(a)). The data therefore provide e\·idence to suggest that a 




Consistent with present findings there is considerable evidence in the 
literature that the PACAP receptor mediates AC and PLC activation and that VIP1 
and VIP2 receptors mediate AC activation. When expressed in COS 7 cells the 
PACAP receptor was represented at a higher level than the VIP2 receptor and 
mediated a higher fold stimulation of cAMP production (see Table 3.1). It has been 
known for some time that the P ACAP and VIP2 receptors stimulate AC in COS 7 
cells (Morrow et al., 1993; Lutz et al., 993) and that agonist activation of the 
PACAP receptor additionally stimulates PLC and mobilises intracellular Ca2+ 
(Gottschall et al., 1991; Deutsch & Sun., 1992; Tatsuno et al., 1992). Our 
observations provide evidence that VIP1 and VIP2 receptors are also capable of 
activating PLC. 
3.4.1 Agonist-evoked [3H]inositol phosphate production mediated by the 
rat VIP2 receptor 
There are a nwnber of reports in the literature suggesting that YIP-preferring 
receptors have the ability to activate PLC. Many reports describe the effects of VIP 
at concentrations which are consistent with VIP1 and VIP2 receptor-mediated 
effects. However, few of the early studies carried out pharmacological 
characterisation such as the relative potencies of VIP and PACAP-38 which could 
lead specifically to identification of VIP receptor-mediated rather than PACAP 
receptor-mediated effects. VIP concentrations in the micromolar range have been 
shown to produce an increased level of phosphatidyl inositol (PI) turnover in 
superior cervical ganglion (Audigier et al., 1986). Malhotra et al. (1988) found VIP 
and muscarine to stimulate PI hydrolysis and mobilise intracellular Ca2+ stores 
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inducing the secretion of catecholamines in adrenal chromaffin cells. Low 
concentrations of VIP were also sufficient to activate PKC in regions of rat 
hippocampus (Weill et al., 1989). Low levels of VIP were shown to mobilise 
calcium in astroglial cells derived from rat cerebral cortex (Russell et al., 1990) and 
Fatatis et al. (1994) observed that in type 1 astrocytes from rat cerebral cortex, 
a-adrenoreceptors were found to act synergistically with VIP receptors to augment 
an intracellular Ca2+ signal which was abolished by thapsigargin treatment. The PI 
hydrolysis mediated by the VIP and a-adrenoreceptors did not appear to be 
additive (Fatatis et al., 1994). Inagaki et al. (1994) cloned a VIP2 receptor from the 
mouse insulin-secreting cell line MIN6. Expression of this receptor in Xenopus 
oocytes showed that calcium-activated chloride currents were stimulated by 
PACAP suggesting that the emptying of intracellular Ca2~ stores as a result of PLC 
stimulation had taken place. 
These examples strongly suggest that VIP receptors can stimulate PI 
hydrolysis. When this study began, no direct evidence of such a mechanism had 
been presented. In this study the ability of the VIP2 receptor to stimulate the 
production of [3H]IP has been clearly demonstrated in COS 7 cells (see Figure 3.3, 
Figure 3.4 and Table 3.1). VIP and PACAP-38 have been shown to be equipotent 
for [3H]IP production mediated by the VIP2 receptor, as they were for cAMP 
production mediated by this receptor. The scale of the [3H]IP production mediated 
by the VIP2 receptor is smaller than that mediated by the P ACAP receptors (see 
Figure 3.4 & Table 3.1) and the potency of PACAP-38 is less potent at the VIP2 
receptor. This may be attributable to the higher expression level of the PACAP 
receptors, a different affinity of interaction with the same G proteins or a different 
mechanism being in operation. 
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It has since been shown that the human VIP1 receptor stably expressed in 
HEK 293 and CHO cells is capable of mediating VIP-evoked increases in 
intracellu lar Ca2+ (Sreedharan et al., 1994). Transient and sustained phases of 
Ca2+ increase were observed in response to VIP. ln stably transfected HEK293 
cells, the transient phase of Ca2+ increase was abolished by thapsigargin treatment, 
indicating that it was due to the release of Ca2+ from intracellular stores, and the 
sustained phase was abolished by removing extracellular Ca2+, indicating that it 
was probably due to Ca2+ entry through channels in the plasma membrane 
(Sreedharan et a l., 1995). PI hydrolysis and the cAMP response were unaffected by 
this treatment. The stimulation of PI hydrol ysis and Ca2"" responses were inhibited 
by cholera toxin or forskolin treatment indicating that cAt'v!P modulated the IP 
response. This is not true of the IP response mediated by the VIP1 and VIP2 
receptors expressed in COS 7 cells. A human intestinal epithelium cell line (HT29 
cells) expresses a low level of VIP1 receptors (Sreedharan et al., 1993) and VIP has 
also been shown to stimulate transient Ca2+ increases in these cells (Sreedharan et 
al., 1994). Van Rarnpelbergh et al. (1997) have recently shown that the rat PACAP 
and VIP1 receptors, when stably expressed in CHO cells, can mediate the 
stimulation of both adenylate cyclase and PLC and that the VIP1 receptor-
mediated stimulation of PLC is PTx-sensitive. These authors found that a 
comparison of clones expressing similar amounts of the PACAP and VIP1 receptor 
revealed tha t the P ACAP receptor still mediated a higher fold stimulation of PLC. 
Although the ECso values are referred to in the text of that publication, the authors 
chose not to quote the actual values simply describing them as being in the 
nanomolar range. The illustrations in that publication indicate that agonist-evoked 
stimulation of PLC became maximal at between 3-5 nM ior the PACAP receptor-
mediated response and at approximately 100 nM fo r the VIP1 receptor-mediated 
response. 
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3.4.2 The pertussis toxin sensitivity of [3H]inositol phosphate production 
mediated by the rat VIP2 receptor 
Murthy et al. (1993) described the stimulation of NOS mediated by a VIP 
receptor in dispersed gastric smooth muscle cells. This is presumed to contribute to 
smooth muscle relaxation (a topic discussed in Chapters 1 and 6). The concomitant 
activation of PKC was found to inhibit NOS activity (Murthy et al., 1994) the 
stimulation of which was postulated to occur by a direct G protein interaction with 
NOS and an indirect Ca2+ influx mechanism, one or both of which are attributable 
to the activation of a PTx-sensitive G protein. The VIP and PACAP-27-mediated 
stimulation of NOS was inhibited by antibodies to G<Xil /2 · The VIP receptor in rat 
lung however, has been demonstrated by cross-linking studies to be capable of 
coupling to both G5 (Kermode et al., 1992) and G<Xi3 (Diehl & Shreeve, 1995). 
An investigation of the PTx-sensitivity of VIP receptor-mediated stimulation 
of [3H]IP production revealed a significant but partial inhibition of both the VIP1 
and VIP2-receptor mediated responses after PTx-treatment of the cells 
(approximately 40% inhibition at 100 ng/ml PTx: see Figure 3.8a). PTx-treatrnent 
was also demonstrated to attenuate the GTPyS -mediated reduction in ligand 
binding to the VIP2 receptor (approximately 45%: see Figure 3.9). This strongly 
suggests that the VIP2 receptor interacts directly with a PTx-sensitive G protein and 
that this PTx-sensitive G protein constitutes a large percentage of the G proteins 
which associate with the receptor. The effect of PTx on VIP receptor-mediated IP 
responses was not attributable to the removal of an inhibitory influence on cAMP 
production since CTx pre-treatment had no significant effect on [3H]IP production 
mediated by the VIP receptors (see Figure 3.8(b)) and PTx-treatment had no effect 
on VIP-€voked cAMP production mediated by the VIP2 receptor (see Figure 3.15). 
The PACAP receptors when transiently expressed in COS 7 cells mediated an 
81 
agonist-evoked stimulation of [3H]IP production which was not PTx-sensitive (see 
Figure 3.8(c)) as did the presumed purinoreceptor in COS 7 cells (see Figure 3.11 ). 
The PTx-insensitivity of the PACAP receptor-mediated response demonstrates that 
the high expression level of a non-native receptor in this cell line is not sufficient to 
cause the activation of PLC by PTx-sensitive G proteins and that the characteristics 
of the receptor itself are the dominant factors. 
The stimulation of [3H]IP production in a PTx-sensitive manner by 
A1Cl3/NaF suggests that the activation of PTx-sensitive G proteins is sufficient to 
stimulate [3H]IP production in COS 7 cells (stimulation was inhibited 
approximately 18% by PTx-treatment). The ability of mastoparan to stimulate 
[3H]IP production in a PTx-sensitive manner (see Figure 3.10) confirms a role for 
PTx-sensitive G proteins in this system. 
Immunoprecipitation of the haemagluttinin-tagged human VIP2 receptor 
expressed in COS 7 cells and immunoblotting for the associated G proteins revealed 
preliminary evidence for the direct association of a member of the Gi/o/t/z family 
of PTx-sensitive G proteins (other than Gil/2) and Gq with the receptor. The PTx-
insensitive component of the VIP2 receptor-mediated stimulation of PLC may 
therefore be explained by the coupling of Gq to this receptor, in addition to the PTx-
sensitive G protein. 
f3y subunit stimulation of PLC 
There have been many cases now in which the stimulation of PLC by PTx-
sensitive G proteins has been reported. There have been \·ery few cases in which an 
isofonn of PLC~ has been shown to be responsive to the ex subunits of PTx-sensitive 
G proteins, ~'Y subunits however, have been shown to cause stimulation 
independently of the ex subunits (Smrcka & Stemweis, 1993; Boyer et al., 1992; 
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Park eta!., 1993). The potency of ~y stimulation of purified PLC~ isoforms has 
been determined as being: PLC ~3>~2>~ 1 (Smrcka & Stemweis, 1993; Park eta!., 
1993), PLC~4 is insensitive to ~y stimulation Giang et al., 1994). The order of 
potency of Gq stimulation of PLC~ isoforms is: PLC ~1~~3>~4>~2 (Lee & Rhee, 
1995). From this it appears that the ~1 isoform appears to be primarily Gexq 
stimulated whereas PLC~2 is primarily ~y-stimulated. The PLC~3 isoform 
however, appears to be responsive to both a and ~y subunits. This indicates that 
the selective expression of PLC isoforms may be a mechanism for controlling PIP2 
hydrolysis in the cell. Most cells contain members of the Gq/11 and Gi/o families of 
G proteins; members of the latter family constituting 1-2% of the protein in bovine 
brain (Stemweis & Robishaw, 1984). The concentration of ~y subunits required to 
stimulate PLC is generally found to be two orders of magnitude greater than for Gaq 
(Exton, 1997), which may explain why the ECsos for VIP2 receptor-mediated 
[3H]IP production in COS 7 cells are so much greater than those for PACAP 
receptor-mediated stimulation. 
Distribution of PLC isoforms activated by G proteins/Ca2 + 
The ~1 and ~3 isoforms of PLC are widespread in cells, ~1 is widespread in 
the brain expressed mainly in the cerebral cortex and hippocampus, ~3 is expressed 
at low level throughout the brain (Rhee et al., 1991; Jhon et al., 1993). The ~2 
isoform appears to be restricted to haematopoetic cells (Park et al., 1992) and the 
~4 isoform is associated with the retina (Lee et al., 1993) although it is expressed in 
the cerebellum and at low levels in other areas of the brain (Kim et al., 1997). The 
PLC8 isozyme was believed to be regulated by Ca2+ alone, but there are now 
reports of its being stimulated by a poorly understood high molecular weight GTP-
binding protein called Gh (Feng et al., 1996) and a Rho-GAP-like protein (Homrna 
& Emori, 1995). 
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3.4.3 The role of Ca2+ influx in VIP2 receptor-mediated stimulation of 
[3H]inositol phosphate production 
There are now many examples of G protein modulation of ion-channel 
activity, especially involving the intensively studied L-type Ca2+ channels. The 
majority of these cases involve the activity of PTx-sensitive G proteins (for reviews 
see: Schultz et al., 1990; Hille, 1994; Wickman & Clapham, 1995; Fasolato et al., 
1997). 
GH3 cell membranes contain large amounts of G0 and at least two isoforms 
of Gi (Rosenthal et al., 1988). It was found that PTx pre-treatment abolished both 
stimulatory and inhibitory effects on calcium currents in GH3 cells. Offermans et 
al. (1989) confirmed this result by demonstrating that the GTPase activity 
stimulated by both stimulatory and inhibitory hormones in GH3 cells is PTx-
sensitive. Ca2+ currents in cardiac and skeletal myocytes are stimulated by cAMP-
dependent phosphorylation (Trautwein & Hescheler, 1990) where the G protein-
regulated channels are apparently L-type channels (Lmoto et al., 1988; Mattera et 
al., 1989; Yatani et al., 1987). In adrenocortical and pituitary cells however this is 
not the case; intracellularly applied cAMP or extracellular forskolin do not 
stimulate Ca2+ currents. In an adrenocortical cell line, Y1 cells, which contain no 
G0 , angiotensin II stimulated a voltage-dependent Ca2+ current(VDCC) which 
involved a PTx-sensitive G protein but was independent of cAMP production 
(Hescheler et al., 1988). 
In work carried out on rat cerebral cortical membranes Sweeney & Dolphin 
(1992) found that L-type 1,4-dihydropyridine sensitive Ca2+ channels act as 
GTPase-activating proteins(GAP) to stimulate GTP hydrolysis by G<Xo. 
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Dihydropyridine agonists were found to stimulate the GTPase activity. Because 
trus was a membrane-delimited system, any effect on soluble second messengers 
was excluded. A PTx-sensitive G protein was also involved in CJ.2A-
adrenoreceptor-mediated stimulation of Ca2+ influx in rat portal vein smooth 
muscle cells (Lepretre & Mironneau, 1994). The Ca2- entry was blocked by 
oxidipine (a voce blocker) and whole-cell patch clamp experiments demonstrated 
that the (a2+ influx occurred through L-type Ca2+ channels. The activation of 
Ca2+ influx by both the receptor and mastoparan was reduced by PTx-treatrnent 
and a PKC inhibitor (GF 109203X). This was consistent with the hypothesis that a 
PTx-sensitive G protein was involved in a pathway leading to the activation of 
PKC ,which then phosphorylates the channel, thereby increasing its activity. 
As was mentioned in section 3.3.6, the VIP receptor in rabbit gastric smooth 
muscle cells has been implicated in the direct stimulation of a Ca2+ channel by a 
PTx-sensitive G protein (Gil / 2: Murthy et al. 1993; :vturthy & Makhlouf, 1994). 
initially the authors found that treatment of the cells with 1 11M methoxyveraparnil 
(a phenylalkylarnine, L-type Ca2+ channel blocker) completely inhibited VIP-evoked 
NO production and cGMP production. In the later publication the authors provide 
data indicating that, in addition to VIP-evoked Ca2+ influx, a direct stimulation of 
NOS by a G protein may also occur. In that system PKC activation effectively 
blocked the Ca2+-mediated responses indicating that VIP receptor stimulation did 
not result in PKC activation in rabbit gastric smooth muscle cells. 
Ionomycin was shown to very effectively activate [3H]IP production in COS 
7 cells demonstrating that Ca2+ influx alone was sufficient to activate PLC in this 
system (see section 3.3.6). Treatrnent of the cells with the divalent cation channel 
blocker Co2+ effectively blocked the VIP2 receptor-mediated stimulation of [3H]IP 
production, wrulst having little effect on the A TP-evoked response in COS 7 cells 
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(see Figure 3.12(a)). This strongly suggests that there is C'l role fo r Ca2+ influx in the 
VIP2 receptor-mediated response. The rat VIP2 receptor when expressed in COS 7 
cells mediates a stimulation of [3H]IP production which is unaffected by the L-type 
Ca2+ channel blockers, methoxyveraparnil, at concentrations up to 100 J.!M, or 
nifedipine, at concentrations of up to 10 J.!M (see Figure 3.12b). These compounds 
are the most commonly used blockers of L-type Ca2+ channels and their 
ineffectiveness strongly suggests that the VIP2 receptor does not stimulate Ca2+ 
influx through this class of channel. 
Calcium-release activated calcium influx 
In human neutrophils Wenzelseifert et al. (1996) found that thapsigargin-
stimulated cation entry involved a PTx-sensitive G protein and a non-selective 
cation channel which was sensitive to SK&F 96365 and Gd3+. The protein 
phosphatase(PP)l / 2A inhibitors, calyculin A and okadaic acid, reduced cation 
entry whereas inhibition of PP2B with cyclosporin A and FK-506 potentiated the 
influx. Thapsigargin-stimulated Ca2+ influx was partially inhibited by PTx pre-
treatment. Thapsigargin also behaved as a partial secretagogue in human 
neutrophils, activating lysozyme release. This activity was inhibited by the removal 
of extracellular Ca2+, PTx pre-treatment or SK&F 96365 treatment which strongly 
suggests that the secretagogue activity was dependent on Ca2+ influx mediated by a 
PTx-sensitive G protein. VIP acts as a secretagogue in a number of tissue and cell 
types, for example, for prolactin in GH3 cells (Rostene, 1984), IL-6 in anterior 
pituitary cells (Tatsuno et al., 1991; Matsumoto et al., 1993; Spangelo et al., 1990; 
Spangelo et al., 1991) and ACTH secretion in AtT-20D16v cultures (Braas et al., 
1994). Further evidence in support of the description of a PTx-sensitive 
mechanism of Ca2+-release activated Ca2+ influx(CRAC; ) by Wenzelseifert et al. 
(1996) was provided by Berven et al. (1995), who identified G;2 as being required 
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for CRACi activation in hepatocytes. It was found to act between the release of 
calcium from intracellular stores (stimulated by vasopressin or thapsigargin) and 
the Ca2+ channel in the plasma membrane. An anti-Gil / 2 antibody and a synthetic 
G<Xi2 C-terminal peptide inhibited vasopressin- and thapsigargin-sti.mulated Ca2+ 
entry without affecting vasopressin-induced release from Ca2+ stores and an anti-
Gq antibody inhibited vasopressin-stimulated Ca2"' entry and partiaUy inhibited 
release from intracellular stores without affecting thapsigargin-stirnulated release. 
In these hepatocytes immunofluorescence studies revealed that Gi2 was distributed 
through the cell interior as well as being at the plasma membrane whereas Gq/11 
was found principally at the plasma membrane. This demonstrated that only 
vasopressin-evoked Ca2+ release from intracellular stores is dependent on Gq, 
whereas both vasopressin- and thapsigargin-evoked Ca2- influx is dependent on a 
mechanism involving Gi2· It would therefore appear that there may be a 
requirement for a PTx-sensitive G protein in calcium-release activated calcium influx 
in a number of cell types. 
SK&F 96365 is structurally distinct from the known calcium channel 
antagonists. This compound was first described by Merritt et al. (1990) and was 
found to block CRACi in both non-excitable and excitable cells The ICso for 
inhibition of CRACi by SK&F 96365 in platelets was 8.5 !1M for ADP- and 11.7 
~ for thrombin-stimulated influx whereas SK&F 96365 had no effect on Ca2+ 
release from internal stores. Similar effects were observed in neutrophil and platelet 
preparations. Voltage-gated Ca2+ entry in GH3 and rabbit ear-artery smooth 
muscle cells was inhibited by SK&F 96365 (with lCso values of 3.6 ).lM and 20-30 
).lM respectively) whereas the activity of the P2X purinoreceptor in rabbit ear-artery 
smooth muscle cells was unaffected. SK&F 96365 does not therefore appear to 
discriminate between voltage-gated- and receptor-mediated- Ca2+ entry, inhibiting 
both within the same concentration range. Howevec based on the P2X 
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purinoreceptor results, SK&F 96365 appears to discriminate between different 
types of receptor-mediated calcium influx. This is a very hydrophobic compound 
but its presence in the membrane does not disrupt general channel function as 
demonstrated by its lack of effect on the ionotropic purinoreceptor activity. 
The VIP2 receptor-mediated stimulation of [3H]IP production was inhibited 
by treatment with SK&F 96365 (see Figure 3.12(c)). The ICso was approximately 30 
J..l.M which is similar to the values quoted by Merritt et al. (1990) for inhibition of 
Ca2+ entry. In conjunction with the inability of the L-type Ca2+_channel blockers 
(methoxyverapamil and nifedipine) to inhibit the VIP2 receptor-mediated 
stimulation of [3H]IP production the data suggest that a calcium channel (other 
than an L-type channel) activated by the emptying of intracellular stores is 
involved. Thapsigargin was observed in this system to stimulate [3H]IP production 
and to potentiate VIP2 receptor-mediated stimulation of [3H]IP production (see 
Figure 3.13). This constitutes further evidence that CRACi is a relevant mechanism 
for VIP2-receptor mediated stimulation of [3H]IP production. The precise nature of 
the channel is unknown. It may be one of the voltage-dependent calcium channels, 
which are highly selective for calcium, or a calcium-permeable cation channel, these 
channels show little or no selectivity for Ca2+, are insensitive to organic calcium-
channel ligands and may also lack a voltage-gating mechanism (Schultz et al., 
1990). 
As mentioned above, the VIP receptor in rabbit gastric smooth muscle cells is 
linked to NOS activation (Murthy et al., 1993), a topic which will be explored 
further in Chapter 5. In rat thoracic aorta the Ca2--:\ TPase inhibitors thapsigargin 
and cyclopiazonic acid(CPA) induced NO-mediated cG:VlP production and 
relaxation. This was blocked by SK&F 96365 but not nifedipine. The nitroprusside 
or A23187-induced relaxation was unaffected by SK&F 96365. ACh-induced 
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relaxation and cGMP production were blocked by SK&F 96365. The data indicates 
that endothelium-dependent relaxation of vascular smooth muscle is due to the 
activation of a constitutive NOS by calcium-release activated (a2+ influx. CPA-
and thapsigargin-induced endothelium-dependent relaxation and cGMP production 
in rat thoracic aorta were inhibited by NOS inhibitors, calmodulin inhibitors and 
removal of Ca2+, suggesting that NO is involved in the relaxation induced by Ca2+_ 
ATPase inhibitors (Moritoki et al., 1994;1996; Zheng et al., 1994). The conclusion is 
therefore that Ca2+ -ATPase inhibitors deplete intracellular stores promoting Ca2+ 
influx which activates eNOS and causes NO production which in tum activates 
guanylate cyclase causing cGMP production and relaxation of vascular smooth 
muscle (Kondoh et al., 1993; Moritoki et al., 1994a,b). 
Ca2+ is recognised as playing a central role in NO production in the vascular 
endothelium (Mulsch et al., 1989; Schmidt et al., 1989). In endothelial cells agonist-
induced increases in Ca2+ concentration have been attributed both to the release of 
Ca2+ from intracellular stores and influx via Ca2+ channels (Schilling et a1.,1988; 
1989; 1992; Jacob, 1990; Dolor et al., 1992). Ku & Williams (1995) also observed 
that thapsigargin selectively increases endothelial (a2+-concentration and produces 
both prostanoid and nitric oxide-dependent relaxation in canine coronary arteries. 
The VIP2 receptor has been shown through preliminary studies using 
immunoprecipitation and Western blotting to be associated with both PTx-sensitive 
G proteins and Gq (see Figure 3.20). Since the VIP2 receptor-mediated stimulation 
of [3H]IP production is only partially PTx-sensitive it is possible that these two G 
proteins are involved in different aspects of this stimulation, for example the PTx-
sensitive G protein may be involved in the Ca2+ channel activity while Gq directly 
activates PLC. The co-immunoprecipitation of these G proteins with the VIP2 
receptor is of course not evidence of a functional interaction. The PTx-sensitive 
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phase of the component of the VIP2 receptor-mediated [3H]IP production however 
appears to be more sensitive to the effects of Co2"'" than the PTx-resistant 
component (see Figure 3.14). This is fuUy consistent with the idea that a PTx-
sensitive G protein is involved in the activation of the Ca2+ channel. Additional 
experiments such as the use of a Gq antiserum in a membrane PLC assay would be 
required in order to positively identify a role for Gq in this system. Although a 
portion of the response appears to be PTx-insensitive this could also be due to the 
incomplete ADP-ribosylation of Gi/o in this system. 
Scott & Dolphin (1987) made the interesting observation that L-type Ca2+ 
channel antagonists (nifedipine, diltiazem and SK&F 96365) actually potentiated 
Ca2+ currents through L-type channels in dorsal root ganglion neurons on the 
application of GTPyS. This was attributed to activated G proteins stabilising the 
channel in a state in which the high affinity binding site was converted from 
antagonist to agonist form such that antagonists developed agonist activity. 
Sanguinetti et al. (1986) reported that DHP agonists bind preferentially to the 
resting state of the channel, which is consistent with the idea that activation of the 
L-type channel causes a change in the characteristics of its binding sites. 
Nifedipine, methoxyveraparnil and SK&F 96365 had a similar potentiating effect on 
AlCl3/NaF-stimulated [3H]IP production in COS 7 cells to that described by Scott 
& Dolphin (1987) on GTP1S modulated Ca2+ currents through L-type channels in 
dorsal root ganglion neurons (see Table 3.2). Although of course, methoxyverapamil 
and nifedipine, had little effect on VIP2 receptor-mediated [3H]IP production, 
whereas SK&F 96365 was inhibitory (see Figure 3.12). The probable reason for the 
different effects of the inhibitors on VIP2 receptor-mediated and AICl3 / NaF 
stimulated [3H]IP production is that the receptor-mediated response does not 
involve the stimulation of L-type Ca2+ channels and therefore is unaffected by 
compounds such as nifedipine and methoxyverapamil which are believed to be 
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active only at L-type Ca2+ channels. It is therefore likely that the broad spectrum G 
protein activator, AICI3/NaF, activates G proteins which stimulate Ca2+ influx 
through L-type Ca2+ channels, in addition to the channels activated by VIP2 
receptor-mediated signalling, and that the VIP2 receptor-activated channels are 
likely to be a minority in the Ca2+ channel population activated by AICl3/NaF. 
The inhibitory effect of SK&F 96365 on the subtype of Ca2+ channel activated by 
the VIP2 receptor would therefore be obscured by the potentiating effect on the more 
abundant L-type Ca2+ channels. 
In this study it has been demonstrated, by ionomycin treatment, that Ca2+ 
influx alone is sufficient to stimulate [3H]IP production (see Section 3.3.6) and, 
through Co2+ inhibition of PACAP-38-evoked [3H]IP production (see Figure 
3.12(a)), that the activity of a divalent cation channel is a central part of the VIP2 
receptor-mediated mechanism. It has been shown that L-type Ca2+ channel 
blockers, despite being active on AlC13/NaF-evoked [3H]IP production (see Table 
3.2), have no effect on VIP2 receptor mediated [3H]IP production but that SK&F 
96365, an inhibitor of L-type Ca2+ channels and CRACi, is an effective inhibitor of 
this activity (see Figure 3.12). It has also been shown, through CTx treatment, that 
cAMP does not modulate [3H]IP production (see Section 3.3.5), providing further 
evidence against a role for L-type Ca2+ channels (which are known to be activated 
by PKA phosphorylation (Tsien et al., 1987; Armstrong & Eckert, 1987)) in VIP2 
receptor mediated [3H]IP production. Thapsigargin treatment has been shown to 
both stimulate [3H]IP production and potentiate VIP2 receptor-mediated [3H]IP 
production (see Figure 3.13), demonstrating that the emptying of intracellular Ca2+ 
stores is part of a mechanism whereby PLC can be activated in COS 7 ceUs and 
may be part of the VIP2 receptor-mediated mechanism. Wenzelseifert et al. (1996) 
and Berven et al. (1995) described a role for PTx-sensitive G proteins in CRACi 
activation. In this study, the Co2+ sensitivity of the PTx-sensitive component of 
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VIP2 receptor-mediated [3H]IP production (see Figure 3.14) also suggests that a 
PTx-sensitive G protein is involved in the mechanism of VIP2 receptor-mediated 
Ca2+ influx. 
A number of additional experiments must be carried out in order to 
accumulate sufficient data to allow a detailed model of the system to be 
formulated. An assay of VIP2 receptor-mediated PI hydrolysis in a membrane-
delimited system (i.e. performed on membranes prepared from COS 7 cells 
transiently expressing the VIP2 receptor) would answer several pertinent questions. 
Agonist-evoked PI hydrolysis under these conditions would demonstrate that the 
response is not entirely attributable to Ca2+ channel activity. Treatment of the 
membranes with antiserum spedfic to Gexq and Gat /o/z would allow an assessment 
of which of these G proteins is likely to act between the receptor and PLC, and 
perhaps even a quantification of the relative extent to which each contributed to the 
response, if any. It would then be instructive to examine the Ca2+ responses 
involved in the VIP2 receptor-mediated activation of PLC. Fura-2 fluorescence dye 
spectroscopy may be the simplest way to accomplish this. This method would 
allow us to determine whether the VIP2 receptor-mediated response involves the 
transient Ca2+ spike followed by the sustained increase in intracellular Ca2+, 
associated with emptying of intracellular stores and influx of Ca2+ through a 
plasma membrane channel, respectively. The PTx-sensitivity of each of those 
responses could be determined and then the PTx-sensitivity of thapsigargin-
stimulated Ca2+ influx in order to identify the phase(s) of the response dependent 
on the PTx-sensitive G protein(s). The role of PLC in the VIP2 receptor-mediated 
increase in intracellular Ca2+ could be determined by using the PLC inhibitor 
U73122. This would allow the identification of a non-PLC mediated increase in 
intracellular Ca2+ e.g. the direct activation of a Ca2+ channel by a PTx-sensitive G 
protein. Further experiments involving various Ca2+ channel inhibitors would be 
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useful, although appropriate characterisation of any Ca2+ channels involved would 
be best carried out using electrophysiological techniques such as patch-clamping in 
combination with specific inhibitors of different Ca2+ channel types. 
3.4.4. The role of PTx-sensitive G proteins in VIP2 receptor-mediated 
cAMP production 
Since VIP2 receptor mediated stimulation of [3H]£P production was found to 
involve a PTx-sensitive mechanism, an investigation of the role of PTx-sensitive G 
proteins in VIP2 receptor-mediated cAMP production was carried out. However it 
was not possible to identify any effect of PTx-pre-treatment on VIP2 receptor 
mediated cAMP production (see Figure 3.15) indicating that there was no tonic 
effect of a PTx-sensitive G protein on VIP2 receptor-mediated cAMP production. It 
is possible that the VIP2 receptor response here is mediated predominantly by an 
isoform of AC which is wtresponsive to Ptx-sensitive G proteins; mammalian AC 
type II, fo r example, is not inhibited by Gai or Gao and is stimulated by Gas, PKC 
and ~y subunits, dependent on coincident Ga5 stimulation (for review see: Sunahara 
et al., 1996). After prolonged CTx treatment in order to cause down-regulation of 
G5, and stimulation of cAMP production with forskolin, it was still not possible to 
demonstrate an inhibitory effect on AC stimulation mediated by the VIP2 receptor. 
In fact a stimulation of cAMP production was observed, over a concentration range 
more typical of [3H]IP production than cAMP production (see Figure 3.16). This 
could be the result of ~y subunit stimulation of an isoform such as AC type II or 
simply an inadequate treatment with forskolin and cholera toxin resulting in a 
system which is still subject to G5-mediated stimulation. Mastoparan, reported to 
be a somewhat selective activator of Ptx-sensitive G proteins (Higashijima, 1996) 
caused a clear inhibition of forskolin/cholera toxin-stimulated cAMP production 
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suggesting that the failure of VIP2 receptor stimulation to inhibit forskolin/cholera 
toxin-stimulated cAMP production was due to a characteristic of the VIP2 receptor 
(see Figure 3.17). The inability of the VIP2 receptor to inhibit CTx/forskolin 
stimulated cAMP production (despite there being considerable evidence of its 
ability to activate PTx-sensitive G proteins) may be attributable to its activating 
different PTx-sensitive G proteins to those activated by mastoparan. Alternatively, 
it may be the concomitant activation of other G proteins, such as G5, which affect 
the VIP2 receptors inhibitory influence. 
3.4.5 Summary 
The VIP2 receptor has been demonstrated to signal through two distinct 
signalling pathways in COS 7 cells; cAMP production and also, for the first time, IP 
production. Stimulation of adenylate cyclase mediated by this receptor appears to 
be PTx-insensitive, indicating that there is no significant tonic inhibition of cAJ.\11P 
production by PTx-sensitive G proteins. The VIP2 receptor-mediated stimulation of 
adenylate cyclase desensitises within 15 minutes, as does the PACAP receptor-
mediated stimulation. The VIP2 and P ACAP receptors have similar ECsos for 
P ACAP-38-evoked cAMP production although the VIP2 receptor stimulates a 
smaller response (which may not be solely due to a difference in expression levels). 
The VIP2 receptor has been shown to stimulate [3H]IP production by a 
partly PTx-sensitive mechanism, while the P ACAP receptors utilise a PTx-
insensitive mechanism and stimulate a larger response with a lower ECso for 
P ACAP-38-evoked [3H]IP production. The VIP2 and P ACAP receptors clearly 
utilise different mechanisms to stimulate PLC. Both Gq and a member of the 
GiJo/ t/ z family of Pix-sensitive G proteins were found to be associated with the 
VIP2 receptor. This suggests that the PTx-insensitive component of VIP2 receptor-
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mediated [3H]IP production is attributable to Gq stimulation of PLC and that the 
PTx-sensitive G protein is involved in an additional stimulatory mechanism. 
VIP2 receptor-mediated [3H]IP production is at least partiaUy dependent on 
Ca2+ influx, which occurs through a channel that may be activated by the emptying 
of intracellular Ca2+ stores (CRACj). Berven et al. (1995) described a role for a 
PTx-sensitive G protein, Gi2, acting between the release of Ca2+ from the 
intracellular stores and the stimulation of Ca2+ influx through the channel in the 
plasma membrane. However, this G protein would presumably not be receptor-
associated. The VIP2 receptor has been shown to be associated with a PTx-
sensitive G protein but this, of course, does not exclude the possibility of a PTx-
sensitive G protein also being associated with the intracellular stores. The receptor-
associated PTx-sensitive G protein may simply be involved in a direct interaction 
\Yith an SK&F 96365-sensitive Ca2+ channel that is not an L-type channel, or the ~y 
subunits from the PTx-sensitive G protein may directly activate PLC. The model 
presented by Murthy & Makhlouf (1994) involves the stimulation of both an effector 
enzyme and a Ca2+ channel by a PTx-sensitive G protein. Lepretre & Mironneau 
(1994) described a pathway which involved a PTx-sensitive G protein stimulating 
Ca2+ influx through an L-type Ca2+ channel as a result of activating PKC. Berven 
et aL (1995) found that the activation of CRACi in human neutrophils involved a 
PTx-sensitive G protein (Gi2) at a point between the emptying of intracellular Ca2+ 
stores and Ca2+ influx. This mechanism was also described in hepatocytes by 
Wenzelseifert et aL (1996) who found the Ca2+ influx to occur through a non-
selective cation channel. Unfortunately the present data do not allow us to 
discriminate between different models other than to exclude a role for L-type Ca2+ 
channels. The simplest model that could be suggested at this stage involves the 
stimulation of PLC (possibly more than one isoform) by Gqa and Gi / o py subunits. 
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The resultant emptying of intracellular s tores stimulates Ca2+ influx, which causes 
further stimulation of PLC. 
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Figure 3.1 Homologous displacement of [125I]PACAP-27 binding to whole 
COS 7 cells expressing the rat VIP2 receptor. 
Binding experiments were carried out at ooc for 60 minutes. [12Sr]PACAP-27 was present 
at a concenrtration of 6.15±0.20 pM. The d ata are expressed as means±SEM. n=9. 
Figure 3.2 Concentration-response curve for VIP-evoked cAMP 
production mediated by the VIP2 receptor. 
A typica l example from 4 experiments is illustrated. In this example the maximum 
stimulation value was 21.1±0.8 fold of basal control. The ECso was 0.84±0.03 nM. The basal 
value was 12.44±1.73 pmol/ml. cAMP production was measured in the presence of 0.5 mM 
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Table 3.1 Relative expression levels, ICso values for homologous displacement of [125f]PACAP-27, ECso and maximal 
stimulation values (fold of basal control) for PACAP-38 and VIP-stimulated cAMP and [3H)inositol phosphate 
production mediated by VIPz, PACAPshort and PACAP1ong receptors transiently expressed in COS 7 cells. 
Bmax and IC50 values were determined by non-linear curve fitting of data from homologous displacement of ligand-binding experiments carried 
out on whole cells at ooc {or 60 minutes. ECso values for [3H]JP production were derived from non-linear curve fitting of concentration response 
curves. Values are expressed as means±SEM (n=6-9). Bmax is expressed as fmol/ protein equivalent of JOS ceUs. ECso is expressed in nM. The 
maximal stimulation (Emax) is expressed as 'fold of basal control'. A typical basal value for cAMP production was 6±2 pmol/ weU. A typical basal 
value for [3Hjinositol phosphate production was 7,700±600 dpm per well. ECsos, ICsos and Maximum Stimuli (Emax) values were derived from 
the non-Linear curve-fitting programme P-fit (Elsevier Biosoft, Cambridge, UK). 
Specific [1251) ~AMf fr~Hh!~liQD I.l.HJif fr2dY~li2n 
PACAP-27 Binding PACAP-38 VIP PACAP-38 VIP 
Receptor Bmax IQ;o EQ;o Ern ax EQ;o Ern ax EQ;o Ern ax EQ;o Em ax 
(fmol/ (nM) (nM) (fold of basal (nM) (fold of basal (nM) (fold of basal (nM) (fold of basal 
t<P cells) control) control) control) control) 
VIP2 59±5 19±1 0.9±0.1 7.8±0.5 0.3±0.1 8.2±0.1 36.9±8.1 3.0±0.3 45.0±6.6 2.4±0.1 
PACAPiong 520±52 31±3 0.5±0.4 22.4±1.1 38.6±3.8 12.08±0.5 17.6±0.6 11.1 ±0.3 nd 
PACAPshort 494±37 30±1 0.7±0.1 19.9±1.4 28.6±2.0 15.7±0.2 10.6±0.6 9.8±0.7 nd 
( nd - no signal detected at doses up to 3 1tM) 
Figure 3.3 Concentration-response curve for VIP- and PACAP-38-evoked 
[3H]inositol phosphate production mediated by the VIP2 receptor 
transiently expressed in COS 7 cells. 
Typical examples from 4-6 experim ents are il lustrated. In this example VIP (0 ) caused a 
maximum stimulation was 2.36±0.22-fold of basa l control. The ECso value was 45.0±6.6 nM. 
For PACAP-38 (0) the maximum stimulation was 1.95±0.19-fold of basal control. The ECso 
value was 56.5±8.9 nM. A typical basa l va lue was 8,900±500 dpm/assay. The values are 
means±SEM. n=6. 
Figure 3.4 Comparison of concentration-response curves for PACAP-38-
evoked [3H]inositol phosphate production mediated by the PACAPshort 
and PACAPtong receptors transiently expressed in COS 7 cells. 
Typica l examples from4 experiments are illustrated . In this example for the PACAPshort 
receptor (0) the maxjmum stimulation was 9.1±0.3 fold of basa l control and the ECso value 
was 10.6±0.6 nM. A typica l basal value was 6,340±56 dpm /assay. For the PACAP!ong 
receptor (V') the maximum stimulation was 12.2±1.2 fold of basal control. The ECso va lue 





0 ·- 2.5 ..... u 
:::J 
-o=-
0 0 T lo-o lo-o 2 c. ..... O·····O c: 
~ 0 o······· l. ..... u cu_ c;l···· ...c: cu c. (/) 1.5 (/) cu .·• o..o o· ...c:--c..o .. 0 .... --o o - 1 ................... ................ o· :;:: 0 
(/)._ o.._ 
c: ·-,........ :r: 0.5 
<;2.... 
0 





0 T ·-..... u .,'r/-'1 :::J...-.. -o- '1 1 0 0 
~o-ob 
C..c: 10 0 
~ u ..... 





c.."' --.8 0 5 ·- ._ (/) .._ 
0 
c: ·-...-. :r: 
<;2.... 
0 
0 1 10 100 1000 
[PACAP-38] nM 
Figure 3.5 Time-course of VIP-evoked [3H]inositol phosphate production 
mediated by the VIP2 receptor transiently expressed in COS 7 cells. 
The VIP (3 J.!M) -evoked stimulation after 80 minutes was 2.16±0.01 fold of basal control. A 
typical basa l value was 4,910±43 dpm/ assay. The values are means±SEM. n=6. 
Figure 3.6 Time-course of PACAP-38-evoked [3H]inositol phosphate 
production mediated by the PACAPiong receptor transiently expressed in 
COS 7 cells. 
For the PACAPtong recep tor the 300 nM PACAP-38-evoked stimu lation after 80 minutes 
was 7.31±1.04 fold of basal control. A typical basal value was 4,337±307 dpm/assay. The 
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Figure 3.7 Time-courses for PACAP-38-evoked cAMP production 
mediated by the PACAPshort, PACAPtong and VIP2 receptors transiently 
expressed in COS 7 cells. 
Intracellular cAMP accumulation was measured over 120 minutes. For the VIP2 receptor 
(/:::,.)the stimulation after 15 minutes was 216±6 pmol/ ml. A typical basal value was 
9.9±0.7 pmol/mJ. For the PACAPshort receptor (0 ) the stimulation after 15 minutes was 
425.9±0.5 £._mol/ mJ. A typical basal value was 8.1±0.5 pmol I m1. For the PACAPtong 
receptor (LJ) the stimulation after 15 minutes was 396.8±8.3 pmol/ ml. A typical basal value 
was 15.7±1.2 pmol/ml. cAMP production was measured in the presence of 0.5 mM IBMX. 
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Figure 3.8 
a) Pertussis toxin-sensitivity of VIPt and VIP2 receptor-mediated [3H]inositol phosphate production. 
Typical basal activity was10,314±280 dpm / assay. Values are means± SEM. n=lO. There was no difference in basat l3H]inositol phosphate 
formation in VIPt or VIP2 receptor-expressing cells and dnta for these is expressed in a combi ned form. The maximum stimulation evoked by 3 11M 
VIP via the VlPt receptor was 2.55±0.16-fo ld of basal control was reduced to 1.84±0.09 fold of basal control after PTx-treatment. The maxim um 311M 
YIP-evoked sti mulation mediated by the VIP 2 receptor was 1.99±0.05-fold of basal control reduced to 1.61±0.10-fo ld of basal control after Pix-
treatment. (*) represents a statistically significant inhibit ion of YIP-induced [3H)inositol phosphate production (p<O.OS by Mann-Whitney U-test). 
b) The effects of prolonged preincubation with a high concentration of cholera toxin and of pertussis toxin B-subunit 
on [3H]inositol phosphate production elicited by the VIPt and VlP2 receptors. 
The control response to 311M VLP was typically around 29,869 dpm per assay. Cfx or PTx B-subunit were present for 16 hours prior to stimulation. 
Values are means± SEM. n=6. 
c) Pertussis toxin-insensitivity of [3HJinositol phosphate production mediated by the PACAPshortand PACAPJong 
receptor. 
The maximum stimulation evoked by 100 nM PACAP-38 at the PACAPshort receptor was 7.7±0.6-fo ld of basal control, 7.8±0.2-fold of basal control 
after Pix-treatment. The maximum stimulation evoked by 100 nM PACAP-38-evoked stimulation mediated by the PACAPtong receptor was 
10.6±0.8-fold of basal control, 11.0±0.3-fold of basal control a fter PTx-treatment. A typical basa l value was 10,110±650 dpm / assay, 9,200±910 
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Figure 3.9 The effect of pertussis toxin-pre-treatment on GTPyS-
s timulated displacement of [125J]helodermin binding to the VIP2 receptor 
trans iently expressed in COS 7 cells. 
The assay was performed on a COS 7 cell membrane fraction. Where appropriate, cells were 
pre-treated with 100 ng/ ml PTx for 16 hours. The maximum speci fic binding of 
[125J]helodermin to the membrane preparation was equivalent to 13,344±252 cpm/ assay for 
the control and 13,321±631 cpm/assay for the PTx treatment. The protein concentration of 
the membrane preparation was identical for the control and PTx-treated samples (100.8±4.1 
and 100.4±14.0 !lg/mJ protein respectively). (*)represen ts a statistically significant 
reduction in the GTP.yS -evoked effect on [125J]helodermin binding by PTx-pretreatment 
(p<0.05 by Wilcoxon matched-pairs signed-rank test). The va lues are means±SEM. n=6. 
Figur 3.10 Pertussis toxin-inhibition of mastoparan-stimulated 
[3H]inositol phosphate production in COS 7 cells. 
The open bars represent the mastoparan alone samples. The maximum response, stimulated 
by 15 11M mastoparan, was 1.34±0.08 fold of basal control. A typical basal value was 
4,649±515 dpm / assay. The filled bars represent the PTx-treated samples. Ptx-treatment 
caused an mean inhibition of 46±11% of the mastoparan-stimulated response. Values are 
means± SEM. n=6-9. (*) represents a statistically significant inhibition of mastoparan-
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Figure 3.11 Concentration-response curve for A TP-evoked [3H]inositol 
phosphate production in COS 7 cells. 
The maximum stimulation was 93,380±255 dpm/assay. The ECso value was 28.2±0.5 J.l.M. A 
typical basal value was 2.837±121 dpm/ assay. Stimulation of COS 7 cells w ith 100 J.1M A TP 
for 10 minutes caused no significant increase in cAMP production (84±29% of the basal 
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Figure 3.12 The effects of Co2+, methoxyverapamil and SK&F 96365 on 
[3H]inositol phosphate production mediated by the VIP2 and p resumed 
P2Y receptors in COS 7 cells. 
The control response for V1P2 receptor-mediated activity (D) was the [3H] IP production 
stimulated by 100 nM PACAP-38 (a typical response was 3.66±0.17 fo ld of basal control, a 
typical basa l control was 3,778±318 dpm/assay). The control response for presumed P2Y 
receptor-mediated activity (0) was the [3H]IP production stimulated by 50 JlM ATP (a 
typica l response was 13.9±0.1 fold of basal control, a typical basal control was 3,597±100 
dpm /assay). The data are means±SEM. n=6-9. 
a) the effects of the divalent cation channel blocker, Co2+, on the [3H] IP production 
med ia ted by the VIP2 and presumed P2Y receptors. 
b) the effects of the dihydropyridine(DHP)-sensitive ca2+ channel antagonist, 
methoxyverapami l, on [3H)JP production mediated by the VIP2 and presumed P2Y 
receptors. Another s tructurally distinct antagonist of DHP-sensitive Ca2+ channels, 
nifedipine, had no inhibitory effect on the PACAP-38 stimu la ted response (120±13% of the 
control response afte r treatment with 10 jlM. nifedipine). 
(c) the effects of the calcium-release activated calcium influx (CRACy) blocker and DHP-
sensitive Ca2+ channel blocker, SK&F 96365, on the [3H)IP production mediated by the 
VIP2 and presumed P2Y receptors. 
(*) represents a statistically significant inhibition of PACAP-38-induced [3H]inositol 
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Figure 3.13 The effect of thapsigargin treatment on basal and VIP2 
receptor-mediated [3H]inositol phosphate production in COS 7 cells. 
The control re~onse was 8,658±493 dpm/assay. A typical basal value was 3~79±320 
dpm/assay. (D ) shows the effect of thapsigargin treatment on 100 nM PACAP-38-evoked 
[3H]IP production. (0) shows the corresponding basal [3H]lP production. The data are 
means±SEM. n=6. ("')indicates a statistically significant potentiation of 100 nM 
PACAP-38-evoked [3H]IP production (p<O.OS by Mann-Whitney U-test). 
Figure 3.14 The effect of Co2+ treatment on PACAP-38-evoked 
[3H]inositol phosphate production in pertussis toxin-treated and control 
COS 7 cells expressing the VIP2 receptor. 
The control response stimulated by 100 nM PACAP-38 was 4,902±203 dpm/assay. (D) 
represents the 100 nM PACAP-38-evoked [3H]IP production. (6 ) represents the 100 nM 
PACAP-38-evoked [3H]lP production after PTx-treatment (100 ng/ml for 16 hours prior to 
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TABLE 3.2 The effect of Ca2+ channel blockers on AlClJfNaF 
-elicited [3H]inositol phosphate production in COS 7 cells. 
Treatment 
AlCl3 (10 ~)/NaF (50 mM) 
+ nifedipine (10 IJ.M) 
+ methoxyverapamil (30 IJ.M) 






The 100% value represents a stimulation of 10.45 ± 0.49-fold of basal control. A 
typical basal value was 3,828±77 dpm per assay. The cells were preincubated 
w ith the inhibitors for 30 mil1utes before stimulation. The data are expressed as 
Means±SEM. n=6-9. (*) represents a statistically significant potentiation of 
AlCI3/NaF-stimulated [3H]inositol phosphate production (p<O.OS by Mann-Whitney 
U -test). 
Figure 3.15 The effect of pertussis toxin-pretreatment on YIP-evoked 
cAMP production in COS 7 cells expressing the VIP2 receptor. 
Total cAMP accumulation was measured. At a concentration of 100 nM VIP the control 
response (open bars) was 106±4 pmol/ ml, and the response from the PTx-treated sample 
(fi lled bars) 111±6 pmol/ ml. There was no significant difference between the basal values 
for the control and PTx-treated samples, a combined basal value was 7.2±0.3 pmol/ ml. PTx 
was applied at a concentration of 100 ng/ ml for 16 hours prior to stimulation with VIP. The 
data are means±SEM. n=6. 
























Figure 3.16 Concentration-response curve for PACAP-38-evoked cAMP 
production mediated by the VIP2 receptor transiently expressed in COS 7 
cells treated with forskolin and cholera toxin. 
The cell s were pre-treated with cholera toxin (20 ~g/ml) for 16 hours prior to stimulation. 
Forskolin (10 ~M) was added immediately prior to the addition of PACAP-38. A typicaJ 
basal value was 1.11±0.02 pmol/ml. Forskolin alone stimulated cAMP production (to 
101.0±3.9 pmol/mJ) as d id cholera toxin-pre-treatment (to 64.8±3.3 pmol/ml). cAMP 
production was measured in the presence of 05 mM IBMX. The va lues are means±SEM. 
n=6-9. (*)represents a sta tistically significant stimulation of cAMP production by 
PACAP-38 over that stimulated by a combined cholera toxin and forskolin treatment (p<O.OS 
by Mann-Whitney U-test). 
Figure 3.17 The effects of cholera toxin, forskolin and mastoparan on 
cAMP production in COS 7 cells. 
The control response (stimulated by cholera toxin and forskoli n trea tment) was 630±26 
pmol/ ml. The basal value was 2.0±0.2 pmol/rnl, the PTx alone value was 2.3±0.1 pmol/rnl. 
The accumulation of both intracellular and extracellular cAMP was measured. Where 
appropriate, cells were pre-incubated for 16 hours with 100 ng/ml PTx and /or CTx at 20 
~g/ml. Forskolin (Fsk) was applied for the period of the assay at 10 ~M. Mastoparan 
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Table 3.3 The effect of various protein kinase inhibitors on [3H]inositol 






























AlCl3 / NaF 
(10 JLMI 50 mM) 
161.9±0.5 
The PKC inhibitor, GF 109203X, the PI<A inhibitor, H89, the broad spectrum kinase 
inhibitor, staurosporine and the tyrosine kinase inhibitor, genistein were all present for 10 
minutes before stimulation and for the period of the assay. The combined basal value for 
the cells used in these experiments was 7,080±1,765 dpm/ assay. The data are expressed as % 
of the control response (Means±SEM). A typical l JLM Vll'-evoked response at the VIP1 
receptor was 2.84±0.19-fold of basal control, at the Vll' 2 receptor this was 2.03±0.04 fold of 
basal control. For the P ACAP!ong receptor a typical 300 nM P ACAP-38-evoked response 
was 7.74±0.63-fold of basal control. A typical10 tlM A1Cl3/ 50 mM NaF-evoked response 
was 13.4±0.3-fold of basal control. n=6-9. 
Fig. 3.18 Concentration response curve for PACAP-38-evoked [3H]inositol 
phosphate production mediated by the HA epitope-tagged human VIP2 
receptor. 
The receptor was transiently expressed in COS 7 cells. The maximum stimulation was 
1.73±0.10 fold of basal control. The ECso vale was 66.7±9.7 nM. A typical basal value was 
4,340±:308 dpm per assay. The data are means±SEM. n=6. 
Figure 3.18 
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Figure 3.19 G protein a subunit isoform immunoreactivity associated with 
immunoprecipitates of the (HA) epitope-tagged human VIP2 receptor. 
The HA-tagged human VIP2 receptor was transiently expressed in COS 7 cells and 
immunoprecipitated from a membrane preparation using an HA-tag-specific antibody. One 
dimensional SDS-PAGE followed by immunoblotting with G protein n subunit isoform 
specific antisera was carried out as described in sections 2.2.13 and 2.2.14. The left lane in 
each case(-) contains the sample irnmunostained with antiserum. The right lane in each 
case (+)contains the sample immunostained with antiserum preincubated with the specific 
peptide antigen. The left arrow indicates the position of the 55.4 kDa molecular weight 
marker. The right arrow identifies the position of any band specifically blocked by antigen 
treatment of the antiserum. 
Figure 3.19 
a) Gail-2 
55.4 KD~ ... 
! . - • I 
.... 1 &a 
- + 
b) 








Characteristics of truncated VIP2 
receptors and chimaeric 
VIP2/ P ACAP receptors 
4.1 Introduction 
Chimaeric receptors created from members of the secretin / calcitonin/ 
PTH/ PTHrP receptor family have been used successfully in a number of studies to 
investigate the ligand-binding and signalling characteristics of specific receptors and 
to identify the contribution of specific functional domains to the receptors' activity. 
Studies have been carried out with, secretin/PTH/PTHrP receptor chimaerics 
(Turner et al., 1996; Lee et al., 1995), glucagon/GLP-I receptor chimaerics (Buggy et 
al., 1995) calcitonin/ glucagon receptor chimaerics (Stroop et al., 1995) and 
VIP /secretin receptor ch.irnaerics (Vilardaga et al., 1995; Holtmann et al., 1995; 
Gourlet et al., 1996). 
This strategy has not previously been applied to the VIP and P ACAP 
receptors despite the similarity in sequence of these receptors and the distinct and 
defined differences in both agonist pharmacology and agonist-induced second 
messenger production (which were described in Chapter 2). The receptors display a 
high degree of identity at the amino acid level (Table 4.3) and an even higher degree 
of similarity at the level of predicted secondary structure. This similarity should 
allow for the exchange of equivalent regions of receptor without the introduction of 
structural incompatibilities which are likely to affect the expression and function of 
the chimaeric receptors. The exchange of large regions of receptor should also 
involve a change in sequence of only a few residues, which means that important 
motifs and residues can be identified without the investment of time and resources 
involved in site-directed mutagenesis. 
Our current understanding of the structure of G protein-coupled receptors is 
based on studies of the rhodopsin receptor for which a low resolution structure has 
been defined (Schertler et al., 1993; Unger & Schertler, 1995; Schertler et al., 1995). 
98 
The seven transmembrane-spanning domains of the rhodopsin receptor constitute 
an aspect of the receptors' structure predicted to apply to all G protein-coupled 
receptors (Baldwin, 1993; 1994). Indeed, a hydropathy plot of a cloned G protein-
coupled receptor's amino acid sequence invariably reveals a reas of hydrophobicity 
compatible with its having seven transmembrane-spanning regions. 
Studies with chimaeric receptors have shown IC2, the N-and C-tenninal 
portions of IC3 and the N-terminal portion of the C-terminus as being important for 
determining G protein selectivity (Dohlman et al., 1991; Savarese & Fraser, 1992; 
Strader et al., 1994; Hedin et al., 1993). Site-directed mutagenesis (SDM) studies of 
the rhodopsin (Francke et al., 1992), muscarinic (Zhu et a l. , 1994), Ct.lf3-adrenergic 
(Scheer et al., 1996) and V2 vasopressin receptors (Rosenthal et al., 1993) identified 
an Arg residue conserved in most GPCRs at the TM3/IC2 boundary as being 
essential for G protein coupling whereas !ida-Klein et al., (1997) identified a basic 
residue in IC2 as being essential for Gq coupling of the PTH receptor. Similar 
studies of the rhodopsin (Francke et al., 1992) and muscarinic receptors (Kunkel et 
al., 1993; Hogger et al., 1995) identified positively charged residues at the C-
terminal portion of IC3 which were critical for efficient G protein activation and 
hydrophobic residues at the N-tenninal end of IC3 in the M3 receptor (Blin et al., 
1995; Burstein et al., 1995; Suprenant et al., 1992) as being important for G protein-
coupling selectivity. Stroop et al. (1995) used GLP-I/glucagon receptor chimaerics 
to identify a high affinity binding site for calcitonin in theN-terminus whereas SDM 
and deletion mutagenesis were used to identify the N-terminus and EC3 of the PTH 
receptor as being crucial for PTH binding (Gardella eta!. , 1996; Lee et al., 1994). 
SDM studies have also revealed a number of residues in the N-termini and EC loops 
of the human VIPt and VIP2 receptors which influence VIP binding (Nicole et al., 
1997; Gaudin et al., 1995; Couvineau et al., 1995). 
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Chimaeric VIP2/PACAP recepto rs were therefore created with exchange 
sites in the TM1, TM3, TM5 and TM7 regions (see Figure 4.9) which allowed the 
swapping of domains implicated in other receptors as being important for 
G protein activation, agonist binding and desensitisation 
The (-terminal tail of secretin/calcitonin/PTH/PTHrP receptor family 
members has been identified as having profound effects on their behaviour. It has 
been shown to affect the intemalisation, signal transduction and ligand-binding 
affinity of the calcitonin receptor (Findlay et al., 1994), the ligand-binding affinity 
and expression of the glucagon receptor (Unson et al. , 1995) and the expression, 
internalisation and G protein selectivity of the PTH/PTHrP receptor (Huang et al., 
1995; Huang et al., 1995b; Schneider et al., 1994). (-terminally truncated VIP2 
receptors were therefore also created (see Figure 4.10) in order to investigate the role 
of the (-terminus in this receptor's ligand-binding and signalling characteristics. 
4.2 Specific Methodology 
Chimaeric and truncated receptors -The chimaeric and truncated receptors were 
designed and constructed in this laboratory by Dr. Eve Lutz. The chimaeric 
receptors were constructed by exchanging equivalent regions of the wild-type rat 
VIP2 and P ACAP receptors. As discussed earlier, two major isoforms of the 
P ACAP receptor have been identified in mammalian tissue. The two 
predominantly expressed splice variants are the 'short' form of 467 a.a. and the 
'long' form which contains a 28 a.a. insert in the predicted IC3 region designated the 
'hopl ' cassette by Spengler et al (1993) (see Figure 1.9). As a means of identifying 
any functional differences between these isoforms of the PACAP receptor, both 
were used for creating the chirnaeric receptors. A Hindi restriction site conserved 
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(within TM1), TM3 exchange sites and C-tenninal exchange sites (TM7) were 
created by overlap extension polymerase chain reaction (PCR) mutagenesis. This 
involved the use of specific eDNA primers to create the required receptor fragments 
with temlinal junction sequences that allow them to anneal as appropriate. The 
product of PCR amplification of the clone was digested with restriction enzymes 
and the fragments separated by agarose gel electrophoresis to confirm that the 
correct sized fragments were produced. All the constructs were sequenced to 
confirm the identity of the chosen clones. 
The wild-type receptors: 
VIP2 wt (1-437) 
PACAPwt short (1-467) 
PACAPwt long (1-495) 
The TM1 chimaeric structures were: 
- VIP2 wt (1-125) and PACAPwt long (153-495) 
- VIP2 wt (1-125) and PACAPwt short (153-467) 
- P ACAP (1-152) and VIP2 wt (126-437) 
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The TM3 chimaeric structures were: 
V3P1ong - VIP2 wt (1-209) and PACAPwt long (234-495) 
V3Pshort - VIP2 wt (1-209) and PACAPwt short (234-467) 
- PACAP(1-233) and VIP2 wt (210-437) 
The TMS chimaerics: 
VsPiong - VIP2 wt (1-293) and PACAPwtlong (319-495) 
VsPshort - VIP2 wt (1-293) and PACAPwt short (319-467) 
PsV - PACAP(1-318) and VIP2 wt (294-437) 
The TM7 chimaeric structures were: 
- VIP2 wt (1-376) and PACAP(429-495) 
Plong7V - PACAPwtiong (1-428) and VIP2 wt (377-437) 
Pshort7V - PACAPwt short (1-400) and VIP2 wt (377-437) 
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Two (-terminal truncated VIP2 wt receptor constructs were prepared. The 391 a.a. 
truncated receptor (construct 6.3T: VIP2 wt (1-391)) was prepared by EcoRI 
digestion of the eDNA for the VIP2 wt receptor followed by subcloning and 
sequencing of the fragments. A more severe truncation, VIP2 wt {1-376), was 
prepared by PCR using a primer specific to a region in TM7 (see Figure 4.9). 
The eDNA was ligated into pBluescript for selection of appropriate clones by 
sequence analysis then inserted into pcDNAl (Invitrogen, R&D Systems Europe 
Ltd., Abingdon, UK) for functional expression in COS 7 cells. Grow up and 
transfection procedures were described in sections 2.2.2 and 2.2.3. 
Expression of receptors- COS 7 cells were transiently transfected with eDNA 
encoding the receptors as described in sections 2.2.1, 2.2.2 and 2.2.3. 
Ligand-binding- Homologous displacement of ligand-binding was carried out on 
membranes preparations using [125J]VIP or [125I]PACAP-27 at 370C for 10 
minutes, or on whole cells at 0°C for 60 minutes, as described in Section 2.2.7. 
Protein assay- Coomassie protein assay reagent was used to determine the protein 
level in samples (see section 2.2.8). 
Second messenger assays - Intracellular cAMP production over a 10 minute 
stimulation period was measured in whole cells by radioimmunoassay as described 
in Section 2.2.5. 
[3H]inositoL phosphate production was used as a measure of PLC activity. The 
cells were normally stimulated for 60 minutes with agonist before separation of 
[3H]inositol phosphate by anion exchange chromatography as described in Section 
2.2.4. 
103 
DClt(l Clm!lysis- Curve fitting was performed by the non-linear curve-fitting 
programme, P-fit (Elsevier Biosoft, Cambridge). 
4.3 Results 
4.3.1 Ligand binding studies to monitor expression levels of chimaeric 
receptors and their affinities for PACAP-27 
In radio ligand-binding experiments homologous displacement of 
[125I]PACAP-27 from whole COS 7 cells (see 'Materials & Methods' section 2.2.7) 
was used to give an estimate of the receptor binding capacity of the system (Bmax) 
and the affinities of the receptors for P ACAP-27 (IC;o) using the method of 
Swillens (Swillens, 1992). PACAP-27 was used as opposed to PACAP-38 because 
it was the only P ACAP and VIP2 receptor agonist commercially available as a 
radioligand. The PACAPwt long receptor had a Bmax of 520±52 fmol/105 COS 7 
cells (see Table 4.1). The Bmax for the VIP2 wt receptor was only 11% of that for 
the P ACAPwt long receptor although its affinity for P ACAP-27 appeared to be 
higher (ICso values of 19±1 and 31±3 nM respectively). The Bmax for 
PACAPwt short was 95% of that for PACAPwt long· The Plong7V and Pshort7V 
chimaerics had expression levels of 59% and 44% of the P ACAPwt long receptor 
respectively whilst having a slight but statistically significant increase in their 
affinities for PACAP-27 (ICsos of 24±2 ru\1 for Plong7V and 16±1 nM for Pshort7V 
as opposed to 31±3 nM for the PACAPwt long receptor and 30±1 nM for 
PACAPwtshort ). The PsV chimaeric with the VIP2 wt receptor body C-terminal to 
TM5 exchange site had a slightly lower expression level than the P7V chimaerics 
(39% of the PACAPwt long value as opposed to 59% or 44%). The P3V chimaeric 
which has the VIP2 wt receptor body C-terminal to the TM3 exchange site had a 
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Bmax value of 234±57 indicating that it was expressed at similar levels to P7V and 
PsV chimaerics. The affinity of the P3V receptor for PACAP-27 was however 
significantly reduced with an ICso of 69±17 nM. The P1 V chimaeric has the VIP2 wt 
receptor body with the PACAP receptor N-terminus. This receptor displayed a 
mean Bmax value 25% of the PACAPwt long receptor value, indicating a further 
drop in expression level from the P7V, P5V and P3V chimaerics. The affinity for 
PACAP-27 at the P1V chimaeric however was unchanged from that for the P3V 
chimaeric (ICsos of 69±17 and 70±17 ru\11 respectively). 
The V7P chlmaeric which has the PACAP receptor (-terminus was 
expressed at a similar level to the VIP2 wt receptor and showed a similar ICso for 
PACAP-27 (19±1 and 16±5 nM respectively). The VsPiong and VsPshort 
chimaerics (which have the PACAP receptor body (-terminal of the TMS exchange 
site) had increased expression levels over the VIP2 wt receptor (44% and 31% of the 
PACAPwt long receptor levels respectively) and reduced affinities for PACAP-27 
(ICsos of 58±4 and 38±4 respectively). In addition to the regions of the PACAP 
receptor contained in the VsP chimaerics, the V3P chimaerics also have the 
IC2/TM4/EC2 region of the PACAP receptor. The V3P1ong had a similar 
expression level (50% of the PACAPwt long receptor level) to the VsP chlmaerics 
whereas the V3Pshort chimaeric appeared to have a somewhat lower expression 
level at 18% of the PACAPwt long receptor level. The affinities of these constructs 
for PACAP-27 was not significantly different to that of the VsP chimaerics with 
ICsos of 72±10 nM and 56±14 nM for the V3P1ong and V3Pshort chimaerics 
respectively. The V1P1ong and V1Pshort chimaerics had expression levels of 29% 
and 41% of the PACAPwt long receptor level respectively, similar to the VsP 
chi.maeric levels. The affinity for P ACAP-27 however was much higher than at the 
VsP and V3P chimaerics with V1P1ong and V1Pshort having ICsos of 13±1 and 
16±2 nM respectively. 
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4.3.2 Agonis t-evoked cAMP Production by Chimaeric VIP2/PACAP 
receptors 
PACAP-38 stimulated cAMP production 
Concentration-response experiments were carried out for each receptor 
construct, in which all of the chirnaeric receptors displayed clear cAMP responses 
to the agonists PACAP-38 and VIP but with some distinctive differences. Based on 
previous experiments on wild-type receptors the cells were stimulated for 10 
minutes with agonist. The ECsos for PACAP-38 stimulated cAMP production lay 
mainly in the range 0.3-0.9 nM (see Table 4.1). The maximal stimulation values 
however showed more marked differences between the constructs. Emax values 
(expressed as fold of basal) for Piong7V and Pshort7V receptors were unchanged 
with respect to the wild-type PACAP receptors. The PsV construct however 
displayed a maximal stimulation value approximately half of that observed for the 
P ACAPwt long and PACAPwt short receptors (10.5±0.5 as opposed to 22.4±1.1 or 
19.9±1.4 fold of basal control respectively). The presence of the VIP2 wt receptor 
C-terminal of TMS appears to reduce the receptor's ability to stimulate adenylate 
cyclase. The P3V chirnaeric values are very similar to those of PsV and P1V 
chirnaerics. The VIP2 wt receptor's maximum stimulation was even lower (7.8±0.5 
fold of basal control). interestingly the presence of the PACAP receptor's 
C-terminus in the V7P chirnaeric increased the maximum stimulation by 
approximately SO% to 12.5±0.5 fold of basal control. The VsP chirnaerics had 
similar maximum stimulation values to the V7P chimaeric whereas the 
corresponding values for the V3P constructs were 50% lower (6.3±0.1 and 7.0±0.3 
fold of basal control fo r V3P1ong and V3Pshort respectively). The final chirnaeric 
receptors in the series with the VIP2 wt receptor N-terminus, V1P1ong and V1Pshort1 
had ECsos of 0.6±0.2 and 0.6±0.3 ru\1 respectively and maxima even greater than 
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those for the wild-type PACAP receptors, 30.1 ±1.-J. and 27.3±1.7 fold of basal 
control respectively. No marked differences were observed between the cAMP 
responses mediated by constructs containing equivalent regions of the PACAPwt 
long or P ACA P wt short receptors. 
The introduction of the regions of the VIP2 wt receptor (-terminal to the 
TMS exchange site into the PACAP receptor reduced its ability to stimulate 
adenylate cyclase. The PACAP receptor (-terminus increased the ability of the 
VIP2 wt receptor to stimulate adenylate cyclase but the whole of the PACAP 
receptor body was required for the most efficient stimulation. The low Emax value 
displayed for the V3P chimaerics is probably due to the disruption of important 
motifs proximal to the exchange site. 
VIP-stimulated cAMP Production 
Since the rat VIP2 and PACAP receptors show characteristic differences in 
their affinities for VIP and PACAP-38 (the wild-type PACAP receptor being very 
poorly responsive to VIP in comparison to PACAP-38) the chimaeric receptor 
responses were also assessed using VIP as an agonist. The ECsos for YIP-
stimulated cAMP production cover a much broader range than those for P ACAP-
38. At the P ACAPwt long and P ACAP wt short receptors the ECsos for YIP-
stimulated cAMP production were 38.6±3.8 and 28.6±2.0 nM, on average 59-fold 
greater than the EC5os for PACAP-38. There was a similar relationship between 
the VIP and PACAP-38 EC5os for the P!ong7V and Pshort7V chimaerics. The 
maximal responses for these receptors lay in the range 12-17 fold of basal control 
and were on average 72% of the maxima achieved with P ACAP-38. The PsV 
chimaerk had a maximum cAMP response approximately 30% of that for the wild-
type PACAP receptors, a reduction was also observed for P ACAP-38 stimulated 
cAMP production. The P3V chimaeric had a VIP ECso of 19.0±1.3 nM which was 
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significantly lower than the EC5os determined for all the other N-terminal PACAP 
chimaerics. The maximum stimulation was also increased to approximately 50% of 
the average PACAP wild-type receptor maxima. The P1 V chimaeric had a greatly 
increased ECso of 302.5±24.8 nM for VIP but a similar maximum stimulation of 
8.3±0.1 fold of basal control which was 60% of the average maxima for PACAP 
wild-type receptors. 
As would be expected, the ECso for YIP-stimulated cAMP production at the 
VIP2 wt receptor (0.3±0.1 nM) was much lower than at the PACAP receptors 
(38±3.8 and 28.6±2.0 nM at PACAPwt long and PACAPwt short)· The maximum 
stimulation was 8.2±0.1 fold of basal control, very similar to that for PACAP-38. 
The VIP2 wt, V7P, VsPiong, VsPshort, V1P1ong and V1Pshort receptors had similar 
ECsos in the range 0.1-0.7 ru\11, the V7P ch.imaeric receptor having the lowest ECso 
(0.1±0.02 nM) and a maximum stimulation over 60% greater than that for the VIP2 
wt receptor (13.4±0.3 fold of basal control). The maximum stimulation levels were 
very similar to those for P ACAP-38 stimulated cAMP production. An interesting 
exception is the V3P chimaeric receptors which showed an increase in their ECsos 
for VIP stimulated cAMP production (2.3±0.1 and 3.4±0.4 nM for V3P1ong and 
V3Pshort respectively) that was not observed for PACAP-38 stimulated cAMP 
production (0.2±0.1 and 0.5±0.1 nM respectively). As with the PACAP-38 
stimulated maxima at the V3P chimaerics, the YIP-stimulated maxima were much 
lower than at the V7P, VsP and VIP chimaerics. The maximal YIP-stimulated 
cAMP responses at the V3P chimaeric receptors were also approximately 33% 
lower than the maximum for PACAP-38 stimulated cAMP production. Therefore 
at these chimaeric receptors a reduced activity is observed for both peptides and a 
significant drop in potency for VIP but not P ACAP-38. These effects can not be 
attributed to a low expression level since the VIP2 wt and V7P receptors are 
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expressed at much lower levels (Bmax values of 59±5 and 46±15 fmol / 105 cells 
respectively) than even the V3Pshort receptor (Bmax of 91±24 fmol/105 cells). 
As was observed for the PACAP-38 evoked cAMP responses, the PACAP 
receptor C-terminal tail increased the efficiency of V!P-evoked adenylate cyclase 
stimulation. However the whole PACAP receptor body was required for the most 
efficient stimulation. The TM3 exchange site Ln the V3P chimaerics appeared to 
disrupt VIP-evoked cAMP production, as it did PACAP-38 evoked signalling, but 
to a greater extent since the EC5o for VIP was increased in addition to the maximal 
response being reduced. The P3V chimaeric, whose PACAP-38 evoked signalling 
characteristics appeared unchanged from those for the PsV and P1 V chimaeric 
receptors, displayed a reduced ECso for VIP over that observed for all the other 
P ACAP N-terminal chimaeric receptors. 
4.3.3 Agonist-evoked [3H]Inositol Phosphate Production by Chimaeric 
VIP2/PACAP receptors 
Concentration response experiments were carried out for all the receptor 
constructs using P ACAP-38 and, in most cases, VIP as agonists: 
PACAP-38 stimulated [3 H]inositol phosphate production 
PACAP-38 stimulated [3H]IP production occurred with similar ECso values (10.6-
17.6 nM) and maximum response levels (7.2-11.1-fold of basal control) for the 
wild-type PACAP receptors and the V1P1ong and V1Pshort chimaerics. The 
Ptong7V and Pshort7V chimaerics showed maximum levels of response 
approximately 50% lower than the wild-type PACAP receptors. This may be due 
to the difference in expression levels, Bmax values of 520±52 and 494±37 frnol/105 
cells for the PACAPwt long and PACAPwt short receptors respectively, and 306±27 
and 228±17 fmol/105 cells fo r the Ptong7V and Pshort7V receptors respectively. 
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The V1 P1ong and V1 Pshort chimaeric receptors however were expressed at lower 
levels (150±14 and 215±22 fmol / 105 cells respectively) than the Piong7V and 
Pshort7V chimaeric receptors yet show nigher maximum levels of response (9.4±0.4 
and 7.2±0.3 nM respectively). This suggests that it is the loss of elements in the 
PACAP receptor body that reduces the maximum level of response. The Pshort7V 
chimaeric receptor appeared to have an increased ECso over the corresponding 
wild-type PACAP receptor (32.0±2.0 ru\tl compared to 10.6±0.6 nM respectively). 
The P5V, P3V and P1 V chimaerics had ECsos in the range 43-56 ru\ll; lower 
potencies for PACAP-38 than the wild-type P ACAP receptors and the P7V 
chimaerics. The maximum stimulation by the PsV chimaeric was 29% , P3V was 
14% and P1 V mediated 9% of the maximum response of the PACAPwt long 
receptor (11.1±0.6 fold of basal control). The VIP2 wt receptor had an ECso of 
36. 9±8.1 nM and a maximum stimulation 29% of the wild-type P ACAP receptor 
maximum. The V7P construct had a similar ECso (40.6±3.6 ru\11) but a reduced 
maximum, 17% of that stimulated by the PACAPwt long receptor. The VsP 
chimaerics had ECsos of approximately 59-64 n.M and similar maxima to the V7P 
chimaeric (14.4-15.3% of the maximum response of the PACAPwt long receptor). 
Despite VIP and PACAP-38 stimulation of a cAMP signal at the V3P chimaerics no 
[3H]IP signal was detected at concentrations up to 3 ~M with either agonist. 
The replacement of the PACAP receptor C-terminus with that of the VIP2 wt 
receptor reduced the PACAP-38-evoked [3H]IP stimulation, whereas chimaeric 
receptors containing sections of the VIP2 wt receptor body (with the exception of the 
V3P chimaerics) displayed VIP2 wt receptor-Like ECso and maximum stimulation 
values. The V3P chimaerics displayed an impaired ability to mediate agonist-
evoked adenylate cyclase stimulation and thls impaired signalling ability was also 
true for P ACAP-38-evoked [3H]IP production. 
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VI P-s timula ted { 3 H ]inositol phosphate product ion 
In section 4.3.2 VIP was shown to be considerably less potent than P ACAP-
38 for cAMP production mediated by the wild-type PACAP receptors and those 
chimaeric receptors which have N-tenninal PACAP receptor sequence (PACAP-38 
ECso values were in the range 0.3 -1.4 nM whilst VIP ECsos were in the range 19-
303 nM). At the VIP2 wt receptor and the N-terrninal VIP2 receptor chimaerics, 
with the exception of the V3P chimaerics, VIP and PACAP-38 were shown to be of 
similar potency for cAMP production (0-4-0.9 nM for PACAP-38 and 0.1-0.7 nM 
for VIP) and to stimulate similar maximal responses (in the range 8-30 fold of basal 
control for P ACAP-38 and 8-33 fold of basal control for VIP). Similarly, for 
[3H]IP production, VIP was less potent than PACAP-38 at the wild-type PACAP 
receptors, to the extent that no [3H]IP signal was detected at concentrations of VIP 
up to 3 ~while the PACAP-38 ECsos were 17.6±0.6 and 10.6±0.6 nM for the 
PACAPwt long and PACAPwt short receptors respectively. No VIP -evoked [3H]IP 
signal was detected at concentrations of up to 3 ~M at the P7V and P1 V chimaeric 
receptors either, in view of this the PsV and P3V chimaeric reveptors were not 
examined for YIP-evoked [3H]IP production. As suggested by the YIP-evoked 
cAMP production results VIP and PACAP-38 were of similar potency for VIP2 wt 
receptor-mediated [3H]IP production (ECsos of 45.0±6.6 and 36.9±3.0 nM 
respectively). The V1P chimaerics have only the N-terrninal portion of the VIP2 wt 
receptor but are capable of YIP-evoked [3H]IP production as well as cAMP 
production. As described in section 4.3.2, VIP and PACAP-38 were equipotent 
and caused a level of maximal stimulation which was similar to that produced by 
the wild-type PACAP receptors. For [3H]IP production at these chimaeric 
receptors VIP and PACAP-38 had similar potencies (15.5±1.3 and 31.3±0.6 nJvt for 
PACAP-38 and VIP respectively at the V1P1ong receptor and 15.7±2.8 and 
20.3±1.3 ru\1 for PACAP-38 and VIP respectively at the V1Pshort receptor) . The 
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maximum stimulations all lay within the 7.2-10.3 fold of basal control range in 
which the maxima for PACAP-38-evoked [3H]lP production by the PACAPwt long 
and PACAPwt short also lay (11.1±0.3 and 9.8±0.7 fold of basal control 
respective! y). 
These results confirm that the equipotency for VIP and PACAP-38 
associated with the VlP2 wt receptor is a characteristic which can be attributed to 
the N-terminus of the receptor and tha t the disruption of domains proximal to the 
TM3 exchange site in the V3P chimaeric may have been responsible for reducing the 
VIP and PACAP-38-evoked cAMP production and abolishing the receptor's abiHty 
to stimulate [3H]IP production. 
4.3.4 Pertussis toxin-sensitivity of [3H]inositol phosphate production 
mediated by VIP2 and PACAP chimaeric receptors 
It was clearly demonstrated that the PACAP receptor mediates a non-PYx-
sensitive stimulation of [3H]IP production whereas the wild-type VIP1 and VIP2 
receptors u tilise a partially PTx-sensitive mechanism to stimulate PLC (see Chapter 
3). In order to determine which of the func tional domains in the VIP2 receptor are 
responsib le for conferring PYx-sensitivity, nine chimaeric VIP2/PACAP receptor 
constructs <Pl V, P3V, PsV, Ptong7V, Pshort7V, VsPJong, VsPshort, V7P) were 
assayed for the PTx-sensitivity of their PLC responses (see table 4.2). 100 nM 
PACAP-38 was used to stimulate [3H]IP production at each construct. The PTx-
treated cells were pretreated for 16 hours with 100 ng/ml PTx before stimulation. 
As described in Chapter 3 the VIP1 wt and VIP2 wt receptor-mediated PLC 
responses were reduced to 5.5±3 and 59±5% of the corresponding control values 
after PYx-pretreatment. The PACAPwt long and PACAPwt short receptor-
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mediated PLC responses were unaffected by PTx -pretreatment, being mClintained 
at 101±3 and 104±3% of the control response. The [3H]IP production responses of 
the P1 V, P3V, PsV and V7P were significantly inhibited by PTx-pretreatment. 
However the VsPtong, VsPshort, Ptong7V and Pshort7V -mediated responses were 
entirely unaffected by PTx-pretreatment. This identifies the IC3/ TM6/EC3 region 
of the VIP2 wt receptor from the exchange site in TMS to the site i.n TM7 (residues 
293-375) as containing elements which are sufficient for the stimulation of PLC 
responses by a PTx-sensitive mechanism although the domains responsible for PTx-
insensitive coupling to PLC cannot be discerned. 
4.3.5 Characteristics of C-terminally Truncated VIP2 Receptors 
Ligand binding studies to monitor receptor expression levels and 
affinities for PACAP-27 
A described in section 4.2.1 two C-terminally truncated VIP2 wt receptors 
were created as a means of assessing the importance and role of the C-terminus in 
the expression of the VIP2 wt receptor and its ability to mediate agonist-evoked 
second messenger production. As described for the chimaeric receptors earlier in 
this chapter, radioligand binding experiments involving the homologous 
displacement of [125I]PACAP-27 were carried out in order to determine whether 
the receptors were being successfully expressed in the plasma membrane and if so 
at what level. These radioligand binding experiments were carried out on whole 
cells at ooc for 60 minutes. The three receptor constructs tested were, the VIP2 wt 
receptor (VIP2(1-437)), the truncated VIP2 receptor which had a C-terminus of 
approximately 13 amino acids VIP2D.(l-391) and the more severely truncated 376 
amino acid construct VIP2D-(1 -376) which was truncated in the C-terminal portion 
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of TM7 (see Figure 4.10). The VIP2 wt receptor wos expressed in COS 7 cells with i'l 
Bmax value of 113±22 fmol/105 cells and the VIP2t.(1-391) construct with a Bmax 
value of 115±23 fmol/105 cells. The truncation of the C-terminal 45 amino acids 
therefore had no effect on the expression level of the construct in comparison to the 
wild-type receptor. Transfection of the VIP2t.(1-376) eDNA into COS 7 cells 
produced no detectable specific binding indicating that this construct was not 
expressed at the cells surface and that truncation of the VIP2 wt receptor in the TM7 
region probably disrupts the processing of the receptor within the cell and/ or 
targetting of the construct to the cells surface. 
The intemalisation of receptors occurs at a negligible rate when binding 
studies are performed at ooc. In order to study the intemalisation of receptors a 
similar binding study was performed on whole cells at 37oc for 10 minutes (see 
'Materials & Methods' Section 2.2.7). Homologous displacement of [125J]VIP 
binding was carried out (see Figure 4.1). COS 7 cells transiently expressing the 
receptor constructs were prepared. Cells expressing the wild-type receptor VIP2 wt 
and the 391 amino acid truncated receptor (VIP2t.(l -391)) displayed similar 
affinities for VIP with IC5o values of 7.0±3.7 and 6.0±1.1 nM respectively. The 
Bmax values were also similar, 0.19±0.04 and 0.11±0.03 pmol/mg protein 
respectively. As expected no specific binding was detected for the more severely 
truncated 376 amino acid receptor (VIP2t.(1-376)). 
Agonist-evoked cAMP production by wild-type and truncated VIP2 
receptors 
The ability of the receptors to stimulate cAMP production was investigated 
in concentration-response and time-course experiments using VIP as agonist. 
Accumulation of intracellular cAMP was measured (see Figure 4.2). The 
concentration-dependence of VIP -evoked cAMP production mediated by the 
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VIP26(1-391) receptor was almost identical to that for the VIP2 wt receptor with 
ECsos of 0.12±0.03 and 0.18±0.03 nM respectively. Although it is not unusual for 
receptors which are expressed at levels too low to be detected by radioligand 
binding assays to mediate the stimulation of second messenger production, cAMP 
production in cells transfected with eDNA for VIP26.(1-391) receptor remained at 
basal levels over the applied concentration range. Tills suggests that the receptor is 
expressed at negligible levels, if at all, since cAMP production is tightly coupled to 
the VIP2 wt receptor. Because the C-terminal tail in a number of related receptors 
has been identified as modulating intemalisation of the receptor and desensitisation 
of the second-messenger responses the time-dependence of the YIP-evoked cAMP 
accumulation by the wild-type and truncated receptors was examined. Figure 
4.3(a) shows time-dependent accumulation of intracellular cAMP, Figure 4.3(b) 
shows the accumulation of total cAMP (intracellular and extracellular) and Figure 
4.3(c) shows how the rate of accumulation changes over the 60 minute period for 
both the VIP2 wt and VIP26(1-391) receptors. These data demonstrate that 
intracellular cAMP accumulation reached a plateau within five minutes for both 
receptors at between 20-25-fold of basal control. The accumulation of total cAMP 
did not appear to plateau for either receptor but the rate of accumulation decreases 
rapidly over the same period, as Figure 4.3(c) demonstrates. The rate of cAMP 
accumulation was maximal at approximately 1 minute and decreased rapidly 
thereafter. cAMP responses mediated by both receptors appeared to desensitise in 
the same way suggesting that the C-terminal tail of the VIP2 wt receptor does not 
modulate cAMP production to any great extent. 
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Agonist-evoked [3 H ]inositol phosphate production by wild-type and 
truncated VIP2 receptors 
The stimulation of [3H]inositol phosphate production by the VIP2 wt receptor is a 
less tightly coupled pathway than that fo r cAMP production and therefore one in 
which small changes in the receptor's ability to stimulate second messenger 
production may be more easily identified. Concentration response curves for VIP 
and P ACAP-38-evoked [3H]inositol phosphate production mediated by the 
VIP2il(l-391) receptor were performed. Both VIP and PACAP-38 stimulated a 
concentration-dependent increase in [3H]inositol phosphate production mediated 
by the VIP2il(l-391) receptor (Fig. 4.4 & 4.5). The ECso value for VIP was 
68.1±14.7 and for PACAP-38, 51.5±3.2, indicating that the peptides are 
equipotent at this receptor as they are at the VIP2 wt receptor where corresponding 
values were 45.0±6.6 and 36.9±8.1 respectively. The maximum stimulation was 
2.5±0.1 fold of basal control for VIP and 3.4±0.1 for P ACAP-38. These values are 
also within the range observed for the VIP2 wt receptor (2.4±0.1 and 3.0±0.3 fold of 
basal control respectively). 
In order to investigate any possible effect that the (-terminal truncation 
might have on desensitisation of the PLC coupling by this receptor, the [3H]IP 
production evoked by 111M VIP at VIP2 wt and VIP2il(1-391) receptors was 
measured over an 80 minute period (Figure 4.6). The accumulation appeared to be 
linear for both receptors and there was no indication of desensitisation over the 
measured time-period, in striking contrast to the rapid desensitisation of cAMP 
responses described above (although the desensitisation behaviours may vary with 
the agonist dose). Since the wild-type VIP2 receptor stimulates [3H]IP production 
in a partially PTx-sensitive manner, experiments were carried out to investigate the 
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Ptx-sensitivity of this response at the VIP2n( 1-391) receptor and assess whether the 
C-terminus influences coupling to this pathway. Figure 4.7 shows a significant and 
comparable inhibition of both wild-type and truncated receptors stimulation of 
[3H]IP production by PTx pre-treatment (100 ng/ ml, 16 hours). There was no 
effect of Ptx on basal [3H]IP levels and PTx pre-treatment reduced the VIP2 wt 
-mediated response by 41±6% and the VIP2~(1-391)-mediated response by 31±6% . 
There is therefore no readily identifiable effect of the 45 amino acid truncation of 
the VIP2 receptor C-terminus on agonist-evoked cAMP production or [3H]IP 
production that is revealed by the concentration response curves for VIP or 
P ACA P-38, the PTx-sensitivity of its [3H] IP production or the time-course of its 
second messenger responses. 
Although there was no evidence for differences in the endogenous 
desensitisation behaviour of the VIP2 wt and VIP2~(1-391) receptors, the 
C-terminus of the VIP2 wt receptor contains a number of putative phosphorylation 
sites including consensus sequences for PKC phosphorylation. Thus the truncation 
could potentially lead to differences in the regulation of the receptor by kinases 
other than those involved in native desensitisation (e.g. PKC). The non-specific 
protein kinase inhibitor, staurosporine (Tamaoki et al., 1986) was used to identify 
any differences in the kinase sensitivity of the wild-type and truncated receptors 
(Figure 4.8). There was a significant potentiation of [3H]IP production mediated by 
both receptors when staurosporine (1 J..1M) was present during the stimulation (from 
1.8±0.15- to 3.49±0.4-fold of basal control and from 2.1±0.3- to 2.98±0.16-fold of 
basal control for the VIP2 and VIP2il(1-391) receptors respective! y), this 
potentiation was also seen when the broad spectrum G protein activator 
NaF I A1Cl3 was used to stimulate [3H]IP production (see Table 3.3) suggesting that 
the effect is downstream of the receptor and may be attributable to attenuation of 
the phosphorylation of a G protein or phospholipase C. 
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4.4 Discussion 
4.4.1 Chimaeric VIP2 and PACAP Receptors 
Despite the homology between the wild-type PACAP and VIP2 receptors 
there are considerable differences in their signalling characteristics. When 
transiently expressed in COS 7 cells the VIP2 receptor mediates a modest 
stimulation of [3H]IP production wi th a relatively high ECso whereas the PACAP 
receptors mediate a larger magnitude response with an ECso approximately 5-fold 
lower. The ECsos for PACAP-38 stimulation of cAMP production are very similar 
at the P ACAP and VIP2 receptors although the maximum stimulation observed is 
two or more times greater at the PACAP receptors. However the most striking 
difference between the receptors is the poor stimulation of second messenger 
production by VIP at the P ACAP receptor, where the ECso for YIP-stimulated 
cAMP production is approximately fifty times greater than for P ACAP-38. No 
detectable [3H]IP signal was produced by VIP stimulation of the PACAP receptors 
within the concentration range tested here. 
Pertussis toxin-sensitive PLC stimulation 
The PACAP receptor stimulates PLC through the classical Gq/11 pathway which 
is PTx-insensitive, whereas the VIP1 and VIP2 receptors stimulate PLC through a 
PTx-sensitive mechanism (MacKenzie et al., 1996). Those chimaeric receptors 
which have the VIP2 wt receptor sequence C-terminal of the exchange site in TMS 
stimulate PLC in a PTx-sensitive manner (see section 4.3.4). Schneider et al. (1994) 
found that a C-terminally truncated PTH/ PTHrP receptor expressed in HEK293 
cells caused a partially PTx-sensitive stimulation of PLC, suggesting that the C-
terminal tail restricted the interaction of the receptor with specific G proteins. 
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However in the VIP2 wt receptor the C-terminal tail did not seem to influence the 
Pix-sensitive coupling, therefore, the major functional domain involved in the 
interaction with the PTx-sensitive G protein seems to be IC3 of the VIP2 wt receptor 
(see Table 4.3). !ida-Klein et al. (1997) identified residues in IC2 of the rat 
PTH/PTHrP receptor as being required for Gq interaction although all three 
intracellular loops have been identified as being important for PLC activation by 
adrenergic, muscarinic and glycoprotein hormone receptors (O'Dowd et al., I988; 
Chazenbalk et al., 1990; Dohlman et al., I99I; Savarese et al., I992; Strader et al., 
1994) with 1C2 and IC3 being the most commonly implicated. TheN-terminal and 
C-terminal portions of IC3 are predicted to be helical in structure and have been 
identified as important for G protein selectivity and activation. It is interesting to 
note that there a number of sequence differences between the VIP and P ACAP 
receptors in this area, such as the arginine (Arg302 in the VIP2 receptor) conserved in 
the VIP receptors yet substituted with a hydrophobic residue in the PACAP 
receptors. 
Exchange of N-termini 
By exchanging the N-terminus of the P ACAP receptor with that of the 
VIP2 wt receptor (VIP), VIP and PACAP-38 were made equipotent for cAMP 
stimulation with a maximum that exceeded that of even the P ACAPwt receptors. 
The VIP construct was also capable of mediating YIP-stimulation of [3H]IP 
production with a maximum response similar to that of P ACAP-38 at the 
PACAPwt receptors and an ECso of 20-30 ru\ll whereas YIP-stimulated [3H]IP 
production at the wild-type PACAP receptors was not detectable at concentrations 
up to 3 ~- The expression level of the V1P construct was 2.5-3.5 times that of the 
VIP2 wt receptor and 2.5-3.5 times lower than that of the P ACAPwt receptors. VIP 
was slightly less potent than PACAP-38 for [3H]IP production at this construct 
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(more marked fo r the PACAPwt long construct). It is possible that because PLC-
coup ling is much weaker than A( -coupLing for these receptors, this difference is not 
apparent for agonist-evoked cAMP production. If the receptor number were 
reduced to the point that it became a limiting factor for AC stimulation, the 
difference might be observed for both pathways. It appears that the VIP2 w t 
receptor N-terminus domain is sufficient to effect a major increase in VIP potency 
for both adenylate cyclase and PLC stimulation mediated by the PACAPwt 
receptors. The N-terminus domain must therefore contribute to the binding of 
agonist and / or its ability to induce an activated conformation of the receptor. 
It has become clear through a number of studies on the 
secretin/calcitonin/PTH/PTHrP receptor family that agonist binding and 
activation of intracellular signalling cascades are separable functions and that both 
optimal binding and receptor activation involve multiple disparate elements in the 
receptor's sequence (Gourlet et al., 1996; Holtmann et al., 1995a; Holtmann et al., 
1995b; Holtmann et al., 1996a; Holtmann et al., 1996b; N icole et al., 1997; Knudsen 
et al., 1997; Turner et al., 1996). Studies on receptors of this family indicate that 
the N-terminus is one of the major sites of agonist binding and that peptide agonists 
have a distinct activation domain which tends to bind to motifs in the extracellular 
loops and transmembrane domains. Stroop et al. (1995) described a chi.maeric 
receptor with the N-terminus of the calcitonin receptor fused to the glucagon 
receptor body which could bind salmon calcitonin (sCT) but could not mediate 
cAMP production as a result of the binding. The reversed construct with the N-
terminus of the glucagon receptor fused to the calcitonin receptor body displayed no 
detectable binding of [125f]sCT but did mediate the stimulation of cAMP 
production by sCT with an ECso value of 2.2±0.6 nM. Their data indicated the 
presence of a high affinity binding-site in the N-terminus and an auxiliary low 
affinity activation site in the receptor body of the calcitonin receptor. Vilardaga et 
120 
al. (1995) created N-terminal exchange rat V IP1 and secretin receptor chimaerics. It 
was found that those with the VIP1 receptor N-terminus were capable of binding 
VIP with a similar ICso to the wild-type VIP1 receptor but with an ECso for YIP-
evoked cAMP production 15-fold greater. The same construct was poorly 
responsive to secretin having an ECso for secretin-evoked adenylate cyclase 
activation 60-fold greater than the wild-type secretin receptor and an ICso 5-fold 
larger. As a means of standardising receptor number the authors adopted the 
rather unusual strategy of downregulating expression of the receptors by a 24 hour 
incubation with agonist. Binding studies were then carried out at 25°C for the 
chimaeric receptors and 370( for the wild-type. It was found that agonist binding 
to the chimaeric receptors occurred with a very short half-life and could be 
completely inhibited by the inclusion of 10 ).lM GTP in the assay. These authors 
were unable to demonstrate ligand-binding to the secretin N-terminal chimaeric 
receptor. The results are not easily interpreted beyond the point of saying that the 
VIP1 receptor N-terminus appears to be sufficient to confer or improve VIP binding 
at the secretin receptor but not VIP-evoked AC activa tion. Gourlet et al. (1996) 
found that the rat VIP1 receptor N-terminus reduced the ECso for YIP-evoked 
adenylate cyclase activity at the secretin receptor by 10-fold. This value was still 
100-fold greater than the ECso for the wild-type VIP1 receptor. In this study the 
ECso for secretin-evoked adenylate cyclase activity for the VIP1 receptor was 
unchanged by the addition of the secretin receptor N-terminus. In contrast 
Holtmann et al. (1995) found that the rat secretin receptor with the VIP1 receptor 
-terminus displayed wild-type VIP1 receptor characteristics with respect to VIP 
binding and VIP -evoked adenylate cyclase activation. However, the ECl region, in 
addition to the N-terminus of the secretin receptor was required in order to confer 
wild-type secretin binding and activation characteristics on the VIP1 receptor. 
Holtmann et al. (1996) demonstrated that the rat secretin receptor was capable of 
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binding VIP with high affinity (Ki values for VIP and secretin were 0.7±0.2 and 
2.1±0.5 nM respectively) but only secretin could stimulate AC activity with high 
potency (ECso values of 0.5±0.1 and 83±12 nM for secretin and VIP respectively). 
The authors also created secretin and VIP1 receptor fragments wh_ich consisted of 
theN-terminus, TM1 and a portion of IC1. These constructs were expressed in 
COS 7 cells and were found to bind VIP but not secretin (Ki values of 3.2±0.9 and 
7.9±2.6 nM for the secretin and VIP1 receptor constructs respectively). This is 
further evidence of a requirement for sequences in the secretin receptors trunk for 
secretin binding. Neither construct was capable of stimulating cAMP production. 
Cao et al. (1995) expressed a similar fragment of the rat P ACAP receptor and 
found that this construct when expressed in COS 7 cells was a high affinity binding 
domain for PACAP with an affinity 20-times greater than the wild-type receptor. 
These studies suggest that for many members of this family of receptors, the major 
determinant of ligand binding is contained in the N-termina1 portion of the receptor, 
as was observed for the VIP2 wt and PACAP receptors in this study. A lower 
affinity binding site in the trunk of the receptor is implicated in the process of 
agonist-evoked AC activation. 
In the present study the construct with the PACAPwt receptor N-terrninus 
in the VIP2 wt receptor body (P1 V) is expressed at more than twice the level of the 
VIP2 wt receptor and is unable to mediate detectable YIP-stimulated [3H]IP 
production. The YIP-stimulated cAMP production had an EC50 100-times greater 
than that for the VIP2 wt receptor and 10-times greater than for the PACAPwt 
receptors. The presence of the P ACAPwt receptor N-terminus on the VIP2 wt 
receptor body is therefore sufficient to attenuate YIP-stimulated signalling with 
respect to both cAMP and inositol phosphate responses with a much lesser effect 
on PACAP-38 potency in the same assays. The affinity of the receptor for 
P ACAP-27 also seems to be reduced. 
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It is possible that the PACAPwt receptor contains a negative element for 
VIP binding/receptor activation. There are a number of cases now where negative 
elements for ligand-binding have been described. Turner et al. (1996) described a 
'selectivity-filter' represented by a single residue near the extracellular surface of 
TM2 in the secretin and PTH/PTHrP receptors. An Asn192Ile mutation in the 
secretin receptor uncovered a response to PTH without affecting the secretin 
responses, the reciprocal mutation in the PTH/PTHrP receptor of lle234Asn made 
the receptor responsive to secretin without affecting PTH responses. Pantaloni et 
al. (1996) have identified an additional splice variant of the PACAP receptor which 
is missing a 21 amino acid section of the N-terrninus. In an earlier study these 
authors found P ACAP-27 to be less potent than PACAP-38 at four splice variants 
of the rat P ACAP receptor (which include the PACAPwt long and PACAPwt short 
splice variants used in this study) with respect to PLC stimulation (Spengler et al., 
1993). The new splice variant does not display this characteristic, showing similar 
affinities for PACAP-27 and -38 and a greatly reduced EC50 for PACAP-27-
evoked [3H]IP production. This indicates that the 21 amino acid deletion may have 
removed a negative element for PACAP-27 binding; an 'exclusion sequence'. 
The N-termini of the VIP and P ACAP receptors contain six conserved 
cysteine residues and in the case of the VIP1 and VIP2 receptors all but one of these 
have been identified, through selective mutation studies, as being crucial for VIP 
binding (Couvineau et al., 1995; Nicole et al., 1997; Gaudin et al., 1995). A cysteine 
and a glutamate residue, which are not conserved in the P ACAP receptors, have 
also been observed to be important for VIP binding at the human VIP1 and / or 
VIP2 receptors (see Table 4.3) (Nicole et al. 1997; Couvineau et al., 1995). The data 
clearly shows that the N-terrninus is the major determinant of ligand-binding 
selectivity in these receptors but studies with receptors of the same family suggest 
that domains in the receptor body may also be involved in binding agonists. 
123 
Selective mutation studies have identified an aspartate residue and two cysteine 
residues in ECl and a cysteine, tryptophan and threonine in EC2 of the human 
VIP1 or VIP2 receptors as being involved in binding VIP (Knudsen et al., 1997; Du 
et al., 1997; Nicole et al., 1997; Gaudin et al, 1995). AU these residues are 
conserved for the VIP and PACAP receptors except for the threonine which is 
replaced with methionine in the PACAP receptors. These data are supportive of a 
two-site co-operation model of agonist binding in this receptor family, optimally 
requiring a second site in addition to the N-terminal domain. 
Replacement of the PACAP receptor (-terminus by the VIP2 wt (-terminus 
(Plong7V and Pshort7V) resulted in a halving of the maximal extent of PACAP-38 
stimulated [3H]IP production and an apparent increase in the ECso for the 
Pshort7V chimaeric. VIP was ineffective on [3H]IP production in both wild-type 
and chimaeric receptors. The reduction in PACAP-38-stimulated [3H]IP 
production compared to wild-type PACAP receptors may be attributable to a drop 
in receptor number but this seems unlikely since the V1P chimaerics, for example, 
are expressed at an even lower level yet mediate a P ACAP-38 stimulated response 
almost twice as large. The potency and maximal extent of cAMP responses were 
little different in the P7V constructs with either P ACAP-38 or VIP as agonist apart 
from a small apparent reduction in potency at the Ptong7V variant. 
The reversed chimaeric, V7P, with the PACAP receptor (-terminus, has the 
lowest expression level of these constructs and a higher affinity for PACAP-27 in 
binding studies than most. With either P ACAP-38 or VIP as agonist the ECso for 
cAMP production appeared correspondingly to be slightly reduced compared to the 
wild-type VIP2 receptor and the maximum increased by approximately 50%. 
[3H]IP responses to PACAP-38 were unaltered. Thus it appea rs that the VIP2 wt 
receptor (-terminal domain has little effect on PACAP receptor mediated cAMP 
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production but reduces the ability of the receptor to stimulate PLC. As was 
discussed earlier, the P ACAP receptor stimulates PLC through a PTx-insensitive G 
protein, presumably Gq/1L whereas the VIP2 wt receptor additionally utilises a 
PTx-sensitive mechanism involving a member of the Gij o/z family. The VIP2 wt 
C-terminus could therefore have a negative influence on the ability of the receptor to 
interact with Gq/11· In contrast, the PACAP receptor C-terminus appears to 
improve the efficiency of the V7P construct compared to VIP2 wt with respect to 
cAMP but not [3H]IP responses. 
The effect of VIP2 wt receptor sequence on expresszon level 
The exchange of the PACAPwt receptor C-terminus (residues 429-495) for 
that of the VIP2 wt C-tenninus (residues 376-437) appears to reduce the 
expression levels of the P ACAP receptor-based chimeras. These are reduced 
further with the introduction of the VIP2 wt TMS-TM7 region (residues 293-375) 
and further still with the VIP2 wt TM1-TMS region (residues 125-293). The 
exchange of the PACAP receptor N-terminus (residues 1-152) with the VIP2 wt 
receptor N-terminus (residues 1-125), to form the VIP2 wt receptor, causes a further 
reduction. This effect could be attributed to the removal of disparate elements 
which have a positive effect on expression level in the P ACAP receptor sequence or 
the introduction of negative elements in the VIP2 wt receptor sequence. The 
exchange of the VIP2 wt receptor C-terminus for that of the PACAP receptor (V7P) 
has no effect on the VIP2 wt expression level but the VsP chimaerics which have 
PACAP receptor sequence C-terminal of the exchange site in TM5 show a definite 
increase which is maintained in constructs with progressively greater C-terminal 
PACAP receptor components. These observations could be explained if the 
P ACAP receptor C -terminus and portions of the TMS to TM7 region co-operated in 
increasing expression levels of the receptors and the N-terminus and TM1 to TM3 
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region of the PACAP receptors also cooperated to increase expression levels. The 
replacement of the PACAP receptor C-terminus with that from the VIP2 wt 
receptor reduced the expression level (P7V) whereas its addition to the VIP2 wt 
receptor (V7P) had no effect. When both regions, PACAP receptor C-terrninus 
(residues 429-425) and TM5-TM7 region (319-428), are present in the VIP2 wt 
receptor (V5P) we see an increase in expression level is observed, as predicted. 
There was a further drop in expression level over that of P7V when the TM5 to TM7 
region (residues 319-428) of the PACAP receptor was replaced with the equivalent 
region of the VIP2 wt receptor suggesting that this region of the P ACAP receptors 
may have had a small positive effect on expression level in the absence of the C-
terminus. The further introduction of the TMl to TM3 region (153-234) of the 
PACAP receptor (progressing from the V3P to V1P construct) had no effect on 
expression levels whereas its removal (progressing from the P3V to P1V construct) 
caused a reduction in expression levels. The drop in expression level in progressing 
from the P1V to VIP2 wt receptor and increase from the V1P to PACAPwt 
receptors is supportive of there being cooperative positive elements in the N-
terminus and TMl to TM3 regions of the P ACAP receptor. The argument against 
there being negative elements in the VIP2 wt receptor dominating this process, as 
opposed to positive elements in the PACAP receptors, is simply that the 
replacement of the PACAP receptor C-terminus with the VIP2 wt C-terminus 
reduced the expression level of the PACAP receptor (P7V) but the replacement of 
the VIP2 wt C-terminus for the PACAP receptor C-terminus (V7P) had no effect on 
expression levels. 
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The role of the JC3(fM6/EC3 region of the receptor 
The PsV, P3 V and PI V chimaerics all displayed VIP2 wt receptor 
characteristics for PACAP-38 -stimulation of cAMP production, maximum 
stimulation being halved from PACAPwt and P7V receptor levels. The introduction 
of residues 293 to 473 (TMS to C-terminus) of the VIP2 wt receptor into the 
PACAPwt receptor body (PsV) caused a significant reduction in this receptor's 
ability to stimulate adenylate cyclase, without affecting its potency. Exchange of 
this region of the receptor also caused an increase in ECso for P ACAP-38 
stimulated [3H]IP production by PsV and a drop in the maximum stimulation 
producing VIP2 wt receptor-like IP signalling characteristics without the VIP 
responses. [3H]IP production by the converse VsP and VIP chimaerics occurs by a 
PTx-insensitive mechanism (Table 4.2) whereas VIP2 wt- and V7P -mediated 
stimulation was partially PTx-sensitive. VIP and PACAP-38 were equipotent for 
[3H]IP production mediated by the VsP chimaeric. The VsP receptor stimulates 
[3H]IP production through a PTx-insensitive mechanism as did the P ACAP 
receptor, but with a much larger ECso and a much lower maximum stimulation. 
This suggests that, as expected, there are multiple elements controlling the ability of 
the receptor to activate specific G proteins and therefore the whole of the PACAP 
receptor trunk appears to be required for optimal P ACAP receptor-like PLC 
stimulation. 
In addition, the data suggest that the TMS to TM7 region of the PACAP 
receptor contains elements crucial for efficient interaction with Gs. Since in terms 
of maximal extent the most efficient stimulation of adenylate cyclase occurs via the 
V1P chimaerics it appears that the whole PACAP receptor body and (-terminus 
are required for an optimal response. The TM7 regions are almost identical in 
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sequence except for Leu to Val, Cys to Gly and Leu to Phe substitutions in the 
PACAP receptor (see Table 4.3). The IC2 regions have little homology with each 
other; the PACAP receptor contains two basic residues and an acidic residue which 
are not present in the VIP2 wt receptor. The TM5, TM6 and IC3 regions are very 
similar for both the VIP2 wt and PACAPwt short receptors. There are several non-
conservative substitutions however, the most striking of which are the Ile to Arg and 
Leu to Lys in 1C3 of the YIP2 wt receptor (see Table 4.3). No specific residues in 
these regions in the VIP2 wt and PACAP receptors have been identified to date as 
being crucial to the receptors function. Key residues in the TM2 and TM7 regions of 
the PTH/PTHrP receptor have however been identified (Gardella et al., 1996; 
Turner et al., 1996). These residues are beHeved to facilitate an interaction between 
the TM2 and TM7 regions that has been proposed for rhodopsin family receptors 
(Henderson et al., 1990; Schertler et aJ., 1995; Suryanarayana et al., 1992; Sealfon et 
al., 1995; Zhou et al., 1994; Mizobe et al., 1996). The residues identified in TM2 are 
believed to form part of a polar face of a helix. The residues in question are all 
conserved in the VIP and PACAP receptors (i.e. Ser166, Arg170 and Ser173 in TM2 
and Gtn365 in TM7 of the rat VIP2 receptor). 
The role of the EC2/TM4/IC2 region of the receptor 
The EC50 for YIP-stimulated cAMP production at P3 V is the lowest of the 
N-terrninal P ACAP receptor chimaerics. The extracellular residues presented by the 
P3 V ch.imaeric may therefore present an improved environment for binding and 
activation by VIP over that for the other chimaerics with N-terminal PACAP 
receptor segments, particularly P1 V. PACAP-38-evoked cAMP and [3H]IP 
production however appeared unchanged between the PsV, P3V and P1 Y 
chimaerics. It is interesting that Holtmann et al. (1996) found that VIP did not bind 
to a chimaeric receptor consisting of the rat secretin receptor N-terminus with the 
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VIP1 receptor body, yet bound with relatively high affin ity to a construct containing 
the secretin receptor N-terrninus and EC1 region in the VIP1 receptor body. Many 
of the residues identified as being important for VIP binding by site-di rected 
mutagenesis studies carried out on the human VIP1 receptor (Knudsen et al., 1997; 
Nicole et al., 1997; Couvineau et al., 1995; Gaudin et al., 1995) and human VIP2 
receptor ( Nicole et al., 1997) and are conserved in the PACAP receptors. The 
exceptions are Glu36 and CysSO (equivalent to Glu23 and Cys37 in the rat VIP2 
receptor) identified in theN-terminus of the human VIP1 receptor (Couvineau et al., 
1995; Nicole et al., 1997). The data presented here emphasises the different binding 
requirements of agorusts at the same receptor, and indeed the same agonist at 
different receptors, and the existence of separate binding and activation domains. 
lt is possible that the PACAP receptor contains a negative element for VIP 
binding as described for PACAP-27 at the P ACAP receptor (Pantaloni et al., 1996) 
or PTH and secretin at the secretin and PTH/ PTHrP receptors respectively (Turner 
at al., 1996). The data suggest that the TM3 to TM5 region (residues 209-293) of 
the VIP2 wt receptor is particularly important for VIP binding/activation of 
signalling pathways. Its presence reduced the ECso and increased the maximal 
extent of VIP- but not PACAP-38-stimulated cAMP production (P3 V). Its absence 
(V3P) increased the EC50 and reduced the maximal stimulation for YIP-stimulated 
cAMP production whilst strikingly preventing stimulation of PLC by VIP or 
PACAP-38. The reduction in adenylate cyclase stimulation mediated by the V3P 
chimaeric and its inability to stimulate PLC in response to VIP or PACAP-38 
suggests that cytoplasmic domains necessary for Gq stimulation are not present in 
the V3P chimaeric and some elements required for Gs activation are also missing or 
disrupted. Common elements for G protein activation and elements for activating 
specific G proteins may be affected. The TM3 exchange site occurs in a region that 
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is not completely conserved between the VIP2 wt and PACAP receptors, the 
residues immediately N-terminal of the site are His for the P ACAP receptor and 
Gln fo r the VIP2 wt receptor. It therefore seems possible that the function of the 
TM3 domain may be disrupted affecting both agonist-receptor and receptor-G 
protein interactions. A network of functional connections between receptor 
domains could potentially be destroyed. 
Functionally important residues, motifs, domains and interactions 
in G protein-coupled receptors 
i) Important residues and motifs in the intracellular loops 
!ida-Klein et al. (1997) identified a basic residue (Lys/ Arg) at the (-
terminal end of IC2 as being essential for Gq/ PTH/ PTHrP receptor interactions. 
Mutation of the GluLysLysTyr sequence to AspSerGluLeu abolished IP stimulation 
without affecting cAMP production. Mutation of the AspSerGluLeu motif to 
AspSerLysLeu or AspSerArgLeu was sufficient to restore the PLC response. 
Unfortunately the authors present no data on changes in ECsos or expression levels 
caused by the different mutations only the effect on maximum stimulation levels. A 
basic residue is conserved at the equivalent position in the VIP and P ACAP 
receptors (Arg237 in the rat VIP2 receptor). A Leu which is conserved at an 
equivalent site in IC2 of the VIP and P ACAP receptors is implicated in GnRH and 
ml and m3 muscarinic receptor stimulation of PLC (Moro et al., 1993; Moro et al., 
1994; Arora et al., 1995). A Phe residue in the ~2-adrenergic receptor at the same 
relative position as Leu in the GnRH, m1 and m3 receptors is also important for 
isoproterenol-stimulated cAMP production (Moro et al., 1993). This suggests that 
the presence of a hydrophobic residue may be required at this position for G 
protein-coupling. The AspArgTyr motif identified in many members of the 
rhodopsin family of GPCRs occurs in IC2 at an equivalent position to the 
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GluLysLysTyr motif of the PTH/PTHrP receptor. In the 0:1I3-adrenergic receptor, 
mutation of the AspArgTyr to AlaArgTyr resulted in a constitutively active 
receptor. Mutation of the Arg143 residue however caused a reduction in inositol 
phosphate production. The authors concluded that the Arg143 residue mediates 
receptor activation by allowing several residues in IC2 and IC3 to interact (Scheer et 
al., 1996). In fact ail three intracellular loops have been implicated in PLC 
activation by the glycoprotein hormone receptors, the adrenergic and the muscarinic 
receptors (O'Dowd et al., 1988; Chazenbalk et al., 1990; Dahlman et al., 1991; 
Savarese et al., 1992; Strader et al., 1994). Kosugi et al. (1992) identified a residue 
in IC3 of the TSH receptor, Ala623, which was required for inositol phosphate 
production. Mutation to Lys or Glu resulted in impaired IP signalling without 
affecting cAMP production. However mutation of the equivalent Ala to any other 
residue in the <X1B-adrenergic receptor resulted in a receptor constitutively active for 
inositol phosphate production (Kjelsberg et al., 1992). 
ii) Interactions between transmembrane domains 
The model of GPCR structure suggested by Baldwin (1993;1994) based on 
the low resolution structure of bovine rhodopsin (Schertler et al., 1993) and analysis 
of over 200 GPCRs has many features confirmed by biochemical analysis. Studies 
of the PTH/PTHrP receptor structure by Gardella et al. (1996) are entirely 
consistent with an interaction between TM2 and TM7. Mutation of Gln451 in TM7 
inhibited PTH(1-34) binding as did mutation of Arg230 in TM2. However the 
double mutation restored binding but prevented any PTH(1-34) stimulation of 
cAMP or [3H]IP production. Binding of the antagonist/ partial agonist PTH(3-34) 
was unaffected by the mutations. The activation domain of PTH is in its N-
terrninus and other evidence shows that this region of the peptide binds to residues 
in EC3. Lee et al. (1995) prevented PTH binding by deleting residues 431-440 in 
131 
EC3. Trp-l37 and Gln440 were identified as important for binding theN-terminus 
of PTH. The Arg230 residue in TM2 of the PTH/PTHrP receptor is one of three 
residues identified by Turner et al. (1996) as being important for signalling (Ser227, 
Arg230 and Ser233) after adopting a strategy of mutating charged residues. These 
residues are thought to form part of a polar face of this transmembrane domain 
which participates in interhelical ionic interactions which stabilise the active or 
inactive conformations of this receptor. A study of rhodopsin receptor structure 
revealed a salt bridge between TM7 (Lys296) and TM3 (Glu 113) disruption of 
which produced a constitutively active receptor (Robinson et al., 1992; Rao et al. , 
1994). Kudo et al. (1996) used FSH and LH receptor chimaerics to define an 
interaction between TMS and TM6 of the LH receptor which is critical for keeping 
the receptor in an inactive state. Hwa et al. (1996) showed that constitutively 
active mutants of the <X1A- and <XIS-adrenergic receptors which had a single point 
mutation in either TMS or TM6 could be silenced by a complementary mutation in 
TM6 or TMS respectively. 
Receptor activation by ligand and transduction of the extracellular signal to 
the cell interior is thought to occur as a result of small changes in the receptor's 
conformation induced by ligand binding to several domains in its extracellular 
surface (for the muscarinic and adrenergic receptors however, the ligand binding site 
is in the receptor's body (Dixon et al., 1987; Rubenstein et al., 1987; Wess, 1993) as 
is the site for activation of the rhodopsin receptor (Zhukovsky et al., 1991)). From 
studies carried out on the rhodopsin receptor (Farahbakhsh et al., 1993; 
Farahbakhsh et al., 1995) activation is believed to involve a small outward 
movement of TM3, a small outward movement of the C-terminal end of TM6 
accompanied by a clockwise rotation of approximately 300 and a small structural 
change in IC2. Cross-linking of the cytoplasmic ends of TM3 and TM6 has been 
shown to prevent activation (Farrens et al., 1996). The exchange site for creation of 
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the TM3 chimaerics occurs in a region of the receptor which has been demonstrated 
as being crucial for the function of related receptors. It is therefore possible that this 
exchange disrupts the precise arrangement of transmembrane domains and 
intracellular loops required for G protein activation or makes a crucial residue 
inaccessible thereby disrupting signalling. 
4.4.2 C-terminal Truncations 
The VIP2t1(1 -376) truncated receptor 
Expression of the VIP2il(l-376) truncated receptor was not detected at the 
cell surface in whole cell ligand-binding experiments and proved unable to mediate 
cAMP production in response to ligand. The truncation point for this construct is 
at the C-terminal end of TM7 and is several residues before the conserved 
GluValGln motif. Huang et al. (199Sb) found that a truncated PTH/PTHrP 
receptor which was truncated immediately before the Glu ValGln motif was not 
successfully expressed at the plasma membrane either but was found localised 
around the nucleus of the cell. The presence of the Glu ValGln motif itself however 
does not seem to be the crucial factor since its mutation to AlaAlaAla had little 
effect on expression levels or location. It may be the intrusion of the truncation 
point into the transmembrane region that affects the expression of the receptor by 
gross structural disruption. Schneider et al. (1994) were unable to express a human 
PTH/PTHrP receptor truncated before the Val of the GluValGln motif. Findlay et 
al. (1994) successfully expressed a calcitonin receptor truncated before the Gln of 
this motif. lntemalisation of the receptor was inhibited slightly and sCT-induced 
cAMP and ca2+ signalling were impaired with respect to the wild-type receptor. 
Unson et al. (1995) attempted to express truncated rat glucagon receptors and 
found that receptors truncated in the mid-region of ICl, 1C2 and IC3 were not 
expressed at the plasma membrane of the cell (as determined by 
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immunofluorescence in permeabilised ce lls). Binding studies on membranes 
prepared from cells transfected with the constructs revealed no detectable binding. 
The authors concluded that all 7 TM regjons were required for correct processing of 
the receptor and its transport to the plasma membrane. The data for such a small 
group of constructs cannot strongly support such a conclusion. Holtmann et al. 
(1996), as previously described, successfully expressed truncated VIP1 and secretin 
receptors which consisted of the N-terminus, TMl and a portion of ICl . Cao et al. 
(1995) also successfully expressed a similar portion of the rat PACAP receptor 
demonstrating that all seven TM regions are not required. Holtmann et al. (1996) 
and Cao et al., (1995) used radioligand binding studies carried out on membrane 
preparations from transfected cells to determine whether the constructs were being 
successfully expressed. 
The truncated VIP2Ll(1-391) receptor 
The 391 amino acid truncated receptor, VIP2~(1-391), has a C-terminal tail 
of 13 amino acids. It was expressed at a similar le,·el to the VIP2 wt recepto r and 
displayed a similar affinity for P ACAP-27 binding. One of the more surprising 
effects that has been observed for C-terminal truncations in this family of receptors 
is an increase in ligand-binding affinity. Findlay et al. (1994) found that C-terminal 
truncation of the porcine calcitonin receptor caused an increase in its affinity for 
sCT. The binding of sCT occurs in an irreversible manner which is not true of pCT. 
The truncations were expressed at varying levels in stably transfected HEK 293 
cells in a range from 10 million receptors per cell for the wild-type receptor to 
52,000 per cell fo r the lowest expressed truncation. Transformations of the data 
reveal a clear linear relationship between the log Kd and log receptor number. The 
authors claim that the increased Kd was not an artefact of the increased receptor 
number because a similar relationship between construct and ligand-binding affinity 
134 
was observed when the receptors were transiently expressed in COS 1 cel ls at a 
uniform level. The only Kd values quoted by the authors however are those for the 
stable transfectants. It is assumed by the authors that the C-tail assists in 
maintaining the receptor in a low-affinity state as described by Lefkowitz et al. 
(1993) and Samama et aL (1993). Unson et al. (1995) described a slight increase in 
ligand binding affinity for glucagon receptors truncated to 443 and 415 amino acids 
from the full-length 483. Parker and Ross (1991) provided an interesting example 
of the effect of (-terminal truncation in their study on the avian ~-adrenergic 
receptor. For the truncated receptor they observed increased basal and agonist-
stimulated adenylate cyclase stimulation, agonist activity for classical antagonists 
at the receptor and an increase in ligand-binding affinity for agonist. In this case the 
(-terminus appears to regulate coupling efficiency to adenylate cyclase as well as 
modulating the receptor's affinity for agonist. This data is supportive of the idea 
that the (-terminus can constrain or stabilise the receptor in an inactive 
conformation. It is now believed that GPCRs can adopt a range of different 
conformations (Kenakin, 1995a; Kenakin 1995b) in the presence of agonists, 
antagonists, inverse agonists etc. If the role of the antagonist is to stabilise the 
receptor in the inactive conformation, then the absence of the (-terminus, which has 
also been credited with this role, may mean that the receptor has a much higher 
probability of being in an active conformation when encountered by the antagonist. 
An alternative possibility is that the antagonist induces a conformational change 
which is distinct from the resting/inactive state but is energetically unfavourable in 
the absence of the ( -terminus and is therefore readily converted to an active 
conformation. 
The role of the (-terminal tail in the ability of the human PTH/PTHrP 
receptor to stimulate adenylate cyclase has been elucidated in experiments by 
Schneider et al. (1994) who produced a series of progressively (-terminally 
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truncated PTH/PTHrP receptor constructs. A receptor with a C-terminal tail of 19 
amino acids was functionally expressed in COS 1 cells without being noticeably 
different from the wild-type receptor in its ability to stimulate adenylate cyclase or 
PLC or in its ligand binding affinity for [Tyr36]cPTHrP-(1-36). Nevertheless when 
the wild-type receptor was expressed in HEK293 cells it was unable to mediate any 
stimulation of PLC, despite there being 155±44 (x103) binding sites per cell. The 
authors estimate this as being 10% of the expression level in COS 1 cells. In 
HEK 293 cells the wild-type receptor had an EC50 for cAMP production identical 
to that displayed by the receptor in COS 1 cells (9.41±0.09 and 9.30±0.10 (-log(M) 
respectively for hPTH-(1-38)). The authors found that truncating the (-terminus to 
a point between residues 504 and 483 restored the ability of the receptor to 
stimulate PLC. The receptor body is therefore thought to interact promiscuously 
with G proteins while the C-terminus serves to restrict this interaction with some G 
proteins more than others, thus in this case directing the receptor towards an 
interaction with G5. 
The potency of VIP for cAMP-production mediated by VIP2 wt and 
VIP26.(1-391) receptors was very similar when expressed in COS 7 cells as were the 
maximum stimulations and basal levels of cAMP production. It is interesting to 
note that when expressed as stable transfectants in CHO cells the rat VIP 1 and 
VIP2 receptors proved unable to mediate significant stimulation of PLC while AC 
stimulation appeared unaffected ([3H]IP production of 0.92±0.06- and 1.03±0.07-
fold of basal control for VIP1 and VIP2 receptors respectively after a 60 minute 
stimulation with 3 11M VIP). ln HEK293 cells however, the human VIP2 receptor 
mediated a stimulation of PLC with a maximum response 10-fold greater than that 
observed in COS 7 cells (data not shown). The effects of C-terminal truncation 
have not been examined on the responses in cell lines other than COS 7 cells. The 
characteristics of the responses observed in the COS 7 cell transient expression 
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system closely resemble the responses mediated by the endogenous VIP2 receptor in 
GH3 cells, a rat pituitary tumour cell-line (see Chapter 5). 
Neither concentration-response curves nor timecourses revealed any 
differences between [3H]IP production mediated by the VIP26(1-391) receptor and 
that mediated by the V1P2 wt receptor. In contrast to a number of older studies on 
related receptors, the wild-type and truncated receptors appear to interact with the 
same G proteins and with similar efficiency. It must be kept in mind that the 
VIP26(1-391) construct still has a ( -terminal tail of 13 amino acids which includes 
the whole of the predicted helical region and may be sufficient for a number of(-
terminal tail-regulated activities. Huang et al. (1995; 1995b) carried out a study on 
the effects of (-terminal truncation on the signalling and expression of the opossum 
PTH/PTHrP receptor. A mutant with a ( -terminus of 9 amino acids was 
expressed and functioned normally with respect to adenylate cyclase stimulation, 
Ca2+ signalling (as measured in Xenopus oocytes by monitoring 4Sca efflux from 
prelabelled pools) and ligand binding. The truncated receptors were however 
expressed at a lower level than the wild-type. This lower level of expression did 
not affect second-messenger production presumably because there was still an 
excess of expressed receptor available for this task. The authors make the point 
that Iida-Klein et al. (1995), working at a much lower expression level, observed 
enhanced AC stimulation as a result of (-terminal truncation of the rat 
PTH/PTHrP receptor, such an effect might be missed if the receptor number was 
not a limiting factor. 
Endocytosis and Desensitisation 
Huang et al. (1995b) did however identify a significant effect of the 
truncations on the intemalisation of the PTH/PTHrP receptor. Mutation of the 
Glu ValGln motif to NaAlaAla resulted in a 40% increase in ligand endocytosis. 
137 
The authors interpreted this as being due to the loss of a signal that negatively 
regulates endocytosis. Application of a hypertonic sucrose solution caused an 80'Yo 
reduction in internalisation which is attributed to the disruption of clathrin lattices 
involved in coated pit formation (Hansen et al., 1993). Silve et at. (1982) had 
already demonstrated the accumulation of iodinated PTH in clathrin-coated pits on 
the surface of cells in clavarial bone. The deletion of residues 475-494 in the C-
terminal tail caused a 50-60% decrease in ligand internalisation suggesting that this 
constitutes a positive signal for endocytosis. It is possible therefore that the 
C-terminal tail of the opossum(OK) PTH /PTHrP receptor contains both inhibitory 
and facilita tory domains for endocytosis. 
Reneke et al. (1988) found that truncation of the yeast a-factor receptor 
C-terrrtinus caused a significant reduction in ligand-induced endocytosis. 
Nussenzveig et al. (1993) determined that there were two domains in the TRH 
receptor C-terminus that facilitate fast TRH-induced endocytosis. There are a 
number of examples however of C-terrninal deletions increasing or facilitating 
internalisation as observed by Huang et al. (1995b) with the GluValGln to 
AlaAlaAla mutation in the PTH/PTHrP receptor. The LH/CG receptor C-
terrninus appears to act to reduce the rate of intemalisation of the receptor 
(Rodriguez et al., 1992). The majority of mammalian forms of adrenergic receptor 
undergo agonist-induced desensitisation whereas the avian form does not. Hertel et 
al. (1990) found that the removal of residues from the avian P 1-adrenergic receptor 
C-terminus allowed ligand-induced endocytosis to occur. The mechanism for 
regulation of this ligand-induced endocytosis is not known although Urena et al. 
(1994) have observed that both receptor availability and cAMP accumulation are 
controlled by certain steroids and cytokines. Blind et al. (1993) identified the 
C-terrninal tail of the rat PTH/PTHrP receptor as a substrate for phosphorylation 
by PKC, PKA and PARK1 in vitro. Blind et al. (1995) demonstrated the 
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constitutive phosphorylation of the OK PTH/PTHrP receptor stably expressed in 
HEK293 cells. The authors found that occupancy of the receptor by activa ting 
hormone increased phosphorylation. Phosphorylation of the receptor could be 
stimulated by the phorbol ester PKC activator, phorbol 12-myristate 13-acetate 
(PMA) and the stimulator of cAMP production and PKA activation, forskolin. 
The agonist-induced phosphorylation however could not be blocked by the PKC 
inhibitor, GF 109203X, the PKA inhibitor, H-89 or the broad-spectrum kinase 
inhibitor, staurosporine which inhibits both kinases at h.igh dose. A role for PKC in 
this system is not strongly supported since the wild-type human PTH/PTHrP 
receptor (Schneider et al., 1994) and the OK PTH/PTHrP receptor (Blind et al., 
1995) expressed in HEK 293 cells were unable to stimulate PLC. The authors 
concluded that a non-second messenger-activated kinase such as a G protein-
coupled receptor kinase (GRK) is probably involved. The P-adrenergic receptor 
kinase (PARK) can mediate the homologous desensitisation of the AC response 
stimulated by P-adrenergic receptor agonists (Hausdorff et a!., 1990) and these 
related GRK family kinases (for review see: Premont et al., 1995) are likely 
candidates for mediating desensitisation of the VIP2 receptor also. 
Staurosporine has a potentiating effect on agonist-stimulated [3H]IP 
production mediated by the VIP2 wt and VIP2D.(1-391) receptors but also has a 
potentiating effect on AlCl3/NaF stimulated [3H]IP production indicating that the 
effect is dependent on G protein activation but is downstream of the receptor. The 
C-terminal portion of the receptor contains four putative PKC phosphorylation 
sites conforming to the PKC consensus specificity motifs as defined by Pearson & 
Kemp (1991). Phosphorylation of the receptor itself has of course not been 
demonstrated in this experiment and the action of PKC need not be directly on the 
receptor. lf the receptor were phosphorylated it may not be on residues in the C-
terminal tail. The phosphorylation may occur at a residue in the receptors body 
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exposed as a result of an interaction between the (-terminal tail <lnd the 
intracellular portion of the receptor's body. The VIP2 wt receptor-mediated IP 
response was unaffected by treatment with the PKC inhibitor GF 109203X (data 
not shown) indicating a lack of tonic influence under the conditions assessed. 
Turner et al. (1988) demonstrated that PMA caused a decrease in VIP-stimulated 
AC activity and in cell-surface VIP receptors in the HT29 human colonic 
adenocarcinoma cell line but concluded that PKC was not involved in agonist-
induced desensitisation. It should however be considered that PKC activation 
mediated by another receptor could be relevant to modulation of VIP receptor 
function in vivo. 
4.4.3 Summary 
In summary, the IC3 region of the VIP2 wt receptor has been identified as the 
major functional domain involved in the activation of a PTx-sensitive G protein by 
which the receptor mediates PLC stimulation. The N-termini of the VIP2 wt and 
P ACAP receptors have been identified as the major determinants of ligand-binding 
specificity by virtue of their effect on the recognition of VIP as opposed to 
P ACAP-38 by each receptor. Agonists for these receptors appear to undergo 'two-
site binding', with auxiliary sites in the receptor body being required in addition to 
the N-termin.us for wild-type receptor responses. The P ACAP receptor appears to 
contain elements which improve its expression level as well as having a (-terminus 
which facilitates an improved interaction with Gs when inserted into the VIP2 
receptor. However the whole of the P ACAP receptor body appears to be required 
for optimal stimulation of AC. The presence of the VIP2 wt receptor (-terminus 
conversely appears to have a negative influence on Gq/11 stimulation by the 
P ACAP receptor. The TM3 region of the receptor seems llkely to be critical for 
receptor function since its disruption in the V3P chirnaerics was the probable cause 
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of attenuated cAMP and IP signalling. Many interactions between transmembrane 
regions and intracellular loops have been postulated (for review see Wess, 1997) 
and it is not possible at this stage to determine which of these may have been 
affected. The removal of the VIP2 wt receptor C-terminus had no significant effects 
on the cAMP or IP signalling. PKC phosphorylation may have a role to play in 
modulating the intemalisation of this receptor, a phenomenon which has not been 
investigated in this study. 
ln studies such as this, the receptor-mediated signalling phenomena should 
ideally be observed at low expression levels since this is a more sensitive way of 
examining effects on tightly-coupled G protein mediated signalling pathways. 
Consideration should also be given to the difference in coupling efficiencies between 
pathways activated by a single receptor. Many studies claim to demonstrate 
selective disruption of a signalling pathway but this is inevitably the less tightly-
coupled response and close examination of the data often reveals a decrease in the 
activity of the other response also. ln this family of receptors, any structural 
manipulation which lead to the disruption of AC stimulation without affecting PLC 
stimulation would be a more convincing demonstration of separable domains for 
coupling to different G proteins than disruption of PLC stimulation. 
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Table 4.1 Relative expression levels, ICso values for homologous displacement of [125I]PACAP-27, ECso and maximal 
stimulation values (fold of basal control) for PACAP-38 and YIP-stimulated cAMP and [3H]inositol phosphate production 
mediated by wild-type and chimaeric receptors transiently expressed in COS 7 cells. 
Specific [1251) cAMP Pr!;u;!yctiQn J_aHliP PrQdyction 
fACAP-27 Bindin& PACAP-38 VIP PACAP-38 VIP 
Receptor Bmax I Cso E~o Em ax E~o Em ax E~o Em ax E~o Em ax 
(£mol/ (nM) (nM) (fold of basal (nM) (fold of basal (nM) (fold of basal (nM) (fold of basal 
HP cells) control) control) control) control) 
"lnn!l PACAPwt long 520±52 31±3 0.5±0.4 22.4±1.1 38.6±3.8 12.08±0.5 17.6±0.6 11.1±0.3 nd PACAPwt short 494±37 30±1 0.7±0.1 19.9±1.4 28.6±2.0 15.7±0.2 10.6±0.6 9.8±0.7 nd 
"lnn!l Plong7V 306±27 24±2 1.4±0.1 20.1±0.9 81.7±0.1 12.6±0.4 16.3±0.6 5.95±0.2 nd Pshort7V 228±17 16±1 0.6±0.1 18.4±0.5 42.9±2.4 16.7±0.6 32.0±2.0 4.19±0.3 nd 
"lnn!l P5V 202±39 30±6 0.3±0.01 10.5±0.5 80.1±19.3 4.3±0.5 48.0±2.9 3.2±0.01 
"lnn!l P3V 234±57 69±17 0.7±0.1 10.1±0.5 19.0±1.3 7.5±0.2 43.2±7.0 1.6±0.1 
Jrul!] P1V 130±32 70±17 0.6±0.2 12.7±0.3 302.5±24.8 8.5±0.2 55.6±22.9 1.3±0.1 nd 
"lrlfl!] V1P2 wt 59±5 ' 19±1 0.9±0.1 7.8±0.5 0.3±0.1 8.2±0.1 36.9±8.1 3.0±0.3 45.0±6.6 2.4±0.1 
"lnn!l V7P 46±15 16±5 0.4±0.1 12.5±0.5 0.1±0.02 13.4±0.3 40.6±3.6 1.8±0.1 
Specific [125I] cAMP Production raH]IP Production 
PACAP-27 Bindin~ PACAP-38 VIP PACAP-38 VIP 
Receptor Bmax ICso ECso Em ax ECso Em ax ECso Em ax ECso Em ax 
(fmol/ (nM) (nM) (fold of basal (nM) (fold of basal (nM) Hold of basal (nM) (fold of basal 
loS cells) control) control) control) control) 
lnn!l V5P1ong 228±20 58±4 0.6±0.1 13.1±0.5 0.4±0.1 12.81±0.6 59.3±16.5 1.6±0.1 V5Pshort 163±21 38±4 0.8±0.1 12.4±0.6 0.6±0.1 11.36±0.8 63.6±10.4 1.7±0.0 
1 V3P1ong 260±36 72±10 0.2±0.02 6.3±0.1 2.3±0.1 4.2±0.3 nd nd UU1!1 V3Pshort 91±24 56±14 0.5±0.1 7.0±0.2 3.4±0.4 4.7±0.2 nd nd , 
lfl1l!] V1P1ong 150±14 13±1 0.6±0.2 30.1±1.4 0.7±0.1 33.1±4.6 15.5±1.3 9.4±0.4 31.3±0.6 10.3±0.0 
V1Pshort 215±22 16±2 0.6±0.3 27.3±1.7 0.4±0.1 32.4±1.1 15.7±2.8 7.2±0.3 20.3±1.3 8.6±0.0 
Bmax and IC5o values were detennined by non-linear curve fitting of data from homologous displacement of ligand-binding experiments carried out 
on whole cells at 0°C for 60 minutes. ECso values for [3H]IP production were derived from non-linear curve fitting of concentration response curves. 
Values are expressed as means±SEM (n=3-6). Bmax is expressed as fmol/ protein equivalent of loS cells. EC5o is expressed in nM. The maximal 
stimulation (E max) is expressed as 'fold of basal control'. A typical basal value for cAMP production was 6±2 pmol/ well. A typical basal value for 
[3H]inositol phosphate production was 7700±600 dpm per well. EC5QS, IC5QS and Emax values were derived from the non-linear curve-fitting 
programme P-fit (Elsevier Biosoft, Cambridge, UK). 'nd' indicates that no stimulation was detected at agonist concentrations up to 3 ~tM. 
Fig. 4.1 Homologous displacement of [125I]VIP binding to COS 7 cells 
express ing the VIP2 w t and VIP26(1-391) receptors. 
1l1e binding assay was ~rformed at ooc for 60 minutes on whole COS 7 cells transiently 
expressing theVIP2 wt (U) or VIP26(1-391) (0) receptors. The values are the means±SEM, 
n=8. The VIP2 wt and VIP26(1-391) receptors had ICso values of 7.0±3.7 and 6.0±1.1 nM 
respectively and Bmax values of 0.19±0.04 and 0.11±0.04 pmol/ mg protein respectively. 
[125r]VIP was present at a concentration of 6.15±0.3 pM. 
Fig. 4.2 Concentration response curves for VIP-evoked cAMP production 
mediated by the VIP2 wtt VIP26(1-391) and VIP2~(1-376) receptor 
constructs. 
1l1e assay was performed on COS 7 cells transiently expressing the VIP2 wt0 ), 
VlP26(1-391) (0) or VIP26(1-376) (¢ )receptors. Stimulation was for 15 minutes in the 
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Fig. 4 .. 3 The time-dependence of VIP-evoked cAMP production mediated 
by the VIP2 wt and VIP2A(l-391) receptors 
a) Intracellular cAMP accumulation mediated by the VIP2 wt (D) and VIP2A(l-391) (0) 
receptors. Basal levels were 5±1 p mol/well. b) Total cAMP accumulation. basal levels were 
6±2 pmol/ well. c) The averaged rate of cAMP accumulation for each time point. The 
receptors were transiently expressed in COS 7 cells. cAMP accumulation was measured in 
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Fig. 4.4 Concentration-response curve for VIP-evoked [3H]inositol 
phosphate production mediated by the VIP2.d(l-391) receptor. 
The receptor was transiently expressed in COS 7 cells and stimuJated with the indicated 
concentrations of VIP for 60 minutes in the presence of 10 mM LiO. Basal values were 
10,334±317 dpm per well. The data are means±SEM from a typical experiment. n=3. 
Fig. 4.5 Concentration-response curve for P ACAP-38-evoked [3H]inositol 
phosphate production mediated by the VIP2.d(l-391) receptor 
The receptor was transiently expressed in COS 7 cells and stimuJated with the indicated 
concentrations of PACAP-38 for 60 minutes in the presence of 10 mM LiCl. A typical basal 
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Fig. 4.6 Time course of VIP-evoked [3H] inositol 
phosphate production mediated by the the VIP2 wt ([]) 
and VIP2A(l-391) (0 ) truncated receptors. 
VIP was added at a concentration of 1 JIM. The illustrated data are means±SEM from a 
typical experiment. There was no significant difference in basal values for cells expressing 
these receptors. A typical mean basal value was 11,000±200 dpm per well. n=3. 
Fig.4.7 Pertussis toxin-sensitive stimulation of PLC mediated by the 
VIP2 wt and VIP2A(l-391) receptors. 
There was no difference in basal [3H]inositol phosphate formation in VIP2 wt or 
V1P2A(l-391) receptor-expressing cells and data for these is expressed in a combined form. 
A typical basal activity was 10,314 (±280) dpm/ assay. Values are means± S.E.M.from 6 
separate determinations. (*)represents statistically significant inhibition of YIP-induced 
[3H]inositol phosphate production (p<O.OS by Mann-Whitney U-test). 
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Fig. 4.8 The effects of staurosporine on VIP-evoked [3H]IP production 
mediated by the VIP2 wt and VIP2A(l-391) receptors. 
The V1P2 wt (open bars) and V1P2A(1-391) (filled bars) receptors were transiently 
expressed in COS 7 cells. Staurosporine (1 JJM) was applied for the period of the assay (60 
minutes). Staurosporine had no significant effect on basal levels. A typical basal 
value was 8,187±485 dpm per well. n=6. (*) represents a statistically significant potentiation 
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Table 4.2 The effect of pertussis toxin pretreatment on PACAP-38 
stimulated [3H]inositol phosphate production mediated by wild-type and 
chimaeric receptors transiently expressed in COS 7 cells. 
% of control 
Receptor constructs response (±SEM) n 
Wild-type Receptors 
VIP1wt 55±3* 11 
VlP2wt 59±5* 11 
P ACAP wt long 101±3 6 
P ACAP wt short 104±3 6 
Chimaerics 
P1V 55±16* 6 
P3V 82±5* 6 
P5V 66±2* 4 
V7P 76±4* 8 
V5P!ong 108±15 6 
V5Pshort 113±15 6 
P!ong7V 102±6 6 
Pshort7V 113±9 6 
Cells were treated for 16 hours with 100 ng/ ml Pertussis toxin before stimulation with 
100 nM PACAP-38 for 60 minutes. The control response is 100 nM PACAP-38 stimulated 
[3HJinositol phosphate production measured without pertussis toxin pretreatment. (*) 
Represents statistically significant inhibition of PACAP-38 stimulated [3H]IP production (p 
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This diagram shows a line-up of the known VIP and PACAP receptor sequences, the residues in the VIP receptors 
focussed on in various site-directed mutagenesis studies are highlighted. 
Mutation of the red residues abolished [125J]VIP-binding and YIP-induced cAMP production. 
Mutation of the light blue residues reduced [125I]VIP-binding and increased the ECso for YIP-induced cAMP production. 
Mutation of the green residues had no effect on [125I]VIP binding. 
The underlined Asn residues are glycosylated and important for delivery of the receptor to the plasma membrane 
The dark blue residues are in the putative transmembrane regions as determined by a hydrophobicity plot. 






























Amino acid sequences of the known VIP and PACAP receptors 
MRPPSPPHVRWLCVLAGALACALRPAGSQAASPQHECEYLQLIEIQ •• RQQCLEEAQLENET.TGCSKMWDNLTCWPTTPRGQAVVLD 
MRPPSPLPARWLCVLAGALAWALGPAGGQAARLQEECDYVQMI EVQ •• HKQCLEEAQLERET.IGCSKMWDHLTCWPATPRGQVVVLA 
••••••••••• MRASVVLTCYCWLLV •• RVSSIHPECRFHLEIQE . • EETKCAELLSSQMENHRACSGVWDNITCWRPADIGETVTVP 
•••••••••• MRTLLPPALLTCWLLA •• QAARLQEECDYVQMI EVQ •• HKQCLEEAQLENET.IGCSKMWDNITCWRPANVGETVTVP 
•••.. ••..•• MRASVVLTCYCWLLV •. RVSSIHPECRFHLEIQE •• EETKCAELLSSQTENQRACSGVWDNTCWRPADVGETVTVPI 
• .•• • ••.•• MARVLQLSLTALLLP ••. VAIAMHSDCIFKKEQAMCLERIQRANDLMGLNESSPGCPGMWDNITCWKPAQVGEMVLVS 
•••••••••• MAGVVHVSLAALLLLP •• MAPAMHSDCIFKKEQAMCLEKIQRANELMGFNDSSPGCPGMWDNITCWKPAHVGEMVLVS 
CPLIFQLFAPIH •• • •••• • •• • ••• . • • •. • • • GYNISRSCTEEGWSQLEPGPYHIACGLNDRASSLDEQQQTKFYNTV 
CPLIFKLFSSIQ •.•••••••••••••••••••• GRNVSRSCTDEGWTHLEPGPYPIACGLDDKAASLDEQQ.TMFYGSV 
CPKVFSNFYSR .•.•.••..•.••• • • •••. • • • PGNISKNCTSDGWSETFP.DFIDACGYNDPEDES •• KI .. TFYILV 
CPKVFSNFYSK •••••••.•• •• ••••••••••• AGNISKNCTSDGWSETFP.DFVDACGYSDPEDES • • KI •. TFYILV 
CPKVFSNFYSR ••• • .•••••• • ••••..••••• PGNISKNCTSDGWSETFP . DFIDACGYNDPEDES .. KI . • SFYILV 
CPEVFRIFNPDQVWMTETIGDSGFADSNSLEITDMGVVGRNCTEDGWSEPFP.HYFDACGFDDYEPESGDQD •• YYYLSV 
CPELFRIFNPDQVWETETIGESDFGDSNSLDLSDMGVVSRNCTEDGWSEPFP . HYFDACGFDEYESETGDQD •• YYYLSV 
KTGYTIGYSLSLASLLVAMAILSLFRKLHCTRNYIHMHLFMSFILRATAVFIKDMALFNSGEIDHCSEAS ••• VGCK 




KALYTVGYSTSLATLTTAMVILCRFRKLHCTRNFIHMNLFVSFMLRAISVFIKDWILYAEQDSSHCFVST •• • VECK 







AVMVFFHYCVVSNYFWLFIEGLYLFTLLVETFFPERRYFYWYTI I GWGTPTVCVTVWAVLRLYFDDAGCWDMNDSTA 
AVMVFFHYCVVSNYFWLFIEGLYLFTLLVETFFPERRYFYWYTIIGWGTPTVCVTVWATLRLYFDDTGCWDMNDSTA 
TM3 TM4 
Fig. 4.9 Exchange sites used for construction of chimaeric VIP2/PACAP receptors. 
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The black bars labeUed TMl, TM3, TMS and TM7 indicate the position of the exchange sites used create the TMl, TM3, TMS and TM7 chlmaerics 
respectively. The residues identified by sin.gle letter code ace conserved between the VlP2 and PACAP receptors, the grey residues are aJso 
conserved in the other members of this receptor family. The grey bac indicates the site at which the signal sequence is cleaved fro m the N-tcrminus. 
Fig. 4.10 Carboxyl-tenninal truncation sites in the rat VIP2 receptor 
~ J
0D0€>00 €>€>00<D<D® lj1 , <D<fXVCU ®lj\ '"""CV®<Dfik ~®00, 
r v'i" !V'-' ~<D 1 
r.\ r c --fi'){i)r,).,-. V(i\,...,. €) ~ (i) . r-"'V&<XDf) '-'IV€fD ,<P.. 
,til ~ !< €)®. lifil(\)<D<il®(!) ~ ~ ~0 ~· ~ (!)<D®XiXD®® ~'Jf.V !%~~· c €Xf/iJ 
G) r 1 ' • ....£><£0 €>' r' <D • <!.r~ c W r l Y I €)€> 0 ~ L I T 0<!.)(!) @ W l® €X!>0 @.._ r.l._ I (i)_ 
\U ' \!1 
0<!) C C L 6L (!) 
04 l \!:.) ~ 
diJ'f"' c.f:! ' ~ ' ' ' 0 
0
, ~ , rv0 , G , I 4 ®~~ G~~ ~~ : : c ~~~€) I (!)(!)~r 
1 
@ @v 4 , ® • €!9,€)0 
00c I Q~® ~" , G~ (f)®'J:00 
L ..-::..<J.T I 0\IU G)~ 
t ! I L I \!:I /t-,0~ 
EXTRAO!I..I..UI.AR 
- {!) (: ' - " l INTJIACP.I.I.III.i\R ~ C ~ ~ ~I o'" (U €) 
~<D€) 'G G"Y.\"'"',-.,. ~-,..(o) r# ~I.'IY'l0 <D L r l L T 1 '"'~<D(!)~_r I  y l I L 
€) (i) 
<U (!)(o)__ €>0. €)®(!) (!) 
€2 _(i} '""Wt:"\ 0 (!) €) ~<i)® ~ ~ v<D r-4!) 0 rfJ c , 
, <D~ _(i)€J iD<D€1--' ®G®G)(!J 1 L 391 ~(!)QJ 
The black bars indicate the positions at which the receptor was C-terminally truncated to create 
the VIP2i\(1 -391) and VIP2£\(1-376) mutant receptors. The residues identified in black are the 
carboxyl terminal residues of the truncated receptors. 'Y' indicates the s ite of a putative N-linked 
glycosylation site. The grey bar indicates the site at which the signal sequence is cleaved from the 
N-terminus. 
Chapter 5 
Characteristics of native VIP2 
receptors in rat tissues 
5.1 Introduction 
This study u tilised the expression of various receptor constructs in a 
heterologous expression system as a means of investigating the contribution made 
by specific VIP2 receptor domains to its signalling characteristics. In order to make 
such a study meaningful, the signalling characteristics of the wild-type VIP2 
receptor must be understood. Chapters 3 and 4 dealt with wild-type receptor 
signalling and the role of specific receptor domains. We have established that in a 
heterologous expression system (transient expression of the receptor in COS 7 cells) 
the VIP2 receptor mediated the stimulation of adenylate cyclase and PI hydrolysis, 
the latter occurring by a partially PTx-sensitive mechanism. The stimulation of PI 
hydrolysis was found to be partially attributable to calcium release-activated 
calcium influx (CRACi) and it is this part of the process that appears to be largely 
dependent on a PTx-sensitive G protein. The logical progression of this work 
required the examination of VIP2 receptor signalling in its native environment to 
ensure that our findings in expression systems were consistent with its physiological 
function. 
VIP is recognised as having an important role to play in the regulation of 
pituitary function. YIP-stimulated PRL release has been demonstrated in vivo and 
in vitro from the pituitary and from clonal cell lines {Vijayan et al., 1979; Kato et 
al., 1978; Gourdji et al., 1979; Enjalbert et al., 1980; Murlarkey et al., 1981; Onali et 
al., 1983; Kato et al., 1984). PACAP stimulation of the VIP2 receptor in GH3 cells 
also causes GH release (Murakami et al., 1995). VIP- and PACAP-like 
immunoreactivity have been found in rat hypothalamic neurons projecting to the 
external zone of the median eminence (Koves et al., 1991). The hypophysial portal 
blood in rat contains high levels of VIP, in the range 400-520 pM (13-17 fold greater 
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than in peripheral plasma: Shimatsu et al., 1981) and PACAP-38levels (54-107 
pM) were found to be 2-4 fold of peripheral levels (Dow et al., 1994). 
The GH3 cell line was therefore chosen for the examination of signalling 
mediated by the VIP2 receptor in its native environment. This cell line was derived 
from a transplantable rat pituitary tumour in the late 1960's (Tashjian et al., 1968). 
The anterior pituitary has been observed to express a relatively high number of VIP2 
receptors (Usdin et al., 1994; Rawlings et al., 1995). The anterior pituitary contains 
5 types of secretory cell; gonadotrophs, somatotrophs, lactotrophs, corticotrophs 
and thyrotrophs. GH3 and GH4C1 cells secrete growth hormone(GH) and 
prolactin(PRL) which means that they have characteristics of both lactotrophs and 
somatotrophs. Pharmacological studies indicated that somatotrophs express a VIP 
receptor (Deutsch & Sun, 1992; Rawlings et al., 1995; Murakami et al., 1995). GH3 
and GH4C1 cells express TRH, somatostatin (Tashjian, 1979) and VIP2 receptors 
(Rawlings et al. 1995) but are not thought to express functional GHRH receptors or 
the D2 receptors normally found in lactotrophs (Zeytin et al., 1984; Bresson et al., 
1991). Of the secretin/calcitonin/PTH/PTHrP receptor family only the VIP2 
receptor mRNA is expressed in GH3 cells (personal communication, E.M.Lutz) and 
GH4C1 cells (Rawlings et al., 1995). cAMP production, phosphoinositide 
hydrolysis and nitric oxide production mediated by the VIP2 receptor in GH3 cells 
were investigated. 
VIP receptors have long been associated with relaxation of smooth muscle, 
in the gut, airway and the vasculature. Nitric oxide is also associated with the 
regulation of blood flow and arterial pressure (Umans, 1995). Murthy & Makhlouf 
(1994) described VIP receptor-mediated activation of nitric oxide synthase(NOS) in 
dispersed gastric smooth muscle cells providing direct evidence of nitric oxide 
production as a result of VIP receptor activation. An isoform of constitutive NOS 
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has been cloned from GH3 cells (Wolf & Gatto, 1992) making it an appropriate cell 
line to investigate VIP2 receptor-mediated stimulation of NOS. 
Radioimmunoassay and immunohistochemical methods have shown VIP 
innervation of cerebral blood vessels (Larsson et al., 1976; Edvinsson et al. , 1981). 
VIP caused vasodilation of isolated cerebral artery or vein upon direct application 
and increased cerebral blood flow when applied intra-arterially to baboons 
(Edvinsson et al., 1981). In rat, PACAP and VIP have similar potencies for 
decreasing systemic arterial pressure (Nandha et al., 1991; Absood et al., 1992) and 
relaxing tail or mesenteric arteries (Absood et al., 1992; Huang et al., 1993). The 
ability of PACAP-27, PACAP-38 and VIP to stimulate adenylate cyclase in rat 
cerebral microvessels has also been demonstrated (Huang & Rorstad, 1983; 
Kobayashi et al., 1994). Anzai et al. (1995) observed similar concentration-
dependent relaxations in canine basilar arteries and rat intracerebral arterioles on 
addition of PACAP-27, PACAP-38 and VIP. It was not known however which 
receptors were present in blood vessels. In this study RT-PCR was used to identify 
the YIP-responsive receptors present in a rat cerebral microvessel preparation. 
5.2 Specific Methodology 
Cells- GH3 cells were cultured as described in Section 2.2.1. The cells were not 
allowed to reach confluency in the flask before being passaged and the growth 
medium was changed every day in order to minimise any autocrine effects. 
Animals- COB-Wistar rats were maintained as desribed in Section 2.2.9. 
Ligand-binding- Homologous displacement of Hgand-binding was carried out on 
membranes prepared from GH3 cells, using [125J]helodermin at 37°C for 10 minutes, 
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as described in Section 2.2.7. GTP)'S modulation of ligand binding was also 
performed on membranes prepared from GH3 cells using [125J]helodermin as 
described in Section 2.2.7. 
Protein assay - Coomassie protein assay reagent was used to determine the protein 
level in samples (see section 2.2.8). 
Second messenger assays- Intracellular cAMP production over a 10 minute 
stimulation period was measured in whole cells by radioimmunoassay as described 
in Section 2.2.5. 
[3H]inositol phosphate production was used as a measure of PLC activity. The 
cells were stimulated for 60 minutes with agonist before separation of [3H]inositol 
phosphates by anion exchange chromatography as described in Section 2.2.4. 
Nitric oxide synthase activity was measured by the conversion of L-[3H]arginine to 
L-[3H]citrulline over a 10 minute stimulation period. [3H]citrulline production was 
measured by cation exchange chromatography as described in Section 2.2.6. 
Microvessel preparations- A crude preparation of cerebral rnicrovessels was 
prepared from the cerebral cortex of male Cob-Wistar rats (see Section 2.2.9). The 
cerebral cortices underwent homogenisation, centrifugation and filtering steps in 
order to isolate the rnicrovessels, the presence of which was confirmed by 
microscopy (see Section 2.2.10). 
RNA extraction- RNA was extracted from rnicrovessel preparations using the 
RNAzol B isolation of RNA kit (Ambion lnc.: see Section 2.2.11). 
Reverse transcriptase-medjated polymerase chain reaction - The Strata gene RT-PCR 
kit was used to amplify eDNA transcribed from mRNAs extracted from the 
rnicrovessel preparation. The resultant fragments were separated by agarose gel 
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electrophoresis and the ethidium bromide-stained bands visualised using the UV 
transilluminator (see Section 2.2.12). Primers for the rat VIPt, VIP2, PACAP and 
ml/m3 muscarinic receptors were used as detailed below. PCR reactions were set 
up in 100 J..ll volumes including 5 111 first strand reaction mix and 15 pmols of each 
of the primers. The reaction was put through 30 cycles of 94°C (1 min), 57°C (1 
min) and extension at 72°C (2 min). After PCR, 10 111 samples were analyzed by 
electrophoresis (see Section 2.2.12). 
m1/m3 muscarinic receptor primers: 37484 [5' 
GCAACGCCTCTGTCATGAATCT], 37485 [5' CGAGCTGCCTTCITCTCCTTGA] 
VIP1 receptor primers: 338 [5'CAACAGCGGGGAGA TAGACC], 19181 
[5'GAAGACCATITTCACCTGGG] 
VIP2 receptor primers: 9502 [5'GAA TGCCGGTITCA TCTGG], 8670 
[5'GGAGA TGAGITCCTGGCTTG] 
PACAP receptor primers: 32204 [5'CAGAAGCTTCAGTCCCCAGACATGG], 
32205 (5'AGTGAA TTCCAAAGAGTGGGATGAG] 
Data analysis -Curve fitting was performed by the non-linear curve-fitting 
programme, P-fit (Elsevier Biosoft, Cambridge). 
5.3 Results 
5.3.1 Ligand binding studies to determine the expression level and 
characteristics of the endogenous VIP2 receptor in GH3 cells 
Homologous displacement of (125I)helodermin binding to GH3 cell 
membranes 
In radioligand-binding experiments, homologous displacement of 
[125I]helodermin from GH3 cell membranes (see 'Materials & Methods' section 2.2.7) 
was used to measure the receptor binding capacity of the system (Bmax) and the 
147 
affinity of the target receptor for helodermin (lCso) using the method of Swillens 
(Swillens, 1993). [125J]helodermin was used as a radioligand because of its 
availability (helodermin was iodinated on site), as well as its reported selectivity 
and affinity at the VIP2 receptor (Robberecht et a l., 1988). Lutz et al. (1993) found 
helodermin to be equipotent with VIP, PACAP-38 and PACAP-27 for cAMP 
production mediated by the rat VIP2 receptor. Available evidence strongly suggests 
that the relevant receptor expressed in GH3 cells is exclusively the VIP2 type. 
Rawlings et al. (1995) found GH4C1 cells to express mRNA for the VIP2 receptor 
and not the VIP1 or P ACAP receptors. The presence of the VIP2 receptor and not 
VIP1 or PACAP receptors in GH3 cells has also been confirmed by RT-PCR (E.M. 
Lutz, personal communication). Homologous displacement of [125J]helodermin 
occurred with an ICso value of 0.35±0.09 nM and a Bmax of 22.06±1.42 fmol/mg 
protein (see Figure 5.1). The samples contained 197±81-lg of protein/100 111 and 
27,178±1030 cpm of a 651!Ci/ml solution of [125J]helodermin was added to each. 
Specific binding (displaced by 1 J!M helodermin) was 678±43 cpm. A standard 
curve was generated relating cell numbers to protein content of the sample (not 
shown) which allowed an estimated figure for receptors per cell to be calculated 
based on one molecule of helodermin binding per receptor. The GH3 cells were 
found to express approximately 3,670±280 VIP2 receptors per cell . 
GTPyS modulation of [125I]helodermin binding to the VIP2 
receptor in GH3 cell membranes 
In order to demonstrate the direct interaction of G proteins with the VIP2 
receptor in GH3 cells and to investigate the possibility of an interaction with a PTx-
sensitive G protein, the effect of GTP.yS on [125J]helodermin binding to GH3 cell 
membranes was investigated. To facilitate the measurement of GTP'y$ 
-displacement of specific [125J]helodermin binding, higher specific activity 
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[125J]helodermin was used. The iodinated peptide was at a stock concentration of 
800 ~Ci/ml as opposed to 65 ~Ci/ml. The addition of 317,331±2,828 cpm to each 
sample produced a specific binding (displaced by 1 ~M helodermin) of 8,965±440 
cpm (see Figure 5.2). A concentration of 10 ~M GTP-yS caused the dissociation of 
69.0±7.8% of the specific binding (6,186±698 cpm). Membranes prepared from cells 
treated for 16 hours with 100 ng/ml PTx were also used. The maximal GTP-yS-
stimulated dissociation of [125J]helodermin from PTx-treated cell membranes was 
53.5±6.3% of the specific binding (4,800±566 cpm). Despite the curves appearing 
to be different, the decrease in [125J]helodermin binding stimu Ia ted by GTP-yS from 
membranes treated with PTx was only significantly different to the decrease 
observed from the control membranes at a single point (P<0.05, Mann-Whitney U 
test, n=6). 
In summary, it appears that the VIP2 receptor in GH3 cells interacts with G 
proteins as demonstrated by the GTPyS modulation of ligand binding but it is 
unclear from these data whether there is any sizeable role for a PTX-sensitive G 
protein. 
5.3.2 Agonist-evoked cAMP production mediated by the VIP2 receptor in 
GH3 cells 
Concentration-response experiments were carried out for VIP-, P ACAP-38-, 
PACAP-27- and helodermin-evoked cAMP production. A concentration-
dependent stimulation of cAMP production was observed for concentrations of VIP 
from 0.1 nM - 1 ~M (see Figure 5.3). The basal level was 3.98±0.64 pmol/ml cAMP 
and the maximum stimulation 8.49±0.63 pmol/ml (2.13±0.16 fold of basal control 
stimulation). The ECso value was 2.86±1.04 nM. A concentration-dependent 
stimulation of cAMP production was also observed for concentrations of PACAP-
38 from 0.1 nM - 100 nM. The basal level was 3.90±0.14 pmoJ/ml cAMP and the 
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maximum stimulation 9.56±0.65 pmol/ml (2.45±0.17 fold of basal control 
stimulation). The ECso value was 3.77±1.16 nM. A concentration-dependent 
stimulation of cAMP production was observed for concentrations of P ACAP-27 
from 0.1 nM - 100 nM. The basal level was 4.63±0.02 pmol/ml cAMP and the 
maximum stimulation 9.32±0.54 pmol/ml (2.01±0.12 fold of basal control 
stimulation). The ECso value was 2.83±0.98 nM. A concentration-dependent 
stimulation of cAMP production was observed for concentrations of helodermin 
from 0.1 nM -100 nM. The basal level was 3.72±0.59 pmol/ml cAMP and the 
maximum stimulation 8.53±0.41 pmol/ml (2.29±0.11 fold of basal control 
stimulation). The ECso value was 0.44±0.20 nM. 
A clear concentration-dependent stimulation of cAMP production was 
observed for all these agonists. VIP, P ACAP-38, P ACAP-27 and helodermin 
stimulated similar maximal levels of cAMP production. As expected, VIP, 
P ACAP-38 and P ACAP-27 were clearly equipotent for cAMP production mediated 
by the VIP2 receptor in GH3 cells. However, helodermin appeared to be slightly 
more potent than the other agonists. In SUP-Tl human lymphoblast cells, which 
express the VIP2 receptor, Robberecht et al. (1988) also observed helodermin to be 
more potent than VIP for AC stimulation and inhibition of [125J]-acetyl-HisLVIP 
binding. 
5.3.3 Agonist-evoked [3H]inositol phosphate production mediated by the 
VIP2 receptor in GH3 cells 
Concentration response experiments were carried out for VIP- and 
P ACAP-38-evoked [3H]inositol phosphate production mediated by the VIP2 
receptor in G H3 cells (see Section 2.2.4). 
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VIP stimulated a concentration-dependent increase in [3H]inositol 
phosphate production in GH3 cells over a 30 nM- 3 J.!M range (see Figure 5.4(a)). 
The maximal stimulation was 1.48±0.14 fold of basal control and the ECso value 
179±103 nM. P ACAP-38 also stimulated a concentration-dependent increase in 
[3H]IP production in GH3 cells over a 30 nM - 1 J.!M range (see Figure 5.4(b)). The 
maximal stimulation was 1.37±0.11 fold of basal control and the ECso value 71±36 
nM. In order to assess whether [3H]IP production mediated by the VIP2 receptor in 
GH3 cells was subject to desensitisation, the accumulation of 1 J.!M P ACAP-38-
evoked [3H]IP production was measured at various times over an 80 minute period 
(see Figure 5.5). The maximum response was 1.92±0.04-fold of basal control after 
80 minutes. The response appeared to be linear over the first 60 minutes, although 
time points earlier than 10 minutes would be advantageous in order to identify any 
early peaks of IP production which may occur. 
Despite reports to the contrary, the VIP2 receptor is clearly able to stimulate 
PLC as well as AC activity in GH3 cells. VIP and P.ACAP-38 had similar ECsos for 
[3H]IP production and, as observed in COS 7 cells, the time-dependent 
accumulation of [3H]IP production mediated by the VIP2 receptor was not subject 
to any rapid desensitisation process. 
5.3.4 Agonist-evoked [3H]citrulline production mediated by the VIP2 
receptor in GH3 cells 
The VIP2 receptor has been associated with nitric oxide (NO) production in 
certain cell types. The L-arginine to L-citrulline conversion method of measuring 
NO production was used (see Section 2.2.6) to investigate the stimulation of nitric 
oxide synthase (NOS) mediated by the VIP2 receptor in GH3 cells. 
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The calcium ionophore, ionomycin, was used to demonstrate the ability of 
Ca2+ -influx to stimulate NOS activity in GH3 cells (see Figure 5.6). At a 
concentration of 10 )1M, ionomycin caused a stimulation of NOS activity equivalent 
to an increase of 11,971±1092 dpm/assay over the basal value of 16,124±379 
dpm/assay. The non-specific G protein-activator, AlC13/NaF, caused a 
stimulation equivalent to 50±2% (5,986±215 dpm/assay) of the ionomycin-
stimulated response. PACAP-38 at a concentration of 300 nM elicited a response 
equivalent to 36±7% (4310±778 dpm/assay) of the ionomycin stimulated-response. 
PACAP-38 at a concentration of 300 nM when applied with 10 11M ionomycin 
appeared to cause no increase in [3H]citrulline production over that stimulated by 
10 11M ionomycin alone (96±4% of the ionomycin-stimulated response; 11,492±479 
dpm/ assay). A concentration-response experiment was carried out to investigate 
the characteristics of VIP -evoked [3H]citrulline production in GH3 cells. VIP caused 
a concentration-dependent increase in [3H]citrulline production over the 
concentration range 1-300 nM (see Figure 5.7). The maximal stimulation was 
1.50±0.04 fold of basal control. The ECso value was 24.0±12.8 nM. As a means of 
confirming that the agonist-evoked [3H]citrulline production was due to NOS 
activity, the effect of the NOS inhibitor, N-nitro-L-arginine (L-NNA), was tested on 
111M VIP -evoked [3H]citrulline production in GH3 cells (see Figure 5.8). Typical 
basal values were 18,139±1,480 dpm/assay and the 111M YIP-evoked response 
1.36±0.01 fold of basal control. L-NNA at concentrations of 10 and 100 11M 
caused a slight decrease in basal levels of [3H]citrulline production but this decrease 
was not statistically significant (Mann-Whitney U-test). Treatment of the cells 
with 10 )1M L-NNA inhibited 1 )1M VIP-evoked [3H]citru1line production (0.76±0.06 
fold of basal control) as did 100 )1M L-NNA (0.73±0.01 fold of basal control). 
In order to determine whether cAMP-dependent protein kinase(PKA) had a 
role to play in VIP-evoked NO production, the cells were treated with the PKA 
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inhibitor, KT-5720 (see Figure 5.9). At a concentration of 1J.JM, KT-5720 had no 
effect on basal [3H]citrulline production (0.96±0.10 fold of basal control). 1 J.l.M 
VIP stimulated a 1.34±0.03 fold of basal control response which became 1.01±0.07 
fold of basal control stimulation after treatment of the cells with 1 J.l.M KT-5720 
(p<0.05, Mann-Whitney U-test). 
The VIP2 receptor in GH3 cells has therefore been demonstrated to be 
coupled to NOS stimulation. This stimulation is specifically blocked by an NOS 
inhibitor (L-NNA). Ionomycin treatment demonstrated that calcium influx alone is 
sufficient to stimulate NOS activity. G protein activation by AlClJ/NaF also 
stimulates NOS activity. PACAP-38 and ionomycin treatment of cells did not 
produce any evidence of an additive effect or synergism suggesting that they do not 
represent separate mechanisms for stimulating NOS. PKA appears to play a 
positive role in YIP-stimulated NOS activity. It would be of interest to determine 
whether PLC, Ca2+ and/ or PKC have a role to play in the regulation of YIP-
stimulated NOS activity. 
5.3.5 VIP receptors in the cerebral vasculature 
A number of pharmacological and binding studies have provided evidence 
of the presence of VIP receptors in the cerebral vasculature. ln order to identify 
which specific receptors are present RT-PCR was performed (see Section 2.2.11 and 
2.2.12) on the mRNA extracted from a crude microvesseJ preparation from rat 
cerebral cortex as described in Section 2.2.10. 
The results clearly show the presence of mRNA for both the VIPt and VIP2 
receptors in this preparation. There was strong evidence for the presence of ml-
and m3-muscarinic receptors in human and bovine brain m icrovessels (Linville & 
Hamel, 1995). Primers for these receptors were therefore used as a positive control 
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and the presence of mRNA for the muscarinic receptors is clearly demonstrated in 
the microvessel preparation (see Fig. 5.10). 
5.4 Discussion 
The VIP2 receptor is an important regulator of pituitary gland function and 
its presence in the GH3 clonal cell line (as the only VIP /P ACAP receptor) provides 
a valuable opportunity to study VIP2 receptor-mediated signalling in its native 
environment. In such conditions the receptor is not over-expressed and the G 
protein complement should be appropriate to its function. 
5.4.1 VIP and the anterior pituitary 
VIP has been shown to stimulate cAMP production in GH3 cells (Gourdji et 
al., 1979; Onali et al., 1983). VIP stimulates pituitary prolactin release in vivo in 
humans (Kato et al., 1984) and rats (Kato et al., 1978) and in vitro in cultured 
normal human pituitary tissue (Marlarkey et al., 1981), normal rat hemipituitaries 
(Enjalbert et al., 1980) and in the GH3 cell line (Gourdji et al., 1979; Onali et al., 
1983). A physiological role for VIP and PACAP in anterior pituitary cell function 
is likely since immunoreactive VIP and P ACAP are present in the neurons of the 
hypothalamic PVN that project to the external zone of the median eminence (Mezey 
& Kiss, 1985; Koves et al., 1991) and VIP immunoreactivity in hypophysial portal 
blood is considerably greater than in peripheral blood (Said & Porter, 1979). VIP 
concentrations measured by RIA in the hypophysial portal blood after 
hypophysectomy were 0.4 nM- 0.52 nM whereas the VIP concentration in 
peripheral plasma was less than 0.03 nM in most animals (Shimatsu et al., 1981). 
5.4.2 GH3 cells 
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GH3 cells, are an immortalised clonal cell line, that has both somatroph and 
lactotroph characteristics. Boockfor et al. (1985) found that GH3 cell cultures 
contained twice as many GH secreting (somatotroph-like) cells as PRL-secreting 
(lactotroph-like) cells and that this was dependent on the influence of autocrine and 
other growth factors. GH3 cells do not express the dopamine receptors (D2) 
normally found in lactotrophs and may not express functional GHRH receptors 
typical of somatotrophs either (Zeytin et al., 1984; Bresson et al., 1991). Missale et 
al. (1994) found that nerve growth factor(NGF) treatment caused the differentiation 
of GH3 cells into lactotrophs as opposed to somatotrophs. The differentiated cells 
expressed the lactotroph-specific D2 dopamine receptor and the spontaneous 
secretion of PRL was increased in these cells whereas GH secretion was inhibited. 
The VIP2 receptor in GH3 cells 
Bjoro et al. (1987) investigated GH4C1 cells and found VIP receptors present 
at the level of 9,000 per cell. TRH receptors were present at the level of 135,000 per 
cell in GH3 cells (Hinkle & Tashjian, 1974) and bombesin receptors at the level of 
3,600 per cell (Westendorf & Schonbrunn, 1983). ln this study, homologous 
displacement of [125I]helodermin binding produced an estimate of 3,700 receptors 
per cell in the GH3 cell line (see Figure 5.1). Initially VIP was believed to be of 
hypothalamic origin (Emson et al., 1978; Simms et al., 1980) but it has also been 
found to be synthesised within the rat anterior pituitary gland (Arnaout et al., 1986; 
Segerson et al., 1989). There is also evidence that VIP modulates basal PRL release 
in an auto- or paracrine manner in normal pituitary and GH3 cells (Hagen et al., 
1986; Nagy et al. 1988). It is therefore possible that VIP could exert an autocrine 
effect on the expression level of VIP receptors and aspects of their signalling 
behaviour. The conditions under which the cells were cultured were designed to 
minimise any autocrine effects on VIP2 receptor expression and function but this is 
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not to say that the expression level could not be increased by altering these 
conditions. It is interesting to note that the VIP2 receptor mRNA level in the 
pituitary is significantly higher in pregnant rats than in normal females (Usdin et al., 
1994) suggesting that VIP2 receptor-mediated stimulation of prolactin release is 
physiologically important and that the receptor number is indeed increased in vivo 
by the appropriate physiological cues. 
5.4.3 Mechanisms of VIPz receptor-stimulated hormone secretion 
VIP has been observed to stimulate cAMP production in pituitary cells 
(Robberecht et al., 1979; Borghi et al., 1979; Onali et al., 1981) and YIP-stimulated 
prolactin release in GH3 cells is thought to occur as a result of this AC activation. 
Tixier-Vidal & Gourdji (1981) identified a role for adenylate cyclase and PKA in 
YIP-stimulated prolactin release in pituitary cells. Gourdji et al. (1979) however, 
found that VIP and TRH had an additive effect on prolactin secretion from GH3 
cells whereas TRH had no effect on cAMP production, indicating that TRH 
stimulates prolactin secretion by a mechanism other than AC stimulation. VIP was 
also found to promote a pattern of phosphorylation in rat pituitary cell lines that 
was distinct from that stimulated by TRH and similar to that stimulated by 
dibutyryl cAMP, 8-bromo-cAMP or cholera toxin treatment (Drust et al., 1982; 
Sobel & Tashjian, 1983). These phosphorylated proteins are presumed to be 
involved in the mechanism of prolactin release. 
TRH was not thought to cause AC activation but Paulssen et al. (1992) 
found that TRH weakly stimulated cAMP production in GH3 cells. The relevant 
aspect ofTRH receptor-mediated signalling however is likely to be something other 
than AC stimulation, since it is primarily a PLC-stimulating receptor. Of the six 
prolactin secretagogues (VIP, TRH, bombesin, epidermal growth factor(EGF), insulin 
and phorbol-12,13-dibutyrate(PDBu)) tested by Derflinger & Schonbrunn (1983) on 
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GH4C1 cells only VIP raised cAMP levels. Onali et al. (1983) also concluded that 
there was probably a cAMP-independent mechanism at work and evidence of a 
stimulatory cAMP-independent mechanism was also provided by Coleman & 
Bancroft (1993) who found that prolactin gene promoter activity was stimulated by 
PACAP without any detectable rise in cAMP production. Lin et al. (1996) 
identified a synergistic activation of cAMP response element-mediated prolactin 
gene expression by Ca2+ and cAMP in GH3 cells. 
The levels of agonist-evoked VIP2 receptor-mediated cAMP production in 
GH3 cells were very much lower than the equivalent levels in COS 7 cells (see 
Chapter 3 and Figure 5.3), Gourdji et al. (1979) however, observed YIP-evoked 
cAMP production levels in GH3 cells at similar levels to those described in this 
study. The ECsos for cAMP production mediated by the VIP2 receptor in GH3 cells 
were sligh tly higher than those for cAMP production in COS 7 cells. This is to be 
expected since the G protein isoforms present and ratio of receptors to G proteins 
may well be very different. 
The possibility of a cAMP-independent pathway being involved in the 
regulation of agonist-evoked VIP2 receptor-mediated prolactin secretion from GH3 
cells is also of interest since it has been demonstrated in COS 7 cells that this 
receptor is capable of stimulating PI hydrolysis and Ca2+ channel activity as well as 
cAMP production (see Chapter 3). Rawlings et al. (1995) observed PACAP-evoked 
cAMP production and Ca2+ oscillations but no stimulation of PI hydrolysis in GH3 
and GH4C1 cells. However the authors make the point that the methods used for 
measuring Ca2+ fluctuations are much more sensitive than those for measuring 
inositol phosphate production. The present investigation has demonstrated a 
modest stimulation of PLC activity mediated by the VIP2 receptor in GH3 cells that 
is not dependent on cAMP production (see Figure 5.4). This response may have a 
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role to play in the modulation of hormone release from the pituitary and clonal cell 
lines through the activation of PKC and/ or an increase in intracellular Ca2+ 
concentration and may also be important in vivo in other cell types. 
Release-inducing hormones are thought to cause negligible inhibition of AC 
(Gordeladze et al., 1988; Offermanns et al., 1989). The activation of receptors 
which have an inhibitory influence on YIP-stimulated prolactin secretion tend to 
reduce cAMP production e.g. the somatostatin receptor reduces cAMP production 
and inhibits YIP-stimulated prolactin release (Chen et al., 1993) and Van Chuoi et 
al. (1993) have shown that GnRH-associated peptide(GAP) inhibits YIP-stimulated 
Ca2+ transients and cAMP production via a PTx-sensitive G protein and thereby 
inhibits YIP-stimulated prolactin secretion from GH3 cells. G0 1, G0 2, Gi2 and Gi3 
have all been detected in GH3 cell membranes (Rosenthal et al., 1988; Offermanns et 
al., 1991; Paulssen et al., 1992). Kleuss et al. (1991) identified G0 2 as the G protein 
activated by the somatostatin receptor in GH3 cells, whereas Paulssen et al. (1992) 
identified the G protein as most likely being Gi2· Gi2 is thought to be involved in 
receptor-mediated inhibition of AC (Simonds et al., 1989) and has been reported to 
be a target for PKC (Katade et al., 1985). 
Secretion of hormones from pituitary cells is believed to be reliant on Ca2+ 
influx which can be acheived by a number of mechanisms. The LHRH, TRH, AT -II 
and vasopressin receptors all stimulate PI hydrolysis and hormone secretion from 
pituitary and other cell lines as a result of [Ca2+] elevation. L-type Ca2+ channels 
have been shown to be directly phosphorylated by both PKA and PKC (Curtis & 
Catterall, 1985; Nunoki et al., 1989). Armstrong & Kalman (1988) have shown that 
this facilitates the activation of the channels. Gollasch et al. (1993) described TRH 
receptor-mediated stimulation of L-type Ca2+ channels in GH3 cells as a result of 
PKC activation (it was blocked by H-7, staurosporine and calphostin C) and an 
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additional direct activation of the channel by Gi2 (with a small contribution from 
Gi3)· So in this scenario, Gi2 is implicated in the stimulation of hormone secretion. 
It is possible that PKC phosphorylation of the channel is required for its activation 
by Gi2· Alternatively, phosphorylation of the G protein itself by PKC might modify 
its activity such that it gained the ability to interact with and activate the Ca2+ 
channel. 
GH release can also be stimulated by GHRH (the GHRH receptor is 
positively coupled to AC stimulation) and inhibited by somatostatin (Frohman & 
Jansson, 1986). This mechanism also involves cAMP and an increase in 
intracellular Ca2+ concentration. Increased cAMP levels have been suggested to 
cause the opening of aNa+ -permeable ion channel, the membrane depolarises as a 
result, and Ca2+ enters through voltage-gated Ca2+ channels which promotes the 
release of GH via exocytosis (Lussier et al., 1991; Naumov et al., 1994). 
The AC and PLC systems seem to converge by causing the activation of L-
type Ca2+ channels and stimulating Ca2+ influx which in turn facilitates exocytosis 
and the release of hormone. Ptx-sensitive G proteins are implicated both in the 
mhibition of hormone secretion, by reducing AC activity, and the stimulation of 
hormone secretion, by activating L-type Ca2+ channels. An interesting question 
regarding the regulation of hormone secretion in pituitary cells .is whether there are 
different mechanisms negatively regulating hormone secretion stimulated by 
receptors which are primarily coupled to AC compared to responses of those which 
are primarily coupled to PLC. 
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The negative regulation of hormone secretion 
As described above, the cAMP-dependent stimulation of hormone secretion 
can be inhibited by the activation of receptors coupled to inhibitory G proteins 
(Onali et al., 1983; Kleuss et al., 1991, Van Chuoi et al., 1993). It has been 
established that the secretion of prolactin from the anterior pituitary is under tonic 
inhibitory hypothalamic control mediated by dopamine (Ben-Jonathan, 1985). 
Dopamine or its receptor agonists inhibit the release and the expression of prolactin 
as well as lactotroph proliferation (Shaar & Clemens, 1974; Pawlikowski et al. 
1978). A physiological stimulus such as suckling causes an immediate drop in 
dopamine levels in the rat anterior pituitary(Chiocchio et al. 1979; Selmanoff & 
Wise, 1981; Demarest et al., 1983) and this is a requirement for prolactin release 
(Grosvenor, 1980). Investigations by Balsa et al. (1996) revealed that DA inhibits 
both the expression of VIP mRNA and the secretion of VIP from anterior pituitary 
cells thereby preventing the autocrine activity of VIP in stimulating prolactin release. 
In vitro studies have confirmed that prolactin release is stimulated after short term 
exposure to DA in superperfused hemipituitaries (Fagin & Neill, 1981) and 
aggregated (Denef et al., 1984) or dispersed (Martinez et al., 1988) anterior 
pituitary cells. VIP is a well-established prolactin-releasing factor (Kato et al., 
1978; Ruberg et al., 1978; Enjalbert et al., 1980), which has also been shown to 
modulate IGF-I- (Lara et al.,1994) and TRH-stimulated prolactin-release from 
anterior pituitary cells 
The role of nitric oxide 
Duvilanski et al. (1995) investigated the stimulation of prolactin release 
from hemipituitaries by VIP and substance P. These authors found that nitric 
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oxide synthase(NOS) inhibitors stimulated prolactin release and that the effect was 
additive with that of VIP. Substance P caused a small increase in prolactin release 
without being affected by NOS inhibitors. The nitric oxide-donor, sodium 
nitroprusside(NP), was found to inhibit prolactin release. Dopamine- and atrial 
natriuretic fac tor-evoked inhibition of prolactin release was inhibited by NOS 
inhibitors. LH release was unaffected. NP was found to increase cGMP levels in 
the anterior pituitary and to reduce cAMP levels. The guanylate cyclase inhibitor, 
LY 83583, an.d the phosphodiesterase inhibitor, 3-isobutyJ-1-
methylxanthin.e(IBMX), both blocked the inhibitory effect of NP on prolactin release, 
the application of 8-bromo-cGMP mimicked the effect of NP on prolactin release. 
Nitric oxide therefore appears to inhibit prolactin release by stimulating guanylate 
cyclase activity. The authors attribute the effects of IBMX to the inhibition of 
cAMP-specific phosphodiesterases(PDEs) and the resultant accumulation of cAMP 
which is believed to have the opposing effect to cGMP in this system. IBMX 
however, is an inhibitor of a broad spectrum of PDEs and the authors did not 
present any data on the effects of IBMX on cAMP and cGMP levels in these cells. 
Duvilanski et al. (1996) suggest that dopamine may utilise cGMP as a component 
of the mechanism by which it inhibits prolactin secretion. However those authors 
showed that it caused only a small increase in NO p.roduction and failed to 
demonstrate that it causes any increase in cGMP levels at all. 
Hartt et al. (1995) however found that cGMP was stimulatory for GH 
release. GH release was stimulated by C-type natriuretic peptide (CNP), which 
stimulates a membrane-bound form of guanylate cyclase, and NP, a NO donor, 
which indirectly stimulates soluble guanylate cyclase. No increase in cAMP was 
observed in response to CNP and intracellular [Ca2+] was slightly reduced. One 
major difference between these studies is that those which found cGMP to be 
inhibitory were carried out on hemipituitaries whereas the study by Hartt et al. 
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(1995) was performed on a static monolayer culture of dispersed pituitary cells. 
The enzymatic digestion process and dispersal of the cells is likely to have 
profound effects on the interactions between the pituitary cells. 
ln this study it has been demonstrated that the agonist stimulation of the 
VIP2 receptor in GH3 cells causes a concentration-dependent increase in NO levels 
in the cell (approximately 40-50% increase above the basal level at 300 nM VIP: see 
Figure 5.7). Ionomycin {10 J.!M) alone caused a 74% increase. Ca2+ influx is 
therefore sufficient to stimulate NO production and P ACAP-38 caused no 
additional stimulation beyond the effect of ionomycin (see Figure 5.6). This 
suggests that there is no additional potentia tory step mediated by the VIP2 
receptor, such as that described by Murthy & Makhlouf (1994) in gastric smooth 
muscle cells, and that the response may be entirely dependent on Ca2+ influx. The 
PKA inhibitor, KT-5720 appears to considerably reduce the stimulation of NOS by 
the VIP2 receptor indicating that PKA may play a role in the activation of a Ca2+ 
channel and the resultant activation of NOS. ln order to fully investigate the 
influence of cAMP /PKA on VIP2 receptor-mediated stimulation of NOS in this 
system a number of additional experiments should be carried out : these should 
include an investigation of the effects of inhibitors of Ca2+-calmodulin dependent 
protein kinase, and of PKA, and the effects of forskolin (which acts at the level of 
AC to stimulate cAMP production) and analogues of cAMP. 
Due to the low expression level of the VIP2 receptor in GH3 cells and the 
small stimulation of NOS and PLC activity mediated by the VIP2 receptor it was 
not possible to determine whether PTx-sensitive G proteins contributed to these 
responses or indeed convincingly demonstrate an interaction with the VIP2 receptor 
by GTP.yS modulation of Ligand binding in these cells (see Figure 5.2). 
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5.4.4 VIP, smooth muscle relaxation and cerebral blood flow 
With respect to the cerebral vasculature, a role for neurotransmitters 
released from the nerves innervating blood vessels in the control of blood flow has 
long been recognised. VIP innervation of cerebral blood vessels has already been 
demonstrated by both immunohistochemical and radioimmunoassay studies 
(Larsson et al., 1976; Edvinsson et al., 1981). Bipolar neurons were identified 
projecting to local blood vessels in the rat cerebral cortex that stained for either 
VIP or cholin.e acetyltransferase with only a small proportion staining for both, 
indicating that there are distinct populations of VIP- and acetylcholine-releasing 
neurons innervating blood vessels in the cerebral cortex; 'VIP' neurons accounting for 
the larger portion of the population (Chedotal et al., 1994). The ability of VIP to 
modulate cerebral blood flow has also been demonstrated on a number of 
occasions. Huang & Rorstad (1983) showed that only VIP out of 22 peptides 
tested could stimulate cAMP production in rat cerebral microvessel preparations 
and identified distinct VIP and PTH receptors in rat cerebral microvessels and 
arteries. VIP has also been shown to stimulate cAMP production in rat mesenteric 
artery rings, mesenteric artery smooth muscle and aortic smooth muscle as well as 
stimulating vasodilation in rat mesenteric artery bed and mesenteric artery and 
aortic smooth muscle. In rat aortic smooth muscle cells VIP stimulated AC 
activation with an ECso of 12±6 nM (Ganz et al., 1986). Nandha et a l. (1991) 
demonstrated that PACAP-27 could displace YIP-binding to blood vessel 
membranes and that P ACAP-38, PACAP-27 and VIP administration caused 
hypotension in the anaesthetised rat. The authors found that VIP and P ACAP-38 
were comparable in effect, whereas P ACAP-27 was three times less potent than 
VIP. Kobayashi et al. (1994) showed that PACAP-38, PACAP-27 and VIP 
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stimulated cAMP production in rat cerebral microvessels with ECsos of 7.0, 4.7 and 
34 nM respectively and suggested that a PACAP receptor may be present. In the 
present study, low levels of PACAP receptor mRNA were found to be present in 
the rat cerebral microvessel preparation (see Figure 5.10). Anzai et al. (1995) 
observed similar relaxation of canine basilar arteries and rat intracerebral arterioles 
by VIP, PACAP-27 and PACAP-38 whereas Foda et al. (1995) found PACAP -38 
to be one-third as potent and only 70% as efficacious as VIP in stimulating 
relaxation of guinea pig airway smooth muscle despite P ACAP -38 being twice as 
effective in stimulating AC. Edvinsson et al. (1981) had shown that the direct 
application of VIP to isolated cerebral arteries or veins produced vasodilation. 
These authors also showed that increased blood flow could be stimulated in 
baboons by intra-arterial administration of VIP. Wilson et al. (1981) showed that 
intracerebroventricular application of VIP caused increased cerebral blood flow in 
dogs. The likelihood is that VlP receptors in the smooth muscle cells of the blood 
vessels media te stimulation of adenylate cyclase, and possibly, nitric oxide 
synthase, thereby facilitating relaxation of the smooth muscle and vasodilation, 
although additional mechanisms may be involved. 
Foda et al. (1995) examined the effects of PACAP-38 and VIP on the 
relaxation of isolated perfused guinea pig airway smooth muscle strips. These 
authors found that PACAP-38 had a more prolonged effect than VIP, probably 
because of its resistance to enzymatic degradation, and that the relaxation was not 
entirely due to cAMP production. The VIP2 receptor has been shown to mediate the 
stimulation of NO production in GH3 cells in this study. Murthy & Makhlouf 
(1995) described the relaxation of dispersed gastric smooth muscle cells as a result 
of VIP receptor activation. This relaxation was found to have both a cAMP 
component and a Ca2+ influx-dependent NO component. These authors went on to 
implicate PKA and cGMP-dependent protein kinase in the inhibition of IP3-
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stimulated Ca2+ release (111M IP3-treated permeabilised cells) and the stimulation 
of smooth muscle relaxation. As mentioned above, it is interesting that Anzai et al. 
(1995) observed PACAP-38, PACAP-27 and VIP to cause similar concentration-
dependent relaxation of both canine basilar arteries and rat intracerebral arterioles. 
In these experiments removal of the endothelium from basilar arteries or treatment 
w ith the cycle-oxygenase inhibitors, aspirin or indomethacin, enhanced the 
maximum PACAP-27-stimulated relaxation. The prostaglandin, PGF2cx., or its 
precursor PGH2, was implicated as an endothelium-derived constricting factor. The 
data also indicate that the VIP /PACAP receptor involved is expressed on smooth 
muscle cells and may additionally be present on the endothelium. An intriguing 
aspect of this system, is that nitric oxide is known to stimulate cycle-oxygenase 
activity (Salvemini et al., 1993). The contrasting actions of nitric oxide are also 
observed in the uterus where nitric oxide-mediated activation of guanylate cyclase 
causes relaxation of smooth muscle, and the release of prostaglandins stimulated 
by nitric oxide causes contraction (Franchi et al., 1994). 
Considerable pharmacological evidence for the presence of a VIP receptor in 
the vasculature has accumulated over the years. In this study the presence of the 
VIP1, VIP2 and a low level of P ACAP receptor mRNA in a crude preparation of rat 
cerebral rnicrovessels has been confirmed by RT -PCR. 
5.4.5 Summary 
ln GH3 cells the endogenous VIP2 receptor has been demonstrated to 
mediate the stimulation of cAMP production, inositol phosphate formation and 
nitric oxide production. This is in agreement with the data described in Chapter 3 
using a heterologous expression system: when expressed in COS 7 cells, the VIP2 
receptor mediates the stimulation of cAMP production and phosphoinositide 
hydrolysis (COS 7 cells do not appear to express any isoforms of constitutive NOS 
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so VIP receptor-mediated stimulation of NOS could not be studied in that system). 
VIP2 receptor-mediated stimulation of phosphoinositide hydrolysis in COS 7 cell 
proved to be partially dependent on Ca2+ influx and the activity of a PTx-sensitive 
G protein. The role of PTx-sensitive G proteins in VIP2 receptor-mediated 
signalling, as described in Chapter 3, needs to be explored further in the context of 
GH3 cells: an examination of the dependence of PLC and NOS activation on Ca2+ 
influx and PTx-sensitive G proteins would be of great interest. When expressing a 
receptor in a host cell system it is a concern that expression of the receptor at 
higher than physiological levels might lead to its coupling promiscuously to various 
G proteins, the end-result being signalling characteristics that are not physiologically 
relevant. In GH3 cells, where the VIP2 receptor is expressed at low level, the 
signalling characteristics of the receptor have proven to be very similar to the YIP2 
receptor in COS 7 cells, where it is expressed at a high level. 
In the anterior pituitary gland the VIP2 receptor appears to stimula te 
prolactin release via cAMP production. Nitric oxide production stimulated by tills 
receptor may act as a negative feedback mechanism. As described above, hormone 
secretion can be stimulated by both the PLC and AC pathways which appear to 
converge at the L-type Ca2+ channel through the action of PKC and PKA. The 
primary mechanism of VIP2 receptor-mediated stimulation of hormone secretion is 
likely to be cAMP production. 
In a rat cerebra] microvessel preparation, mRNA for both the YIP1 and YIP2 
receptors has been shown to be present, in addition to low levels of PACAP 
receptor mRNA. Nitric oxide production and cAMP production may act as dual 
arms of a smooth muscle relaxation mechanism as described by Murthy & Makhlouf 
(1995). 
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Fig. 5.1 Homologous displacement of [125J]helodermin binding to GH3 
cell membranes. 
The binding assay was performed at 37°C for 10 minutes on GH3 cell membranes. The 
va lues are the means±SEM, n=6. [125r]helodermin was present at a concen tration of 
31.8±1.2 pM. Curve fitting was performed by the non-linear curve-fitting programme P-fit 
(Elsevier Biosoft, Cambridge, UK). 
Fig. 5.2 The effect of pertussis toxin pre-treatment on GTPyS modulation 
of [125I]helodermin binding to GH3 cell membranes. 
The binding assay was performed at370C for 10 minutes on control (D) and PTx-treated 
(• ) GH 3 cell membrane preparations. The va lues are the means±SEM, n=6. For the PTx 
treatment the cells were pre-incubated for 16 hours with 100 ng/ml PTx before the 
membranes were prepared. [125J]helodermin was present at a concentration of 30.2±0.3 pM. 
(*) Represents statistically significant inhibition of GTP-yS-mediated dissociation of 
[125J]helodermin by PTx treatment (p<O.OS by Mann-Whjtney U-test). 
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Figure 5.3 Concentration-response curves for agonist-evoked cAMP 
production in Gli3 cells. 
Typical concentration-response curves for VIP (0), PACAP-38 (¢), P ACAP-27 P> and 
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Figure 5.4 Concentration-response curves for agonist-evoked (3H]inositol 
phosphate production in Gli3 cells. 
a) VIP-evoked [3H)inositol phosphate production. b) PACAP-38-evoked [3H)inositol 
phosphate production. Typical basal values were 5,329±96 dpm/ assay and 4,706±13 
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Figure 5.5 Time-course of PACAP-38-evoked [3H]inositol phosphate 
production in GH3 cells. 
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Figure 5.6 The effects of ionomycin, PACAP-38 and AlCl.3/NaF on 
[3H]citrulline production in GH3 cells. 
The control response was the [3H]citrulline production stimulated by a 10 minute 
incubation with 10 11M ionomycin (28,095±1025 dpm/ assay, the basal value was 16,124±377 
dpm/ assay). PACAP-38 was applied at a concentration of 300 nM, AlCI3 at 10 11M and NaF 
at 50 mM. The data are means±SEM. n=6-8. 
Figure 5.7 Concentration-response curve for YIP-evoked [3H]citrulline 
production in GH3 cells. 
The values are means±SEM. n=6. Curve-fitting was performed by the non-linear curve-
fitting programme, P-fit (Elsevier Biosoft, Cambridge, UK). 
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Figure 5.8 The effect of N-nitro-L-arginine, the nitric oxide synthase 
inhibitor, on VIP-evoked [3H]citrulline production in GH3 cells. 
N-Nitro-L-arginine was applied for 30 minutes prior to stimulation with VIP. The data are 
means±SEM. n=6. 
Figure 5.9 The effect of KT-5720, the protein kinase A inhibitor, on VIP-
evoked [3H]citrulline production in GH3 cells. 
The KT-5720 was applied for 30 minutes prior to stimulation with VIP. The data are 
means±SEM. n=6. (*) Represents statistically significant inhibition of YIP-evoked 
[3H]citruUine production by KT-5720 treatment (p<0.05 by Mann-Whitney U-test). 
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Figure 5.10 Gel electrophoresis of RT-PCR products in order to determine 
which receptors are expressed in rat brain microvessels 
After 30 cycles of amplification, 10 ~ of each reaction was run on an 0.7% agarose (BRL, 
Paisley, UK) gel in lx Trisl acetate I EDT A buffer (see Section 2.2.12). The molecular weight 
markers (1 kb DNA ladder, BRL, Paisley, UK) were run in the lane marked M, the m11m3 
receptor primer reactions were run in lanes 1-3, the PACAP receptor primer reactions in 
lanes 4-7, the VIP1 receptor primer reactions in lanes 8-11 and the VIP2 receptor primer 
reactions in lanes 12-15. The cDNAs for the VIP1 (PV19), the V1P2 (6.3) and the PACAP 
receptors (9.1: encoding the long IC3 splice variant of the PACAP receptor) were used as 
positive controls. The sizes of DNA fragments in the molecular weight marker lane are 
listed along the lefthand side of the figure. The m1 I m3 receptor primers amplified two 
fragments which correspond to the sizes expected for the m1 receptor (759 bp) and m3 
receptor (1018 bp) in the rnicrovessel extract (lane 2) whilst only the 1 kb fragment was 
detected in the brain extract (lane 1). In previous reactions, both fragments were detected in 
the brain preparation. The PACAP receptor primers amplified two fragments which 
correspond to the sizes expected for the short form (100 bp) and the 84 bp intracellular loop 
3 splice variant (184 bp) of the PACAP receptor in both rnicrovessel (lane 5) and brain (lane 
4) extracts. Both the VIP1 (lane 9) and V1P2 (lane 13) receptor primers amplified fragments 
which corresponded to the expected size ( 520 bp and 1844 bp respectively) for each set of 
primers from microvessel extract. Only a very faint band could be detected for the VIP1 
receptor in brain extract (lane 8). 
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1 Brain extract ml I m3 receptors 
2 Microvessel extract ml/ m3 receptors 
3 Negative control m l I m3 receptors 
4 Brain extract PACAP receptors 
5 Microvessel extract PACAP receptors 
6 Negative control P ACAP receptors 
7 Positive control PACAP receptors 
8 Brain extract VlP 1 receptor 
9 Microvessel extract VIP 1 receptor 
10 Negative control VIP 1 receptor 
11 Positive control VIP 1 receptor 
12 Brain extract VIPz receptor 
13 Microvessel extract VIPz receptor 
14 Negative control VIPz receptor 
15 Positive control VIPz receptor 
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Early studies on VIP receptor function in native tissues were hampered by 
the problems of distinguishing different receptor types using pharmacological 
methods: PACAP was isolated (Miyata et al., 1989) nineteen years before VIP was 
discovered (Said & Mutt 1970) and many studies were performed without, what 
would now be considered, the most basic pharmacological characterisation of the 
observed responses i.e. determining the relative potencies of VIP, P ACAP-38 and 
P ACAP-27. Many studies are still carried out without sufficient characterisation of 
the responses, a number of interesting VIP and PACAP-evoked physiological 
reponses have therefore been observed without being convincingly attributed to the 
activity of specific receptor types. In recent years the lack of selective antagonists 
has been the main impediment to identifying the physiological roles of specific 
receptors. A few 'selective agonists' such as the lizard peptide helodermi.n (which 
was thought to be selective for the VIP2 receptor over the VIPt or PACAP receptors 
(Robberecht et al., 1988)) were available, but did not prove to be equally selective 
under all conditions, the same was generally found to be true of the available 
'selective antagonists'. It is also unfortunate that the characterisation of responses 
is still complicated by an artificial division that exists between the those who work 
on VIP and and those who work on PACAP. 
The breakthrough in this field came with the molecular cloning of the VIPJ, 
VIP2 and PACAP receptors (Lutz et al., 1993; Ishihara et al., 1992; Sreedharan et 
a l., 1993; Adamou et al., 1995; Morrow et al., 1993; Ogi et al., 1993; Ohtaki et al., 
1993). This meant that the receptor of interest could be expressed in a heterologous 
expression system and its responses and interactions studied in isolation from the 
other VIP- and P A CAP-responsive receptors. The distribution of specific receptors 
in tissue could then also be detected by Northern blotting, in situ hybridisation or 
RT-PCR. 
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In this study the rat VIP2 receptor (first cloned by Eve Lutz in this 
laboratory) and the two splice variants of the PACAP receptor most commonly 
expressed in mammalian tissue (a long form with a 28 amino acid insert in IC3 and 
short form without the insert: Morrow et a l., 1993) were expressed transiently in 
COS 7 cells, as were a series of chimaeric VIP2/PACAP receptors created by Eve 
Lutz in this laboratory. The rat VIP2 and P ACAP receptors are 51% homologous at 
the amino acid level yet they have distinct pharmacological characteristics (Lutz et 
al., 1993), the homology between the receptors was exploited in the creation of the 
chimaeric receptors (see Fig. 4.9 and Table 4.3) in order to investigate the role of 
different receptor domains on the VIP2 receptors signalting characteristics. TheN-
terminal domain of the VIP2 and PACAP receptors was identified as the major 
determinant of ligand specificity, in chimaeric receptor VtP, the VIP2 receptor 
N-terminal domain proved sufficient to cause a major increase in the potency of VIP 
at the PACAP receptor while having little effect on the PACAP-38-evoked 
signalling, whereas the PACAP receptor N-terminus prevented YIP-evoked VIP2 
receptor-mediated PLC stimulation and greatly decreased the potency of VIP for 
AC stimulation. For the secretin, calcitonin, PTH and VIP receptors, agonist 
binding has been found to be dependent on residues at multiple sites through the 
receptor's N-terminal domain and extracellular regions (Gourlet et al., 1996; 
Holtmann et al., 1995a; Holtmann et al., 1995b; Holtmann et al., 1996a; Holtmann 
et al., 1996b; Nicole et al., 1997; Knudsen et al., 1997; Turner et al., 1996). In this 
study we found that theN-terminus is crucial for determining the ligand-binding 
specificity of the VIP and PACAP receptors. 
It would be of considerable interest in the future to define any significant 
differences that may exist between the activities of the VIPt and VIP2 receptors. 
Based on the differences in their amino acid sequences and the fact that they co-
exist in the same cell types it is reasonable to assume that differences do exist. 
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However, it is possible that the difference between the receptors lies entirely in their 
specific ligand interactions: helodermin was found to be more potent than VIP at 
the VIP2 receptor in SUP-T1lymphoblast cells (Robberecht et al., 1988) and less 
potent than VIP at the VIP1 receptor expressed in COSGs1 cells (Ishihara et al., 
1992), secretin was found to be less potent than VIP at the VIP1 receptor, expressed 
in COSGs1 cells (Ishihara et al., 1992), but was inactive at the VIP2 receptor, 
expressed in COS 7 cells (Lutz et al., 1993). There is therefore evidence of a 
difference in ligand specificity between the VIP1 and VIP2 receptors which has yet 
to be shown to be physiologically relevant. 
In this study we have shown that the VIP2 receptor can mediate the 
activation of NOS in GH3 cells. Similarly Murthy & Makhlouf (1995) showed that a 
VIP receptor in gastric smooth muscle was coupled to NOS activation. (there is no 
evidence that a PACAP receptor can activate NOS ). We have also established 
that the VIP and P ACAP receptors stimulate PLC by different mechanisms and to 
different extents. In view of their different signalling characteristics it would be of 
interest to determine whether any cross-talk occurs between P ACAP and VIP 
receptors especially since they have ligands in common and are sometimes co-
expressed in the same cell types. The response of neighbouring cell types in tissue 
to the same ligand, e.g. P ACAP-38 or P ACAP-27, may be dependent on the 
combination of VIP1, VIP2 and PACAP receptor splice variants expressed in the 
cell. 
The activation of VIP family receptors has been found to have a synergistic 
effect on the activity of a number of other receptor types. The VIP receptor in 
various tissues has been shown to potentiate glucose-induced insulin secretion 
(Bertrand et al., 1996) and there are several examples now of synergism between 
a.1-adrenergic receptor and VIP receptor activities; causing an increase in the 
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magnitude of a Ca2+ signal in astrocytes from rat cerebral cortex (Fatatis et al., 
1994), stimulating pineal N-Acetyltransferase activity (Yuwiler et al., 1987) and 
potentiating YIP-evoked cAMP and cGMP production in pinealocytes (Chlk et al., 
1998a; 1998b). It seems unlikely that many physiological responses are truly 
attributable to the activity of a single receptor stimulated in isolation, synergistic 
interactions are therefore an aspect of VIP receptor activity that deserves further 
attention and may prove to be an important general mechanism for modulating the 
receptors function. 
Studies in native cells have suggested that there may be a physiological role 
for VIP receptor-mediated PLC activation. YIP-stimulated PI hydrolysis was 
observed in superior cervical ganglion (Audigier et al., 1986) and adrenal chromaffin 
cells (Malhotra et al., 1988), VIP augmented a-adrenoreceptor-.mediated PI 
hydrolysis and release of calcium from intracellular stores in type 1 astrocytes from 
rat cerebral cortex (Fatatis et al., 1994), and stimulated calcium release in astroglial 
cells from rat cerebral cortex (Russell et al., 1990). Low VIP concentrations were 
also sufficient to activate PKC in regions of rat hippocampus (Weill et al., 1989) 
and signifigantly stimulation of the mouse VIP2 receptor expressed in Xenopus 
oocytes caused the activation of calcium-activated chloride currents suggesting that 
intracellular calcium stores were being emptied. It is in this study however that it 
has been directly demonstrated for the first time, that the rat VIP1 and VIP2 
receptors mediate the activation of PLC, in addition to AC, when transiently 
expressed in COS 7 cells. This mechanism was found to be at least partially 
dependent on a PTx-sensitive G protein. The use of chimaeric receptors allowed the 
identification of a VIP2 receptor domain likely to interact with the PTx-sensitive G 
protein. The portion of the receptor from the exchange site in TMS to the exchange 
site in TM7 contains the relevant functional domain, which is likely to be the IC3 
region of the receptor (the carboxyl terminal tail of the VIP2 receptor was found to 
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have no identifiable effect on its signalling capability in terms of AC or PLC 
activation). The PACAP receptor was shown to mediate PLC stimulation by a 
different mechanism, which does not include PTx-sensitive G proteins. The GH3 rat 
anterior pituitary tumour cell line (Tashjian, 1979) expresses VIP2 receptors (E.M. 
Lutz; personal communication) and in these cells it was confirmed that native VIP2 
receptors, even when expressed at a low level, will mediate the stimulation of PLC. 
This demonstrates that PLC activation mediated by the VIP2 receptor does not only 
occur as a result of promiscuous coupling of G proteins to the VIP2 receptor, a 
phenomenon which has been attributed to high receptor expression level in a 
heterologous expression system (Zhu et al., 1994). 
There are a number of instances in which VIP receptors have been found to 
act through PTx-sensitive G proteins, Diehl & Shreeve (1995) demonstrated an 
interaction between the VIP2 receptor and Gai3 in rat lung and Murthy & Makhlouf 
(1994) found that VIP receptor-mediated effects in gastric smooth muscle cells were 
dependent on Gail/2· In order to determine which PTx-sensitive G protein was 
involved in VIP receptor mediated stimulation of PI hydrolysis in COS 7 cells the 
HA-tagged human VIP2 receptor was also transiently expressed in COS 7 cells and 
immunoprecipitated from membrane preparations of the cells to allow identification 
of the receptor-associated G proteins. In these experiments, Western blotting of the 
immunoprecipitate with specific anti-sera revealed the presence of Gaq and a 
member of the Gaifo/t/z family, other than Gan/2, associated with the human VIP2 
receptor. This suggests that the PTx-insensitive component of the VIP2 receptor-
mediated stimulation of PLC may be due to an interaction with Gq and the PTx-
sensitive component is due to an interaction with a PTx-sensitive G protein other 
than Gail/2· 
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Experiments on the rat VIP2 receptor-mediated activation of PLC in COS 7 
cells have revealed a role for Ca2+ influx through a plasma membrane channel 
sensitive to SK&F 96365, a calcium-release activated calcium influx (CRACi) and 
L-type Ca2+ channel inhibitor (Merritt et al., 1990). The concentration-dependent 
inhibition of VIP2 receptor-mediated [3H]IP production by Co2+ indicated a 
requirement for Ca2+ influx. The lack of effect of the classical L-type Ca2+ channel 
inhibitors, methoxyverapamil and nifedipine (Nowycky et al., 1985; Fox et al., 
1987), on VIP2 receptor-mediated [3H]IP production, and the inhibitory effect of 
SK&F 96365, indicates that a Ca2+ channel other than an L-type Ca2+ channel is 
involved and that the mechanism may well involve a Ca2+ channel activated by the 
emptying of intracellular Ca2+ stores. Thapsigargin is a high affinity inhibitor of 
sarcoplasmic and endoplasmic reticulum Ca2+-ATPases (SERCA: Thastrup et al., 
1990). Treatment of cells with thapsigargin causes the emptying of the intracellular 
Ca2+ stores by inhibiting their ATP-dependent refilling mechanism and can thereby 
stimulate CRACi. Thapsigargin treatment proved to both stimulate [3H]IP 
production and potentiate VIP2 receptor-mediated [3H]IP production providing 
further support for the idea of CRACi being a fundamental part of this mechanism. 
The additional experiments which must be done to provide enough data to 
construct a detailed model of the system are outlined in Section 3.4. The simplest 
model that could currently be suggested involves the stimulation of PLC activity by 
both Gq and a Pix-sensitive G protein, the resultant production of inositol 1,4,5-
trisphosphate causes the emptying of intracellular Ca2+ stores which in turn causes 
Ca2+ influx and the further stimulation of PLC activity. It is possible that a number 
of PLC isozymes are stimulated and that Pix-sensitive G proteins are involved at 
several stages of the process. 
Murthy & Makhlouf (1995) also defined a role for Ca2+ influx in VlP-evoked 
relaxation of gastric smooth muscle. It is probable that the regulation of smooth 
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muscle relaxation is the major physiological role for VIP receptors. Gastric smooth 
muscle (Grider & Rivier, 1990; Gu et al., 1992; Murthy & Makhlouf, 1995), intestinal 
smooth muscle (Grider & Makhlouf, 1986), sphinteric smooth muscle (Goyal et al., 
1995), vascular smooth muscle (Edvinsson et a l., 1981) and airway smooth muscle 
(Foda et al., 1995) have all been shown to be responsive to VIP. The VIP receptors 
that we have demonstrated to be present in rat cerebral microvessels are likely to be 
expressed in the vascular smooth muscle cells. Murthy & Makhlouf (1995) 
described the VIP receptor-mediated relaxation of gastric smooth muscle as being 
due to both cAMP production and NO-evoked cGMP production. In this study, in 
GH3 cells, it was demonstrated that the VIP2 receptor-mediated the activation of 
AC, PLC and NOS. 
It is not surprising that VIP receptor-mediated control of smooth muscle has 
proven to be the major focus of therapies based on modulating VIP receptor 
function. The human lung has been shown to contain VIP immunoreactive neurons 
(Carstairs & Barnes, 1986) and high levels of VIP (Polak & Bloom, 1982). Usdin et 
al. (1994) found VIP1 receptor mRNA in large and moderate size bronchi and VIP2 
receptor mRNA in the smaller and terminal bronchioles. VIPt and VIP2 receptor 
mRNA were both detected in the vascular epithelium of the lung. Ollerenshaw et al. 
(1989) suggest that the absence of VIP in the lung is responsible for the development 
of asthma since imunohistochemical methods failed to detect VIP in samples from 
asthmatic patients. Treatments with inhaled VIP however have proved ineffective 
(Altiere et al., 1984; Barnes & Dixon, 1984; Bundgaard et al., 1983; Mojarad et al., 
1985). O'Donnell et al. (1994a;1994b) therefore designed a VIP analogue which 
was a more potent bronchodilator, and more resistant to proteolytic degradation, 
than VIP. This compound, Ro 25-1553, has also proven to be a more effective 
bronchodilator than isoproterenol or salbutamol and was found to be effective in 
relaxing airway smooth muscle and reducing inflammation in guinea pig lung in vitro 
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and in vivo. Ro 25-1553 was found to be highly selective for the VlP2 receptor over 
the VIP1 receptor (Gourlet et al., 1997). Both the YIP-evoked calcium influx 
mediated by the VIP2 receptor in COS 7 cells and the activation of NOS in GH3 
cells that we have described are relevant to the observed relaxation of smooth 
muscle in lung since both nitric oxide and cAMP are known to facilitate relaxation 
of smooth muscle and NOS is likely to be activated by the influx of calcium as 
described by Murthy & Makhlouf (1995). 
Similar mechanisms are likely to be present in the penisi VIPergic neurones 
innervate the cavernous smooth muscle and blood vessels. VIP levels are elevated 
during erections (Dixson eta., 1984i Ottesen et al., 1984) and Gu et al. (1984) 
found penile VIP to be reduced in impotent men. It was also observed that VIP can 
stimulate sexual behaviours in rats and that these effects can be reversed by a 
VIP / neurotensin hybrid peptide which acts as an antagonist of VIP (Gazes et al., 
1989). Gazes et al. (1994) tested a VIP analogue, stearyl-norleucine-vasoactive 
intestinal peptide, as a treatment for impotence. This Upophilic VIP analogue was 
applied as an ointment, as opposed to by injection (which is more common for 
impotence treatments) and was found to be incorporated more effectively than VIP. 
The replacement of the methionine in position 17 of the VIP sequence with 
norleucine in stearyl-norleucine-vasoactive intestinal peptide increased its activity 
over that observed for VIP, presumably by reducing the sensitivity of the molecule 
to proteolytic degradation. 
There is considerable evidence for VIP receptor-mediated control of the 
cerebral vasculature, not least the identification of YIP-releasing neurons innervating 
blood vessels in the rat cerebral cortex (Chedotal et al., 1994). In this study, RT-
PCR of the RNA extracted from a rat brain microvessel preparation demonstrated 
the presence of VIP1, VIP2 and a low level of PACAP receptor mRNA. The 
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additional demonstration of VIP2 receptor-mediated activation of NOS further 
strengthens the case for the involvement of the VIP2 receptor in the control of the 
vasculature. Because of the role of VIP in regulating cerebral blood flow (Edvinsson 
et al., 1981; Anzai et al., 1995) it is possible that a VIP receptor agonist could be 
used to reduce ischaernic damage in stroke victims. Distinct from effects on blood 
flow, Brenneman et al. (1990) described a YIP-evoked increase in neuronal survival 
in dissociated spinal cord cultures suggesting a neuroprotective role for VIP receptor 
agonists. 
VIP was also found to be an astroglial mitogen (Brenneman et al., 1990) and 
a growth factor for whole cultured mouse embryos (Gressens et al., 1993). However 
Maruno & Said (1993) found the growth of certain cell lines of small cell lung cancer 
to be inhibited by VIP treatment. VIP receptors have been found to be present in 
cells from breast, pancreatic and intestinal tumours (Waschek et al., 1995) and the 
possibility of regulating tumour growth through VIP receptor activity is being 
.investigated. 
The YIP-evoked stimulation of melatonin secretion from the pineal gland has 
been well documented and is central to the photic regulation of circadian rhythms 
(Ibata et al., 1989; Watts & Swanson, 1990; Kalsbee.k et al., 1992; Spessert, 1993; 
Sirnrnoneaux et al., 1993; Duncan et al., 1995; Simrnoneaux et al., 1998). It is 
possible that VIP receptor agonists may therefore be used to treat "jet-lag" and sleep 
disorders. In addition the close relationship between circadian rhythms and fertility 
in many mammals (McArthur et al., 1997; Duncan et al., 1995) suggests that VIP 
receptor agonists may provide a means of regulating fertility. 
As a result of the large number of studies carried out to investigate the 
physiological roles of VIP and P ACAP there are several promising therapeutic 
applications for VIP receptor agonists and antagonists. There are however many 
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questions still remaining regarding the fundamental intracellular signalling 
capabilities of the VIP receptors. This study has begun to address these issues. 
Fahrenkrug (1993) suggested that the role of VIP in the brain is to regulate 
coupling between energy metabolism, blood flow and neuronal activity. Whereas 
Usdin et al. (1994) differentiate between the functions of the receptors in the brain 
suggesting that the VIP1 receptor in the brain is primarily involved in regulating 
behaviour and higher cortical functions, because of it's presence in the cortex, 
hippocampus and amygdala, whereas the VIP2 receptor is involved in sensory 
information processing, because of its presence in the brain stem, motor nuclei and 
thalamus. VIP also has activity in both the central and peripheral nervous systems 
and has been shown to be an important regulator of the immune (Ottaway, 1991) 
and endocrine systems (Koves et al., 1991; Rostene, 1984; Dow et al., 1994). It is 
apparent that a fuller understanding of the basic signalling characteristics of the 
VIP receptors will provide an invaluable insight into the regulation of a number of 
major physiological systems. 
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INTRODt: CTION 
The vasoactive intestinal peptide t VIP) :1nd pi[U itary adenylate cyclase-activming 
polypepude ( PACAP) recepwrs belong 10 the secretin/calciwni niparathyroid hormone 
recepwr family. This is a fami ly of seven-transmembrane spanning G-protein-coupled 
receptors distinct from the rhodopsin and me:abotropic glutamate receptor families. : 
Although all the known members or· this i·amily couple to adenylyl cyclase and a 
number have been shown to couple 10 phospholipase C CPLC).:..; their ability to 
couple to other second-messenger pathways iemains largely to be elucidated. When 
expressed in COS 7 cells the VIP, and VIP: receptors efficiently activate adenylyl 
cycl~e (AC)7 and also phosph0I:;:.1se D (PLDl (D.A. McCulloch. unpublished datal. 
VIP and PACAP have also been shown to stimulate nitric oxide synthase (NOS) in 
gastric smooth muscle cells through a common recepwr and a mechanism involving 
l penussis toxin WTxJ-sensitive G-protein.3 We therefore investigated VIP, and V!Pl 
recepcor coupling to PLC and PLD and the pote:1tial PTx-sensitivity of these responses. 
In this paper we demonstrate PTx-sensitive coupling of the VIP, and YIP: receptOrs 
to PLC. 
MATERIALS AN"D METHODS 
COS 7 cells were transfected with cDNAs for the rat VIP" VIP:, or PACAP 
receptors using DEAE dextran as previously iescribed by Morrow and coworkers.9 
Twenty-four hours after transfection the cell5 were trypsinized and plated into 12 
.... el l plates. The VIP, eDNA {PV19) was a ki.nd gift from Proi. S. Nagata. 
[lHjinosicol Phosphaies Assay 
C~!llS in 12-well tissue-culture plates (maintained at 37°C in a 5% C0:/95% 0~ 
::l\ tronmentl were labeled with l ).l.CilmL o r" mYo-(2-;Hlinositol ( AmershamJ for \6 
~Td. : 4 13 1 650 3550: fax: .J4 131 662 0240: ~-=1: cmack.:nzte@srvl.bmu.mrc.o.c.uk. 
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h in Earle's Balanced Sait Sulution with 10 m1vl gl ucose;:. At -+3 h after transfection 
the cells were washed twice;: in E:.1rle · s Balanced Salt Solution with I 0 mM glucose 
and 0.2% bo\·ine serum albumin and pre1ncubated fo r 10 min with 10 rru\1 LiCl 
before agonist stimulation fo r 30 mi n. Reactions were stopped by aspiration of 
medium and :lddi tion of 700 !J.L of ice-cold 1. 3..1-:Vf trich loroacetic acid. The wells 
were scraped :md the solutiOn .:entnfuged to peile[ the precipitated pr01ein (5 min. 
12.000 g) . . -\ 500- i-lL sample of the supernatant was then added w 50 i-lL of 0.1 M 
EDT A and 500 i-lL o f a I: I mixture or 1. 1.~- trichlorotritluoroethane and tri-n-
octylam ine. The samplt! was \·onexed :.~ nd cemriruged !5 min. 12.000 g) and 300 
!J.L of the aqueous phase was added to 200 i-lL of l .\ I ~aHCO, comaining universal 
i ndic:.~tor. The sample was applied to a 1-mL .:ol umn or Dowex anion exchange resin 
( I x 8 resin. fo rmate form. 200--+00 mesh: Bio-Radl. and a stepwise gradient of 
ammonium rormate was used tO elute the ('H}inosiwl phosphates. a method previously 
descri bed by Berridge era/. 1'1 .-\ 500-!-lL sample or the eluate was taken for scintillation 
COUnting. 
.-lssay of Phospholipase D .-lcriviry 
The phosphatidyl moiety of phosphatidyichoiine \vas labeled by incubating the 
cells overnight with [;H) palmitate (5 )J.Ci per 0.5 mL at 3T'C) under 5% C0:/95% 
0 :- The cells were washed twice with warm (3/zC) :vtE vt containing 1% bovine 
serum albumin tBSA) fraction V. This was replaced with ! mL warm MEM containing 
0.5% BSA. Cells were incubated in the presence of 30 rru\1 butan-1-ol to allow 
generation oi [!H) phosphatidylbutanol and the quantification of PLD activity. Reac-
tions were tenninated by aspiration of the :1ssay medium and addition of 0.5 mL of 
ice-cold methanol. The 12 well plates were kept on ice and the cells scraped and 
transferred into 2-mL glass screw-tOp vials. Phosphatidylbmanol was extracted using 
the chlorofonnfmethanol procedure as described pre\' iously by Bligh and Dyer.: 1 The 
organic phase was retained and dried under vacuum in a centrifugal evaporator for 
50 min at 30°C and resuspended in 50 !-lL chloror'ormlmethanol (19:1). The sample 
was spotted onto a thin-layer chromatography silica gel plate and developed usi~g 
the organic phase of a mixture of ethyl acetate/ 2.2.4-uimethylpemane/acetic J!:ldl 
water ( 110:50:20: 100). The region of the plate corres~onding to the running position 
of authentic phosphatidylbutanol was scraped and me radioactivity quantilied by 
liquid scintillation counting. 
When required. cells were preincubated for 16 hours with either I 00 or 200 ngf 
mL !)ertussis holotoxin or its B subunit. 
RESULTS 
VIP <I nM- 3 !J.ivl) caused a concemrmion-de::e:1dent increase in [!H]inositol 
phosphate form~ti?n \~ith a 2.55 = 0.16-fo~d increas~ over basal for the VIP, recep<: 
and 1.99 = O.O:Hold mcrease over basal tor the VIP- receptor at a concentr.~uon 
3 !J..\1. Treatment of the cells with 10 )J.ivl AlCl; and- 50 mM ~aF produceJ J .1.00 














fiGURE 1. Perrussis toxin ser.snivny of lhe VIP1 and VIP! receptor-mediated PLC response. 
A typical basal activity was 10314 1=::!80) dpmlassay. Values :1re means = S.E.:vt. from 6 
separ:ue determmations. There was no difference in basal [lH]inositol phospnate iormalion in 
VIP. or VIPl receptor-expressing cells and dal:l for lhese are expressed in a combined iorm. 
1· 1 Represents statistically significant inhibition or' YIP-induced (;H]inositol phosphate produc-
uon •p < 0.05 by Mann-Whimey U-teso. 
= 0.57-fold increase over basal acuvnv. Frct:RE I demonstrates that PTx causes 
partial inhibition of [3H]inositol phosph~te production stimulated through the V1P1 
.md VTP2 receptors. PTx at lOO ng/mL reduced the YIP-stimulated response by 46 
= 9"0 for the VIP, receptor and 38 = 10% for the VTP2 receptor. A PTx treatment 
oi 200 nglmL had no effect on basal PLC activity (100 := 2% of control). The 
Jddiuon of the PTx B subunit (200 nglmL) had no significant effect on the VIP-
'umuiated PLC activity; the VIP1 receptor maintained 100 = 3% of irs VIP stimulated 
Jcm·ny and the VIP2 receptor 99 = 7%. 
In order to determine whether a pathway mediated by the G-protein G, could be 
:"l:sponsible fo r either the PTX-sensitive or -insensitive components of PLC activation 
:he -:::lls were preincubared with cholera toxin (CTx). CTx caused no increase in 
Oa.'i."!l [lHlinositol phosphate formation (data not shown) and preincubation with 20 
JJ.!;fml CTx for 16 h (a protocol reported to downregulate G,) had no effect on PLC 
:"e.\ponses to VIP. FrcURE 2 shows that in the presence of 20 J..L.g/mL CTx the VIP-
'IImulated PLC response for the VIP, receptor was 105 :: 6% of control and for the 
\ IP: receptor. 95 :: 6%. 
Both VIP, and VIP: receptors showed concentration-dependent activation oi PLD 
.. 11X> n.'vt-1 J..L.M). One IJ.:vl VIP elicited a 1.93 = 0.13-fold over bas:~! incre:J.Se in 













FIGURE 2. The eifect oi CTx :1nd PTx B subunn on mosnol phosphate production elicited 
by the VIP, and VIP: recepwrs. The comroi response to .3-!J..M VIP was typically around 29.869 
dpm per assay. Toxins were present for 16 h pnor to stimulation. 
increase through the VIP~ recepwr. After PTx pretreatment the responses were 97 
= 4% and 109 = 6% of the controls. respectively. for the VIP1 and VIP1 receptors. 
FIGURE 3 shows the PTx-insensitivity of PLC activi ty stimulated through rwo 
splice variants of the PACAP type [ receptOr. the ·'shon" and ·'Jong" forms. The 
long form includes a 28-amino-acid insen in intracellular loop III. the ·'hopl" cassette 
of Spengler er al. 5 One hundred nM PACAP-38 caused a 7.71 = 0.55-fold incre:LSe 
over basal PLC activiry for the short form of the receptor: in the presence of ~00 
ng/rnL PTx this was a 7.8 1 = 0.20-fold increase. The long form of the recepwr 
mediated a 10.59 :: 0.82-fold increase over basal PLC activity in response to 100 
nM PACAP-38: after PTx treatment the response was a 11.00 = 0.27-fold inc~ 
over basal. PTx treatment alone had no effect on basal activity (91 = 9% of con troD. 
DISCUSSION 
The present results demonstrate for the tirst time that VIP1 and VIP: but nO( 
P.-\CAP receptors can elicit a PTx-sensitive activation of PLC in a heterol~go~ 
exoression svsrem. The stimulation of PLC throu!!h a PTx-sensitive G-protetn IS. 
ho~vever. weil documented for a number of receoto;s of both rhodopsin and mc:tabo-
tro!Jic glutamate receptOr families. . 
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FIGURE 3. P.:m~>siS toxm msensHivny or the PLC response mediated by :! splice variams 
or the PAC.\P receptor. Values are me:ms = S.E.:VI. irom 6 separate deterrmnauons. 
The PLCp I. p2. and (33 subtypes can a ll be activated by p-y subunits .. : but only 
PLCp I and PLCp3 were stimulated to any great extent by a subunits. particularly 
or the PTx-insensitive G.,11 subfamilyY The fact that PTx tre:ument does nor totally 
inhibit the VIP receptor-mediated PLC activity indicates that a ponion or· the response 
may be attributable to the more convenuonai G.,wmediated mechanism. whereas 
stimulation or· PLC by G,-derived by (3-y subunits could account for the remainder. 
These results suggest that in addition to G,, VIP, and VIP: receptors are capable 
oi interaction independently with G proteins of the Gq~11 and G,., classes and that the 
Jbility to elicit G,.-mediated PLC activation is not shared by PAC.-\P receptors. 
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Chimaeric \TIPj P.A.CJ.-\.P Receptors 
Reveal That Agonist Pharmacology 
but not Signal Transduction Is 
Determined bv Extracellular 
"' 
Domain 1 
E. yf. LUTZ.:J C. I. Yf..\c~)JZ~. J. yfQRROW. 
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IJ.'lTR 0 D U CTI 0 N 
Re:::eprors for 'he se:::::e~irugiuc::1gon .family :::r large pe;mae hormones. '-vhic:t 
includes VIP and PACA.P. be!ong co a family J f seven-u-ansi:le:norane spanning 
G-ororein-.:ouoied re:::emors that ue dis tine: from che rhodoosin suoedarnii v. : All 
:o; • • • • .. 
members of t.his ~amiiy coupie to stimulation or· ::.denyiare cyciase. most probaoiy 
mediated by G,. Ylany are also capable or stimulating inositOl phosphate ;:>roduc-
tion.:..s Tnis re:::eptor i'arniiy has common saucrur..:.i features such as eig.ht conse:"'ted 
cysteines. sLx or which are within a large ~-,e::ninal extracei.luiar domain. 
We have isolated cDNAs encoding ~wo members or' this r'arnily. the VIP: re:::e~cor: 
and rwo splice variants of the PAC.-\P rece?ror. :1 :ong form containing m additional 
84 bp casserre in the region encoding the iliird intraceiluiar loop. and a short fonn 
which is without this casserre.3 Strucruraily the snort form of the PAC.-\P re~epror 
and the VIP: re:::eptor are 50% identical at the :lil'li.no acid leveL c.he greatest sirnilariry 
being within the rr:msrnemorane spanning regions. The PAC.-\P rece?tOrs. when 
expressed in COS I ce!ls. exhibit a distinctive phar::J.acologica.l pror'iie in chat PAC.-\.P-
38 is 100-c'old more potent than VIP in eiic:ting :.~\1P stimuiation.l In comrasr. me 
V1Pz rece?tOr does not disc::irninare be~wee:'l me -.:wo peptides.; We have begun to 
c.harac~e::ize the domain responsible for agonist bir:ding by domain swap experiments 
between the VIP: and PAC.-\P re:::eptors. Here we iave replaced the l52-arnino-ac:d 
extracellular domain of both the long and snon: :·vrms of the PACAP re:::epcor wich 
c.he 125-arnino-ac:d exrrace!luiar domain of :rie v-:?: rece?tor. When these :::timaeric 
receptors were expressed in COS 7 ce!ls. we four:d mac this exchange incre:l.Ses me 
re:::e?tor aifiniry ror V1P such that ic displays V1P:-l.il<e pharmacology with P.~C.-\P· 
like coupling whe::e both VIP :md PAC.-\.P-::8 ue equipore:1r in the nanomoiar :ange 
.zTc!.; (:.+.:1131) 6.50-3547: fax: (..U l31 ) 662-02-+0: ::-m:ul: ~!ucz@srv.l.bmu.mrc.:.c.~ 
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FIGURE l. Line!.!;J or VIP! rece;nor ::.nd P.'\CAP ~ece ;:aor seque:-~ces Sf>anntng !he oouno:uv 
between !he exu::~ce!Iuiar I dom:11n ::..no tr:lnsme:nor:lne ~e ;pon l dom::~tn. Tne tHrow marKs 
che Sf>O£ :l£ which the crossove:- by ~mme:- .\133.J.i is m::~ae. 
at sdmuiaring cAMP :md inosico i phosph::ue 9roduc:ion. This sugg~sts Juu the Jmino 
te:-m.inai domain or· rhe VIP: re:::eptor is sur"fic:e:n r"or de~e:-;nining ~he pilarmacoiogic::i 
spe::::ficity or Jgonist binding. 
MATERIALS AND :.viETHODS 
Preparation of Chimaen·c eDNA 
In orde=- to make the chimae:ic ~e:::eptors. ~d./9. ! :llld N417b. cwo oiigonucleoride 
primers (Oswei DNA Service. Depamnem of Che:nisrry, Unive=-sicy or Edinburgh. 
Scodand) we=-e designed to the VIP: re:::epror (R4. pBluescripc) and the PACAP 
recepror encoding cDNAs (R7 and R7b. pB luescript). In the first round or PCR 
ampiific:uion. ilie prime=-. ! 143 (5'C.-\CC.-\GAATAT.-\rV-~.CGTGATCTIAC) along 
with pBluescript prime=-. was used ~o amplify the ;· region of me R4 eDNA. The 
prime=-. M3347. (5'CGTITTATXITCTGGTGAAGGCTCTCTACAC.-\GTC) was 
designed to overlap me cDNAs e::~coding ilie region of the exrrace!luiar domain V 
transmembrane domain I or' the VIP, and PAC.-\P re:::eptors (see F:G. l) . Along with 
the pBluescripc primer. M3347 was used to amplify the 3' region or· both the long 
and shorr forms or' PAC.-\P re:::epror encoding cDNA.s. For me second round or' PCR 
amplific:uion. the 5' R4 PCR fragme::~t and either the Yf3347 primed R/ or R7b PCR 
t'ragmencs were mixed and amplified using pBluesc:ipt prime=-s. Tne PC~ produc:s 
were digested with Eco Rl and ligated inro pBiuesc:ipt for sequence analysis. Ar'te=-
se[ec:.ion or J. positive clone for eac:,. a further sre? involved ligation of the 2.14-kb 
o.nd '2.06-kb Eco Rl fragmentS imo the expression vec:or pCDNA (Invicrogen. R& 
D Systems Europe Ltd .. Abingdon. UK) and seie:::tion o f c!ones in me proper orienrr..-
tion (N4/9.1 and N417b). 
E::perimencai 
COS 7 ce!Is were cransr'ec:ed using DE.-\.E dextr:ln as desc:ibed previously3 and 
allowed to recove=- for '24 h ber·ore crypsiniz:uion and replacing. For me:LSuremenc of 
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[nosiwi phosphate ;Jroduc:IOn. 2-+ h :1fte:- cr:tpsimz:mon. ce!ls I in I : wd a bees l were 
iabe!ed wah ~ ~ Hl-myo- inosuoi t I f.LC:imll (or l6 ~. washed. che:1 tnc:lbared in 
:nedium conr:umng co nu\1 LiC! for 1.5 mm be:·ore ;.;:-:aile:1gwg wich vanous pe;:tides 
{or .30 min. Re::tcaons were stopped in ice-coid mchioroace:ic :1cid. ce!ls scraped 
from tht: we!!s :J.nd ce:1mfuged oe:·ore e:mac:mg :he supe::nacanc in :ln equal voiume 
(SO : 50 mix l l.! . .2-mc~ioronifluoroe(hane/m-,z- i)C :t ryi :J.mine. The :1queous ~n:J.se was 
:1e:.m:1iize::i (0 pH 7-:3 wich :'-faHCO!. fnosiwi phospnate were :se?o.race::i oy ion 
exchange on Dowex .-.l...G l-XS." The produc:ion or· cAMP by ce!ls 1 in 2..!. we!! piaces ) 
was me:lsured during :1 20-min scimuiation pe~cd :J.S Jescribed pre·;,ousiy.3 
RESULTS AND DISCUSSION 
Tne ?AC.~.P :-ece;:Hor is able ~o couple w ooch ~de:1y iace :::::ciase :1nd ohosphoiipase 
C in (ransfec:ed COS 7 ce!!s whe:1 srimu iace::i oy PAC.;P-::8."0 wich EC.l vaiues of 
0.5 nM and 7 n!'vl. respec:iveiy. r'or each parhway."·10 VIP is o.pproximate!y !00-roid 
:ess poce:1c tn snmuiating cAMP producrion :J.t d: is rece!JCOr.J Tne VIP: rece;Hor does 
noc :1ppe:1r w discriminate !Je(wee:1 VIP or PAC..:..P: boch are equ ivaie:1c in stimulating 
::.::~.!Y{p ?roducnon in cos 7 ceils (f:lnsr'ec:ed wnh chis !ece:nor' s cDNrl .. WHh cC;.)'s 
of 0.17 o.nd 0.18 nM. respec:1ve!y. : We have ;:::2.rac:e~zed two ci1imae~c rece:;Jcors 
wnere ·.ve re?iaced rhe :J.rruno-\erminai region or' 'he ?AC.~P ~ece:;Jtor -_v ich that or 
~he VTP: rece;nor. :n che :1pproximare boundary ·Je:wee:1 c:mace!luiar domain I and 
~he ri rsr ~ransme:nbrane region. O!igonucieoticie ~rime:-s w che regron e::coding r:he 
junc:ion oerwee:1 excrace!!uiar domamitransme:norane region one were designed for 
ooth the PAC...l..P and the VTP, rece:;Jror cDN rl.s co enable the c:-ossover during 
PC::<. ampiific:J.rion. w cre::tte cDNAs encoding ~ece:nors with the l25-arnino-acid N 
<erminai of che VIP: rece;nor foilowe::i by the :;:.:.3-arnino-acid (long form) or 2.59-
arruno-acici (shorr formJ C ce:minai or the PAC.~.P :-ecepror. When expressed ir COS 
7 cells. me c~imaeric rece-;nors (Nii/9.1 and .:'-f.!.,'7b. respecriveiy) cioseiy rese::nbie 
the wiid-cype VIP: receptOr in their ability sirniiariy to couple co ade:1ylate c:rciase 
whe:1 stimulated with PACAP-38 or with VIP 'see frG. 2(aJ). In addition. these 
chimaeric receptors activated phospholipase C \vhe:1 stimulated with eithe::- peptide 
(f:G. 2(b'J), in a manne::- sirniiar co c.he PAC.-\.P receptor when activated by PAC.-\.P-
'38 (data noc shown·0) . The presence of c.he additionai 28-arnino-acid insen: in inrraceilu-
lar loop three (long form) did not appear co meet c.he functional aspec:s of the 
chimaeric receptors c.har we::-e o.ssesse::i he::-e. T..u3L=: l shows the respective EC~0 values 
for PAC.-\.P-38 and VIP at c.hese cwo receptors. Tnis suggests c.hac che rirst exrrace!lular 
domain of c.he VIP: receptor is c:1pable of determining che agonist pharmacology of 
these chimaeric receprors. but that the signal cransduc:.ion c:1pabiiities are conr'e:red 
by che re::nainde::- of c.he molecule. 
The large exrracelluiar domain [ of the secre~niPTd/co.lcitonin rece:;Jcor farniiy 
contains seve::-:ti conserved amino acids. including six cysteines. Mutation of :1 con-
served :J.spartate (residue 60), in the mouse Gn'K...Y: receptor ge:1e disrupts GHRH 
inter:J.ction wic.h its rece?tOr and has bee:1 ide:1cif:ed as tile c:1use of tile "Dwarf· 
l irrie mouse synd.rome. 11 Several conserved residues within che N-ce:minai domain 
of che human VTPt receptOr are imporranc for VIP binding. ::: A c!one of c.he human 
VIP, ieCe?COr thac contains an alce::native 67 -amino-acid N-cerminal region combined 
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FIGURE :. COS - c:::!ls u:msicmy tr:Jmr·ec:e:J with lhe VTP:( 1- ; ::5'1/P.c..CAP( I S}-..:.95'J c~t ­
mae:ic receptors . e:1codea ov :--1~/9.!. ·.vhic:1 .:onwns 'he :!:ma 84-bp -::::on in me region 
e:1coding !ncrace!!u!:u- loop 3. :md 'i<ll7b. whic~ does noc com:11n this e.'(.OnJ <.ve:e $Urnuiacea 
with VIP 1• N-!.:9.! : 0 :--1..!.//bl and P.o..C.l.P-:8 ce Nt!/9. 1 ~ 'i.tl7bl . Tne vaiues repre$e:1C :ne 
me:m ( = SEM. 1 = ; -5·,. (a J c.WP !eve!s :n response w :1 :O-min sumuiacion w1th e:JC:1 
peptide we:e me:JSured. 3as;:i leve!s ·.ve:e : = l pmoi/weil. ! bJ [!H]inositoi phospnate !e•1e!s 
~n response m a .:0-min sumuiation wilh e:Jch peptide were me:!Sured. Basal leve!s were 3387 
= 669 dom pe: ·.ve!L E:ror oars not shown r'ail Wtthin lhe dime:1SIOn oi the symboL 
TAB L E 1. Table or" EC;.J Vaiues for PAC..;.F-38 and VIP in COS 7 C~ils 
Transfe~~ed with the C1imae:ic Rece:nors NLL/9.1 (VIP: t - !::SPAC.\1' 153-.195. 
long form 'J and )i4//b t VIP: 1- l25iPAC.\Pl53-l95. short ··ormJa 
E.'( pressed EC;0 cANlP 
Receptor T re:Jtment Production 
:--/d/9.1 PACA.P-38 0.5 = 0.1 nivl 
V1P 1.! = 0.1 nM 
:--l417b PACA.P-38 0.5 = 0.04nM 
VIP 0.5 = 0.03 ru\1 
" Resuits ilre jJe me:!Ils = SE:Vl r"rom 3 to 5 e~pe:imems. 
EC0 Inosimi Phosphate 
Production 
9.5 = 0.8 ru\1 
:36.5 = 9.8 nM 
10.8 = 0.7 ru'v{ 
27.6 = 1.6 ru\1 
wir.h tbe ..l28 residues or" r.he C ce:minus is ~xoressed normallv buc does not bind ::!I-
VIP. 13 Reoiacin2 r.he N-\emtinal :extwce!lul~ domain or m~ sec:ec:in recencor with 
the :--r -::e:rrtinai ::!~rr.J.ceilular domain of the :-ac VIP 1 rece?cor confers VIP ph~acology 
to me c:llmae:ic rece?cor. : ~ Howeve:. che chimae:ic rece?cor mac was c:eaced by :.he 
reverse tr:lnsfe: did noc respond co sec:-etin in a manne: similar co its wild-cype ! :.: 
I··· : 
\,'li'lt\ L~ .'lEW YO RK .\C.\DE:'YtY OF SCE:"CES 
re:::::;Jtor. :.:.nJ reauiret.i the: :.:ulliuun:.1i tr::.nsr"e:- o r" the: sc::conJ c::~rr:J.ce!iul:.lr Jom:.1in along 
WHh the: fl f!)( r"o r tnis [0 oe obsc:"\"C::.l. ; J Rc:sitiues ne:lr ;he .\1 re:mt n:li :.~nd :.llso WHhin 
che chmi c::m:J.cdui:.lr loop h :~vc: he::::1 r"ounti ;o be: impu11::.nc r"o r PTH otnuing. ·! 
In conclusion these resuics intiic:.ae th:.1r in the VIP: re:.::::?COr :.1gon tst ~e::ognicion 
:~ ppe:.u-s to be ;~chievc:d c:1ure:y within the t!rs< e:m::.ce:lui::tr dom:.1in. Whiie this 
appe:J.rS w be rhe c::.se in ce:utn othc:- memoc::-s o r" che t:1mtiy ( e.~ .. VIP. rece;Jtor;~) , 
ache:- re!:ue:i rece:){ors. r"or ::::~:;.mptc:. £he sec:-e~tn ami the PTH re::e;:){or. d c::uiy have 
more compiex muicisite require:ne:1cs for :.:.gon ist recogni tio n. 
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Endothelin and NPY receptors in human parathyroid gland. 




and Frank Sunoler' . 
Department of Phys1ology ano Neuroscience: Section fo r Neuroendocnne Cell 
Biology ', Un1vers1ty of Lund, Lund, Sweden. 
Departments of Surgery~ ano Internal Medlcine3 , University Hospital ol Lund, Luno. 
Sweden. 
Endothelins and NPY are distributed in neuronal elements both within CNS and in the 
periphery, and endothelins also in non-neuronal cells. They are thought to play important 
roles as messengers. Endothelins and NPY are known to be vasoconstrictors in the 
periphery, but also non-vascular smooth muscle. and exocrine as well as endocrine glands, 
are known as targets. Enc1othelin·1 has been demonstrated in the pituitary ,adrenal and 
parathyroid glands and has been shown to increase imracellular calcium in a uov1ne 
paratllyroid endothelial cell line. In lluman parat11yro1d glands and in parat11yro1d (llanos ol 
several other species NPY occurs in nerve fibers which preoominate around blood vessels. 
In this study we used reverse transcriptase- polymerase c.;ha1n reaction (AT-PCA) to 
demonstrate endotllelin receptors. ET' and ET11 • and tile NPY receptor. Y ,, in human 
normal and hyperplastic parathyroid glands and in parathyroid adenomas. Since enoothelin 
and NPY have been demonstrated in human parathyroid glands we were interested to know 
whether the receptor mANAs were detectable and which receptors were dom1naung. We 
found ET"-. ET0 - and Y,-receptors in all tissue samples analyzed. ET8·rec~tors were the 
predominating receptor in both normal glands ano adenomas. ET" and ET receptors are 
functionally coupled to phospholipase C·mediated phophoinositide hydrolySIS anc1 activation 
of these receptors bnngs about an increase in intracellular Ca2 ' and Ca influx. Enoothelin- t 
may therefore induce receptor-meoiated increase in intracellular Cal• concentrations to 
inhibit basal PTH secretion from parathyroid cells. The abundant expression of ET receptors 
!n parathyroid tissue favors a rote of enaothelins as local modulators of PTH secretion. The 
Y, receptors are likely to be expressed in intragtandular blood vessels and invotveo in the 
regulation of local blood flow. 
SIGNALLING BY THE WILD TYPE RAT VIP2 RECEPTOR AND CARBOXYL TAIL TRUNCATED FORMS 
TRANSIENTLY EXPRESSED IN COS 7 CELLS 
E.M. Lutz. C.J. MacKenzie, A. Mitchell, J. Bennie, S. Carroll. and A.J. Harmar, MAC Brarn Metabolism Unit. 
UniversitY Oepanment of Pharmacology, 1 George Square. Edinburgh. EH8 9JZ. UK. 
Receptors for VIP and the VIP-tlke peptide PACAP belong to a distinct subgroup of the seven transmembrane-
spanning G prote1n-coupted receptor fam1ty which includes receptors for secretin. PTH and calcitonin. All members 
of this fam1ly couple to adenytate cyclase, through the heterotrimeric G protein G, and are capable of activating 
multiple s1gnat transduction pathways. We and others have snown that the PACAP receptor couples to 
phospholipase C via a pertussis toxin-insensitive G protein, most likely G~ In contrast. VIP 1 and VIP2 receptors 
transiently expressed in COS 7 cells activate (3HJinoslt.ot phosphate formation through a mecnanism which is in part 
pertuSSIS tox1n-sens1tive (MacKenzie er al .. Ann. NY Acad. Sci .. in press). Here we repon comparison ot the wild 
type rat VtP 2 receotor (VIP2w
1) and two carboxyl tail truncated forms ot 391 anuno actds. VIPz(<l392-437) and 376 
amrno ac1ds. VIP2(A377-437). COS 7 cells transtected with VIP2(A377-437) yielded no detectable spec1tic binding 
ot (125qPACAP-27 or stimulation of cAMP produc:tion in response to VIP. The 39 1 am1no ac1d VIP2(u392-437) was 
well expressed and functional in COS 7 cells. show1ng levels of specific (1251JPACAP-27 binding s1m1far to VIPz"'. 
The Kd tor VIP2(A392-437) was however markedly tower than tor ViP zw1. VIP2(6392·437) ehcned cAMP production 
in response to VIP and hetodenn1n w1th potencies very similar to VIP 2w1{Table 1 ). 






0.10:!: 0.01 nM 
Hetodennln 
0.25 = 0.005 nM 
0. II : 0.0 I nM 
The inaual rate ot cAMP stimulation and its time dependent desensitisation were also s1m11ar tor VIP2"' and 
VIPz(A392·" 37) receptots. Penussas toxan anh1bated VIP ana PACAP·38 evoked (JHjinosuol pnospnate tormauon an 
cells olxpress1ng eather VtP2w• or V1Pz(A::l92·437l. However EC~s lor (lH]inos1tol pnospnate 1ormauon meoaa1eo by 
VIP2"'1 (3 1 : 8 nM and 35 :t 5 nM tor PACAP 38 and VIP respectively) were lower rnan lhat tor VIP 2(6392·-137) (64 
± 3 nM and 68 :: 15 nM respectively) . Basal levels of cAMP and ot (3H]inos1tol pnospnate were Slnular an cells 
transtected wllh VtP2"'1 or w1th the truncated receptors. The "6 am1no ac1d truncauon ot the VIP2 receptor theretore 
increases ligand atllnity whilst attecting signalling through one pathway ((3H]inositol phospnatel but not attecuna 
anomer (cAMP). II is apparent rrom studies of truncated calc1tonan and PTH receptors rnat the carboxyl ta11 is 
involvl!d 1n normal prot ern traltlcking and expressron of the receptor. Ellects on &Hector coupling were tess clear 
cut. Coupling to cAMP sumulauon was very s1m1lar tn wald type and truncated receptors which wero normally 
olxpressuaJ. However till! Cal ' s1gna1 was attocted by carooxyl tall truncauon ot the pag ca1cuon1n reccp1or. wnereas 
tor human and for opposum PTH receptors 11 was unalfecred by reduced cart>oxyl ta111ongtn. Further studies walt be 
necessary to eluCidate the mechamsms anvolved. 
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PEPTIDES, NEW ORLEANS USA, 4-7 OCTOBER 1995 
CHIMERIC VIPiPACAP RECEPTORS REVEAL THAT AGONIST PHARMACOLOGY BUT 
NOT SIGNAL TRANSDUCTION IS DETERMINED BY EXTRACELLULAR DOMAIN 1 
E.M. Lutz, C.J. Mackenzie, J. Morrow, R. Mitchell and A.J. Harmar 
MRC Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ, UK 
Receptors for the secretin/glucagon family of large peptide hormones, which 
includes VIP and PACAP, belong to a family of seven transmembrane spanning G 
protein-coupled receptors which are distinct from the rhodopsin superfamily. All 
members of this fami ly are coupled to stimulation of adenylate cyclase, most 
probably mediated by Gs. Many are also capable of stimulating inositol phosphate 
production. We have isolated cDNAs encoding two members of this family, the VIP2 
receptor and two splice variants of the PACAP receptor. When expressed in COS 7 
cells , the short and long forms of the PACAP receptor couple in a very similar 
fashion to both stimulation of cAMP and inositol phosphate production. PACAP-38 
is 100 fold more potent than VIP in eliciting cAMP production , with an ECso of 0.5 
nM. PACAP-38 stimulates inositol phosphate production with an ECso of 7 nM 
whereas VIP was inactive at concentrations up to 1 J..LM. Both PACAP-38 and VIP 
are equipotent at the VIP2 receptor in stimulating cAMP production, with ECsos of 
0.18 and 0.17 nM, respectively. 
Structurally the unspliced PACAP receptor and the VIP2 receptor are 50% 
identical at the amino acid level. We have designed oligonucleotides to a region at 
the extracellular domain/transmembrane region one junction for PCR 
amplification in order to exchange the amino terminal extracellular domains of the 
two receptors. Two chimeric receptors which we have created replace the N-
terminal 152 amino acids of both the short and long forms of the PACAP receptor 
with the 125 amino acid N-terminal of the VIP2 receptor. This exchange increases 
the receptor affinity for VIP such that it displays VIP2-Iike pharmacology with 
PACAP-Iike coupling where both VIP and PACAP-38 are equipotent in the 
nanomolar range at stimulating cAMP and inositol phosphate production. This 
suggests that the amino terminal domain of the VIP2 receptor is sufficient for 
determining the pharmacological specificity of agonist binding by these receptors. 
117 
P25 
2ND INTERNATIONAL SYMPOSIUM ON VIP, PACAP, & RELATED 
PEPTIDES, NEW ORLEANS USA, 4-7 OCTOBER 1995 
PHOSPHOUPASE C ACTIVATION BY VIP1 AND VIP2 RECEPTORS EXPRESSED IN COS 7 
CELLS INVOLVES A PERTUSSIS TOXIN-SENSITIVE MECHANISM 
C.J. MacKenzie, E.M. Lutz, D.A. McCulloch , R. Mitchell and A.J. Harmar 
MRC Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ, UK 
The V!P1 and VIP2 receptors are members of the secretin/glucagon/parathyroid 
hormone family of G protein-linked seven transmembrane spanning receptors. The 
ability of the VIP1 and VI P2 receptors to interact with different G proteins and to 
activate different second-messenger pathways largely remains to be elucidated. 
When expressed in COS 7 cells the VIP1 and VIP2 receptors have been shown to 
couple to the adenylate cyclase, phospholipase C (PLC) and phospholipase D (PLD) 
pathways. VIP and PACAP-38 have also been shown to stimulate nitric oxide 
synthase in gastric smooth muscle cells through a common receptor and a pertussis 
toxin (PTx)-sensitive G protein. 
We have demonstrated that activation of PLC mediated by the V!P1 and VIP2 receptors 
involves a Ptx-sensitive mechanism. Stimulation of the V!P1 receptor with 3 .uM 
VIP caused a 3.64 ± 0.18 -fold increase over basal [3H]inositol phosphate 
production , the VIP2 receptor a 1.96 ± 0.09 -fold increase, while 50 mM A!F ~­
elicited a 4.00 ± 0.57 -fo ld increase over basal. Pretreatment with 100 ng/ml PTx 
caused a 46% ± 10% inhibition of PLC activity stimulated through the V!P1 receptor 
and a 38% ± 17% inhibition of VJP2 receptor mediated activity. PTx treatments up 
to 200 ng/ml had no effect on basal PLC activity. 
In contrast, the PLC response mediated by two splice variants of the PACAP receptor 
("short" and "long" intracellular loop 3 sequences) was not PTx-sensitive. 100 nM 
PACAP-38 caused a 6.75 :: 0.05 -fold increase over basal [3H]inositol phosphate 
production for the "short" receptor and 8.87 ± 0.44 -fold increase for the "long" 
receptor. In the presence of PTx the responses were 101% ± 6% and 104% ± 7% 
of control respectively for the "short" and "long" form receptors. V!P1 and VIP2 
receptor-mediated PLD activity is also PTx-insensitive. 1 ~-tM VIP elicited a 1.93 :: 
0.13 -fold over basal increase in [3H]phosphatidylbutanol production through the 
VI P1 receptor and 1.62 = 0.24 -fold increase through the VIP2 receptor. After PTx 
pretreatment the responses were 97% ± 4% and 109% ± 6% of the controls 
respectively for the VIP1 and VJP2 receptors. 
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Rhodopsin-family receptors 
associate with small G proteins 
to activate phospholipase D 
Rory Mitchell, Derek McCulloch, Eve Lutz, Melanie Johnson, 
Chris MacKenzie, Myles Fennell, George Fink, Wei Zhou· 
& Stuart C. Sealfon· 
,\lfRC Brni11 Merabolism Unit. I George Square, Edi11burg!r. EH8 9/Z. UK 
• Fis!rberg Ccmer for Neurobiology t111d Deparcmem of Neurology, Moum Sinm 
School of Medicine, .\lew York, NeiV York 10029. USA 
G-protein-coupled receptors of the rhodopsin family transduce 
many important neural and endocrine signals. These receptors 
activate heterotrimeric G proteins and in many cases also cause 
activation of phospholipase D, an enzyme that can be controlled 
by the small G proteins ARF and RhoA1- 3• Here we show that the 
activation of phospholipase D that is induced by many, but not all, 
Ca1+ -mobilizing G-protein-coupled receptors is sensitive to inhi-
bitors of ARF and of RhoA. Receptors of this type were co-
immunoprecipitated with ARF or RhoA on exposure to 
agonists, and the effects of GTP analogues on ligand binding to 
the receptor changed to a profile that is characteristic of small G 
proteins. These receptors contain the amino-acid sequence Asn-
ProX:XTyr in their seventh transmembrane domain, whereas 
Figure 1 Propenres of agonist·evol::eo PLD responses •n 1321N1 cells and co· 
immunoprecipitation of M3 receptors with ARF 113 and RheA antibodies. a. the 
effects of BFA on eHJphosphatidylbutanol ([3H]PtdBut) production elicited by: e 
200 "'M carbachol, • 10 iJ.M bradykinin. "' 2 mM histamine, o 0.5 units per m1 
thrombin, or 0 30 I'-M U46619 (a TXA2-receptor agonist). IC~ values for effects of 
BFA on M1. bradykinm and histamine responses were 72 = 11. iS= 15 a no 
82 = 13 IJ.M. respectiVely. whereas thrombin-receptor and TXA2-receptor 
resoonses were resistant up to 200 I'-M BFA. b. Production of PtdBut in response 
to carbachol and thrombin is shown by hatched and open columns. respecuvely. 
Corresponding values for reagent-treated cells are shown by adjacent blacK 
columns. Reagents were U73122 (20 "'M; U 73), pertussis toxm (200 ng ml-' for 
18h: Ptx). C3 exoenzyme (4.8~-'gml-' : C3) and wild-type or negauve RheA con· 
structs (WT and .n. Carbachol was used at a concentration of 200 "'M except in 
C3 and WT RheA expenments. where 100 "'M and 20 "'M. respecuvety. were 
used. Thrombin was usually 0.5 units per ml but 0.2 unns Per ml in WT RheA 
experiments. In a. b . values are means= s.e.m.: n = 4- 10; sigmticant changes 
:rom the control levels are indicated by asterisks (P < 0.05: Wilcoxon test). c. 
Solubilized membrane ormems from cells ore•ncuoated w•th carbachol (hatcnec 
columns) or from controls (open columns! were immunoprec•onated wnh sheep 
anu-ARFt/3 anubooy (ARF), rabbit anu-RhoA antibody (RheA). non-immune 
sheep lgG (NIS) or non-immune rabb1t lgG (NIR) or comoinauons of these 
ant1bod1es. beiore laoelling M 3 receotors wnh ['HJNMS. In some ARF /RhoA 
1mmunoprecipitations. blocking peptldes were •ncluded (shown as =l. Values 
are means = s.e.m. (n = 6-9). For astensked bars. P < 0.05 compared \VI!h 
unpnmed controls. and for bars w1th daggers P < 0.05 compared w1th non· 
1mmune lgG controls (Wilcoxon test). We estimate that up to 48% and 27% of 
ligand binding to solubilized M 1 receptor may be assoc•ated spec•fically (in a 
oeoude·blockable manner) wnh ARF a no RheA •mmunoorec•p•tates after agon•st 
pnming. 
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receptors capable of activating phospholipase D without involving 
ARF contain the sequence AspProXXTyr. Mutation of this latter 
sequence to AsnProX.X.Tyr in the gonadotropin-releasing 
hormone receptor conferred sensitivity to an inhibitor of ARF, 
and the reciprocal mutation in the 5-HT zA receptor for 5-hydroxy· 
tryptamine reduced its sensitivity to the inhibitor. Receptors 
carrying tJ1e AsnProX.,'\.Tyr motif thus seem to form functional 
complexes with ARF and RheA. 
The activation of phospholipase D (PLD) (measured as forma· 
tion of [3H]phosphatidylbutanol) by a number of receptors that are 
native to 1321 N I human astrocytoma cells4 was differentially 
inhibited by brefeldin A (BFA), an inhibitor of guanine-nucleotide 
exchange on ARF;. Activation of PLD by H 1 histamine, B2 brady-
kinin and M3 muscarinic receptors in these cells" (as for M3 
receprors expressed in HEK 293 cells;) was sensitive to BFA whereas 
act ivation of PLD by thrombin and thromboxane A2 receptors was 
BFA-resistant (Fig. Ia). Thrombin- but not M3-receptor responses 
were attenuated by the phospholipase C (PLC) inhibitor U73122, 
but neither response was affected by pertussis toxin (Fig. !b). The 
Rho inhibitor C3 exoenzyme and a negative construct, CMVS 
Asn 19 RhoA (ref. 8), both reduced M3- but not thrombin-recep-
tor-mediated activation of PLD, whereas wild- type RhoA increased 
responses to a lower concentration of carbachol but not thrombin 
(Fig. I b). These results indicate that some Ca!+ -mobilizing G-
protein-coupled receptors (GPCRs) use a pathway of PLD activa-
tion that is independent of Gq/11 (which activates PLC) and Gi/o, 
yet involves ARF and RhoA. 
We used co-immunoprecipitation to test whether Mrreceptor-
mediated PLD activation might involve a step in which the receptor 
and small G proteins interact closely. figure lc shows that solubi-
lized M3 receptors (levels of which were measured by binding of 
(
3H]N-methyl scopolamine W HJ NM$)) could be immunopreci-
pitated using polyclonal antibodies against ARFI/3 (ref. 9) or 
Rho A 10• Yields from using combinations of antibodies were less 
than additive. Co-immunoprecipitation required pre-exposure to 
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using control immunoreagents or in the presence of excess peptide 
antigen. Use of BFA ( 100 !J.M) during priming reduced the yield of 
M~ recepwrs in ARFl/3 immunoprecipitates by 7.J ::!: 19%. Thrombin 
receptors, labelled with [12"l)Aia-pFPhe-Arg-Cha-HArg-Tyr-NH~ 
([mi]TRP; ref. I I ) could not be co-immunoprecipitated by anti-
bodies against ARF/Rho after priming with thrombin agonist (data 
not shown}. When a control immunoprecipitating antibody (anti-
PKCcx, Transduction Laboratories) was used to collect another 
signalling protein known to translocate to 132 1 11 cell membranes, 
preincubation with carbachol caused no increase in (3H]NMS 
binding to immunoprecipitates despite a 3.1 ::!: 0.3-fold increase 
in membrane binding of [~H ] phorbol 12,1 3-dibutyrate (data not 
shown). 
lmmunoblotting using distinct (monoclonal) antibodies showed 
that authentic ARF and Rho were present in ARF/Rho-directed 
immunoprecipitates from carbachol-primed .:ells; ARF and Rho 
were not present in immunoprecipitates when peptide antigens to 
the polyclonal reagents were added (Fig. 2a, b }. In the detergent/ 
NaCI conditions that \ve used, the monoclonal anti-ARF antibodies 
ID9 (ref. 12) and clone 26 (Transduction Laboratories) were much 
less effective or completely ineffective, respectively, at precipitating 
ARF immunoreactivity and [3H)NMS-binding sites (data not 
shown). An Mrreceptor antiserum fraction•, but not non-
immune lgG, caused co-precipitation of immunoreactive ARF 
and RhoA after priming with carbachol (Fig. 2c, d). Similarly, 
polyclonal antibodies to the AT1 receptor (BFA inhibited PLD 
activation by this receptor; half-maximal inhibitory concentration 
(JC50) 58 ::!: 51J.M) caused priming-dependent. peptide-blockable 
co-precipitat ion of authentic ARF (Fig. 2e) and Rho (data not 
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Figure 2 lmmunoblots for ARF and Rho on 1mmunoprec•o1tates generated with 
polyclonal ARF1 13. RheA and receptor antibodies. BIO!S a - d are from 1321N1 
cells and e IS irom rat antenor p1tu1tary cells. For each oanel. the labels beiow 
indicate the premcubauon condit1ons ICC h. carbachol. AT. AT II: -. control. Labels 
above show tne 1mmunoprec•pnauon reagents (ARF(p). sheep polyclona1 ami· 
ARFl /3 antibooy: RhoA(p). rabb•t polyclonal ant•-RhoA antibody: M3• raobn 
polyclonal anti·M.;·receotor antibody: Nl. non·1mmune rabbit lgG: AT 1 R(p). rabbit 
polyclonal anu·AT,·receptor antibody). w 1th (+)or without (-) blocking oepudes. 
Labels to the nght ind1cate the immunoblonmg reagents (ARF(m). mouse 
monoclonal ant1·ARF antibody: Rho(m). mouse monoclonal anti·Rho antibody). 
The arrow md1cates the POSitiOn of the 20 kDa molecular mass standard . 
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shown). ln addition, when ATu-primed membranes were treated 
with the crosslinker ethylene glycolbis (succinimid~·lsucci nate ) and 
immunoprecipitations carried out with antibod~· ID9 in the pre-
sence of Triton X- 1 00/SDS, specific AT1-receptor immunoreacti,·itv 
became detectable in immunoprecipitated high-molecular-mass 
complexes of approximately 170K (data not sh0\\11 1. These results 
indicate that certain receptors may be able to form phvsical com-
plexes involving ARFI/3 and/or RhoA and that this mav be 
important in the activation of PLD. 
\l>.le used GTP analogues to determine whether the effects of these 
analogues on both receptor and effector properties ,,·ere consistent 
with the above hypothesis. The affinity of M3 receptOrs labelled with 
(
3H]NMS for carbachol was reduced by guanosine 3' -0-(3-thio)-
triphosphate (GTP)'S), BeF3 (an isostere of :\.IF: t ref. !3 )) and 
guanosine 5'-[f3-y- methylene]triphosphate (GPPCH:P) (Table Ia). 
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Figure 3 PLD and PLC responses of wild-type, Asn 318 and Asp 318 pius Asp 87 
Asn 318 mutant GnRH receptors expressed in COS 7 cells and receptor 
1mmunoprec1p1tauon with ARF1 /3 and RheA antibodies. a. b Show the ume 
course of [3H)phosphatidylbutanol (eHJPtdBut) and ['H]inosnol phosphate 
(f'H]InsP) producnon evoked by 100nM GnRH at • wild-type. • Asn318 mutant 
and 1. Asp87 Asn318 mutant receptors and by \ AIF~ ( 10mM NaF and 30 ,.,.M 
AICI3) 1n Asn 318 mutant expressmg cells. Values are percentages ol wild· type 
response at 40mln (means= s.e.m.: n = 4-6). c. d Show effects o' aFA and 
U73122 on f'H]PtdBut production evoked by 100nM GnRH at • wild·tyoe and • 
Asn 318mutant receptors. Values are means= s.e.m.:n = 4-6. e. Shows 01no•ng 
of ['2; 1)buserelln to •mmunoprec1pnates I rom cells express•ng wild-type or Asn 318 
mutant receptors. Extracts !rom cells preincubated with GnRH (hatcheo columns) 
or from controls (open columns) were immunoorec1p1tated w1th antibod•es 
against ARF 1/3 IARF). RheA (RheA). p21 Ras (Ras) or ERK l / 2 !ERK). Blocking 
pepudes for ARF /RhoA antibod1es were sometimes incluoed (indiCated as =>· 
Values are means :!: s.e.m.: n = 4-8. Astensks relate toP values oi <0.05 com-
pared to controls. by Wilcoxon test. After agon•st pnmmg. 26<lo and 33":> of ilgand 
b1nd1ng to solubilized mutant GnRH receptor (1100-1400 c.o m. oe· samole) 
seemed to be associated specihcally (in a peptlde·blockable mannen w1lh ARF 
and RheA 1mmunoprec1p1tates whereas specihc assOCiation wnn tnes~ orec:ol· 
tates of the w•ld-type was negligible. 
After carbachol priming, the cfkct of GTP-yS was unaltered. that of 
BeFj was attenuated and that of GPPCH~P was increased in a wav 
that was 57 ::!:: I 0% inhibited by BrA. Table I b shows that GTP 
analogues activated PLD in permeabilized cells nnd that their effects 
were modified by agonist p riming" - '". Atter carbachol priming of 
1321 N I cells. the effect of GTP-yS did not change significantly but 
that of BeFj was reduced and that of GPPCH~P was greatly 
increased. Agonist priming lowered the etfective concentration for 
half maximum response (EC;u) for GPPCH~P from 367 ± 741!-M to 
97 ::!:: 11 1!-M ( 6o/o and 22%, respectively, of the potency of GTP-yS 
( itself with an unaltered EC;0 of 2 I-22 1J..M )). Agonist exposure 
causes ARFl/3 and RhoA7•16·' 7 to translocate to cell membranes and 
the increased effect of GPPCH~ P here wns abrogated by BFA or C3 
exoenzyme (Table lb). Effects of AIF~ and BeFj may involve 
trimeric, but not small, G proteinsu.ls (although selectivity may 
be modified in vivo). In contrast, [3-y-methylene analogues of GTP 
may retain a substantial fraction of the potency of GTP-yS at ARF, 
Rab5 and other small G proteins, despite being very weak _activators 
oftrimeric G proteins and Ras 19•20• Indeed in an assav of [ h SIGTP-yS 
association to native ARF. collected from ID9 immunoprecipitates 
(which were later renatured) of urea-trea ted ext racts from 
carbachol-primed 132 1 N !-cell membranes, GPPCH~P retained 
30o/o of the potency of GTP-yS with mean IC;o values of 54 and 
l61J..M. respectively (R.M. and D.M., unpublished observations). 
These results concur with the idea that agonist-induced transloca-
tion of ARF/RhoA to membranes may promote their involvement 
in some form of complex with GPCRs, and may ultimately enhance 
receptor-mediated activation of PLD. 
Each of the receptors that were sensitive to BFA, C3 exoenzyme or 
CMV5 Asn 19 Rl10A or that could be co-immunoprecipitated with 
ARF 1/3 or RhoA contains the canonical AsnProXXTyr motif 
(where X represents any amino acid) in transmembrane domain 
VII (TMD VII), whereas the other receptors contain AspProXXTyr 
instead. The wild-type gonadotropin-releasing hormone (GnRH ) 
receptor (which contains AspProX,'<Tyr) and two mutants contain-
ing an AsnProXXTyr motif (containing mutation of Asp 318 - Asn 
or Asn 87 - Asp as well as Asp 318 - Asn (ref. 21)) were expressed 
in COS 7 cells. The wild-type receptor activated PLD linearly over 
30-40min. like the receptor in o:T3-l cells2~. In contrast, the 
Asn 318 and Asp 87 Asn 318 mutants displayed initial rates of 
Table 1 Effects of GTP analogues on agonist recognition by M 3 and GnRH 
receptors and on PLD activation 
Assay and treatment 
.............................................. . .................................. . 
(a) Carbachol afflmtY ior 
e HJNMS·b•nomg s•tes 1:1 
1321N1 cells (fold increase 
in IC50) 
Comrot 5.23 :: 0.97 
Carbachol·onmeo 4.48 :: 0.34 
GTP analogue 
4.06::0.80 
1.82 :: 0.31 " 
GPPCH2P 
231 :: 0.34 
3.46:: 0.40t ..................................... . ............................. ........................ . 
(b) ActiVation oi PLD •n 
permeabdizeo 1321 N 1 
cells (Increase over basal 
acuvauon 1"0\) 
Comro1 150::9 115:: 14 
+BFA 117 ::9 
"'-C3 exoenzyme 95 :: 11 
Carbacnoo·onmed 168 = 10 78 = 10· 
+BFA 69:: l l 
+C3 exoenzyme 85 :: 9 
ici {ii5ilii·c;;~~e;;;:;·;;·;;;$;;·c;;a·i;;;;;····················· ······················· ··········· ········· · 
rate on trans;ecteo COS7 
cells (Recucuon 10 t. l of 
slow comconem !%)) 
W•ld·tYoe GnRH recemor 43 :: 4 36 :: 8 
Asn318 mutant 40:: 5 7 = 5· 
48 = 8 
31 = 3l 
27 = 5l 
110 = l2t 
38 = 9~ 
23 = 7l 
12::5 
38:: 8t 
GTPyS. F· a no GP"CH·P were oresent at 100 ,..M. 10 m~·l ana 200 ,..M. resoecttvely. exceot •n 
c wnere 3 mM ;::· ana 100 .,.M GPPCH,P were used. BFA and C3 exoenzyme were used at 
100 .,.M and ~ 8 .,.g ml". ·escectrvely. Values are means = s.e.m .. .., = • -10. Stat,sucally 
signiiicant 01Harances (P-: 0.05 by Wilcoxon test): · .ess than corresponding unpromed 
control (a. bl cr wtld·type control (cl: t greater than co,esponding unprimed or wlld·type 
control: ; reversal o; GiP·analogue eHec1. 
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[-'HI phosphatidylbutanol formation that 1vere more than 2.5-told 
that of the wild-type receptor ( Fig. 3aJ. Enhanced PLD coupling in 
the mutants was observed despite reduced I'H iinositol phosphate 
p roduction ( Fig. 3b) and reduced membrane [ 1 ~5 fl buserelin binding 
(for which values of 589 ::!:: 39, 230 ::!:: 41 and 148 ::!:: 361inol per mg 
protein 811'"' were obtained for cells expressing wild-type, single 
mutant and double mutant receptors. respectively). PLD-activation 
responses of the mutants desensitized rapidly, whereas PLC-activation 
responses did not. In contrast, post receptor stimulation of trimeric 
G proteins with AlF; caused non-desensitizing act ivation of both 
PLD and PLC in Asn 318 mutant cells. Neither altered receptor 
kinetics nor enhanced receptor internalization to allow contact with 
intracellular PLD'~ could explain the enhanced PLD coupling, as 
[ 
115Ijbuserelin association with the membrane and receptor inter-
nalization rates in wild-type and Asn 318-mutant cells were indis-
tinguishable. In addition, 200 IJ..M monodansylcadaverine and 
30 IJ..M monensin (which caused 70-80% inhibition of receptor 
internalization ) increased rather than reduced, both PLD responses 
(data not shown). 
PLD activation by the wild-type receptor was inhibited by 
U73122 ([C50 of 11 :!:. l IJ..l'vl) but not by BFA in concentrations up 
to 200 IJ..M (these data are similar to da ta from cxT3-l cells), whereas 
the Asn 318-mutant response was sensitive to BFA {IC,.0 of 
54= 81J..Ml but not U73122 in concentrations up to 20 f.I.M ( Fig. 
3c. d). ATP, an agonist for the native P2u receptor (which contains 
the AspProXXTyr motif), and ionomycin/phorbol ester both 
caused BFA-resistant PLD activation (data not shown). The gain 
ofBFA-sensitive PLD (but not PLC) activation upon replacement of 
the AspProXXTyr motif with AsnProXXTyr indicates that this 
structural motif may be important in gating ARF/Rho-mediated 
coupling to PLD. This hypothesis is supported by the greater 
sensitivity to BFA (IC50 47 ::!:: 1l~J..M) of PLD activation by the 
wild-type 5-HT2A receptor (which contains AsnProXXTyr) than its 
Asp 376 mutant ( ref. 24) (24 :::: 13 inhibition at 200 ~J..M BFA) 
expressed in COS 7 cells. 
The importance of the AsnProXXTyr motif in the proposed 
linkage between receptor and small G proteins was directly 
indicated by co-immunoprecipitation of agonist-treated Asn 318 
mutant but not wild-type GnRH receptors using ARF and RhoA 
antibodies ( Fi~: 3el. Furthermore, although GTP-yS increased dis-
sociation of (1"0 l]buserelin from both the Asn318 mutant and the 
wild-type receptor in permeabilized cells, GPPCH2P was effective 
towards the mutant only and the inverse was true for BeF3 (Table 
1c). The effect of GTPyS at the mutant, but not the wild-type, 
receptor was inhibited (by 62 ± 12%) by 50 J.i.M BFA. 
Our results suggest a model involving a previously unrecognized 
association between certain rhodopsin-family receptors and the 
small G proteins ARF and RhoA. One functional consequence of 
this appears to be an enhanced coupling of receptors to PLD 
activation. The interaction seems to occur when an AsnProXXTyr, 
but not AspProX..'<Tyr, receptor motif is present and may be 
enhanced by agonist-induced translocation of ARF/RhoA to the 
plasma membrane. The form and site of interaction of small G 
proteins with receptors is unknown, but it seems likely that other 
proteins that act as adapters or regulators of small G protein 
function :s-Js may participate or mediate in the association. CJ 
Methods 
Phospholipase assays. PLD and PLC actiVIties were monitored as 
p roduction of (·'H i phosphatidylbutanol and ('H l inositol phosphates. 
respect ively'"· For .tssays of PLD activity in acutely permeabilized cells. 
prelabelled 132 IN I c~lls were primed with 100 f.i.M carbacho l ( 10 min. 3i,Cl 
or control bdorc intracellular buffer was added. This buffer contained 2 m,\ I 
~lg:\TP, lO f.I.M NAD. 6 f.i.M digitonin. 30 mM butan· I -ol. and GTP·rS. 
GPPCH 1P or F" c:-:aF in the presence of 30f.l.l'vl BeCI1) and BFA or C3 
exoenzyme as required. Male rat an terior hemipituita r ies were labelled for 
2 h i11 vitro for assay of ATwevnked PLD act ivation. 
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Liposome treatment and transfection of 1321 N1 cells. Cells were treated 
with hpofcctamine containing C3 cxoenz~'ITle ( 1 1-LS per 1\'dl. 5 h ). CMV5-RhoA 
constructs (0.5 1-LS DNA per ~.5 em~ well . 7 h) or contror. Rho-const ruct cdb 
were assayed after 48 h. 
Solubiliution and immunoprecipitation of (3H]NMS-Iabelled M3 recep· 
tors and (1251]TRP-Iabelled thrombin receptors . 1321 :-..: I cells {preincubated 
with carbachol ( 100 IJ.M 1 or the thrombin a!!onist Scr-Ph,··Leu·Arg· Asn· NH: 
(30 JiM ) for 10 min I were homogenized in cold J-kpes hufier with peptidase 
and phosphatase inhibitors. Membranes were solubiliud in 5 mM C HAPS. 
0.1% Na cholate and I M NaCI for 30 min at 4 •c. An .:qual volume of 20'1-o 
glycerol in CHAPS/cholate buffer without l'aCI was addc:d 1\,•i th 0.6 mg mr' 
phosphatidylcholine for M; receptors). Supernatant "'.IS preclcared and 
incubated (4 "C. ISh) " 'ith sheep anti·ARFI/3 immum,):lobulins (10-15jJ.IJ 
ml; antigen ARF19~_ 111; gift from M. J. 0. \\'akclam)' or " 'ith an immunopre· 
cipitating rabbit an ti-RhoA lgG (2-3 1J.gmr'; antigen Rh(l.-\ 11 • • 131; Santa Cruz 
Biotechnology)'". The ARF antiserum immunoprc:.:1pita ted authentic 
immuno reactive ARF from CHAPS/chohuc/N~1CI membrane extracts 
(Fig. 2a) and from c~·t osol after its incubation with GTP:·S and the addition 
of CHAPS/cholate/NaCI but not without this treatment (R.M. and M.J., 
unpublished observations). Blocking peptides were u>o:d at 6 1J.g mr ' and 
control non-immune lgG at 3 liS m r 1. Immune complexes were collected 
with protein·G-Sepharose. M3 receptors were assa1•ed in 10 mM MgCI1, 
200 mM l'aCl. 10% glycerol. 3 mg mr' phosphatidylchohne. 20 mi\1 Hepes 
pH 7.5, IOnl\1 13HINMS {85Ci mmor'. DuPont) with or ll'ithout 10 JJ.ll•l /\'· 
methyl atropine for 40 min at 37°C, before precipitation with polyethylene 
glycol. Thrombin receptors were assayed in IOmM l\lg.CI1, 150mM NaCI, 
0.25% BSA. 0.05% bacitracin, 0. 1 mM 4·(2-aminoethyl '·benzene sulphonyl 
fluoride (AEBSF), 2 1-lS mr' aprotinin. 7% glycerol. 2 mg. mr1 phosphatidyl· 
choline, Tris HCI (50 mM pH 7.4), [ 11;l]TRP (ref. II ; 120.000 c.p.m. per assay) 
w ith or without 300 nM unlabelled TRP, for 60 min at ~ 'C. 
Western blotting of lmmunoprecipltated extracts. Extracts from 1321NI 
cells or male rat anterior hemipituitaries (preincubated "ith 10 fJ.M AT11 for 
10 min at 37"C) were immunoprecipitated using pokdonal anti-ARFI /3 
antibodies at 20JJ.Imr ' (peptide at SJJ.gml- 1 ) , polyclon.tl anti-RhoA lgG at 
5 liS mr ' (peptide at 20 IJ.S mr' J. rabbit anti-M , receptor serum• !antigen M3 
receptor361 • .,~J (or non-immune rabbit lgG) at 2.5 li!! mr' and polyclonal 
anti-AT, receptor l~G at5 JJ.gmr ' (antigen AT, receptor,, _,: 20 J.Lgmr: : Santa 
C ruz). Proteins collected by protein G beads were separat,•d by SDS-PAGE and 
blots were incubated with m onoclonal anti-ARF JgG (cion ~ 26, 1:200 dilution; 
Transduct ion Laboratories). or ami-Rho lgG (clone 26C4. l :200 dilution: Santa 
C ruz). Detec ti on was by horseradish · peroxidasc-coni u!!ated secondary anti· 
body and enhanced chemiluminescence. 
Modulation of agonist affinity at M 3 receptors by GTP analogues. 1321 N l 
cells were incubated with or without carbachol (20 JJ.l\1 1 and/or SF . .>. 1100 JJ.I\1 ) 
for 10 min at 37 •c. Carbachol displacement ( I 0-3.000 ~J.M ) of membrane 
[·' H ]NMS bmding was measured in 10 mM MgCl~. 10(1 ml\1 XaCI. 20 ml\1 
Hepes pH 7.5. I nM [·'H INMS. with or without GTP-yS. GPPCH:P or F. for 
60min at 37 •c. 
[1251]buserelin·binding studies in transfected COS 7 cells. Receptor 
constructs Ill pcDNAI (refs 21. 24) were transfected usmg DEAE dextran 
l 20 liS DNA per 4 X I 0" cells) and were assayed 72 h later. X lembranc binding 
was assayed as described'". For cell-surface binding. cell s 111 I 2-wd l plates were 
incubated with ligand, with or without 3 1J.M G nRH. at 4 •c or 3;- •c as 
appropriate '". Internal ization wa~ measured at 37°C fur 0-40 min after pre· 
equilibration with ligand for 90 min at ~ •c. ~urface-bound ligand was 
dissociated with cold 0.2M acetic acid in O.SM NaCI. Li!!and dissociation in 
permcabilized cells was measured br prclahclling at 4 •c. and then successive 
incubation> 1VIIh medium containing 2~ JJ.M d•gitomn and GTP analogues at 
37 •c. lnitiJI dis.<uciation occurred idcnticallr from wild-type and Asn 3111 
mutant GnRH receptors. reflecting a temperaturt··dcp~ndent reduction in 
G nRH bind mg.. From 15-5() min. slower dissociation rat<'< " 'ere rcacht'<l .md 
plot> of lnf.:. aga 111 't tim<' rew.tled smgle lmcar cwnpuncnt- of hJi f-lh·cs: wild-
1)1)C: ~~ ::: .\ 111111 , and A>n 31X mutant: 26 = 3 mm in control-. 
Solubilization and immunoprecipitation of wild-type and mutant GnRH 
receptors labelled by [1251]buserelin. Alter Jm·incuha tmg •~II' with or 
without IOiinl\1 (, nfU I for 1:'-min. mcmhr:tn <"' w.:r<· >e>lub iiiZ<·d 111 ~ ml\1 
CHA I':O. .md 1.~,\1 :-:a (:I 1rd . . >o 1. l.:xJr.lCb 1\'l'rt' .td iu<t<'<l to 05;\l :-..:.1CI .md 
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predeared before incubating tat o~•c fur 1~ hl "'ith the poh·donal antibodies 
anti·ARFI/3 ( 10 ILl mr') and anti-RhoA (I f.l.l!mr '1. described above. or with 
mouse monoclonal anti-Ras lgG !antigen p21"': Tr.msduction Laboratories ) or 
mouse monoclonal anti ERKI/2 lgG (antigen ERKI.'!'- ' ' ' : b ·med Labora· 
tories ) as controls at l1J.gml"1 (both of which are reported to recognize native 
conformations of their targets !. l31ocking peptides for the pol~·clonal reagents 
1vere used at 2 li!\ mr'. Immune complexes were collected using protein G-
Sepharosc, and [ •~;llbuserelin binding was measured in pol,·ethylene glycol 
precipitates .... 
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